<SEC-DOCUMENT>0001628280-23-017951.txt : 20230512
<SEC-HEADER>0001628280-23-017951.hdr.sgml : 20230512
<ACCEPTANCE-DATETIME>20230512170210
ACCESSION NUMBER:		0001628280-23-017951
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		62
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230512
DATE AS OF CHANGE:		20230512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		23916855

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cpix-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:918a0a89-5dad-4ed0-b568-e96d686f2112,g:1ebee0a3-fb1a-41df-91cd-eb248c2cddb5,d:04c341cdfaf14da59111ae7d8142fa3a--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:cpix="http://www.cumberlandpharma.com/20230331" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cpix-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80L2ZyYWc6YzJiODBlOGU4MTQ1NGE1M2FiZmY5Nzk5NzkxOWViNDEvdGFibGU6NDYxMGEyMzA2NWI5NGU4Yjk0ODMwM2M3YTYwN2M1NGUvdGFibGVyYW5nZTo0NjEwYTIzMDY1Yjk0ZThiOTQ4MzAzYzdhNjA3YzU0ZV81LTEtMS0xLTQ1OTA2_e91dbbd5-1772-4069-a4e0-721551a937e4">2023</ix:nonNumeric><ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80L2ZyYWc6YzJiODBlOGU4MTQ1NGE1M2FiZmY5Nzk5NzkxOWViNDEvdGFibGU6NDYxMGEyMzA2NWI5NGU4Yjk0ODMwM2M3YTYwN2M1NGUvdGFibGVyYW5nZTo0NjEwYTIzMDY1Yjk0ZThiOTQ4MzAzYzdhNjA3YzU0ZV82LTEtMS0xLTQ1OTA2_36bc45fc-12a0-4b9c-aab1-1f66cd59c20d">Q1</ix:nonNumeric><ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80L2ZyYWc6YzJiODBlOGU4MTQ1NGE1M2FiZmY5Nzk5NzkxOWViNDEvdGFibGU6NDYxMGEyMzA2NWI5NGU4Yjk0ODMwM2M3YTYwN2M1NGUvdGFibGVyYW5nZTo0NjEwYTIzMDY1Yjk0ZThiOTQ4MzAzYzdhNjA3YzU0ZV83LTEtMS0xLTQ1OTA2_258061ea-699d-496c-ac95-b3c8fa0d8b76">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80L2ZyYWc6YzJiODBlOGU4MTQ1NGE1M2FiZmY5Nzk5NzkxOWViNDEvdGV4dHJlZ2lvbjpjMmI4MGU4ZTgxNDU0YTUzYWJmZjk3OTk3OTE5ZWI0MV83OA_34250378-6ef5-4082-b78a-f6f24b0a7182">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80L2ZyYWc6YzJiODBlOGU4MTQ1NGE1M2FiZmY5Nzk5NzkxOWViNDEvdGV4dHJlZ2lvbjpjMmI4MGU4ZTgxNDU0YTUzYWJmZjk3OTk3OTE5ZWI0MV83OQ_4aa1bcf5-8a18-4e5b-bcfd-0f3411d6ec03">0001087294</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cpix-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27c4c4f9bc9f49feb1b517e2603bb2ba_I20230508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96d025b4c8184275861452edd929096a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3eac396c436f4fae8b8a3e449c851b53_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id21988457a994b099a86739b6cdbca82_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1f4ea962c494b878bb4241ac43c41fa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8ec9abedb8c43f19d55e4f7e45c8eb7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e57b172666d4a2288b8e5fde755512d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8e03fa7b331473ab77acfc2afa51189_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc23b71a673d4599bd2a0ba1407fe4fb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd26126c59e14812b272518a9b7d3f44_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0a37457ed334e9b9592ba8aed5a1663_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i616be1943a9849518944ae4c97161c10_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i744c798ff3df40f18e613495868bac21_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide3cf6fd3f4f4b59bea565cd4bff5a6e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i530b250ef27949bba5fb487444051c84_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf9186d88cd34c189ca611958661dbf7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i253227b0f5924873a6f1b2ff8dcc1d6f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i940da1c588fe4d13ad77dfd49e66aad3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieaa823ff0ab54452af8bbfadfb40cf88_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie061a82abf3d48ddab2142be4e8bf214_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44a1615e590c493a868e0826fbbf8abd_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>cpix:Segment</xbrli:measure></xbrli:unit><xbrli:context id="ic5ec9fd4fee24747aa5425a2da34ca15_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1390383e91148dca5ab8bb6aec95eaa_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifaee959e87604f9b8afd1f3f35e7279f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:SancusoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b5edc8419e647ee824fdb81e180ad31_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:SancusoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica71cbb512a74596b40cd7a2f3f45ac6_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie245a45f71a44cf49e04fb9e7a1b64c0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f492dd29e9e496ab0c32db9bde2fad5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fa8cd8c9bc645fd917139e4733faee9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff66fc78303f42288cd05a0391f52e8d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b303705e50348069ce4d7d41176c589_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7b3c21a06344e6daf54cef8c4bea836_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34fd69d4d0114a3891b1fd1b5cd85e8f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if792fa0d44004e868ffe0fb9dcc009a6_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i877bdcd11bf84e83a844f6f7f0340018_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if834c35329184e12bfc00925eb9c78b3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:RediTrexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89705d4ba770443aa81891ed098d2e82_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:RediTrexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefe426f8f9cf4fadacc86244be87455b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56a471ba8e2a4536a4fee60860c84a40_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if42572ad56a64b2a829bd4df6389654b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2233569d7a744fb9be2b55c9f18e5f65_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c76ad6b0d9d43bea791e5d7ff63409c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if921eb31fa6f45b39876cdd2bde81d95_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b68b7b01134465aa81635021c31c2ee_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:IfetrobanClinicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i939a45f5061a4a48958225d296e46077_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:IfetrobanClinicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f1ce978139642ffa57f5d8efd6a152c_I20211115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i3a8364b46d1349f89526bbca803b9b2b_I20211115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cpix:BroadwestLeaseFiveYearRenewalOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="renewalterm"><xbrli:measure>cpix:renewalTerm</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerSqft"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="iaf2b4c3ed09b49c69ab36803117edced_I20211115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i049b67a4ada841f8a2827489c1ede626_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50b28adc088b4efea984106ab32c61d9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:A1600WestEndAvenuePartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia97aab9d7d684fd486afb0916cc296bb_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:CETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4afbcb5fba4d4a1d8a087e5d9008e5d9_I20100513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2010-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d99bf36d0104e0388920db036eb3ed2_I20160131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b57a58712e74809ae2518a342bbfc8a_D20171101-20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c55618f6c5a49939c91a52e719a9556_D20211227-20211227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-27</xbrli:startDate><xbrli:endDate>2021-12-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i418c071f773e493bbdd32949f539f542_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i013a01798b674990bda32746a63a9bcd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dd89fce4bbe496ab54a639f67e6966d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e8b5ebbe5f54d37acb467699b819d53_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cpix:IncentiveStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63b30cb0dab0416e82e2367680b40f47_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cpix:IncentiveStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffcd93d62bab4e44a26be01fd717844c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:SixthAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ee792037ad24f32a193eaf0a425d5ac_D20220401-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:EightAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8989818d082428f810a0f2d67d1ba2a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:EightAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bf205d89d0f4bbc97a466819e38a259_I20220929"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:NinthAmemdmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="q"><xbrli:measure>utr:Q</xbrli:measure></xbrli:unit><xbrli:context id="ib87aa9b105bd42a19d2435ddfe7a7834_D20200814-20200814"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-14</xbrli:startDate><xbrli:endDate>2020-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47da99f45e0440398ffd975817b2efce_D20200814-20200814"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-14</xbrli:startDate><xbrli:endDate>2020-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8117fb7667394b2f8d51eb672ad660af_D20200814-20200814"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-14</xbrli:startDate><xbrli:endDate>2020-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa9c80f982f947eebf8cfe734dbb223d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17124cadeabb43b783b97a30611b1131_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i314d6baf5bd141d09dc589a0d087077a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i014f95ecf28e47dc9a81e3356a78cbfa_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:WinHealthInvestmentSingaporeLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd2a67aac74043969c46355ae44bb9ff_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:WinHealthInvestmentSingaporeLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90e00eccd5aa49ab87f56422938153e5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i910d1c8e30b447a685124ae92adb5f51_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i499b37cd8cf54392a0f2ec322fe40eee_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idee1724666bd4296b087588595669561_D20161101-20161130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-01</xbrli:startDate><xbrli:endDate>2016-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8321269afd0c421ebdd0224b1a27d392_D20161101-20161130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-01</xbrli:startDate><xbrli:endDate>2016-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47826f88ea0b4a6eb3f2a0fbce1e5c79_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4038ab9268e54e9ea5e0321e85b66082_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55d3542573f24209aee0933490837ee7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90fc46e8567a4446ba6f1f69166c1051_I20220712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:NordicGroupBVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0e8f0a1b5ac44cfa0861149a172d293_I20220712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:NordicGroupBVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20b2ea64a45e4649b835fa2bde154e6d_I20220103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:KyowaKirinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcdddac945434b87b9564d50977a987e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:KyowaKirinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44f4dc27a7c64611b4e00cd930bd4746_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:KyowaKirinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb7fb24ed38f426d9b39670f3390245e_I20220103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:KyowaKirinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9300edb1e774e3ea979ca48d8d32a68_I20220103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:SancusoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id571878b227b429aabb39f702150f09b_D20220103-20220103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:SancusoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i339eef896e214990b9293f54ead2c9f0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:SancusoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34ec3c62de204f83a7f07694bba18e4f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:SancusoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i339bfc5c1c8e48d58f19079fc7a04235_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:SancusoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i04c341cdfaf14da59111ae7d8142fa3a_1"></div><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGV4dHJlZ2lvbjpkODE2OTJiNTAxMDQ0NWEyYjIyZGU5M2Q2ZmVlZjA0ZV8xOTc4_eb280995-c009-44ad-84be-472cdf787274">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGFibGU6MGI3Njc5MDVhY2M3NDk5ZGIzY2NlMzJlNjVhMGViZDcvdGFibGVyYW5nZTowYjc2NzkwNWFjYzc0OTlkYjNjY2UzMmU2NWEwZWJkN18wLTAtMS0xLTQ1OTA2_f7f1cd2c-3205-43a6-894d-0c7373a2c6b5">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGV4dHJlZ2lvbjpkODE2OTJiNTAxMDQ0NWEyYjIyZGU5M2Q2ZmVlZjA0ZV8xMzA_a63e72d7-6d83-41ed-b7aa-3d24b5bd6f27">March 31, 2023</ix:nonNumeric> </span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGFibGU6N2FkZjNlMjRkZWFhNGY5MjhmYWQ2ODY2YjRmMjg4OTAvdGFibGVyYW5nZTo3YWRmM2UyNGRlYWE0ZjkyOGZhZDY4NjZiNGYyODg5MF8wLTAtMS0xLTQ1OTA2_735fe5b7-b0cc-4f3f-940b-88e36f739a3e">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGV4dHJlZ2lvbjpkODE2OTJiNTAxMDQ0NWEyYjIyZGU5M2Q2ZmVlZjA0ZV8xOTc5_f6576d62-11a4-4f54-b6e0-82dd3cbc6db6">001-33637</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGV4dHJlZ2lvbjpkODE2OTJiNTAxMDQ0NWEyYjIyZGU5M2Q2ZmVlZjA0ZV8xOTgw_4cd3f967-5aba-4551-975d-1ae1cd28f842">Cumberland Pharmaceuticals Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified In Its Charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:48.532%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGFibGU6NmIwNTZhOTIyYzUyNGY0NTg2MjYzZjY5MGFiOTdhMjIvdGFibGVyYW5nZTo2YjA1NmE5MjJjNTI0ZjQ1ODYyNjNmNjkwYWI5N2EyMl8wLTAtMS0xLTQ1OTA2_0b940a30-fe8d-4f77-88d1-8497fc426aca">Tennessee</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGFibGU6NmIwNTZhOTIyYzUyNGY0NTg2MjYzZjY5MGFiOTdhMjIvdGFibGVyYW5nZTo2YjA1NmE5MjJjNTI0ZjQ1ODYyNjNmNjkwYWI5N2EyMl8wLTItMS0xLTQ1OTA2_4b710a0f-4c16-48db-8a9e-a874c7733132">62-1765329</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or Other Jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporation or Organization)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGFibGU6NmIwNTZhOTIyYzUyNGY0NTg2MjYzZjY5MGFiOTdhMjIvdGFibGVyYW5nZTo2YjA1NmE5MjJjNTI0ZjQ1ODYyNjNmNjkwYWI5N2EyMl8zLTAtMS0xLTQ1OTA2L3RleHRyZWdpb246ODVjYmU4OTQ3OTBlNGZkOWI4YzUzYWNlNWQ2NWJkOGVfNQ_33ec143c-0001-4c90-ad27-0edf7125ac50">1600 West End Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGFibGU6NmIwNTZhOTIyYzUyNGY0NTg2MjYzZjY5MGFiOTdhMjIvdGFibGVyYW5nZTo2YjA1NmE5MjJjNTI0ZjQ1ODYyNjNmNjkwYWI5N2EyMl8zLTAtMS0xLTQ1OTA2L3RleHRyZWdpb246ODVjYmU4OTQ3OTBlNGZkOWI4YzUzYWNlNWQ2NWJkOGVfOQ_db723715-6376-4734-bf26-e1211ac3cd17">Suite 1300</ix:nonNumeric>,</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGFibGU6NmIwNTZhOTIyYzUyNGY0NTg2MjYzZjY5MGFiOTdhMjIvdGFibGVyYW5nZTo2YjA1NmE5MjJjNTI0ZjQ1ODYyNjNmNjkwYWI5N2EyMl8zLTAtMS0xLTQ1OTA2L3RleHRyZWdpb246ODVjYmU4OTQ3OTBlNGZkOWI4YzUzYWNlNWQ2NWJkOGVfMTM_73865011-75a0-4674-a453-66edbb0fe090">Nashville</ix:nonNumeric>, <ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGFibGU6NmIwNTZhOTIyYzUyNGY0NTg2MjYzZjY5MGFiOTdhMjIvdGFibGVyYW5nZTo2YjA1NmE5MjJjNTI0ZjQ1ODYyNjNmNjkwYWI5N2EyMl8zLTAtMS0xLTQ1OTA2L3RleHRyZWdpb246ODVjYmU4OTQ3OTBlNGZkOWI4YzUzYWNlNWQ2NWJkOGVfMTc_a8ae3e36-64a8-41d5-a754-38efec4ced61">Tennessee</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGFibGU6NmIwNTZhOTIyYzUyNGY0NTg2MjYzZjY5MGFiOTdhMjIvdGFibGVyYW5nZTo2YjA1NmE5MjJjNTI0ZjQ1ODYyNjNmNjkwYWI5N2EyMl8zLTItMS0xLTQ1OTA2_7bb1f5e5-c8df-4de9-bddd-d66ca9e0a55f">37203</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGV4dHJlZ2lvbjpkODE2OTJiNTAxMDQ0NWEyYjIyZGU5M2Q2ZmVlZjA0ZV8xOTc2_dd4ff52a-9bb0-4f1d-bd4e-8d951d4d9b58">615</ix:nonNumeric>) <ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGV4dHJlZ2lvbjpkODE2OTJiNTAxMDQ0NWEyYjIyZGU5M2Q2ZmVlZjA0ZV8xOTc3_4bc63d07-dd48-482d-86c1-4f0ed0b7e261">255-0068</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.269%"><tr><td style="width:1.0%"></td><td style="width:31.774%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.585%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGFibGU6NWJjNTYxZGM4NjNhNGMxYmI5OGJiN2E5ZmQ1M2YxYWMvdGFibGVyYW5nZTo1YmM1NjFkYzg2M2E0YzFiYjk4YmI3YTlmZDUzZjFhY18yLTAtMS0xLTQ1OTA2_669c1c3d-df60-4cad-b95b-501ad4dfeb4d">Common stock, no par value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGFibGU6NWJjNTYxZGM4NjNhNGMxYmI5OGJiN2E5ZmQ1M2YxYWMvdGFibGVyYW5nZTo1YmM1NjFkYzg2M2E0YzFiYjk4YmI3YTlmZDUzZjFhY18yLTItMS0xLTQ1OTA2_dc4d9de5-6041-4b71-b6a5-090e46699ffd">CPIX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGFibGU6NWJjNTYxZGM4NjNhNGMxYmI5OGJiN2E5ZmQ1M2YxYWMvdGFibGVyYW5nZTo1YmM1NjFkYzg2M2E0YzFiYjk4YmI3YTlmZDUzZjFhY18yLTQtMS0xLTQ1OTA2_7a869293-0705-4f7f-b275-449a83a9a2e3">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGV4dHJlZ2lvbjpkODE2OTJiNTAxMDQ0NWEyYjIyZGU5M2Q2ZmVlZjA0ZV8xOTgx_b53a9907-2ce4-4445-84c1-586343aa3574">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGV4dHJlZ2lvbjpkODE2OTJiNTAxMDQ0NWEyYjIyZGU5M2Q2ZmVlZjA0ZV8xOTcx_3570e918-7d27-4a96-b85c-4153695c1a60">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.431%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.923%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.434%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Large&#160;accelerated&#160;filer</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGFibGU6OTc2NDk5ODc1NDQzNDEzMGJkYjQ5NzM1ZGM2YmNlMjAvdGFibGVyYW5nZTo5NzY0OTk4NzU0NDM0MTMwYmRiNDk3MzVkYzZiY2UyMF8xLTAtMS0xLTQ1OTA2_4527e1e6-0d82-4a15-9609-326daa172a0b">Non-accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGFibGU6OTc2NDk5ODc1NDQzNDEzMGJkYjQ5NzM1ZGM2YmNlMjAvdGFibGVyYW5nZTo5NzY0OTk4NzU0NDM0MTMwYmRiNDk3MzVkYzZiY2UyMF8xLTUtMS0xLTQ1OTA2_e38f9779-56ed-435f-9a95-71be5b060999">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Emerging growth company</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGFibGU6OTc2NDk5ODc1NDQzNDEzMGJkYjQ5NzM1ZGM2YmNlMjAvdGFibGVyYW5nZTo5NzY0OTk4NzU0NDM0MTMwYmRiNDk3MzVkYzZiY2UyMF8yLTItMS0xLTQ1OTA2_9f6fe5f6-1705-4e37-b1a7-c883d1d1c208">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to&#160;Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGV4dHJlZ2lvbjpkODE2OTJiNTAxMDQ0NWEyYjIyZGU5M2Q2ZmVlZjA0ZV8xMDk5NTExNjI5NzU4_c90b406b-1099-4403-b521-c9ef7ed66cb5">&#9746;</ix:nonNumeric></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable date: <ix:nonFraction unitRef="shares" contextRef="i27c4c4f9bc9f49feb1b517e2603bb2ba_I20230508" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGV4dHJlZ2lvbjpkODE2OTJiNTAxMDQ0NWEyYjIyZGU5M2Q2ZmVlZjA0ZV8xOTM2_2d088b15-f3cb-43f4-9ad1-509cd36dc7d5">14,449,107</ix:nonFraction> shares of common stock as of May&#160;8, 2023.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:9pt"><span><br/></span></div><div id="i04c341cdfaf14da59111ae7d8142fa3a_7"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:82.331%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.469%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i04c341cdfaf14da59111ae7d8142fa3a_10">PART I &#8211; FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i04c341cdfaf14da59111ae7d8142fa3a_10">1</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;padding-right:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i04c341cdfaf14da59111ae7d8142fa3a_13">Item&#160;1. Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i04c341cdfaf14da59111ae7d8142fa3a_13">1</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i04c341cdfaf14da59111ae7d8142fa3a_16">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i04c341cdfaf14da59111ae7d8142fa3a_16">1</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i04c341cdfaf14da59111ae7d8142fa3a_19">Condensed Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i04c341cdfaf14da59111ae7d8142fa3a_19">2</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i04c341cdfaf14da59111ae7d8142fa3a_22">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i04c341cdfaf14da59111ae7d8142fa3a_22">3</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i04c341cdfaf14da59111ae7d8142fa3a_25">Condensed Consolidated Statements of Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i04c341cdfaf14da59111ae7d8142fa3a_25">3</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i04c341cdfaf14da59111ae7d8142fa3a_28">Notes to the Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i04c341cdfaf14da59111ae7d8142fa3a_28">5</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i04c341cdfaf14da59111ae7d8142fa3a_61">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i04c341cdfaf14da59111ae7d8142fa3a_61">15</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i04c341cdfaf14da59111ae7d8142fa3a_82">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i04c341cdfaf14da59111ae7d8142fa3a_82">28</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i04c341cdfaf14da59111ae7d8142fa3a_85">Item&#160;4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i04c341cdfaf14da59111ae7d8142fa3a_85">28</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i04c341cdfaf14da59111ae7d8142fa3a_88">PART II &#8211; OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i04c341cdfaf14da59111ae7d8142fa3a_88">29</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i04c341cdfaf14da59111ae7d8142fa3a_91">Item&#160;1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i04c341cdfaf14da59111ae7d8142fa3a_91">29</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i04c341cdfaf14da59111ae7d8142fa3a_94">Item&#160;1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i04c341cdfaf14da59111ae7d8142fa3a_94">29</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i04c341cdfaf14da59111ae7d8142fa3a_97">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i04c341cdfaf14da59111ae7d8142fa3a_97">29</a></span></div></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i04c341cdfaf14da59111ae7d8142fa3a_100">Item&#160;6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i04c341cdfaf14da59111ae7d8142fa3a_100">30</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i04c341cdfaf14da59111ae7d8142fa3a_103">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i04c341cdfaf14da59111ae7d8142fa3a_103">31</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i04c341cdfaf14da59111ae7d8142fa3a_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I &#8211; FINANCIAL INFORMATION</span></div><div id="i04c341cdfaf14da59111ae7d8142fa3a_13"></div><div style="-sec-extract:summary;margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. Financial Statements (Unaudited)</span></div><div id="i04c341cdfaf14da59111ae7d8142fa3a_16"></div><div style="-sec-extract:summary;margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:58.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMy0xLTEtMS00NTkwNg_a56c3c10-7ba8-4990-beac-f208dd46079a">16,386,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMy0zLTEtMS00NTkwNg_880a2df1-a79a-431f-a531-e86248d01360">19,757,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfNS0xLTEtMS00NTkwNg_3cf420bb-ebf2-46ef-8361-c8cfc35ff6af">14,529,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="0" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfNS0zLTEtMS00NTkwNg_14324f0d-e24c-4c73-8086-b69dadad8850">13,163,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfNi0xLTEtMS00NTkwNg_5a9a75d0-57f3-4bdc-868b-2b4e8bdcdcab">10,180,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="0" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfNi0zLTEtMS00NTkwNg_dd3af581-6c64-46fe-a41f-29093c94937f">9,863,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfNy0xLTEtMS00NTkwNg_89a417c2-df29-4767-ad9c-48a169861bdf">2,715,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="0" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfNy0zLTEtMS00NTkwNg_dc096af7-11f3-40f9-a4a4-6530440b08de">3,084,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfOC0xLTEtMS00NTkwNg_090d2977-d3f9-41a6-9d10-4bdd580087b0">43,810,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfOC0zLTEtMS00NTkwNg_f8d57035-5185-45c3-8a3a-5f995c532135">45,870,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfOS0xLTEtMS00NTkwNg_dd1d229e-99f8-40fa-8160-7a6bc17a4522">7,534,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="0" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfOS0zLTEtMS00NTkwNg_25de867d-342e-4a2f-81b1-a0460151e24d">7,527,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMTAtMS0xLTEtNDU5MDY_05d7ab5c-ca33-401b-940c-74af713670b4">354,857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMTAtMy0xLTEtNDU5MDY_8005443d-c397-4a28-92f7-e7589b3f953c">284,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMTEtMS0xLTEtNDU5MDY_54ec5223-02f5-47dd-9caf-e1384419821d">29,390,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMTEtMy0xLTEtNDU5MDY_86f2ee84-426b-4299-874e-e7338080b516">30,590,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMTItMS0xLTEtNDU5MDY_de45a86c-64d6-4f6d-9bba-547be00d3f15">914,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="0" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMTItMy0xLTEtNDU5MDY_0037ca50-1824-452c-9f85-347018fbced0">914,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMTMtMS0xLTEtNDU5MDY_fe814e99-2316-4fc7-bc16-8b89207dd3c2">4,919,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMTMtMy0xLTEtNDU5MDY_1fb1f54e-49bc-4d03-acca-49f1251cccb3">5,218,403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMTQtMS0xLTEtNDU5MDY_e8bf450a-3ca7-44c5-aeae-631e7be06fd1">2,545,424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMTQtMy0xLTEtNDU5MDY_07d85e11-ee9a-4bee-8f7e-65e2eeaf639f">2,520,661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMTUtMS0xLTEtNDU5MDY_ae96760f-fa46-4587-85f4-be1d8809a8a3">89,468,635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMTUtMy0xLTEtNDU5MDY_4c6911a8-4aee-4331-b61a-f872ec63c21a">92,925,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMTgtMS0xLTEtNDU5MDY_8f2f2e65-e7c1-4d02-b7a1-a9baecc601b8">11,222,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="0" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMTgtMy0xLTEtNDU5MDY_5c507205-49a3-49ed-978a-41ca85a3f381">10,819,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMTktMS0xLTEtNDU5MDY_625592fc-26c1-4aef-a368-e3f63d6aa880">158,369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMTktMy0xLTEtNDU5MDY_27bceb99-63df-4736-b85f-1937d17866ff">172,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjAtMS0xLTEtNDU5MDY_bf40b15b-ce1c-466f-9a64-0abd251a952e">14,326,712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="0" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjAtMy0xLTEtNDU5MDY_4f54f7b7-a621-423e-8b8b-5eea91210acf">17,587,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjEtMS0xLTEtNDU5MDY_f8711102-a83b-48b5-98e5-bb8254513f61">25,707,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjEtMy0xLTEtNDU5MDY_1414c7b4-f333-4dd7-b2c1-f00e76dbee07">28,579,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving line of credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:LongTermLineOfCredit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjItMS0xLTEtNDU5MDY_f320458a-4117-4286-8880-9f3e4e895174">16,072,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="0" name="us-gaap:LongTermLineOfCredit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjItMy0xLTEtNDU5MDY_ea2b9cd5-fbe7-41a5-a8f1-9084ac8cee58">16,200,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjMtMS0xLTEtNDU5MDY_26722223-5f54-4237-b6cd-cbdb09e88c91">4,549,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjMtMy0xLTEtNDU5MDY_72671995-3378-470a-ab53-704fa0cbdb4b">4,586,301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjQtMS0xLTEtNDU5MDY_0b126fd1-3a4b-4427-8854-e22483ba8c03">7,091,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="0" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjQtMy0xLTEtNDU5MDY_e61de44f-883d-4665-982a-1b8d2b30356e">7,585,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjUtMS0xLTEtNDU5MDY_0c1025f9-51f9-41a3-8847-5247a00835b3">53,420,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjUtMy0xLTEtNDU5MDY_68773356-161b-4fde-8cc3-7951f6a5dfe0">56,951,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjYtMS0xLTEtNDU5MDY_9a5b7527-aa83-4a22-a8fb-3d5d16bcbc81"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjYtMy0xLTEtNDU5MDY_2f959384-b609-4900-9d49-90d50db57e59"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock&#8212;<ix:nonFraction unitRef="usdPerShare" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="INF" name="us-gaap:CommonStockNoParValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjktMC0xLTEtNDU5MDYvdGV4dHJlZ2lvbjoxNGQwNzUwY2MyNWI0YTgzYTYxOTY4MjU2MzZhNjgxOF8xNw_796cdd08-b154-44d2-a010-6a49d7e0e236"><ix:nonFraction unitRef="usdPerShare" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="INF" name="us-gaap:CommonStockNoParValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjktMC0xLTEtNDU5MDYvdGV4dHJlZ2lvbjoxNGQwNzUwY2MyNWI0YTgzYTYxOTY4MjU2MzZhNjgxOF8xNw_9564c557-af45-4f13-9037-324faa01c50a">no</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjktMC0xLTEtNDU5MDYvdGV4dHJlZ2lvbjoxNGQwNzUwY2MyNWI0YTgzYTYxOTY4MjU2MzZhNjgxOF8zMQ_4d6f73ea-b037-4b0d-a91b-e57a0e85507a"><ix:nonFraction unitRef="shares" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjktMC0xLTEtNDU5MDYvdGV4dHJlZ2lvbjoxNGQwNzUwY2MyNWI0YTgzYTYxOTY4MjU2MzZhNjgxOF8zMQ_a668b94f-79d6-4e65-9c94-8d6fb39902ff">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjktMC0xLTEtNDU5MDYvdGV4dHJlZ2lvbjoxNGQwNzUwY2MyNWI0YTgzYTYxOTY4MjU2MzZhNjgxOF81Mw_d566e791-201f-49c3-89a7-1c755233c38b"><ix:nonFraction unitRef="shares" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjktMC0xLTEtNDU5MDYvdGV4dHJlZ2lvbjoxNGQwNzUwY2MyNWI0YTgzYTYxOTY4MjU2MzZhNjgxOF81Mw_dfc5f9d7-cc1b-43bb-aa36-3d08b1ab52c3">14,430,047</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjktMC0xLTEtNDU5MDYvdGV4dHJlZ2lvbjoxNGQwNzUwY2MyNWI0YTgzYTYxOTY4MjU2MzZhNjgxOF82MA_483eb954-9161-423e-a74a-bab28e7d4ec8"><ix:nonFraction unitRef="shares" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjktMC0xLTEtNDU5MDYvdGV4dHJlZ2lvbjoxNGQwNzUwY2MyNWI0YTgzYTYxOTY4MjU2MzZhNjgxOF82MA_5d91b084-7042-44b6-aebd-342378e6f5c6">14,366,316</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March 31, 2023 and December 31, 2022 , respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjktMS0xLTEtNDU5MDY_e7ae363e-91e6-463c-b095-5d663e917342">47,377,168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjktMy0xLTEtNDU5MDY_edc123a8-d798-4e82-8c98-7a72c83604c4">47,474,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings (deficit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMzAtMS0xLTEtNDU5MDY_5c6c6891-8379-47ce-bb55-2cc3d2a848b4">11,016,657</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMzAtMy0xLTEtNDU5MDY_befbf3de-900f-476e-816c-e2b6ada33229">11,208,841</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMzEtMS0xLTEtNDU5MDY_dd2eaed8-17d9-4059-8991-f27b339bed77">36,360,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMzEtMy0xLTEtNDU5MDY_09b26740-a511-4f30-bdb2-0895c0e071b8">36,266,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" sign="-" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMzItMS0xLTEtNDU5MDY_1f7d4575-2615-4621-aa0e-1b1c1034db57">312,024</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="0" sign="-" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMzItMy0xLTEtNDU5MDY_b58bbf7d-a3db-4f6d-a463-bda3633ad109">292,126</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMzMtMS0xLTEtNDU5MDY_4bf829a3-ad2a-4808-9c60-e1bee6c648ad">36,048,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMzMtMy0xLTEtNDU5MDY_65e149c9-e976-41d6-a80b-f7a82e9a0217">35,974,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMzQtMS0xLTEtNDU5MDY_49a0250a-7c78-4957-9718-b5432977dfad">89,468,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMzQtMy0xLTEtNDU5MDY_bec5dc1c-a6b1-4f93-a997-446adb4bebc4">92,925,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i04c341cdfaf14da59111ae7d8142fa3a_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.684%"><tr><td style="width:1.0%"></td><td style="width:64.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.792%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.766%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMi0xLTEtMS00NTkwNg_ebe1a0b1-7037-4e47-bfe1-ba00584cc0c5">9,224,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMi0zLTEtMS00NTkwNg_6bc33ea4-5f60-4aea-a8ff-74ce5216684b">11,175,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfNC0xLTEtMS00NTkwNg_dcfba141-4df3-49e1-8c28-8c41571c6b92">1,250,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfNC0zLTEtMS00NTkwNg_f038a7e5-cee2-4c7c-bceb-4be4289f1929">2,211,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfNS0xLTEtMS00NTkwNg_9ec22f6f-8ae8-472f-8c80-292dfaeeea2f">4,277,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfNS0zLTEtMS00NTkwNg_ae3b5cac-7aa9-4ae4-b66c-4f7e3724e8bb">4,614,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfNi0xLTEtMS00NTkwNg_4d0d22bb-ed3e-488b-be10-4aa83dbebd1a">1,499,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfNi0zLTEtMS00NTkwNg_acc35761-4b12-4c8a-b456-adc388add733">1,745,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfNy0xLTEtMS00NTkwNg_1bc226b2-510a-4559-9280-4bc41151a2e7">2,498,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfNy0zLTEtMS00NTkwNg_1647bfc4-b067-46f4-8bd8-743c5e57371d">2,302,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfOC0xLTEtMS00NTkwNg_03eff909-93b5-4e53-af8a-7f263df133af">1,230,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfOC0zLTEtMS00NTkwNg_a831904f-8ec2-47bc-8afe-3d2c3833ac3c">1,593,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfOS0xLTEtMS00NTkwNg_14028cf5-1a2c-4567-8657-e1f44d8eee8f">10,756,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfOS0zLTEtMS00NTkwNg_1b541a13-8db5-4324-91d2-fcaea3610afc">12,467,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMTAtMS0xLTEtNDU5MDY_bbb3fc65-14b1-4e2b-928c-82d317c1c384">1,531,678</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMTAtMy0xLTEtNDU5MDY_f87e7195-fc3e-471d-a31f-cb556ed5432a">1,291,999</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMTEtMS0xLTEtNDU5MDY_7c6d2cbf-3bb2-480f-8b3a-b8b293285972">50,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMTEtMy0xLTEtNDU5MDY_9cd6d27c-d8af-423a-80bf-190d76b21d86">16,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMTItMS0xLTEtNDU5MDY_aa383fd2-a70a-4fc3-a6a4-1a7249e9117f">1,847,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" name="us-gaap:OtherIncome" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMTItMy0xLTEtNDU5MDY_2746ca63-edb2-4cc2-88b3-77f7030aede5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMTQtMS0xLTEtNDU5MDY_35d29e7f-a457-4ae6-bb32-7152f7424f90">186,353</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMTQtMy0xLTEtNDU5MDY_04624263-e175-468d-87f8-0895016732c7">119,575</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMTUtMS0xLTEtNDU5MDY_806a88c5-4721-4c1b-b846-c8f360aa0332">179,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMTUtMy0xLTEtNDU5MDY_1c13fe6c-d86c-419e-ba92-f7558eb33499">1,395,533</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMTYtMS0xLTEtNDU5MDY_f5ed8099-02d2-4db5-b95c-65edf8e74478">6,938</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMTYtMy0xLTEtNDU5MDY_d99c7b4b-fdb6-4165-a7a3-2a3ab739b6fc">6,900</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMTctMS0xLTEtNDU5MDY_dac7a762-07af-4eef-ad3c-2e4b2904da5d">172,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMTctMy0xLTEtNDU5MDY_42df67d0-8226-42f5-8dd2-a81458216df1">1,402,433</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss at subsidiary attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMjAtMS0xLTEtNDU5MDY_6c485852-ab79-4700-aaf5-61a01f38492c">19,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMjAtMy0xLTEtNDU5MDY_7fbe3dd3-3ebd-4632-afb8-bf4977ff3bbd">17,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMjEtMS0xLTEtNDU5MDY_bbc16342-8d6a-4237-a6cc-6fdee92e670e">192,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMjEtMy0xLTEtNDU5MDY_cb3570f5-137c-4426-bef8-0b65078e1d72">1,385,253</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share attributable to common shareholders</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMjMtMS0xLTEtNDU5MDY_3cbce3fc-3d2c-4285-8c4c-0e3a3cc72279">0.01</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMjMtMy0xLTEtNDU5MDY_d9b20e2c-d02c-4f9e-8a14-f859f9c907d6">0.09</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMjctMS0xLTEtNDU5MDY_ec675850-e82f-4772-a306-134820e9e4f4">0.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMjctMy0xLTEtNDU5MDY_93eeccc2-80ef-4fb2-804a-1111719e8401">0.09</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMzEtMS0xLTEtNDU5MDY_9cb396bd-0c06-4f16-bc03-2b7324b4a7e1">14,359,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMzEtMy0xLTEtNDU5MDY_86597605-03c9-4828-ac13-efebb90a7ea0">14,691,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMzItMS0xLTEtNDU5MDY_920c7810-d3b9-4a1c-b38e-e0e4f535cb90">14,587,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMzItMy0xLTEtNDU5MDY_bcca58ed-032f-4718-a6fa-baf785d59798">14,691,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i04c341cdfaf14da59111ae7d8142fa3a_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMy0xLTEtMS00NTkwNg_abb0169a-acaf-4736-8b2b-c89f2bc77ce3">172,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMy0zLTEtMS00NTkwNg_af524ac1-49ad-4592-aa62-7110a0952c1d">1,402,433</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income (loss) to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfNy0xLTEtMS00NTkwNg_f78909b4-0111-4500-b245-c9524fc80205">1,255,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfNy0zLTEtMS00NTkwNg_8a6f4e78-2053-4e94-a42b-79bc4cc01dd3">1,653,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfOC0xLTEtMS00NTkwNg_595a3f02-b43a-4cd5-b1d6-afa95eeb60bc">90,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfOC0zLTEtMS00NTkwNg_441a1ff3-454f-47e6-bd14-c19e08eba497">159,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in non-cash contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfOS0xLTEtMS00NTkwNg_410cdd8d-39d7-450f-8f67-9a614cec978a">267,637</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfOS0zLTEtMS00NTkwNg_6a7cc043-224f-483b-83ea-2613f32ec6ba">370,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease (increase) in cash surrender value of life insurance policies over premiums paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" name="cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMTAtMS0xLTEtNDU5MDY_7329a324-1dde-4919-9d62-f6eefe9381f0">30,799</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" sign="-" name="cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMTAtMy0xLTEtNDU5MDY_0e24217e-5c60-4f03-8e31-7104b9f11e79">222,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in noncash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMTEtMS0xLTEtNDU5MDY_ca39e02a-2aa1-41fe-9231-cc87c6aee351">4,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMTEtMy0xLTEtNDU5MDY_53da35d6-e1c7-4453-ad40-c66172584403">2,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on receivable of FDA fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" name="us-gaap:InsuredEventGainLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMTMtMS0xLTEtNDU5MDY_abf4484c-a74f-4191-973f-bdf2b998a66b">1,847,065</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" name="us-gaap:InsuredEventGainLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMTMtMy0xLTEtNDU5MDY_c22318b1-1ba3-4ed3-89fb-0385681cffda">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net changes in assets and liabilities affecting operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMTUtMS0xLTEtNDU5MDY_10e3e7aa-6205-4685-8e25-990917d0575e">481,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMTUtMy0xLTEtNDU5MDY_34139708-0440-4f2e-adaf-0a732b3d4278">7,758,089</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMTYtMS0xLTEtNDU5MDY_e8fa922b-562a-478a-8078-2c74f1de708f">323,557</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMTYtMy0xLTEtNDU5MDY_175bdcc5-b357-4f9d-a836-1faaac620987">2,271,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMTctMS0xLTEtNDU5MDY_a101869a-96e2-42e3-918e-b9bb1863fe57">682,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMTctMy0xLTEtNDU5MDY_6cf89de2-f542-4dd2-88ea-9bdc4a1a78fd">239,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMTgtMS0xLTEtNDU5MDY_e1d01de6-0a00-49cc-8aea-7138926931a5">1,105,263</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMTgtMy0xLTEtNDU5MDY_44d60043-c80c-44b5-aeeb-afd36a76bbc2">4,461,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMTktMS0xLTEtNDU5MDY_068b2954-53b2-43e5-be93-64f97ccd8f75">530,872</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMTktMy0xLTEtNDU5MDY_8270cd08-13f7-4257-aad9-3139308ffbc4">371,214</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMjAtMS0xLTEtNDU5MDY_7ce7ead2-6b61-42c2-93f1-ed3ad831ef39">1,418,209</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMjAtMy0xLTEtNDU5MDY_d9169438-d092-4d17-998d-ab1b099c9ee0">150,498</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMjQtMS0xLTEtNDU5MDY_4def164f-57cc-43db-ab54-339a3063d6fa">107,260</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMjQtMy0xLTEtNDU5MDY_392e0ee3-1599-4318-95ce-2a347c176c28">26,986</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for acquisitions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMjgtMS0xLTEtNDU5MDY_3a0367b7-714e-4f96-a857-9d3f7c82555d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMjgtMy0xLTEtNDU5MDY_334ed57b-4b0d-45b8-a1c9-99e40fe32429">13,500,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMjktMS0xLTEtNDU5MDY_39fcbf30-a7b4-4857-ba4e-479f2ad15ec7">67,193</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMjktMy0xLTEtNDU5MDY_2ad82271-8234-4a75-86ab-3513f42ccd70">14,912</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMzAtMS0xLTEtNDU5MDY_28d3c5d0-7a22-4baf-adce-162d3b91f595">174,453</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMzAtMy0xLTEtNDU5MDY_789147fb-228e-4c03-80f9-a96a92f62c9c">13,541,898</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Borrowings on line of credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" name="us-gaap:ProceedsFromRepaymentsOfLinesOfCredit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMzMtMS0xLTEtNDU5MDY_abdd7ff3-ff66-45ed-929b-3e13dfac2f05">8,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" name="us-gaap:ProceedsFromRepaymentsOfLinesOfCredit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMzMtMy0xLTEtNDU5MDY_15079344-6451-4b45-a6cd-c36716b24033">20,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayments on line of credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMzQtMS0xLTEtNDU5MDY_80aaf450-e572-4352-be8f-dbb380f37fc0">8,127,714</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMzQtMy0xLTEtNDU5MDY_d0613347-dd66-4898-8cbd-b620e177d214">15,000,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMzUtMS0xLTEtNDU5MDY_ee880d01-a149-4a93-af9d-021a4bd04a84">1,464,311</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMzUtMy0xLTEtNDU5MDY_b08247c5-f758-4789-ae9e-e6b1e22c9e49">501,505</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMzYtMS0xLTEtNDU5MDY_90be9e48-ae6d-49cd-af33-93ad839113b7">187,117</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMzYtMy0xLTEtNDU5MDY_a82dbfc3-00ae-4d14-990a-a001c59d2b3e">580,130</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMzctMS0xLTEtNDU5MDY_f03086b0-76b5-46db-9778-af5b434d3f68">1,779,142</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMzctMy0xLTEtNDU5MDY_185a5331-0add-427b-925a-c7fd5fc717c8">3,918,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMzgtMS0xLTEtNDU5MDY_b4806f08-d5aa-41ed-9cf6-00f62c02c3da">3,371,804</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMzgtMy0xLTEtNDU5MDY_4bab6ff4-95ea-434e-8421-ffb67a766b47">9,774,031</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMzktMS0xLTEtNDU5MDY_fb9d3654-ed2c-4c6a-b9f3-50e67d9b176b">19,757,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96d025b4c8184275861452edd929096a_I20211231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMzktMy0xLTEtNDU5MDY_cbb5862d-79d8-4df4-9e4d-c3ce560c6d64">27,040,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfNDAtMS0xLTEtNDU5MDY_568d0fcc-b1cb-4c1c-9157-3b68a5fa413a">16,386,166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3eac396c436f4fae8b8a3e449c851b53_I20220331" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfNDAtMy0xLTEtNDU5MDY_f188d91b-7d35-4c41-8bdf-5e2a7c653c95">17,266,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</span></div><div id="i04c341cdfaf14da59111ae7d8142fa3a_25"></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retained earnings (deficit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id21988457a994b099a86739b6cdbca82_I20211231" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOjY4MjMzNDJjOGQ1YTQzYzQ4YzBhOWRjZGJlYjI3ODM5L3RhYmxlcmFuZ2U6NjgyMzM0MmM4ZDVhNDNjNDhjMGE5ZGNkYmViMjc4MzlfMi0xLTEtMS00NTkwNg_24917ba4-d758-41bb-b51a-3b9a62ec48e8">14,742,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id21988457a994b099a86739b6cdbca82_I20211231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOjY4MjMzNDJjOGQ1YTQzYzQ4YzBhOWRjZGJlYjI3ODM5L3RhYmxlcmFuZ2U6NjgyMzM0MmM4ZDVhNDNjNDhjMGE5ZGNkYmViMjc4MzlfMi0zLTEtMS00NTkwNg_4ed5e19c-b02f-4e81-bfd3-651468ac88b8">48,452,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1f4ea962c494b878bb4241ac43c41fa_I20211231" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOjY4MjMzNDJjOGQ1YTQzYzQ4YzBhOWRjZGJlYjI3ODM5L3RhYmxlcmFuZ2U6NjgyMzM0MmM4ZDVhNDNjNDhjMGE5ZGNkYmViMjc4MzlfMi01LTEtMS00NTkwNg_57decc3c-7c20-4e3e-90af-eb9ee14f3898">5,638,600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8ec9abedb8c43f19d55e4f7e45c8eb7_I20211231" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOjY4MjMzNDJjOGQ1YTQzYzQ4YzBhOWRjZGJlYjI3ODM5L3RhYmxlcmFuZ2U6NjgyMzM0MmM4ZDVhNDNjNDhjMGE5ZGNkYmViMjc4MzlfMi03LTEtMS00NTkwNg_d981d84f-0ade-4142-833a-c49b2e6cdd31">212,328</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96d025b4c8184275861452edd929096a_I20211231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOjY4MjMzNDJjOGQ1YTQzYzQ4YzBhOWRjZGJlYjI3ODM5L3RhYmxlcmFuZ2U6NjgyMzM0MmM4ZDVhNDNjNDhjMGE5ZGNkYmViMjc4MzlfMi05LTEtMS00NTkwNg_d39f1229-8639-473a-a756-df300ce0416d">42,601,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e57b172666d4a2288b8e5fde755512d_D20220101-20220331" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOjY4MjMzNDJjOGQ1YTQzYzQ4YzBhOWRjZGJlYjI3ODM5L3RhYmxlcmFuZ2U6NjgyMzM0MmM4ZDVhNDNjNDhjMGE5ZGNkYmViMjc4MzlfMy0xLTEtMS00NTkwNg_463b9ef9-4bb6-4804-b6d7-ed0c43092f8b">162,155</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e57b172666d4a2288b8e5fde755512d_D20220101-20220331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOjY4MjMzNDJjOGQ1YTQzYzQ4YzBhOWRjZGJlYjI3ODM5L3RhYmxlcmFuZ2U6NjgyMzM0MmM4ZDVhNDNjNDhjMGE5ZGNkYmViMjc4MzlfMy0zLTEtMS00NTkwNg_2b33cb74-35c4-4096-8883-41c7131e0b35">159,901</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOjY4MjMzNDJjOGQ1YTQzYzQ4YzBhOWRjZGJlYjI3ODM5L3RhYmxlcmFuZ2U6NjgyMzM0MmM4ZDVhNDNjNDhjMGE5ZGNkYmViMjc4MzlfMy05LTEtMS00NTkwNg_537b05c0-1273-4c91-89e9-32c39646c2d4">159,901</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6e57b172666d4a2288b8e5fde755512d_D20220101-20220331" decimals="0" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOjY4MjMzNDJjOGQ1YTQzYzQ4YzBhOWRjZGJlYjI3ODM5L3RhYmxlcmFuZ2U6NjgyMzM0MmM4ZDVhNDNjNDhjMGE5ZGNkYmViMjc4MzlfNC0xLTEtMS00NTkwNg_4f707b8e-735e-4f3d-80c4-f3928d0e1ab4">174,149</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e57b172666d4a2288b8e5fde755512d_D20220101-20220331" decimals="0" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOjY4MjMzNDJjOGQ1YTQzYzQ4YzBhOWRjZGJlYjI3ODM5L3RhYmxlcmFuZ2U6NjgyMzM0MmM4ZDVhNDNjNDhjMGE5ZGNkYmViMjc4MzlfNC0zLTEtMS00NTkwNg_dff7d4fd-059c-4eaf-9146-45b66e1eccdd">566,043</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOjY4MjMzNDJjOGQ1YTQzYzQ4YzBhOWRjZGJlYjI3ODM5L3RhYmxlcmFuZ2U6NjgyMzM0MmM4ZDVhNDNjNDhjMGE5ZGNkYmViMjc4MzlfNC05LTEtMS00NTkwNg_667c151b-1baf-4082-8ff7-fd0af7023492">566,043</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8e03fa7b331473ab77acfc2afa51189_D20220101-20220331" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOjY4MjMzNDJjOGQ1YTQzYzQ4YzBhOWRjZGJlYjI3ODM5L3RhYmxlcmFuZ2U6NjgyMzM0MmM4ZDVhNDNjNDhjMGE5ZGNkYmViMjc4MzlfNS01LTEtMS00NTkwNg_013d813b-e512-4e2d-bc64-a55de4039299">1,385,253</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc23b71a673d4599bd2a0ba1407fe4fb_D20220101-20220331" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOjY4MjMzNDJjOGQ1YTQzYzQ4YzBhOWRjZGJlYjI3ODM5L3RhYmxlcmFuZ2U6NjgyMzM0MmM4ZDVhNDNjNDhjMGE5ZGNkYmViMjc4MzlfNS03LTEtMS00NTkwNg_25cf2a3c-adf3-4d02-82fc-f5bfe8fe5985">17,180</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOjY4MjMzNDJjOGQ1YTQzYzQ4YzBhOWRjZGJlYjI3ODM5L3RhYmxlcmFuZ2U6NjgyMzM0MmM4ZDVhNDNjNDhjMGE5ZGNkYmViMjc4MzlfNS05LTEtMS00NTkwNg_d4f9bf67-1f95-4685-9d10-3693d4775210">1,402,433</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd26126c59e14812b272518a9b7d3f44_I20220331" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOjY4MjMzNDJjOGQ1YTQzYzQ4YzBhOWRjZGJlYjI3ODM5L3RhYmxlcmFuZ2U6NjgyMzM0MmM4ZDVhNDNjNDhjMGE5ZGNkYmViMjc4MzlfNi0xLTEtMS00NTkwNg_c576c66f-52bd-4b1c-8292-009031d2c272">14,730,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd26126c59e14812b272518a9b7d3f44_I20220331" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOjY4MjMzNDJjOGQ1YTQzYzQ4YzBhOWRjZGJlYjI3ODM5L3RhYmxlcmFuZ2U6NjgyMzM0MmM4ZDVhNDNjNDhjMGE5ZGNkYmViMjc4MzlfNi0zLTEtMS00NTkwNg_0054dbc0-a943-4360-9a8e-d8fcf44fe9a9">48,046,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0a37457ed334e9b9592ba8aed5a1663_I20220331" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOjY4MjMzNDJjOGQ1YTQzYzQ4YzBhOWRjZGJlYjI3ODM5L3RhYmxlcmFuZ2U6NjgyMzM0MmM4ZDVhNDNjNDhjMGE5ZGNkYmViMjc4MzlfNi01LTEtMS00NTkwNg_6344b46c-3bfd-4f5d-86f1-2fba9ad14002">7,023,853</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i616be1943a9849518944ae4c97161c10_I20220331" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOjY4MjMzNDJjOGQ1YTQzYzQ4YzBhOWRjZGJlYjI3ODM5L3RhYmxlcmFuZ2U6NjgyMzM0MmM4ZDVhNDNjNDhjMGE5ZGNkYmViMjc4MzlfNi03LTEtMS00NTkwNg_796a37e4-ba5a-4be1-a6d9-baf34020f321">229,508</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3eac396c436f4fae8b8a3e449c851b53_I20220331" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOjY4MjMzNDJjOGQ1YTQzYzQ4YzBhOWRjZGJlYjI3ODM5L3RhYmxlcmFuZ2U6NjgyMzM0MmM4ZDVhNDNjNDhjMGE5ZGNkYmViMjc4MzlfNi05LTEtMS00NTkwNg_27506859-8138-444b-b166-f38408e680c5">40,793,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retained earnings (deficit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i744c798ff3df40f18e613495868bac21_I20221231" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOmNlZWEzZjhlOWFhYjQ5NjNiYWMzOTFmYzIzN2FiMGVhL3RhYmxlcmFuZ2U6Y2VlYTNmOGU5YWFiNDk2M2JhYzM5MWZjMjM3YWIwZWFfMi0xLTEtMS00NTkwNg_8a399381-78f0-4802-93c0-75ed1656b48f">14,366,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744c798ff3df40f18e613495868bac21_I20221231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOmNlZWEzZjhlOWFhYjQ5NjNiYWMzOTFmYzIzN2FiMGVhL3RhYmxlcmFuZ2U6Y2VlYTNmOGU5YWFiNDk2M2JhYzM5MWZjMjM3YWIwZWFfMi0zLTEtMS00NTkwNg_eb2166bb-0d8f-4bd4-91fb-feec26c0b50f">47,474,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide3cf6fd3f4f4b59bea565cd4bff5a6e_I20221231" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOmNlZWEzZjhlOWFhYjQ5NjNiYWMzOTFmYzIzN2FiMGVhL3RhYmxlcmFuZ2U6Y2VlYTNmOGU5YWFiNDk2M2JhYzM5MWZjMjM3YWIwZWFfMi01LTEtMS00NTkwNg_b0f01dae-7127-4c33-9c5b-31f32cf0d982">11,208,841</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i530b250ef27949bba5fb487444051c84_I20221231" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOmNlZWEzZjhlOWFhYjQ5NjNiYWMzOTFmYzIzN2FiMGVhL3RhYmxlcmFuZ2U6Y2VlYTNmOGU5YWFiNDk2M2JhYzM5MWZjMjM3YWIwZWFfMi03LTEtMS00NTkwNg_7961d971-98fb-470c-b9f3-0972f2123ca0">292,126</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOmNlZWEzZjhlOWFhYjQ5NjNiYWMzOTFmYzIzN2FiMGVhL3RhYmxlcmFuZ2U6Y2VlYTNmOGU5YWFiNDk2M2JhYzM5MWZjMjM3YWIwZWFfMi05LTEtMS00NTkwNg_f9abb5fb-4b78-4b4d-ab70-7a2301ce32bb">35,974,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icf9186d88cd34c189ca611958661dbf7_D20230101-20230331" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOmNlZWEzZjhlOWFhYjQ5NjNiYWMzOTFmYzIzN2FiMGVhL3RhYmxlcmFuZ2U6Y2VlYTNmOGU5YWFiNDk2M2JhYzM5MWZjMjM3YWIwZWFfMy0xLTEtMS00NTkwNg_73115917-b8b2-465f-97f4-491785b9f522">150,260</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf9186d88cd34c189ca611958661dbf7_D20230101-20230331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOmNlZWEzZjhlOWFhYjQ5NjNiYWMzOTFmYzIzN2FiMGVhL3RhYmxlcmFuZ2U6Y2VlYTNmOGU5YWFiNDk2M2JhYzM5MWZjMjM3YWIwZWFfMy0zLTEtMS00NTkwNg_2579e97b-ffbd-43cd-8df7-0f318ca2cf62">90,156</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOmNlZWEzZjhlOWFhYjQ5NjNiYWMzOTFmYzIzN2FiMGVhL3RhYmxlcmFuZ2U6Y2VlYTNmOGU5YWFiNDk2M2JhYzM5MWZjMjM3YWIwZWFfMy05LTEtMS00NTkwNg_9c44c9c3-4125-4615-ae7e-b666cd21cc83">90,156</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="icf9186d88cd34c189ca611958661dbf7_D20230101-20230331" decimals="0" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOmNlZWEzZjhlOWFhYjQ5NjNiYWMzOTFmYzIzN2FiMGVhL3RhYmxlcmFuZ2U6Y2VlYTNmOGU5YWFiNDk2M2JhYzM5MWZjMjM3YWIwZWFfNC0xLTEtMS00NTkwNg_c303cd8d-d3bc-42f0-9f4d-6d5f64a13897">86,829</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf9186d88cd34c189ca611958661dbf7_D20230101-20230331" decimals="0" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOmNlZWEzZjhlOWFhYjQ5NjNiYWMzOTFmYzIzN2FiMGVhL3RhYmxlcmFuZ2U6Y2VlYTNmOGU5YWFiNDk2M2JhYzM5MWZjMjM3YWIwZWFfNC0zLTEtMS00NTkwNg_124e231c-811e-48f0-bd08-06b27f62c1e7">187,961</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOmNlZWEzZjhlOWFhYjQ5NjNiYWMzOTFmYzIzN2FiMGVhL3RhYmxlcmFuZ2U6Y2VlYTNmOGU5YWFiNDk2M2JhYzM5MWZjMjM3YWIwZWFfNC05LTEtMS00NTkwNg_2ec0ca12-46f3-4798-b567-89b385e2eb54">187,961</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i253227b0f5924873a6f1b2ff8dcc1d6f_D20230101-20230331" decimals="0" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOmNlZWEzZjhlOWFhYjQ5NjNiYWMzOTFmYzIzN2FiMGVhL3RhYmxlcmFuZ2U6Y2VlYTNmOGU5YWFiNDk2M2JhYzM5MWZjMjM3YWIwZWFfNS01LTEtMS00NTkwNg_42659e2a-fa5f-41b6-8007-9730ef480435">192,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i940da1c588fe4d13ad77dfd49e66aad3_D20230101-20230331" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOmNlZWEzZjhlOWFhYjQ5NjNiYWMzOTFmYzIzN2FiMGVhL3RhYmxlcmFuZ2U6Y2VlYTNmOGU5YWFiNDk2M2JhYzM5MWZjMjM3YWIwZWFfNS03LTEtMS00NTkwNg_d00eb749-94d0-4e59-b059-181068b4a403">19,898</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOmNlZWEzZjhlOWFhYjQ5NjNiYWMzOTFmYzIzN2FiMGVhL3RhYmxlcmFuZ2U6Y2VlYTNmOGU5YWFiNDk2M2JhYzM5MWZjMjM3YWIwZWFfNS05LTEtMS00NTkwNg_835ce9d5-1287-4c38-8459-2b743455702b">172,286</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieaa823ff0ab54452af8bbfadfb40cf88_I20230331" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOmNlZWEzZjhlOWFhYjQ5NjNiYWMzOTFmYzIzN2FiMGVhL3RhYmxlcmFuZ2U6Y2VlYTNmOGU5YWFiNDk2M2JhYzM5MWZjMjM3YWIwZWFfNi0xLTEtMS00NTkwNg_a2713dab-0984-4de7-a9f1-86ad394a4203">14,430,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaa823ff0ab54452af8bbfadfb40cf88_I20230331" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOmNlZWEzZjhlOWFhYjQ5NjNiYWMzOTFmYzIzN2FiMGVhL3RhYmxlcmFuZ2U6Y2VlYTNmOGU5YWFiNDk2M2JhYzM5MWZjMjM3YWIwZWFfNi0zLTEtMS00NTkwNg_4b600f22-b6bc-4105-b535-cb9706f92c48">47,377,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie061a82abf3d48ddab2142be4e8bf214_I20230331" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOmNlZWEzZjhlOWFhYjQ5NjNiYWMzOTFmYzIzN2FiMGVhL3RhYmxlcmFuZ2U6Y2VlYTNmOGU5YWFiNDk2M2JhYzM5MWZjMjM3YWIwZWFfNi01LTEtMS00NTkwNg_dfbebf09-f6fb-4d50-af75-b442b637a02c">11,016,657</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44a1615e590c493a868e0826fbbf8abd_I20230331" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOmNlZWEzZjhlOWFhYjQ5NjNiYWMzOTFmYzIzN2FiMGVhL3RhYmxlcmFuZ2U6Y2VlYTNmOGU5YWFiNDk2M2JhYzM5MWZjMjM3YWIwZWFfNi03LTEtMS00NTkwNg_32945ab8-fc09-4bf5-9f76-6ed1854c83cf">312,024</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOmNlZWEzZjhlOWFhYjQ5NjNiYWMzOTFmYzIzN2FiMGVhL3RhYmxlcmFuZ2U6Y2VlYTNmOGU5YWFiNDk2M2JhYzM5MWZjMjM3YWIwZWFfNi05LTEtMS00NTkwNg_b056946f-e3f2-4e6f-b7b8-a0962e9aaf7b">36,048,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="30" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i04c341cdfaf14da59111ae7d8142fa3a_28"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="i04c341cdfaf14da59111ae7d8142fa3a_31"></div><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1) <ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zMS9mcmFnOmVkZGY1NGVkYzVhYTRmZWE5ODlkZWViMmNkOTE5MGQ3L3RleHRyZWdpb246ZWRkZjU0ZWRjNWFhNGZlYTk4OWRlZWIyY2Q5MTkwZDdfOTUyOQ_b4c54bbf-b01b-436f-acb4-5316df3eb60f" continuedAt="i04dd4fc438b94f518c780f4ee491fdf3" escape="true">ORGANIZATION AND BASIS OF PRESENTATION</ix:nonNumeric></span></div><ix:continuation id="i04dd4fc438b94f518c780f4ee491fdf3" continuedAt="i9bc2e91829c5404aa94ad0867d3fa760"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription pharmaceutical products.  The Company's primary target markets are hospital acute care, gastroenterology and oncology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be served effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.  The Company promotes its approved products through its hospital, oncology and field sales forces in the United States.  We are continuing to build a network of international partners to register and provide our medicines to patients in their countries.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#8217;s products are manufactured by third parties, which are overseen by Cumberland&#8217;s quality control and manufacturing professionals. The Company works closely with its hospital, field and oncology sales teams and its third-party distribution partners to make its products available in the United States.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the December 31, 2022, audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;), and certain information and disclosures have been condensed or omitted as permitted by the SEC for interim period presentation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2022 (the &#8220;2022 Annual Report on Form 10-K&#8221;). The results of operations for the three months ended March 31, 2023, are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.</span></div><ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zMS9mcmFnOmVkZGY1NGVkYzVhYTRmZWE5ODlkZWViMmNkOTE5MGQ3L3RleHRyZWdpb246ZWRkZjU0ZWRjNWFhNGZlYTk4OWRlZWIyY2Q5MTkwZDdfOTUzMQ_762ee2f5-ff64-4245-b64d-7987cefd6c30" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies are required to use a new forward-looking &#8220;expected loss&#8221; model that generally result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies measure credit losses in a manner similar to what they do today, except that the losses are recognized as allowances rather than as reductions in the amortized cost of the securities. Companies have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies apply the ASU&#8217;s provisions as a cumulative-effect adjustment, if any, to retained earnings (deficit) as of the beginning of the first reporting period in which the guidance is adopted.</span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted both ASU 2016-13 and ASU 2019-05 on January 1, 2023.  Please refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trade and Notes Receivables Policy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><ix:continuation id="i9bc2e91829c5404aa94ad0867d3fa760" continuedAt="ia5f914f911114d3180e437ef2c2e4485"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Policies:</span></div><ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zMS9mcmFnOmVkZGY1NGVkYzVhYTRmZWE5ODlkZWViMmNkOTE5MGQ3L3RleHRyZWdpb246ZWRkZjU0ZWRjNWFhNGZlYTk4OWRlZWIyY2Q5MTkwZDdfOTUyNg_2842a09c-46ee-4e41-a1d6-8b75b770e908" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of contingent consideration liabilities associated with business combinations.</span></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zMS9mcmFnOmVkZGY1NGVkYzVhYTRmZWE5ODlkZWViMmNkOTE5MGQ3L3RleHRyZWdpb246ZWRkZjU0ZWRjNWFhNGZlYTk4OWRlZWIyY2Q5MTkwZDdfOTUyOA_49237524-ac7e-4dd0-a2b4-ea0c58ddc7bc" continuedAt="ie1012bb2ef4c4d7790029b2841860cc4" escape="true">Operating Segments</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie1012bb2ef4c4d7790029b2841860cc4">The Company has <ix:nonFraction unitRef="segment" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zMS9mcmFnOmVkZGY1NGVkYzVhYTRmZWE5ODlkZWViMmNkOTE5MGQ3L3RleHRyZWdpb246ZWRkZjU0ZWRjNWFhNGZlYTk4OWRlZWIyY2Q5MTkwZDdfODcxOQ_20b74a07-f26e-4d09-bbd5-602d2983259d">one</ix:nonFraction> operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.</ix:continuation> </span></div><ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="cpix:TradeAndNoteReceivablesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zMS9mcmFnOmVkZGY1NGVkYzVhYTRmZWE5ODlkZWViMmNkOTE5MGQ3L3RleHRyZWdpb246ZWRkZjU0ZWRjNWFhNGZlYTk4OWRlZWIyY2Q5MTkwZDdfMTA5OTUxMTY1MDgzOQ_b4af2038-4fb2-4af3-8d3d-6ed025b4d588" continuedAt="id1bae9a867614ad2a1b4ab219d6dc4e9" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Trade and Note Receivables Policy</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management performed a scoping exercise to ensure completeness over the application of Current Expected Credit Losses (CECL) across the various financial instruments including trade and note receivables. CECL is applicable to all financial assets measured at amortized cost. The authoritative guidance requires that all financial instruments should be evaluated, including cash equivalents such as 3-month T-Bills, even if the expected loss is determined to be zero, or materially zero.  All bank balances are maintained in cash or money market funds.  Therefore for the Company, this principally relates to trade receivables and two note receivables. CECL also requires the measurement of expected credit losses on a collective (pool) basis when similar risk characteristics exist. This may include, either individually or in combination, some of the following characteristics (326-20-55-5):</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Internal or external credit score/rating</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Risk ratings or classification</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Financial asset type</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Size</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Effective interest rate</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.17pt">Term</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Geographical location</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Historical or expected credit loss patterns</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">Reasonable and supportable forecast periods</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The standard requires entities to pool financial assets but allows them to choose which risk characteristics to use. Under the requirements of the guidance, the Company would need to reassess at the end of each reporting period whether the pool of assets continue to display similar risk characteristics. </span></div></ix:nonNumeric></ix:continuation><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia5f914f911114d3180e437ef2c2e4485"><ix:continuation id="id1bae9a867614ad2a1b4ab219d6dc4e9">With twenty years of experience, Cumberland has experienced virtually no write downs of receivables as most of our receivables are due from large successful pharmaceutical, healthcare or government customers, consistently making payments on account. Although the payment behaviors of all of our customers are consistently reliable, for the sake of transparency, we have separated our customer base into seven separate pools. The Company performs a monthly analysis of aged accounts receivable to determine how much, if any, of the accounts receivable balance should be reserved as potential bad debt. The Company reviews all balances over 90 days past due for a possible reserve and considers any specific factors or information for balances aged under 90 days if there are indicators that the balance should be reserved, such as other aged balances with the customer or bankruptcy as well as any economic issues with a customer industry or region.</ix:continuation></ix:continuation>  The adoption of ASC 326 did not result in a material impact to the company.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i04c341cdfaf14da59111ae7d8142fa3a_34"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2) <ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNC9mcmFnOjZmYTc5OTIzZDg1YTRjNDJhMjJjMWVhZTViZDk3ZmYzL3RleHRyZWdpb246NmZhNzk5MjNkODVhNGM0MmEyMmMxZWFlNWJkOTdmZjNfNDI2_0f74ff20-e483-4260-af92-e496d7d9a180" continuedAt="id802168729c74a49ac6dfeb58733cc52" escape="true">EARNINGS (LOSS) PER SHARE</ix:nonNumeric></span></div><ix:continuation id="id802168729c74a49ac6dfeb58733cc52"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNC9mcmFnOjZmYTc5OTIzZDg1YTRjNDJhMjJjMWVhZTViZDk3ZmYzL3RleHRyZWdpb246NmZhNzk5MjNkODVhNGM0MmEyMmMxZWFlNWJkOTdmZjNfNDI5_75bd5f1f-887d-4e40-8ec0-6840458bed71" continuedAt="i60ee669a120f437c819397d3459b171b" escape="true">The following table reconciles the numerator and denominator used to calculate basic and diluted earnings (loss) per share for the three months ended March 31, 2023 and 2022:</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify"><ix:continuation id="i60ee669a120f437c819397d3459b171b"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNC9mcmFnOjZmYTc5OTIzZDg1YTRjNDJhMjJjMWVhZTViZDk3ZmYzL3RhYmxlOjM5NmUzNjM2NTQwZjQ5ZDFiNjRjNTZkYTM0ZTc5ZmZkL3RhYmxlcmFuZ2U6Mzk2ZTM2MzY1NDBmNDlkMWI2NGM1NmRhMzRlNzlmZmRfNC0xLTEtMS00NTkwNg_dac7a762-07af-4eef-ad3c-2e4b2904da5d">172,286</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNC9mcmFnOjZmYTc5OTIzZDg1YTRjNDJhMjJjMWVhZTViZDk3ZmYzL3RhYmxlOjM5NmUzNjM2NTQwZjQ5ZDFiNjRjNTZkYTM0ZTc5ZmZkL3RhYmxlcmFuZ2U6Mzk2ZTM2MzY1NDBmNDlkMWI2NGM1NmRhMzRlNzlmZmRfNC0zLTEtMS00NTkwNg_42df67d0-8226-42f5-8dd2-a81458216df1">1,402,433</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss at subsidiary attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNC9mcmFnOjZmYTc5OTIzZDg1YTRjNDJhMjJjMWVhZTViZDk3ZmYzL3RhYmxlOjM5NmUzNjM2NTQwZjQ5ZDFiNjRjNTZkYTM0ZTc5ZmZkL3RhYmxlcmFuZ2U6Mzk2ZTM2MzY1NDBmNDlkMWI2NGM1NmRhMzRlNzlmZmRfNy0xLTEtMS00NTkwNg_6c485852-ab79-4700-aaf5-61a01f38492c">19,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNC9mcmFnOjZmYTc5OTIzZDg1YTRjNDJhMjJjMWVhZTViZDk3ZmYzL3RhYmxlOjM5NmUzNjM2NTQwZjQ5ZDFiNjRjNTZkYTM0ZTc5ZmZkL3RhYmxlcmFuZ2U6Mzk2ZTM2MzY1NDBmNDlkMWI2NGM1NmRhMzRlNzlmZmRfNy0zLTEtMS00NTkwNg_7fbe3dd3-3ebd-4632-afb8-bf4977ff3bbd">17,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNC9mcmFnOjZmYTc5OTIzZDg1YTRjNDJhMjJjMWVhZTViZDk3ZmYzL3RhYmxlOjM5NmUzNjM2NTQwZjQ5ZDFiNjRjNTZkYTM0ZTc5ZmZkL3RhYmxlcmFuZ2U6Mzk2ZTM2MzY1NDBmNDlkMWI2NGM1NmRhMzRlNzlmZmRfOC0xLTEtMS00NTkwNg_bbc16342-8d6a-4237-a6cc-6fdee92e670e">192,184</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNC9mcmFnOjZmYTc5OTIzZDg1YTRjNDJhMjJjMWVhZTViZDk3ZmYzL3RhYmxlOjM5NmUzNjM2NTQwZjQ5ZDFiNjRjNTZkYTM0ZTc5ZmZkL3RhYmxlcmFuZ2U6Mzk2ZTM2MzY1NDBmNDlkMWI2NGM1NmRhMzRlNzlmZmRfOC0zLTEtMS00NTkwNg_cb3570f5-137c-4426-bef8-0b65078e1d72">1,385,253</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNC9mcmFnOjZmYTc5OTIzZDg1YTRjNDJhMjJjMWVhZTViZDk3ZmYzL3RhYmxlOjM5NmUzNjM2NTQwZjQ5ZDFiNjRjNTZkYTM0ZTc5ZmZkL3RhYmxlcmFuZ2U6Mzk2ZTM2MzY1NDBmNDlkMWI2NGM1NmRhMzRlNzlmZmRfMTAtMS0xLTEtNDU5MDY_b1d693f6-7c89-4180-b374-831fd2c8dec9">14,359,322</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNC9mcmFnOjZmYTc5OTIzZDg1YTRjNDJhMjJjMWVhZTViZDk3ZmYzL3RhYmxlOjM5NmUzNjM2NTQwZjQ5ZDFiNjRjNTZkYTM0ZTc5ZmZkL3RhYmxlcmFuZ2U6Mzk2ZTM2MzY1NDBmNDlkMWI2NGM1NmRhMzRlNzlmZmRfMTAtMy0xLTEtNDU5MDY_86597605-03c9-4828-ac13-efebb90a7ea0">14,691,623</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNC9mcmFnOjZmYTc5OTIzZDg1YTRjNDJhMjJjMWVhZTViZDk3ZmYzL3RhYmxlOjM5NmUzNjM2NTQwZjQ5ZDFiNjRjNTZkYTM0ZTc5ZmZkL3RhYmxlcmFuZ2U6Mzk2ZTM2MzY1NDBmNDlkMWI2NGM1NmRhMzRlNzlmZmRfMTEtMS0xLTEtNDU5MDY_82d32efb-2022-43ca-92f8-91dcdb8497e1">228,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNC9mcmFnOjZmYTc5OTIzZDg1YTRjNDJhMjJjMWVhZTViZDk3ZmYzL3RhYmxlOjM5NmUzNjM2NTQwZjQ5ZDFiNjRjNTZkYTM0ZTc5ZmZkL3RhYmxlcmFuZ2U6Mzk2ZTM2MzY1NDBmNDlkMWI2NGM1NmRhMzRlNzlmZmRfMTEtMy0xLTEtNDU5MDY_95ab9514-8366-459c-91b7-2073428e7c2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNC9mcmFnOjZmYTc5OTIzZDg1YTRjNDJhMjJjMWVhZTViZDk3ZmYzL3RhYmxlOjM5NmUzNjM2NTQwZjQ5ZDFiNjRjNTZkYTM0ZTc5ZmZkL3RhYmxlcmFuZ2U6Mzk2ZTM2MzY1NDBmNDlkMWI2NGM1NmRhMzRlNzlmZmRfMTItMS0xLTEtNDU5MDY_920c7810-d3b9-4a1c-b38e-e0e4f535cb90">14,587,843</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNC9mcmFnOjZmYTc5OTIzZDg1YTRjNDJhMjJjMWVhZTViZDk3ZmYzL3RhYmxlOjM5NmUzNjM2NTQwZjQ5ZDFiNjRjNTZkYTM0ZTc5ZmZkL3RhYmxlcmFuZ2U6Mzk2ZTM2MzY1NDBmNDlkMWI2NGM1NmRhMzRlNzlmZmRfMTItMy0xLTEtNDU5MDY_bcca58ed-032f-4718-a6fa-baf785d59798">14,691,623</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:58.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.518%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023 and 2022, restricted stock awards and options to purchase <ix:nonFraction unitRef="shares" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNC9mcmFnOjZmYTc5OTIzZDg1YTRjNDJhMjJjMWVhZTViZDk3ZmYzL3RleHRyZWdpb246NmZhNzk5MjNkODVhNGM0MmEyMmMxZWFlNWJkOTdmZjNfMjQ5_2f38b626-ee48-4503-843f-8bd285d6eccf">331,338</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNC9mcmFnOjZmYTc5OTIzZDg1YTRjNDJhMjJjMWVhZTViZDk3ZmYzL3RleHRyZWdpb246NmZhNzk5MjNkODVhNGM0MmEyMmMxZWFlNWJkOTdmZjNfMjU2_85238779-b7e2-4a9c-853b-930cd68d4b7e">131,225</ix:nonFraction> shares of common stock, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect would be antidilutive.</span></div></ix:continuation><div id="i04c341cdfaf14da59111ae7d8142fa3a_37"></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3) <ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RleHRyZWdpb246NTM4MGQzMjg5YjkwNDk3YTk1YmIwNDU5MWU2M2MxNTdfMzI2MQ_af8f61f2-cf59-4cbe-9627-04c39e298ab8" continuedAt="i03986284ddec4527a6431eb55db3c671" escape="true">REVENUES</ix:nonNumeric></span></div><ix:continuation id="i03986284ddec4527a6431eb55db3c671" continuedAt="i76909b6e8d6341d78eca38bb4de62d40"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenues</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018. </span></div><ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RleHRyZWdpb246NTM4MGQzMjg5YjkwNDk3YTk1YmIwNDU5MWU2M2MxNTdfMzI2MA_f4e6b726-c837-48e7-a54e-feaf0cd564f9" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net revenues consisted of the following for the three months ended March 31, 2023 and 2022:</span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.883%"><tr><td style="width:1.0%"></td><td style="width:56.849%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.264%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.195%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5ec9fd4fee24747aa5425a2da34ca15_D20230101-20230331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RhYmxlOmEzYjE2ZThjYjcwMzQxNDI4NjkxMDM1ODQxMzQ2ZDkyL3RhYmxlcmFuZ2U6YTNiMTZlOGNiNzAzNDE0Mjg2OTEwMzU4NDEzNDZkOTJfMy0xLTEtMS00NTkwNg_a4b8f7ab-af32-440c-96bd-2389738a0fc0">4,315,128</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1390383e91148dca5ab8bb6aec95eaa_D20220101-20220331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RhYmxlOmEzYjE2ZThjYjcwMzQxNDI4NjkxMDM1ODQxMzQ2ZDkyL3RhYmxlcmFuZ2U6YTNiMTZlOGNiNzAzNDE0Mjg2OTEwMzU4NDEzNDZkOTJfMy0zLTEtMS00NTkwNg_09b53694-a33e-4b5a-ac98-4b8443137084">3,945,097</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sancuso</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaee959e87604f9b8afd1f3f35e7279f_D20230101-20230331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RhYmxlOmEzYjE2ZThjYjcwMzQxNDI4NjkxMDM1ODQxMzQ2ZDkyL3RhYmxlcmFuZ2U6YTNiMTZlOGNiNzAzNDE0Mjg2OTEwMzU4NDEzNDZkOTJfNC0xLTEtMS00NTkwNg_ea3b6f32-a390-4970-b577-a3749644a280">1,886,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b5edc8419e647ee824fdb81e180ad31_D20220101-20220331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RhYmxlOmEzYjE2ZThjYjcwMzQxNDI4NjkxMDM1ODQxMzQ2ZDkyL3RhYmxlcmFuZ2U6YTNiMTZlOGNiNzAzNDE0Mjg2OTEwMzU4NDEzNDZkOTJfNC0zLTEtMS00NTkwNg_e248cb8a-1752-4026-9f49-4a0d2f4e669e">3,397,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica71cbb512a74596b40cd7a2f3f45ac6_D20230101-20230331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RhYmxlOmEzYjE2ZThjYjcwMzQxNDI4NjkxMDM1ODQxMzQ2ZDkyL3RhYmxlcmFuZ2U6YTNiMTZlOGNiNzAzNDE0Mjg2OTEwMzU4NDEzNDZkOTJfNS0xLTEtMS00NTkwNg_989ee7e1-67de-4a13-9ca8-9ffc8e8acd26">1,848,187</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie245a45f71a44cf49e04fb9e7a1b64c0_D20220101-20220331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RhYmxlOmEzYjE2ZThjYjcwMzQxNDI4NjkxMDM1ODQxMzQ2ZDkyL3RhYmxlcmFuZ2U6YTNiMTZlOGNiNzAzNDE0Mjg2OTEwMzU4NDEzNDZkOTJfNS0zLTEtMS00NTkwNg_111983b1-9a45-4075-a3aa-094a9bc55b29">2,501,434</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f492dd29e9e496ab0c32db9bde2fad5_D20230101-20230331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RhYmxlOmEzYjE2ZThjYjcwMzQxNDI4NjkxMDM1ODQxMzQ2ZDkyL3RhYmxlcmFuZ2U6YTNiMTZlOGNiNzAzNDE0Mjg2OTEwMzU4NDEzNDZkOTJfNi0xLTEtMS00NTkwNg_ce9da458-d5dc-4ddc-ba62-f990a78452e8">935,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fa8cd8c9bc645fd917139e4733faee9_D20220101-20220331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RhYmxlOmEzYjE2ZThjYjcwMzQxNDI4NjkxMDM1ODQxMzQ2ZDkyL3RhYmxlcmFuZ2U6YTNiMTZlOGNiNzAzNDE0Mjg2OTEwMzU4NDEzNDZkOTJfNi0zLTEtMS00NTkwNg_c3a6d18a-22fc-4436-b89f-933732ad4757">959,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff66fc78303f42288cd05a0391f52e8d_D20230101-20230331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RhYmxlOmEzYjE2ZThjYjcwMzQxNDI4NjkxMDM1ODQxMzQ2ZDkyL3RhYmxlcmFuZ2U6YTNiMTZlOGNiNzAzNDE0Mjg2OTEwMzU4NDEzNDZkOTJfNy0xLTEtMS00OTIzMA_3ad15e86-50fa-4ab8-b228-7e9956ee22bf">169,856</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b303705e50348069ce4d7d41176c589_D20220101-20220331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RhYmxlOmEzYjE2ZThjYjcwMzQxNDI4NjkxMDM1ODQxMzQ2ZDkyL3RhYmxlcmFuZ2U6YTNiMTZlOGNiNzAzNDE0Mjg2OTEwMzU4NDEzNDZkOTJfNy0zLTEtMS00OTIzNA_cb2a7742-70e9-4fc9-a0f7-529367fd21de">111,090</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7b3c21a06344e6daf54cef8c4bea836_D20230101-20230331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RhYmxlOmEzYjE2ZThjYjcwMzQxNDI4NjkxMDM1ODQxMzQ2ZDkyL3RhYmxlcmFuZ2U6YTNiMTZlOGNiNzAzNDE0Mjg2OTEwMzU4NDEzNDZkOTJfNy0xLTEtMS00NTkwNg_f8cdd0fa-d5a2-45e6-9672-433e07534db6">16,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34fd69d4d0114a3891b1fd1b5cd85e8f_D20220101-20220331" decimals="0" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RhYmxlOmEzYjE2ZThjYjcwMzQxNDI4NjkxMDM1ODQxMzQ2ZDkyL3RhYmxlcmFuZ2U6YTNiMTZlOGNiNzAzNDE0Mjg2OTEwMzU4NDEzNDZkOTJfNy0zLTEtMS00NTkwNg_a0d263a8-449d-4a4c-99c7-96002783a646">117,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if792fa0d44004e868ffe0fb9dcc009a6_D20230101-20230331" decimals="0" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RhYmxlOmEzYjE2ZThjYjcwMzQxNDI4NjkxMDM1ODQxMzQ2ZDkyL3RhYmxlcmFuZ2U6YTNiMTZlOGNiNzAzNDE0Mjg2OTEwMzU4NDEzNDZkOTJfOS0xLTEtMS00NTkwNg_8b47b794-4725-4ed6-ba6f-476ff384ec82">2,518</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i877bdcd11bf84e83a844f6f7f0340018_D20220101-20220331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RhYmxlOmEzYjE2ZThjYjcwMzQxNDI4NjkxMDM1ODQxMzQ2ZDkyL3RhYmxlcmFuZ2U6YTNiMTZlOGNiNzAzNDE0Mjg2OTEwMzU4NDEzNDZkOTJfOS0zLTEtMS00NTkwNg_29015bfa-743d-489d-810d-7a410baff4e7">22,737</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if834c35329184e12bfc00925eb9c78b3_D20230101-20230331" decimals="0" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RhYmxlOmEzYjE2ZThjYjcwMzQxNDI4NjkxMDM1ODQxMzQ2ZDkyL3RhYmxlcmFuZ2U6YTNiMTZlOGNiNzAzNDE0Mjg2OTEwMzU4NDEzNDZkOTJfMTAtMS0xLTEtNDU5MDY_1d37848c-fd4b-4a2c-92fc-5a43dc168ffb">141,045</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89705d4ba770443aa81891ed098d2e82_D20220101-20220331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RhYmxlOmEzYjE2ZThjYjcwMzQxNDI4NjkxMDM1ODQxMzQ2ZDkyL3RhYmxlcmFuZ2U6YTNiMTZlOGNiNzAzNDE0Mjg2OTEwMzU4NDEzNDZkOTJfMTAtMy0xLTEtNDU5MDY_5467682e-e2d2-4e90-ab12-6e8adcf8c8af">59,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefe426f8f9cf4fadacc86244be87455b_D20230101-20230331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RhYmxlOmEzYjE2ZThjYjcwMzQxNDI4NjkxMDM1ODQxMzQ2ZDkyL3RhYmxlcmFuZ2U6YTNiMTZlOGNiNzAzNDE0Mjg2OTEwMzU4NDEzNDZkOTJfMTEtMS0xLTEtNDU5MDY_f11e78f0-19fc-40a7-980f-f4bf5c006f27">197,186</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a471ba8e2a4536a4fee60860c84a40_D20220101-20220331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RhYmxlOmEzYjE2ZThjYjcwMzQxNDI4NjkxMDM1ODQxMzQ2ZDkyL3RhYmxlcmFuZ2U6YTNiMTZlOGNiNzAzNDE0Mjg2OTEwMzU4NDEzNDZkOTJfMTEtMy0xLTEtNDU5MDY_5c1f36f2-db73-457a-b8c3-0f07c1e02c82">295,618</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RhYmxlOmEzYjE2ZThjYjcwMzQxNDI4NjkxMDM1ODQxMzQ2ZDkyL3RhYmxlcmFuZ2U6YTNiMTZlOGNiNzAzNDE0Mjg2OTEwMzU4NDEzNDZkOTJfMTItMS0xLTEtNDU5MDY_764ba6c2-496a-405f-8e90-86b79f65fb98">9,224,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RhYmxlOmEzYjE2ZThjYjcwMzQxNDI4NjkxMDM1ODQxMzQ2ZDkyL3RhYmxlcmFuZ2U6YTNiMTZlOGNiNzAzNDE0Mjg2OTEwMzU4NDEzNDZkOTJfMTItMy0xLTEtNDU5MDY_c8b6f868-27f2-43d0-82a6-856657219fff">11,175,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Omeclamox-Pak net revenue for the first quarter of 2023 and 2022 was the result of Cumberland currently being out of commercial inventory of this product.  The packager for our Omeclamox-Pak product encountered financial difficulties due to the impact of COVID-19.  They are under new management and are in the process of a reorganization. Discussions with the packager are ongoing.  In the first quarter of 2023, the amounts noted were normal adjustments by channel partners.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With regard to Vaprisol, we are in the process of transitioning to a new manufacturer, who was issued an FDA Form 483 in the second quarter of 2022.  Once these 483 related issues are satisfactorily resolved by the manufacturing plant, we will then resubmit our application to the FDA for approval.  Net revenue was positively impacted by product return adjustments.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Revenues</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with international partners for commercialization of the Company's products with associated payments included in other revenues. Those agreements provide that each of the partners is responsible for seeking regulatory approvals for the product, and following approval, each partner will be responsible for the ongoing distribution and sales in the respective international territories. The Company provides a dossier for product registration and maintains responsibility for the relevant intellectual property. Cumberland is typically entitled to receive a non-refundable, up-front payment at the time each agreement is executed as consideration for the product dossier and for the rights to the distinct intellectual property rights in the respective international territory. These agreements also typically provide for additional payments upon a partner&#8217;s achievement of a defined regulatory approval and sales milestones. The Company may also be entitled to receive royalties on future sales of the products and a transfer price on supplies.  The contractual payments associated with the partner&#8217;s achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.</span></div></ix:continuation><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i76909b6e8d6341d78eca38bb4de62d40">Other revenues also include funding from federal grant programs including those secured from the FDA and from those secured by Cumberland Emerging Technologies Inc. ("CET") through the Small Business Administration as well as lease income generated by CET&#8217;s Life Sciences Center. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from these federal grant  programs totaled approximately $<ix:nonFraction unitRef="usd" contextRef="if42572ad56a64b2a829bd4df6389654b_D20230101-20230331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RleHRyZWdpb246NTM4MGQzMjg5YjkwNDk3YTk1YmIwNDU5MWU2M2MxNTdfMzE3Mw_a9190535-be4b-4279-9a53-7c708756c3dd">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i2233569d7a744fb9be2b55c9f18e5f65_D20220101-20220331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RleHRyZWdpb246NTM4MGQzMjg5YjkwNDk3YTk1YmIwNDU5MWU2M2MxNTdfMzE4MA_bbe0916b-6eb8-474f-91a7-e83d55c613bd">0.04</ix:nonFraction> million for the three months ended March 31, 2023 and 2022, respectively</ix:continuation>.</span></div><div id="i04c341cdfaf14da59111ae7d8142fa3a_40"></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(4) <ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RleHRyZWdpb246Zjk2ZDdkYmQ2ZGQxNDRmODk1M2UzOWYzYTZmNDkzZWFfMjMxMQ_8486ce76-4110-438e-9b5e-2b9a245d92c9" continuedAt="ib1acade6e7694d5a85d14c7533b00381" escape="true">INVENTORIES</ix:nonNumeric></span></div><ix:continuation id="ib1acade6e7694d5a85d14c7533b00381"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company works closely with third parties to manufacture and package finished goods for sale.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the arrangements with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival at the Company&#8217;s warehouses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company then holds such goods in inventory until distribution and sale. These finished goods inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving goods by comparing sales history and projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value.  At March 31, 2023, there were <ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="INF" name="us-gaap:InventoryValuationReserves" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RleHRyZWdpb246Zjk2ZDdkYmQ2ZGQxNDRmODk1M2UzOWYzYTZmNDkzZWFfMTA5OTUxMTYzMTE4Ng_9716c19b-ac7e-46e1-abdf-b3f2658da2b5">no</ix:nonFraction> cumulative obsolescence and discontinuance losses necessary. At December 31, 2022, the Company had recognized and maintained cumulative net realizable value charges for potential obsolescence and discontinuance losses of approximately $<ix:nonFraction unitRef="usd" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="-5" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RleHRyZWdpb246Zjk2ZDdkYmQ2ZGQxNDRmODk1M2UzOWYzYTZmNDkzZWFfMTA0Ng_b8ba1925-79d6-4a59-a3e7-3817ee2e5327">0.5</ix:nonFraction> million.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is responsible for the purchase of the active pharmaceutical ingredient (&#8220;API&#8221;) for Kristalose and maintains the inventory at third-party packagers. As that API is consumed in production, the value of the API is transferred from raw materials to finished goods.  API for the Company's Vaprisol brand is also included in the raw materials inventory at March 31, 2023 and December 31, 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consigned inventory represents Authorized Generic inventory stored with our partner until shipment.   </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Vibativ acquisition, the Company acquired API and work in process inventories of $<ix:nonFraction unitRef="usd" contextRef="i7c76ad6b0d9d43bea791e5d7ff63409c_I20221231" decimals="-5" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RleHRyZWdpb246Zjk2ZDdkYmQ2ZGQxNDRmODk1M2UzOWYzYTZmNDkzZWFfMTYzOQ_5bbde86d-a4d3-4191-880a-fbd45c0aa713">15.6</ix:nonFraction> million that were all initially classified as non-current inventories at the date of acquisition.  At March 31, 2023 and December 31, 2022, total non-current inventory, including Vibativ and our clinical trial drug ifetroban, was $<ix:nonFraction unitRef="usd" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="-5" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RleHRyZWdpb246Zjk2ZDdkYmQ2ZGQxNDRmODk1M2UzOWYzYTZmNDkzZWFfMTk0Mg_1adc7a15-5645-48e6-8671-161044dd6713"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="-5" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RleHRyZWdpb246Zjk2ZDdkYmQ2ZGQxNDRmODk1M2UzOWYzYTZmNDkzZWFfMTk0Mg_414a73c9-9eb8-49a4-93d2-fc627c350be8">7.5</ix:nonFraction></ix:nonFraction> million for each period. The Company had Vibativ finished goods of $<ix:nonFraction unitRef="usd" contextRef="if921eb31fa6f45b39876cdd2bde81d95_I20230331" decimals="0" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RleHRyZWdpb246Zjk2ZDdkYmQ2ZGQxNDRmODk1M2UzOWYzYTZmNDkzZWFfNTQ5NzU1ODE2NDc3_0dfeff50-30ce-4caa-9151-f488b35a3864">0.9</ix:nonFraction> million included in non-current inventory at March 31, 2023, and <ix:nonFraction unitRef="usd" contextRef="i7c76ad6b0d9d43bea791e5d7ff63409c_I20221231" decimals="0" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RleHRyZWdpb246Zjk2ZDdkYmQ2ZGQxNDRmODk1M2UzOWYzYTZmNDkzZWFfMTY0OTI2NzQ0NTQxMg_280aa7cc-c282-4e3f-a3cb-cefe120c764d">no</ix:nonFraction> non-current inventory at December 31, 2022.  The Company also had $<ix:nonFraction unitRef="usd" contextRef="i0b68b7b01134465aa81635021c31c2ee_I20230331" decimals="-5" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RleHRyZWdpb246Zjk2ZDdkYmQ2ZGQxNDRmODk1M2UzOWYzYTZmNDkzZWFfMjEwNA_4117e1cc-abe1-426b-be6e-20999edd1a50">0.3</ix:nonFraction> million in non-current inventory for API related to its ifetroban clinical initiatives at March 31, 2023 and December 31, 2022, and $<ix:nonFraction unitRef="usd" contextRef="i0b68b7b01134465aa81635021c31c2ee_I20230331" decimals="0" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RleHRyZWdpb246Zjk2ZDdkYmQ2ZGQxNDRmODk1M2UzOWYzYTZmNDkzZWFfNTQ5NzU1ODE2NTY4_f330e456-cd33-41b9-a3d6-7e8d2f235ac9">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i939a45f5061a4a48958225d296e46077_I20221231" decimals="0" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RleHRyZWdpb246Zjk2ZDdkYmQ2ZGQxNDRmODk1M2UzOWYzYTZmNDkzZWFfNTQ5NzU1ODE2NTgw_f7f8124d-cbaf-4c94-b470-eb89bf2acf45">0.1</ix:nonFraction> million of finished goods, respectively.</span></div><div style="margin-top:8pt"><ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RleHRyZWdpb246Zjk2ZDdkYmQ2ZGQxNDRmODk1M2UzOWYzYTZmNDkzZWFfMjMxMg_4b5e32d0-7ce1-4dda-b4e9-6e256da9bbb0" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2023 and December 31, 2022, the Company's net inventories consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:57.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RhYmxlOjlmZmI5Y2M3ODY3MDQ5YWZiMDNlZDE2MjYxMTE4ZDUxL3RhYmxlcmFuZ2U6OWZmYjljYzc4NjcwNDlhZmIwM2VkMTYyNjExMThkNTFfMi0yLTEtMS00NTkwNg_d244e1cd-538d-4c39-9290-23bac93ae6e8">12,548,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="0" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RhYmxlOjlmZmI5Y2M3ODY3MDQ5YWZiMDNlZDE2MjYxMTE4ZDUxL3RhYmxlcmFuZ2U6OWZmYjljYzc4NjcwNDlhZmIwM2VkMTYyNjExMThkNTFfMi00LTEtMS00NTkwNg_001aece3-3fec-4820-a944-c9c3ec43593b">12,899,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RhYmxlOjlmZmI5Y2M3ODY3MDQ5YWZiMDNlZDE2MjYxMTE4ZDUxL3RhYmxlcmFuZ2U6OWZmYjljYzc4NjcwNDlhZmIwM2VkMTYyNjExMThkNTFfMy0yLTEtMS00NTkwNg_1495a8e7-4c47-4cad-8067-a7f5058b3071">179,786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="0" name="us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RhYmxlOjlmZmI5Y2M3ODY3MDQ5YWZiMDNlZDE2MjYxMTE4ZDUxL3RhYmxlcmFuZ2U6OWZmYjljYzc4NjcwNDlhZmIwM2VkMTYyNjExMThkNTFfMy00LTEtMS00NTkwNg_b538d69c-d39f-44f8-b8d3-7dfd4dac3f4c">168,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RhYmxlOjlmZmI5Y2M3ODY3MDQ5YWZiMDNlZDE2MjYxMTE4ZDUxL3RhYmxlcmFuZ2U6OWZmYjljYzc4NjcwNDlhZmIwM2VkMTYyNjExMThkNTFfNC0yLTEtMS00NTkwNg_f3ca0144-49ce-47d2-81e8-59342d2235e8">4,985,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="0" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RhYmxlOjlmZmI5Y2M3ODY3MDQ5YWZiMDNlZDE2MjYxMTE4ZDUxL3RhYmxlcmFuZ2U6OWZmYjljYzc4NjcwNDlhZmIwM2VkMTYyNjExMThkNTFfNC00LTEtMS00NTkwNg_7d16ae11-a3ed-448f-83c9-66befeda1722">4,322,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RhYmxlOjlmZmI5Y2M3ODY3MDQ5YWZiMDNlZDE2MjYxMTE4ZDUxL3RhYmxlcmFuZ2U6OWZmYjljYzc4NjcwNDlhZmIwM2VkMTYyNjExMThkNTFfNS0yLTEtMS00NTkwNg_93be856f-2978-4277-af6e-bc996914c1e5">17,714,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="0" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RhYmxlOjlmZmI5Y2M3ODY3MDQ5YWZiMDNlZDE2MjYxMTE4ZDUxL3RhYmxlcmFuZ2U6OWZmYjljYzc4NjcwNDlhZmIwM2VkMTYyNjExMThkNTFfNS00LTEtMS00NTkwNg_5d5500e3-a0de-4421-b618-60136a7c5982">17,390,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RhYmxlOjlmZmI5Y2M3ODY3MDQ5YWZiMDNlZDE2MjYxMTE4ZDUxL3RhYmxlcmFuZ2U6OWZmYjljYzc4NjcwNDlhZmIwM2VkMTYyNjExMThkNTFfNi0yLTEtMS00NTkwNg_64f7c503-45e8-4e4b-bc1f-8a3481d74350">7,534,303</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="0" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RhYmxlOjlmZmI5Y2M3ODY3MDQ5YWZiMDNlZDE2MjYxMTE4ZDUxL3RhYmxlcmFuZ2U6OWZmYjljYzc4NjcwNDlhZmIwM2VkMTYyNjExMThkNTFfNi00LTEtMS00NTkwNg_d285bd5c-85e4-401c-9766-114cdcee0e3f">7,527,167</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RhYmxlOjlmZmI5Y2M3ODY3MDQ5YWZiMDNlZDE2MjYxMTE4ZDUxL3RhYmxlcmFuZ2U6OWZmYjljYzc4NjcwNDlhZmIwM2VkMTYyNjExMThkNTFfNy0yLTEtMS00NTkwNg_da4b3a9f-9392-4bb1-bb82-d11438780d1c">10,180,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="0" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RhYmxlOjlmZmI5Y2M3ODY3MDQ5YWZiMDNlZDE2MjYxMTE4ZDUxL3RhYmxlcmFuZ2U6OWZmYjljYzc4NjcwNDlhZmIwM2VkMTYyNjExMThkNTFfNy00LTEtMS00NTkwNg_389a371d-9817-4257-b6fc-5645ad10c779">9,863,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div id="i04c341cdfaf14da59111ae7d8142fa3a_43"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(5) <ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RleHRyZWdpb246NDY2ZTlhMGExYWIwNGE4YzhkMWIzNDRjMjhiMjcyNjFfMjk4Mw_8271889e-d5aa-4b54-aff5-e4e9c9f4cce2" continuedAt="i41d7e594db6a40f8beea5d9469ffc9eb" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="i41d7e594db6a40f8beea5d9469ffc9eb" continuedAt="i083078684cc7465da5a7b30b973079ce"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 15, 2021, Cumberland entered into a lease, pursuant to which the Company leases approximately <ix:nonFraction unitRef="sqft" contextRef="i4f1ce978139642ffa57f5d8efd6a152c_I20211115" decimals="0" name="cpix:LesseeOperatingLeaseLeasedArea" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RleHRyZWdpb246NDY2ZTlhMGExYWIwNGE4YzhkMWIzNDRjMjhiMjcyNjFfNTQ5NzU1ODE3MTgz_d021e62c-18c6-4dc1-9e07-9a1f2ab651ba">16,903</ix:nonFraction> rentable square feet of space at the new development Broadwest located in Nashville, Tennessee with 1600 West End Avenue Partners, LLC. The Leased Premise serves as the Company's new corporate headquarters. The initial term of the Lease is one hundred fifty-seven (<ix:nonNumeric contextRef="i4f1ce978139642ffa57f5d8efd6a152c_I20211115" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RleHRyZWdpb246NDY2ZTlhMGExYWIwNGE4YzhkMWIzNDRjMjhiMjcyNjFfNTQ5NzU1ODE3NDUy_ad3e66d6-17a5-4b96-a8ae-82452e8a76be">157</ix:nonNumeric>) months, with <ix:nonFraction unitRef="renewalterm" contextRef="i3a8364b46d1349f89526bbca803b9b2b_I20211115" decimals="INF" name="cpix:LesseeOperatingLeaseNumberOfRenewalTerms" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RleHRyZWdpb246NDY2ZTlhMGExYWIwNGE4YzhkMWIzNDRjMjhiMjcyNjFfNTQ5NzU1ODE3NDcw_c2b2dd94-e6ef-41bb-8bf5-3e1654f5ce2e">two</ix:nonFraction> consecutive options to renew for a period of <ix:nonNumeric contextRef="i3a8364b46d1349f89526bbca803b9b2b_I20211115" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RleHRyZWdpb246NDY2ZTlhMGExYWIwNGE4YzhkMWIzNDRjMjhiMjcyNjFfNTQ5NzU1ODE3NTE5_3c370c86-6662-48ed-9fed-bfa7463e184f">five years</ix:nonNumeric> each, with the commencement date of October 25, 2022.  This lease currently expires in November 2035.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is responsible for paying rent to the Landlord under the Lease beginning three months after the commencement date. The Company pays a base rent of $<ix:nonFraction unitRef="usdPerSqft" contextRef="i4f1ce978139642ffa57f5d8efd6a152c_I20211115" decimals="2" name="cpix:LesseeOperatingLeaseBaseRent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RleHRyZWdpb246NDY2ZTlhMGExYWIwNGE4YzhkMWIzNDRjMjhiMjcyNjFfNTQ5NzU1ODE3Nzg0_44424a3f-d8ac-412c-be4c-e2ca3075c7c5">33.06</ix:nonFraction> per square foot of rentable space with a gradual rental rate increase of <ix:nonFraction unitRef="number" contextRef="iaf2b4c3ed09b49c69ab36803117edced_I20211115" decimals="3" name="cpix:LesseeOperatingLeaseRentIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RleHRyZWdpb246NDY2ZTlhMGExYWIwNGE4YzhkMWIzNDRjMjhiMjcyNjFfNTQ5NzU1ODE3ODYx_d6794c16-1f4d-4c08-8929-d27c87f27686">2.5</ix:nonFraction>% for each year period thereafter of the prior year's base rental. In addition to the monthly base rent, the Company is responsible for its percentage share of the operating expenses of the Building. The Lease also provides for a tenant improvement allowance for the space.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company's operating leases also include the lease of approximately <ix:nonFraction unitRef="sqft" contextRef="i049b67a4ada841f8a2827489c1ede626_I20230331" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RleHRyZWdpb246NDY2ZTlhMGExYWIwNGE4YzhkMWIzNDRjMjhiMjcyNjFfMjg5_0c37f554-d94c-4922-9313-3bec9cc733ef">14,200</ix:nonFraction> square feet of wet laboratory and office space in Nashville, Tennessee by CET, our majority-owned subsidiary, where it operates the CET Life Sciences Center.  The research lab space at CET, under an agreement amended in July 2012, is leased through April 2023, with an option to extend the lease through April 2028. The Company also subleases a portion of the space under these leases. </span></div></ix:continuation><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><ix:continuation id="i083078684cc7465da5a7b30b973079ce"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities were recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As the Company&#8217;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019 and October 25, 2022.  Incremental borrowing rates reflect the Company&#8217;s estimated interest rates for collateralized borrowings over similar lease terms.  The weighted-average remaining lease term for the Broadwest lease is <ix:nonNumeric contextRef="i50b28adc088b4efea984106ab32c61d9_I20230331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RleHRyZWdpb246NDY2ZTlhMGExYWIwNGE4YzhkMWIzNDRjMjhiMjcyNjFfNTQ5NzU1ODMwMTAz_2096a5d3-8d5d-4c20-b2a6-cdfab5dd282c">12.62</ix:nonNumeric> years at March 31, 2023.  The weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments is <ix:nonFraction unitRef="number" contextRef="i50b28adc088b4efea984106ab32c61d9_I20230331" decimals="INF" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RleHRyZWdpb246NDY2ZTlhMGExYWIwNGE4YzhkMWIzNDRjMjhiMjcyNjFfNTQ5NzU1ODMwMTIw_87f96d81-fb9a-4a5f-be6c-26a28d61ebb7">9.28</ix:nonFraction>% for the Broadwest lease and <ix:nonFraction unitRef="number" contextRef="ia97aab9d7d684fd486afb0916cc296bb_I20230331" decimals="INF" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RleHRyZWdpb246NDY2ZTlhMGExYWIwNGE4YzhkMWIzNDRjMjhiMjcyNjFfMTIzNw_ff11c69b-3ef8-420a-b464-da9a7b9783d9">7.42</ix:nonFraction>% for the remaining CET lease.  </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease Position</span></div><ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="cpix:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RleHRyZWdpb246NDY2ZTlhMGExYWIwNGE4YzhkMWIzNDRjMjhiMjcyNjFfMjk4NA_652c4b3e-b983-4d0a-8ac0-6a40ae3afd86" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2023 and December 31, 2022, the Company's lease assets and liabilities were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-Use Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RhYmxlOjYyZDg0ODlhMmE3ZjQzNjVhZGQwMTZlOGIxNWM1ZGFiL3RhYmxlcmFuZ2U6NjJkODQ4OWEyYTdmNDM2NWFkZDAxNmU4YjE1YzVkYWJfMS0yLTEtMS00NTkwNg_fe814e99-2316-4fc7-bc16-8b89207dd3c2">4,919,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RhYmxlOjYyZDg0ODlhMmE3ZjQzNjVhZGQwMTZlOGIxNWM1ZGFiL3RhYmxlcmFuZ2U6NjJkODQ4OWEyYTdmNDM2NWFkZDAxNmU4YjE1YzVkYWJfMS00LTEtMS00NTkwNg_1fb1f54e-49bc-4d03-acca-49f1251cccb3">5,218,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RhYmxlOjI0ZGU5YWE2MmExZjQzZmE4Mjg1YWY0NmZkYTcxMTRiL3RhYmxlcmFuZ2U6MjRkZTlhYTYyYTFmNDNmYTgyODVhZjQ2ZmRhNzExNGJfMS0yLTEtMS00NTkwNg_625592fc-26c1-4aef-a368-e3f63d6aa880">158,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RhYmxlOjI0ZGU5YWE2MmExZjQzZmE4Mjg1YWY0NmZkYTcxMTRiL3RhYmxlcmFuZ2U6MjRkZTlhYTYyYTFmNDNmYTgyODVhZjQ2ZmRhNzExNGJfMS00LTEtMS00NTkwNg_27bceb99-63df-4736-b85f-1937d17866ff">172,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RhYmxlOjI0ZGU5YWE2MmExZjQzZmE4Mjg1YWY0NmZkYTcxMTRiL3RhYmxlcmFuZ2U6MjRkZTlhYTYyYTFmNDNmYTgyODVhZjQ2ZmRhNzExNGJfMy0yLTEtMS00NTkwNg_26722223-5f54-4237-b6cd-cbdb09e88c91">4,549,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RhYmxlOjI0ZGU5YWE2MmExZjQzZmE4Mjg1YWY0NmZkYTcxMTRiL3RhYmxlcmFuZ2U6MjRkZTlhYTYyYTFmNDNmYTgyODVhZjQ2ZmRhNzExNGJfMy00LTEtMS00NTkwNg_72671995-3378-470a-ab53-704fa0cbdb4b">4,586,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="cpix:LeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RhYmxlOjI0ZGU5YWE2MmExZjQzZmE4Mjg1YWY0NmZkYTcxMTRiL3RhYmxlcmFuZ2U6MjRkZTlhYTYyYTFmNDNmYTgyODVhZjQ2ZmRhNzExNGJfNC0yLTEtMS00NTkwNg_342d7b11-a3c7-47a5-9b15-04119a326b35">4,707,519</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="0" name="cpix:LeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RhYmxlOjI0ZGU5YWE2MmExZjQzZmE4Mjg1YWY0NmZkYTcxMTRiL3RhYmxlcmFuZ2U6MjRkZTlhYTYyYTFmNDNmYTgyODVhZjQ2ZmRhNzExNGJfNC00LTEtMS00NTkwNg_7b3e01f2-5e2a-4719-b425-5b660f2c72a9">4,759,211</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, cumulative future minimum sublease income under non-cancelable operating subleases totals approximately $<ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="-4" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RleHRyZWdpb246NDY2ZTlhMGExYWIwNGE4YzhkMWIzNDRjMjhiMjcyNjFfMjQ3Mw_1ad1c4ac-77b6-4bfd-972a-61fe72840d5e">0.03</ix:nonFraction> million and will be paid through the leases ending in April 2023. <ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RleHRyZWdpb246NDY2ZTlhMGExYWIwNGE4YzhkMWIzNDRjMjhiMjcyNjFfMjk4NQ_13dfa298-e87d-4f83-bcd7-7bfeb4dc94ba" continuedAt="i18c9fa1784114e5bbba07e00adb7c38c" escape="true">Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:</ix:nonNumeric></span></div><div><ix:continuation id="i18c9fa1784114e5bbba07e00adb7c38c"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.554%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of Lease Liabilities at March 31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RhYmxlOjhkMjE0YzIzMGY0NDQ5NGRhYmVhMGMxODIyOWZmZDk4L3RhYmxlcmFuZ2U6OGQyMTRjMjMwZjQ0NDk0ZGFiZWEwYzE4MjI5ZmZkOThfMS0yLTEtMS00ODAzNg_5c4f2d8a-6895-4866-90f9-084f8fa65aa0">587,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RhYmxlOjhkMjE0YzIzMGY0NDQ5NGRhYmVhMGMxODIyOWZmZDk4L3RhYmxlcmFuZ2U6OGQyMTRjMjMwZjQ0NDk0ZGFiZWEwYzE4MjI5ZmZkOThfMi0yLTEtMS00ODAzNg_b461ba31-4e29-4d6a-86cf-f63a6580ad17">578,759</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RhYmxlOjhkMjE0YzIzMGY0NDQ5NGRhYmVhMGMxODIyOWZmZDk4L3RhYmxlcmFuZ2U6OGQyMTRjMjMwZjQ0NDk0ZGFiZWEwYzE4MjI5ZmZkOThfMy0yLTEtMS00ODAzNg_011276fb-b9f6-4b3b-8402-67c2a2fbdd5d">543,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RhYmxlOjhkMjE0YzIzMGY0NDQ5NGRhYmVhMGMxODIyOWZmZDk4L3RhYmxlcmFuZ2U6OGQyMTRjMjMwZjQ0NDk0ZGFiZWEwYzE4MjI5ZmZkOThfMS0yLTEtMS00NTkwNg_de52644f-7835-4603-9971-6d6139e89a84">608,015</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RhYmxlOjhkMjE0YzIzMGY0NDQ5NGRhYmVhMGMxODIyOWZmZDk4L3RhYmxlcmFuZ2U6OGQyMTRjMjMwZjQ0NDk0ZGFiZWEwYzE4MjI5ZmZkOThfMi0yLTEtMS00NTkwNg_9e20af19-7af2-4509-a860-b648b952f9eb">623,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RhYmxlOjhkMjE0YzIzMGY0NDQ5NGRhYmVhMGMxODIyOWZmZDk4L3RhYmxlcmFuZ2U6OGQyMTRjMjMwZjQ0NDk0ZGFiZWEwYzE4MjI5ZmZkOThfNi0yLTEtMS00ODAzNg_0d1f0946-2e3d-4c47-bf15-3f278b817b94">5,324,178</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RhYmxlOjhkMjE0YzIzMGY0NDQ5NGRhYmVhMGMxODIyOWZmZDk4L3RhYmxlcmFuZ2U6OGQyMTRjMjMwZjQ0NDk0ZGFiZWEwYzE4MjI5ZmZkOThfMy0yLTEtMS00NTkwNg_adefbaaa-aece-47c4-9a1f-fd0a19a41440">8,264,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RhYmxlOjhkMjE0YzIzMGY0NDQ5NGRhYmVhMGMxODIyOWZmZDk4L3RhYmxlcmFuZ2U6OGQyMTRjMjMwZjQ0NDk0ZGFiZWEwYzE4MjI5ZmZkOThfNC0yLTEtMS00NTkwNg_fcc103e2-7e9a-46db-a0d0-9937c14ab741">3,557,166</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RhYmxlOjhkMjE0YzIzMGY0NDQ5NGRhYmVhMGMxODIyOWZmZDk4L3RhYmxlcmFuZ2U6OGQyMTRjMjMwZjQ0NDk0ZGFiZWEwYzE4MjI5ZmZkOThfNS0yLTEtMS00NTkwNg_44ed131a-90b9-4ddb-96d3-f87e67df16bb">4,707,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense is recognized over the expected term of the lease, including renewal option periods, if applicable, on a straight-line basis as a component of general and administrative expense. <ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="cpix:ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RleHRyZWdpb246NDY2ZTlhMGExYWIwNGE4YzhkMWIzNDRjMjhiMjcyNjFfMjk4Mg_3d7a1101-f9b5-479b-b9fe-b2866787f829" continuedAt="i43ff62e1073b48b494bcfc77e117de60" escape="true">Rent expense and sublease income were as follows:</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><ix:continuation id="i43ff62e1073b48b494bcfc77e117de60"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RhYmxlOmZmYzE1ZjU3NzlmMzRkNjJiN2IzOGRlMDRkNzJkMjY5L3RhYmxlcmFuZ2U6ZmZjMTVmNTc3OWYzNGQ2MmI3YjM4ZGUwNGQ3MmQyNjlfMi0yLTEtMS00NTkwNg_7e307118-b835-4da6-8041-d84297356e1e">234,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RhYmxlOmZmYzE1ZjU3NzlmMzRkNjJiN2IzOGRlMDRkNzJkMjY5L3RhYmxlcmFuZ2U6ZmZjMTVmNTc3OWYzNGQ2MmI3YjM4ZGUwNGQ3MmQyNjlfMi00LTEtMS00NTkwNg_8ecc0cbe-81f5-4e2e-948e-02cf7494cb39">285,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="0" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RhYmxlOmZmYzE1ZjU3NzlmMzRkNjJiN2IzOGRlMDRkNzJkMjY5L3RhYmxlcmFuZ2U6ZmZjMTVmNTc3OWYzNGQ2MmI3YjM4ZGUwNGQ3MmQyNjlfNC0yLTEtMS00NTkwNg_1904dc81-5cd7-4d5c-8c3f-a16df0a00fcb">115,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331" decimals="0" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RhYmxlOmZmYzE1ZjU3NzlmMzRkNjJiN2IzOGRlMDRkNzJkMjY5L3RhYmxlcmFuZ2U6ZmZjMTVmNTc3OWYzNGQ2MmI3YjM4ZGUwNGQ3MmQyNjlfNC00LTEtMS00NTkwNg_ec8f0de9-5e52-4778-bfac-ca766b9aaa21">161,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div id="i04c341cdfaf14da59111ae7d8142fa3a_46"></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(6) <ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfNjU1Mg_960ed3e8-142c-4c24-b568-fdbacc3612ed" continuedAt="i81f5bcca5414441aa37e195bbc2ac2a1" escape="true">SHAREHOLDERS&#8217; EQUITY AND DEBT</ix:nonNumeric></span></div><ix:continuation id="i81f5bcca5414441aa37e195bbc2ac2a1" continuedAt="ibd5edca950b34b009e58d86b31d4305e"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share repurchases</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland currently has a share repurchase program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i4afbcb5fba4d4a1d8a087e5d9008e5d9_I20100513" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfMTMw_6360c4bd-9252-466b-844f-0ea053cccce8">10</ix:nonFraction> million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. In January 2019, the Company's Board of Directors established the current $<ix:nonFraction unitRef="usd" contextRef="i7d99bf36d0104e0388920db036eb3ed2_I20160131" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfMjkx_20d2a2e8-7240-4bb3-bc9f-d99c6c0c756b">10</ix:nonFraction> million repurchase program to replace the prior authorizations.  During the three months ended March 31, 2023 and March 31, 2022, the Company repurchased <ix:nonFraction unitRef="shares" contextRef="icf9186d88cd34c189ca611958661dbf7_D20230101-20230331" decimals="0" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfMzk3_8f22d20f-b4e9-464a-aa47-931ad1a83efc">86,829</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i6e57b172666d4a2288b8e5fde755512d_D20220101-20220331" decimals="0" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfNDEx_781aa853-665f-4488-aa27-ec67f74223e2">174,149</ix:nonFraction> shares of common stock for approximately $<ix:nonFraction unitRef="usd" contextRef="icf9186d88cd34c189ca611958661dbf7_D20230101-20230331" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfNDU1_8126f23c-dab0-44c9-80a6-4714e1fb10c1">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6e57b172666d4a2288b8e5fde755512d_D20220101-20220331" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfNDYy_7bccb21c-fa32-401d-9435-1f3ce8b0a262">0.6</ix:nonFraction> million, respectively.  At March 31, 2023, approximately $<ix:nonFraction unitRef="usd" contextRef="ieaa823ff0ab54452af8bbfadfb40cf88_I20230331" decimals="0" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfNTAy_572d7316-a17c-4881-9371-45e3104cb0f4">3.6</ix:nonFraction> million of common shares was left to repurchase under this program.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share purchases and sales</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Company's May 2023 trading window, several members of Cumberland's Board of Directors will enter into share purchase agreements of the Company's stock pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934. These purchases are designed to increase ownership in the Company by the members of the Board.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Sales</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, Cumberland filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to $<ix:nonFraction unitRef="usd" contextRef="i4b57a58712e74809ae2518a342bbfc8a_D20171101-20171130" decimals="-6" name="cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfMTE1NQ_9855b1b6-fa39-493b-9060-6580bb20177b">100</ix:nonFraction> million in corporate securities. The Shelf Registration was declared effective in January 2018. It also included an At the Market ("ATM") feature that allowed the Company to sell common shares at market prices, along with an agreement with B. Riley FBR Inc. to support such a placement of shares. The Company filed an updated Form S-3 with the SEC in December 2020, which was declared effective in January 2021.  On December 27, 2021, the Company filed a related prospectus supplement in connection with the sale and issuance of shares having an aggregate gross sales price of up to $<ix:nonFraction unitRef="usd" contextRef="i1c55618f6c5a49939c91a52e719a9556_D20211227-20211227" decimals="-6" name="cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfMTczMw_b914d49b-36e4-442a-bb20-73be3c5339a6">19</ix:nonFraction> million.  The Company intends to continue an ATM feature through B. Riley FBR, Inc. that would allow the Company to issue shares of its common stock. The Company did not issue any shares under an ATM during the three months ended March 31, 2023 or March 31, 2022.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Share Grants and Incentive Stock Options</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023 and March 31, 2022, the Company issued <ix:nonFraction unitRef="shares" contextRef="i418c071f773e493bbdd32949f539f542_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfMjA0Mg_7a78c78e-dac3-433e-b217-dffe109a28c9">28,250</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i013a01798b674990bda32746a63a9bcd_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfMjA1Ng_268d6065-692d-4389-b93b-11ea281f97c2">65,225</ix:nonFraction> shares of restricted stock to employees, advisors and directors, respectively. Restricted stock issued to employees and advisors generally cliff-vests on the fourth anniversary of the date of grant and for directors on the <ix:nonNumeric contextRef="i3dd89fce4bbe496ab54a639f67e6966d_D20230101-20230331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfNjU1MQ_6263aa08-e990-491c-8fc2-0b1f38613735">one-year</ix:nonNumeric> anniversary of the date of grant.  During the three months ended March 31, 2023 and 2022, the Company also issued <ix:nonFraction unitRef="shares" contextRef="i4e8b5ebbe5f54d37acb467699b819d53_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfMjM3MQ_bae6d6b4-72d4-4b41-a96b-7eee617efc15">183,250</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i63b30cb0dab0416e82e2367680b40f47_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfMjM3OA_0cae8b9a-4885-4124-9f83-0683c56ad9b3">166,350</ix:nonFraction> incentive stock options, respectively, to employees that cliff-vest on the fourth anniversary of the date of grant, that are set to expire in 2033 and 2032, respectively. Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations.  For the three months ended March 31, 2023, we recorded a credit of $<ix:nonFraction unitRef="usd" contextRef="i418c071f773e493bbdd32949f539f542_D20230101-20230331" decimals="-4" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfMjczOA_aedd9cb4-370b-417b-91e1-231a377da2d2">0.04</ix:nonFraction>&#160;million to share-based compensation related to the forfeiture of unvested restricted stock awards.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Agreement</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2021, the Company entered into a Fifth Amendment to the Revolving Credit Note and Sixth Amendment (the "Sixth Amendment") to Revolving Credit Loan Agreement with Pinnacle Bank (the "Pinnacle Agreement"). The Sixth Amendment increased the principal amount by $<ix:nonFraction unitRef="usd" contextRef="iffcd93d62bab4e44a26be01fd717844c_I20211231" decimals="-6" name="cpix:LineOfCreditFacilityAdditionalBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfNTQ5NzU1ODIyNDQ5_d0807d08-3279-49f2-95e9-a09a170bf5f6">5</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="iffcd93d62bab4e44a26be01fd717844c_I20211231" decimals="-6" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfNTQ5NzU1ODIyMzk3_072026e6-ce51-41b8-a54e-d4317711c925">20</ix:nonFraction> million. On October 28, 2021, the Company entered into a Fourth Amendment to the Revolving Credit Note and Fifth Amendment to Revolving Credit Loan Agreement with Pinnacle Bank. Among other terms, the Fourth Amendment extended the maturity date to October 1, 2024.  The Pinnacle Agreement includes specific financial covenants.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the Company and Pinnacle Bank agreed to modify the financial covenants to align with the current use of the line of credit.  On March 31, 2022, the Company and Pinnacle Bank entered into a Seventh Amendment to the Revolving Credit Loan Agreement to revise and update the Maximum Funded Debt Ratio financial covenant and to delete from the Pinnacle Agreement the Funded Debt to Tangible Capital Ratio financial covenant. These changes were made to more appropriately reflect the impact from the Sancuso acquisition. On June 30, 2022, the Company entered into the Eighth Amendment to the Revolving Credit Loan Agreement with Pinnacle Bank permitting the Maximum Funded Debt Ratio to be calculated on a rolling four-quarter basis to be no more than <ix:nonFraction unitRef="number" contextRef="i0ee792037ad24f32a193eaf0a425d5ac_D20220401-20220930" decimals="0" name="cpix:DebtInstrumentCovenantFundedDebtRatioMaximum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfMTA5OTUxMTY0MDY4Nw_f5d45ca5-a473-4e09-b2c4-1fb8524db413">3.00</ix:nonFraction> to 1.00 for the second and third quarters of 2022 and <ix:nonFraction unitRef="number" contextRef="id8989818d082428f810a0f2d67d1ba2a_D20220101-20221231" decimals="2" name="cpix:DebtInstrumentCovenantFundedDebtRatioMaximum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfMTA5OTUxMTY0MDY5OQ_a6acafb5-616b-4402-ba25-642fb11dbcb8">2.50</ix:nonFraction> to 1.00 for each quarter thereafter.   On September 29, 2022, the Company entered into the Ninth Amendment to the Revolving Credit Loan Agreement with Pinnacle Bank (as amended, the "Pinnacle Agreement") to update the Funded Debt Ratio to mean the ratio of (i) Funded Debt less the amount of Unrestricted Cash in excess of $<ix:nonFraction unitRef="usd" contextRef="i7bf205d89d0f4bbc97a466819e38a259_I20220929" decimals="0" name="cpix:DebtInstrumentCovenantUnrestrictedCashThreshold" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfMzEzMQ_4e0e615b-2c2a-4edd-85ec-536a2daedc25">8,500,000</ix:nonFraction>, to (ii) EBITDA, as determined at the end of each fiscal quarter on a rolling four (<ix:nonFraction unitRef="q" contextRef="i7bf205d89d0f4bbc97a466819e38a259_I20220929" decimals="0" name="cpix:DebtInstrumentCovenantEvaluationFrequency" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfMzIxOA_092e4f5c-0842-49b7-b119-72466f0e6ebe">4</ix:nonFraction>) quarter basis.  For the quarter ended March 31, 2023, we were in compliance with the Funded Debt Ratio financial covenant.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><ix:continuation id="ibd5edca950b34b009e58d86b31d4305e" continuedAt="ifb61ebd0f87a47df9aeb1fa5ed025a18"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. The current pricing under the Pinnacle Agreement provides for an interest rate spread of <ix:nonFraction unitRef="number" contextRef="ib87aa9b105bd42a19d2435ddfe7a7834_D20200814-20200814" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfNTA0Mg_73314cd3-2abe-4722-95d3-71b1729f4691">1.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i47da99f45e0440398ffd975817b2efce_D20200814-20200814" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfNTA0OA_c6aeb981-c29e-4325-b784-660b787f40e0">2.75</ix:nonFraction>% above LIBOR with a minimum LIBOR of <ix:nonFraction unitRef="number" contextRef="i8117fb7667394b2f8d51eb672ad660af_D20200814-20200814" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfNTA4Nw_0334973d-957d-44ae-82f9-89c8cd535803">0.90</ix:nonFraction>%. The applicable interest rate under the Pinnacle Agreement was <ix:nonFraction unitRef="number" contextRef="ifa9c80f982f947eebf8cfe734dbb223d_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfNTE1Mw_f3dc0a45-6b1b-4153-ae1e-30d7e505fe2c">7.375</ix:nonFraction>% at March 31, 2023.  In addition, a fee of <ix:nonFraction unitRef="number" contextRef="i17124cadeabb43b783b97a30611b1131_D20230101-20230331" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfNTE4Ng_c7a8eee2-3b42-48de-a6ef-67d719b9724a">0.25</ix:nonFraction>% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  The LIBOR rate will no longer be used as of June 30, 2023, at which time the benchmark rate will be changed from LIBOR to Term SOFR.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023 and December 31, 2022, the Company had $<ix:nonFraction unitRef="usd" contextRef="i314d6baf5bd141d09dc589a0d087077a_I20230331" decimals="-5" name="us-gaap:LongTermLineOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfNTUwNQ_8ff6ca57-e06d-4f0e-85be-c733125db3fb">16.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231" decimals="0" name="us-gaap:LongTermLineOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfNTUxMg_ea2b9cd5-fbe7-41a5-a8f1-9084ac8cee58">16.2</ix:nonFraction> million, respectively, in borrowings outstanding under its revolving credit facility.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the line of credit are collateralized by substantially all of our assets.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joint Venture Agreement</span></div></ix:continuation><div style="margin-top:8pt;text-align:justify"><ix:continuation id="ifb61ebd0f87a47df9aeb1fa5ed025a18" continuedAt="icf9f0dec0c2942889934c11bd171975a"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, Cumberland entered into an agreement with WinHealth Investment (Singapore) Ltd creating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">WHC Biopharmaceuticals, Pte. Ltd</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="icf9f0dec0c2942889934c11bd171975a">. The joint venture, as a limited liability company, will focus on acquiring, developing, registering, and commercializing development stage and commercial stage biopharmaceuticals for China, Hong Kong and other Asian markets.  The agreement provides for initial investment from WinHealth in the form of a $<ix:nonFraction unitRef="usd" contextRef="i014f95ecf28e47dc9a81e3356a78cbfa_I20200831" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfNjE1Mg_ba99d4c2-a890-49c7-857d-b226048e1b53">0.2</ix:nonFraction>&#160;million equity contribution and an initial investment from Cumberland in the form of a $<ix:nonFraction unitRef="usd" contextRef="idd2a67aac74043969c46355ae44bb9ff_I20200831" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfNjIzNA_3ea8b28e-3f8a-49a6-bfa5-0dd7db3eeb6a">0.2</ix:nonFraction>&#160;million convertible note, which was funded during the first quarter of 2021. The joint venture will seek additional future capital from additional investors and has entered into exclusive option agreements to license product candidates from both Cumberland Pharmaceuticals Inc. and Cumberland Emerging Technologies Inc.</ix:continuation>   </span></div><div id="i04c341cdfaf14da59111ae7d8142fa3a_49"></div><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(7) <ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80OS9mcmFnOjY3MTRlN2Q5OWQxNTQ0MGRiZTYzMDY0ZjQyMTMxNGNkL3RleHRyZWdpb246NjcxNGU3ZDk5ZDE1NDQwZGJlNjMwNjRmNDIxMzE0Y2RfNjM3_0e9cd085-5fe0-4ad7-909b-9b5e2b5eae56" continuedAt="ib1e2c3a53d514acd979313e995a359fe" escape="true">INCOME TAXES</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib1e2c3a53d514acd979313e995a359fe">As of March 31, 2023, the Company has approximately $<ix:nonFraction unitRef="usd" contextRef="i90e00eccd5aa49ab87f56422938153e5_I20230331" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80OS9mcmFnOjY3MTRlN2Q5OWQxNTQ0MGRiZTYzMDY0ZjQyMTMxNGNkL3RleHRyZWdpb246NjcxNGU3ZDk5ZDE1NDQwZGJlNjMwNjRmNDIxMzE0Y2RfNjI_e1b077bc-e246-4cf0-91b5-a1afa9ebcc6a">57.8</ix:nonFraction> million in federal net operating loss carryforwards including approximately $<ix:nonFraction unitRef="usd" contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331" decimals="0" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80OS9mcmFnOjY3MTRlN2Q5OWQxNTQ0MGRiZTYzMDY0ZjQyMTMxNGNkL3RleHRyZWdpb246NjcxNGU3ZDk5ZDE1NDQwZGJlNjMwNjRmNDIxMzE0Y2RfMTMz_813d8a8b-1752-40ad-95f6-e8500897cef7">44.1</ix:nonFraction> million of net operating loss carryforwards resulting from the exercise of nonqualified stock options. These have historically been used to significantly offset income tax obligations. The Company expects it will continue to pay minimal income taxes during 2023 and beyond, through the continued utilization of these net operating loss carryforwards, on any taxable income generated from our operations.</ix:continuation> </span></div><div id="i04c341cdfaf14da59111ae7d8142fa3a_52"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(8) <ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81Mi9mcmFnOjQyODNmYjFiMzJlYjQxOWZiOTg5MTU2NDdjNTBkNzAzL3RleHRyZWdpb246NDI4M2ZiMWIzMmViNDE5ZmI5ODkxNTY0N2M1MGQ3MDNfMTA5OTUxMTYyOTAyNA_259319d0-f854-4089-af46-bc932ff0288e" continuedAt="i139df4daf8be4adcafc9634037089480" escape="true">OTHER INCOME</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i139df4daf8be4adcafc9634037089480">The Company realized a $<ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="-5" name="us-gaap:InsuredEventGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81Mi9mcmFnOjQyODNmYjFiMzJlYjQxOWZiOTg5MTU2NDdjNTBkNzAzL3RleHRyZWdpb246NDI4M2ZiMWIzMmViNDE5ZmI5ODkxNTY0N2M1MGQ3MDNfMTA5OTUxMTYyOTAxMQ_2b6b8a87-1690-4211-8201-8fdba17a1a6f">1.8</ix:nonFraction>&#160;million gain in the first quarter of 2023 for previously paid prescription drug fees.  In March 2023, the Company was granted a barrier-to-innovation waiver from the FDA for the fiscal year 2022 RediTrex prescription drug fees resulting in a refund of $<ix:nonFraction unitRef="usd" contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" decimals="-5" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81Mi9mcmFnOjQyODNmYjFiMzJlYjQxOWZiOTg5MTU2NDdjNTBkNzAzL3RleHRyZWdpb246NDI4M2ZiMWIzMmViNDE5ZmI5ODkxNTY0N2M1MGQ3MDNfMTA5OTUxMTYyOTAzOQ_9b1b1083-3649-413a-942e-beae61cc46c5">1.8</ix:nonFraction>&#160;million.  This refund is expected to be paid in second quarter of 2023.</ix:continuation></span></div><div id="i04c341cdfaf14da59111ae7d8142fa3a_55"></div><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(9) <ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81NS9mcmFnOjhkZmY1ZjA1N2EyZTQ4M2FhOTE2ZWU1ZWM3NjQ2ODcyL3RleHRyZWdpb246OGRmZjVmMDU3YTJlNDgzYWE5MTZlZTVlYzc2NDY4NzJfMTAyNg_04821286-0202-477d-8704-0fc66bc47aed" continuedAt="i4351a7818c784e2ea45155e652c9a876" escape="true">COLLABORATIVE AGREEMENTS</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify"><ix:continuation id="i4351a7818c784e2ea45155e652c9a876"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment received related to RediTrex, do not meet the criteria for accounting under ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The agreements do not specifically designate each party&#8217;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party.  Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed consolidated statements of operations.</span></ix:continuation></div><div id="i04c341cdfaf14da59111ae7d8142fa3a_526"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(10) <ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81MjYvZnJhZzo4M2I5MjA3MmRkYzI0MTU1OTY0OTdhMzc0YzFlNmFkZS90ZXh0cmVnaW9uOjgzYjkyMDcyZGRjMjQxNTU5NjQ5N2EzNzRjMWU2YWRlXzEwOTk1MTE2MjgwOTI_d5510047-2655-4d80-91a3-d2c4a041d456" continuedAt="i327ab5debd8d4ace8766c7a5f771de64" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i327ab5debd8d4ace8766c7a5f771de64">The company is involved in litigation arising in the normal course of business.  The Company does not believe that the disposition or ultimate resolution of existing claims or lawsuits will have a material adverse effect on the business or financial condition of the Company.</ix:continuation></span></div><div id="i04c341cdfaf14da59111ae7d8142fa3a_58"></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(11) <ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfOTQ1MA_f2b38df6-c7cb-4ce1-a60b-09bffd0a1142" continuedAt="i6c631979a453467a8a2dc3c0f4056a4b" escape="true">ADDITIONS AND RETURN OF PRODUCT RIGHTS</ix:nonNumeric></span></div><ix:continuation id="i6c631979a453467a8a2dc3c0f4056a4b" continuedAt="ic09644d92fd14cd1a50c735905b557ea"><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vibativ</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand.  Vibativ is a patented, Food and Drug Administration ("FDA") approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i910d1c8e30b447a685124ae92adb5f51_D20181101-20181130" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfOTY5_1b29ccf8-545d-4927-8e30-ea874b179332">20.0</ix:nonFraction>&#160;million at the closing of the transaction and a $<ix:nonFraction unitRef="usd" contextRef="i910d1c8e30b447a685124ae92adb5f51_D20181101-20181130" decimals="-5" name="us-gaap:OtherPaymentsToAcquireBusinesses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfMTAxMg_55b86aed-d7b0-44f0-b62b-1b069c028511">5.0</ix:nonFraction>&#160;million milestone payment in early April 2019. In addition, Cumberland has agreed to pay a royalty of up to <ix:nonFraction unitRef="number" contextRef="i910d1c8e30b447a685124ae92adb5f51_D20181101-20181130" decimals="2" name="cpix:TieredRoyaltyPaymentsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfMTExNQ_6f871b39-2025-4ee8-8840-9289a1520246">20</ix:nonFraction>% of on-going net sales of the product after the $<ix:nonFraction unitRef="usd" contextRef="i910d1c8e30b447a685124ae92adb5f51_D20181101-20181130" decimals="-5" name="cpix:TieredRoyaltyPaymentsThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfMTE2NQ_2ab9d591-826a-4199-9112-d0f59b9ed204">2.5</ix:nonFraction>&#160;million threshold is met. The future royalty payments were required to be recognized at their acquisition-date fair value as a contingent consideration liability, as part of the contingent consideration transferred in the business combination. Cumberland prepared the valuations of the contingent consideration liability utilizing significant unobservable inputs.  As a result, the valuation is classified as Level 3 fair value measurement. </span></div><div style="margin-top:6pt;text-align:justify"><ix:nonNumeric contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfOTQ0NQ_9857956f-2e03-41d8-a65d-02a1877aad64" continuedAt="ic48dc91015cc4872a143a1ec515a2262" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to Theravance quarterly.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.345%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c76ad6b0d9d43bea791e5d7ff63409c_I20221231" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RhYmxlOjdjNTJhZDVjYjgxMDQ5Yzk4ZDcxYzNkMjdlMDkyMzIzL3RhYmxlcmFuZ2U6N2M1MmFkNWNiODEwNDljOThkNzFjM2QyN2UwOTIzMjNfOS0xLTEtMS00NTkwNg_24184fc6-90c7-43fb-857f-98e8689f2979">4,154,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i499b37cd8cf54392a0f2ec322fe40eee_D20230101-20230331" decimals="0" name="us-gaap:PaymentsForRoyalties" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RhYmxlOjdjNTJhZDVjYjgxMDQ5Yzk4ZDcxYzNkMjdlMDkyMzIzL3RhYmxlcmFuZ2U6N2M1MmFkNWNiODEwNDljOThkNzFjM2QyN2UwOTIzMjNfMTAtMS0xLTEtNDU5MDY_265a02c3-c277-413c-815f-7048223bb938">245,391</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i499b37cd8cf54392a0f2ec322fe40eee_D20230101-20230331" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RhYmxlOjdjNTJhZDVjYjgxMDQ5Yzk4ZDcxYzNkMjdlMDkyMzIzL3RhYmxlcmFuZ2U6N2M1MmFkNWNiODEwNDljOThkNzFjM2QyN2UwOTIzMjNfMTEtMS0xLTEtNDU5MDY_62b9ad52-cb21-4295-add7-adfb9ddf582f">176,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i499b37cd8cf54392a0f2ec322fe40eee_D20230101-20230331" decimals="0" name="cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RhYmxlOjdjNTJhZDVjYjgxMDQ5Yzk4ZDcxYzNkMjdlMDkyMzIzL3RhYmxlcmFuZ2U6N2M1MmFkNWNiODEwNDljOThkNzFjM2QyN2UwOTIzMjNfMTItMS0xLTEtNDU5MDY_2c1c599d-a774-4e64-be47-72af42a439c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if921eb31fa6f45b39876cdd2bde81d95_I20230331" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RhYmxlOjdjNTJhZDVjYjgxMDQ5Yzk4ZDcxYzNkMjdlMDkyMzIzL3RhYmxlcmFuZ2U6N2M1MmFkNWNiODEwNDljOThkNzFjM2QyN2UwOTIzMjNfMTMtMS0xLTEtNDU5MDY_5d87c106-bb2e-49f3-adc2-bd12e5b287ed">4,085,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></ix:nonNumeric></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liability of $<ix:nonFraction unitRef="usd" contextRef="if921eb31fa6f45b39876cdd2bde81d95_I20230331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfMTg5MQ_9cb055aa-0a76-455b-a7a7-ba49e405144b">4.1</ix:nonFraction> million was accounted for as $<ix:nonFraction unitRef="usd" contextRef="if921eb31fa6f45b39876cdd2bde81d95_I20230331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfMTkxNQ_fc975862-6c51-4913-81d4-d1c225b87d1b">1.2</ix:nonFraction> million of other current liabilities and $<ix:nonFraction unitRef="usd" contextRef="if921eb31fa6f45b39876cdd2bde81d95_I20230331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfMTk1MQ_daf37173-b453-4556-84f9-2ec9d42aaf7e">2.9</ix:nonFraction> million of other long-term liabilities on the condensed consolidated balance sheet as of March 31, 2023.  </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RediTrex</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, the Company announced an agreement with the Nordic Group B.V. ("Nordic") to acquire the exclusive U.S. rights to Nordic&#8217;s injectable methotrexate product line designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for the license, Cumberland paid a deposit of $<ix:nonFraction unitRef="usd" contextRef="idee1724666bd4296b087588595669561_D20161101-20161130" decimals="0" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfMjQ0MA_9bdc7028-1ac9-492e-885e-6d315f596e85">100,000</ix:nonFraction> at closing.  The Company provided $<ix:nonFraction unitRef="usd" contextRef="idee1724666bd4296b087588595669561_D20161101-20161130" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfMjQ3Nw_e5d419d1-356a-4dfd-8ae0-42deb02f0f87">0.9</ix:nonFraction>&#160;million in consideration through a grant of <ix:nonFraction unitRef="shares" contextRef="i8321269afd0c421ebdd0224b1a27d392_D20161101-20161130" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfMjUxNg_3e5a05c9-f228-4cc3-b7ac-93258c8c7bce">180,000</ix:nonFraction> restricted shares of Cumberland common stock to be vested upon the FDA approval of the first Nordic product. Cumberland also agreed to provide Nordic a series of payments tied to the products&#8217; FDA approval, launch and achievement of certain sales milestones. Under the terms of the agreement, Cumberland is responsible for the product registration and commercialization in the U.S. Nordic is responsible for product manufacturing and supply.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2019, Cumberland received FDA approval for the first Nordic injectable product and authorization to market them under the RediTrex brand name.  The <ix:nonFraction unitRef="shares" contextRef="i8321269afd0c421ebdd0224b1a27d392_D20161101-20161130" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfMzEyNw_702e1a3e-3480-43e2-9120-d8a6885d71af">180,000</ix:nonFraction> shares of restricted Cumberland common stock previously provided to Nordic vested upon approval and were valued at $<ix:nonFraction unitRef="usd" contextRef="i47826f88ea0b4a6eb3f2a0fbce1e5c79_D20230101-20230331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfMzI0NQ_1425efcc-852b-469d-b507-62a58c094f3d">0.9</ix:nonFraction>&#160;million on the vesting date. The FDA approval also resulted in a $<ix:nonFraction unitRef="usd" contextRef="i4038ab9268e54e9ea5e0321e85b66082_I20200731" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfMzMwNQ_df46be43-66e4-4f20-8457-30e7c426f9e1">1.0</ix:nonFraction>&#160;million milestone payment due to Nordic.  During December 2020, Cumberland introduced RediTrex and the launch that took place in late 2021 resulted in a $<ix:nonFraction unitRef="usd" contextRef="i55d3542573f24209aee0933490837ee7_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfMzQ1Mw_f5c1ec60-593b-4279-8bdc-ec9837be9c0d">1.0</ix:nonFraction>&#160;million milestone payment due to Nordic.  </span></div></ix:continuation><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><ix:continuation id="ic09644d92fd14cd1a50c735905b557ea" continuedAt="i6d1f43b6f0a1401ba0eaf533d787712c"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective July 12, 2022, the Company entered into an amendment to our agreement with Nordic whereby they may assume responsibility for RediTrex marketing authorization in the U.S. and the opportunity to commercialize the product in the U.S. after June 30, 2023. Cumberland will continue to distribute and support the product until then.  In accordance with the terms of the amendment, Nordic has returned the <ix:nonFraction unitRef="shares" contextRef="i90fc46e8567a4446ba6f1f69166c1051_I20220712" decimals="0" name="cpix:CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfMzkxMA_aa321a13-a666-4991-a872-6b67c90838c8">180,000</ix:nonFraction> restricted Cumberland shares we previously issued to Nordic which were cancelled, refunded to Cumberland the milestone payment of $<ix:nonFraction unitRef="usd" contextRef="id0e8f0a1b5ac44cfa0861149a172d293_I20220712" decimals="-5" name="cpix:CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfNDA0NA_02a13b8b-0841-436c-ab12-ec9944e7824c">1.0</ix:nonFraction>&#160;million we made associated with the brand's U.S. approval and issued a credit note in favor of the Company in the amount of $<ix:nonFraction unitRef="usd" contextRef="id0e8f0a1b5ac44cfa0861149a172d293_I20220712" decimals="-5" name="cpix:CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfNDE2Mg_4f65be64-18d9-43d8-b6ba-117f2d444267">1.0</ix:nonFraction>&#160;million for the unpaid milestone payment due from us for launch of the product line. The companies will cooperate on any transition and Cumberland will receive a long-term royalty on any Nordic sales of the product.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sancuso</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 3, 2022, Cumberland acquired the U.S. rights to the FDA-approved oncology-supportive care medicine Sancuso from Kyowa Kirin, Inc. ("Kyowa Kirin"), the U.S. affiliate of Japan-based Kyowa Kirin Co., Ltd. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sancuso is the first and only FDA-approved prescription patch for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment. The active drug in Sancuso, granisetron, slowly dissolves in the thin layer of adhesive that sticks to the patient&#8217;s skin and is released into their bloodstream over several days, working continuously to prevent chemotherapy-induced nausea and vomiting (&#8220;CINV&#8221;). It is applied 24 to 48 hours before receiving chemotherapy and can prevent CINV for up to five consecutive days. Alternative oral treatments must be taken several times (day and night) to deliver the same therapeutic doses.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland acquired U.S. rights to Sancuso and assumed full commercial responsibility for the product in the U.S. &#8211; including its marketing, promotion, distribution, manufacturing and medical support activities.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i20b2ea64a45e4649b835fa2bde154e6d_I20220103" decimals="-5" name="cpix:CollaborativeArrangementRightsAndObligationsUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfNTY5Nw_157d2d64-cc9f-433b-855e-eb9cc603ff27">13.5</ix:nonFraction>&#160;million at the closing of the transaction. The Agreement calls for milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="i20b2ea64a45e4649b835fa2bde154e6d_I20220103" decimals="-5" name="cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfNTc4Nw_24eeee42-5097-460e-8fda-9a716660eb5e">3.5</ix:nonFraction>&#160;million based on the attainment of various approvals and sales performance. The Company believes that $<ix:nonFraction unitRef="usd" contextRef="ibcdddac945434b87b9564d50977a987e_D20230101-20230331" decimals="-5" name="cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfNTg4NA_2ff37bf9-e681-4695-95ad-81f72e0b8602">1.5</ix:nonFraction>&#160;million of the milestone payments will be earned and paid.  In March 2023, Cumberland paid $<ix:nonFraction unitRef="usd" contextRef="i44f4dc27a7c64611b4e00cd930bd4746_I20230331" decimals="-5" name="cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfMTA5OTUxMTY0MTUwNg_9335a07b-c666-4bb5-9bb2-89c29a7f35e9">1.0</ix:nonFraction>&#160;million of the $3.5&#160;million milestone payments to Kwoya Kirin for the approval by the FDA of the manufacturing site for the product.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Cumberland has agreed to pay a royalty of up to <ix:nonFraction unitRef="number" contextRef="icb7fb24ed38f426d9b39670f3390245e_I20220103" decimals="2" name="cpix:CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfNTk5OQ_8b65df24-f29c-4d3c-b16e-d237978fa673">10</ix:nonFraction>% of on-going net sales of the product.  The future royalty payments were required to be recognized at their acquisition-date fair value as a contingent consideration liability, as part of the contingent consideration transferred in the business combination. Cumberland has prepared a valuation of the contingent consideration liability utilizing significant unobservable inputs.  As a result, the valuation is classified as Level 3 fair value measurement.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition was funded by cash and the Company's revolving credit facility.  The Company worked with an outside consultant to finalize the Sancuso valuation of the transaction.  The fair value for the assets and liabilities assumed were as follows: prepaid expenses $<ix:nonFraction unitRef="usd" contextRef="ie9300edb1e774e3ea979ca48d8d32a68_I20220103" decimals="0" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfNjgyMA_3013a448-d682-4ac0-b36e-e294e0ed2cdb">1.8</ix:nonFraction>&#160;million, inventory $<ix:nonFraction unitRef="usd" contextRef="ie9300edb1e774e3ea979ca48d8d32a68_I20220103" decimals="0" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfNjgzNA_e9616d76-1efd-4a2e-ab47-6e7556700dce">2.6</ix:nonFraction>&#160;million, goodwill $<ix:nonFraction unitRef="usd" contextRef="ie9300edb1e774e3ea979ca48d8d32a68_I20220103" decimals="0" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfNjg0Nw_0c26028c-0837-4bae-a848-65a076ae8bf0">0.03</ix:nonFraction>&#160;million, intangible assets $<ix:nonFraction unitRef="usd" contextRef="ie9300edb1e774e3ea979ca48d8d32a68_I20220103" decimals="0" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfNjg2OQ_ebf49070-4296-4a7f-b2d6-9960f353e269">14.1</ix:nonFraction>&#160;million, milestone payable $<ix:nonFraction unitRef="usd" contextRef="id571878b227b429aabb39f702150f09b_D20220103-20220103" decimals="-5" name="us-gaap:OtherPaymentsToAcquireBusinesses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfNjg5MQ_2c449dc7-7d7d-4ab3-9230-1ead20c3051b">1.7</ix:nonFraction>&#160;million and contingent liability $<ix:nonFraction unitRef="usd" contextRef="ie9300edb1e774e3ea979ca48d8d32a68_I20220103" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfNjkxOQ_6afaddc2-500f-4b56-be60-7f2e0dc975c9">3.4</ix:nonFraction>&#160;million.</span></div><ix:continuation id="ic48dc91015cc4872a143a1ec515a2262"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.345%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i339eef896e214990b9293f54ead2c9f0_I20221231" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RhYmxlOjMxYzgwNDNjMGNkYjQ4YmE5ODJkZGZkYWUxMjFiMjE0L3RhYmxlcmFuZ2U6MzFjODA0M2MwY2RiNDhiYTk4MmRkZmRhZTEyMWIyMTRfOS0xLTEtMS00NTkwNg_6a585d64-268e-4844-a720-5b691d52196f">3,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34ec3c62de204f83a7f07694bba18e4f_D20230101-20230331" decimals="0" name="us-gaap:PaymentsForRoyalties" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RhYmxlOjMxYzgwNDNjMGNkYjQ4YmE5ODJkZGZkYWUxMjFiMjE0L3RhYmxlcmFuZ2U6MzFjODA0M2MwY2RiNDhiYTk4MmRkZmRhZTEyMWIyMTRfMTAtMS0xLTEtNDU5MDY_770bc2c4-67fe-492f-a534-0ccbd6b1e311">244,920</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34ec3c62de204f83a7f07694bba18e4f_D20230101-20230331" decimals="0" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RhYmxlOjMxYzgwNDNjMGNkYjQ4YmE5ODJkZGZkYWUxMjFiMjE0L3RhYmxlcmFuZ2U6MzFjODA0M2MwY2RiNDhiYTk4MmRkZmRhZTEyMWIyMTRfMTEtMS0xLTEtNDU5MDY_4d83979e-3158-46fc-932a-c6c818c109e0">443,759</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34ec3c62de204f83a7f07694bba18e4f_D20230101-20230331" decimals="0" name="cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RhYmxlOjMxYzgwNDNjMGNkYjQ4YmE5ODJkZGZkYWUxMjFiMjE0L3RhYmxlcmFuZ2U6MzFjODA0M2MwY2RiNDhiYTk4MmRkZmRhZTEyMWIyMTRfMTItMS0xLTEtNDU5MDY_bb2924e5-37ef-43a0-9e0b-4fca8b7b6fb9">188,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i339bfc5c1c8e48d58f19079fc7a04235_I20230331" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RhYmxlOjMxYzgwNDNjMGNkYjQ4YmE5ODJkZGZkYWUxMjFiMjE0L3RhYmxlcmFuZ2U6MzFjODA0M2MwY2RiNDhiYTk4MmRkZmRhZTEyMWIyMTRfMTMtMS0xLTEtNDU5MDY_9787da57-2e6e-4f0a-aa52-a7ebdb87feef">2,500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div></ix:continuation></ix:continuation><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6d1f43b6f0a1401ba0eaf533d787712c">The contingent consideration liability earned and accrued in operating expenses is paid to Kyowa Kirin quarterly.  The contingent consideration liability of $<ix:nonFraction unitRef="usd" contextRef="i339bfc5c1c8e48d58f19079fc7a04235_I20230331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfNzIyMw_d0b6f7ea-f38e-4b0d-8b35-10cf36f8efa3">2.5</ix:nonFraction> million was accounted for as $<ix:nonFraction unitRef="usd" contextRef="i339bfc5c1c8e48d58f19079fc7a04235_I20230331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfNzI0Nw_c2e13cc0-5f5a-49d3-89d0-12562ac9d466">1.3</ix:nonFraction> million of current liabilities and $<ix:nonFraction unitRef="usd" contextRef="i339bfc5c1c8e48d58f19079fc7a04235_I20230331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfNzI3Nw_d57b3f88-5f69-4c10-b0c6-23b1097c1a03">1.2</ix:nonFraction> million of other long-term liabilities on the condensed consolidated balance sheet as of March 31, 2023.</ix:continuation>  </span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="i04c341cdfaf14da59111ae7d8142fa3a_61"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure regarding forward-looking statements</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion contains certain forward-looking statements which reflect management&#8217;s current views of future events and operations. These statements involve certain risks and uncertainties, and actual results may differ materially from them. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ significantly from the results discussed in these forward-looking statements. Some important factors which may cause results to differ from expectations include: availability of additional debt and equity capital; market conditions at the time additional capital is required; our ability to continue to acquire branded products; product sales; management of our growth and integration of our acquisitions and generally unpredictable conditions in national and international markets. While forward-looking statements reflect our beliefs and best judgment based upon current information, they are not guarantees of future performance. Other important factors that may cause actual results to differ materially from forward-looking statements are discussed in the sections entitled &#8220;Risk Factors&#8221; and &#8220;Special Note Regarding Forward-Looking Statements&#8221; of our Annual Report on Form 10-K for the year ended December 31, 2022, and our other filings with the SEC.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not undertake to publicly update or revise any of our forward-looking statements, even in the event that experience or future changes indicate that the anticipated results will not be realized. The following presentation of management&#8217;s discussion and analysis of financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes included in this report on Form 10-Q.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div><span><br/></span></div><div id="i04c341cdfaf14da59111ae7d8142fa3a_64"></div><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OVERVIEW</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Business</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;), is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. We are dedicated to providing innovative products that improve the quality of care for patients and address poorly met medical needs. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary target sectors are hospital acute care, gastroenterology and oncology. These medical specialties are characterized by relatively concentrated prescriber bases that we believe can be served effectively by small, targeted sales forces. We promote our approved products through our hospital, oncology and field sales forces in the United States.  We have also established international partnerships and are continuing to build a network of companies outside the U.S. to register and provide our medicines to patients in their countries.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of FDA approved brands includes:</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Acetadote</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">acetylcysteine</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) injection, for the treatment of acetaminophen poisoning; </span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Caldolor</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ibuprofen</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) injection, for the treatment of pain and fever;</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Kristalose</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">lactulose</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) oral, a prescription laxative, for the treatment of constipation;</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Omeclamox</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-Pak</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">omeprazole, clarithromycin, amoxicillin</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) oral, for the treatment of Helicobacter pylori (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">H. pylori</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) infection and related duodenal ulcer disease;</span></div><div style="margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">RediTrex</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">methotrexate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) injection, for the treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis, as well as disabling psoriasis;</span></div><div style="margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Sancuso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">granisetron) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment;</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Vaprisol</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">conivaptan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Vibativ</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">telavancin</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to these commercial brands, we have Phase II clinical programs underway evaluating our ifetroban product candidates for patients with cardiomyopathy associated with 1) Duchenne Muscular Dystrophy (&#8220;DMD&#8221;), a fatal, genetic neuromuscular disease; 2) Systemic Sclerosis (&#8220;SSc&#8221;) or scleroderma, a debilitating autoimmune disorder characterized by fibrosis of the skin and internal organs; and 3) Aspirin-Exacerbated Respiratory Disease (&#8220;AERD&#8221;), a severe form of asthma. We are designing a fourth Phase II program to evaluate the use of ifetroban to treat patients with Progressive Fibrosing Interstitial Lung Diseases, and we have submitted an application to the FDA to support the new program, which we expect to launch in 2023.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has built core competencies in the acquisition, development and commercialization of pharmaceutical products in the U.S. &#8211; and we believe we can leverage this existing infrastructure to support our continued growth both domestically and internationally. Our management team consists of pharmaceutical industry veterans with experience in business development, product development, regulatory, manufacturing, sales, marketing and finance. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business development team identifies, evaluates, and negotiates product acquisition, licensing and co-promotion agreements. Our product development team creates proprietary formulations, manages our clinical studies, prepares our FDA submissions and staffs our medical call center. Our quality and manufacturing professionals oversee the manufacturing, release and shipment of our products. Our marketing and sales organization is responsible for our commercial activities, and we work closely with our distribution partners to ensure the availability and delivery of our products.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GROWTH STRATEGY</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland&#8217;s growth strategy involves maximizing the success of our existing brands while continuing to build a portfolio of differentiated products. We currently feature eight products approved by the FDA in the United States. We are also continuing to explore international partnerships to bring our medicines to patients in other countries. Additionally, we look for opportunities to expand our products into additional patient populations through clinical trials, new presentations and our support of select, investigator-initiated studies. We actively pursue opportunities to acquire additional marketed products, as well as late-stage development product candidates in our target medical specialties. Our clinical team is developing a pipeline of new product candidates largely to address poorly met medical needs.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are supplementing these activities with the earlier-stage drug development at Cumberland Emerging Technologies (&#8220;CET&#8221;), our majority-owned subsidiary. CET partners with academic research institutions to identify and support the progress of promising new product candidates, which Cumberland could further develop and commercialize.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, we are seeking long-term sustainable growth by:</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Supporting and expanding the use of our marketed products. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to evaluate our products following their FDA approval to determine if additional clinical data could expand their market and use. For example, we have secured pediatric approval of Acetadote and Caldolor and are expanding the labeling for both brands accordingly. We also recently further expanded the labeling for Caldolor to allow its use prior to surgery. We will continue to explore such opportunities to bring our products to new patient populations.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Selectively adding complementary brands. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our product development activities, we are also seeking to acquire products or late-stage development product candidates to continue to build a portfolio of complementary brands. We focus on under-promoted, FDA-approved drugs as well as late-stage development products that address poorly met medical needs. We will continue to target product acquisition candidates that are competitively differentiated, have valuable intellectual property or other protective features, and allow us to leverage our existing infrastructure. Our acquisitions of Vibativ and Sancuso are examples of this strategy.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Progressing our clinical pipeline and incubating future product opportunities at CET.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We believe it is important to build a pipeline of innovative new product opportunities, as we are doing though our ifetroban Phase II development programs. We are also supplementing our acquisitions and late-stage development activities with early-stage drug development activities with CET. </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Leveraging our infrastructure through co-promotion partnerships. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our commercial infrastructure can help drive prescription volume and product sales. We look for strategic partners that can complement our capabilities and enhance opportunities for our brands. For example, our co-promotion partnerships have allowed us to expand the support for Kristalose and Sancuso across the U.S.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Building an international contribution to our business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have established our own commercial capabilities, including three sales divisions, to cover the U.S. market for our products. We are also building a network of select international partners to register our products and make them available to patients in their countries. We will continue to develop and expand our network of international partners while supporting our partners&#8217; registration and commercialization efforts in their respective territories. The acquisition of Vibativ resulted in several new international partners and market opportunities.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Managing our operations with financial discipline.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We continually work to manage our expenses in line with our revenues to deliver cash flow from operations. We remain in a strong financial position, with favorable gross margins and a strong balance sheet.</span></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECENT DEVELOPMENTS</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Headquarters Location </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In late 2022, we opened our new headquarter offices at the Broadwest campus in the Vanderbilt/West End corridor of Nashville. Our move into the new state-of-the-art facilities will accommodate our growth, support our team, and better serve our international base of customers and partners. The location allows us to remain close to and continue our collaboration with the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vanderbilt Medical Center, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">while also maintaining our presence in the Nashville healthcare community &#8211; which represents the nation&#8217;s largest concentration of healthcare companies. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">International Agreements</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2022, we signed a new agreement with PiSA Pharmaceutical ("PiSA") for the exclusive supply and distribution of our ibuprofen injection product in Mexico. Cumberland will be responsible for sharing the U.S. dossier and providing product supply, while PiSA will be responsible for obtaining the regulatory approval and then commercializing the product in Mexico. PiSA expects to provide the product in both 400- and 800-milligram vials.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Meanwhile, we continue to support our international partners in their efforts to register our Vibativ brand in their countries.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In late 2022, we announced a new partnership with Saudi Arabia-based Tabuk Pharmaceutical to introduce Vibativ into the Middle East. The arrangement provides Tabuk exclusive rights to distribute Vibativ in Saudi Arabia and Jordan, with the option to expand into other countries in the region. Tabuk is in the process of updating the Vibativ registration in Saudi Arabia with new manufacturing information as they also prepare for the launch in that country.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in 2022, we entered into an agreement with D.B. Pharm to register and commercialize our Vibativ product in South Korea. D.B. Pharm who also distributes our Caldolor product in South Korea, is progressing their application for the approval of Vibativ.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Meanwhile, our Vibativ partner for the Chinese market, SciClone Pharmaceuticals, had their approval application in China accepted for review in September 2021. We&#8217;ve since been supporting SciClone and their requests associated with review of that submission. They are working toward the approval and believe that there is significant potential for Vibativ in their country.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nordic Pharma Arrangements</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, we entered into an amendment to our agreement with Nordic Pharma (&#8220;Nordic&#8221;) that addresses the responsibilities and financial arrangements regarding our license to Nordic&#8217;s methotrexate line of products for the U.S. (the &#8220;License&#8221;). Our line of prefilled methotrexate syringes, marketed under the brand name RediTrex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S., is covered by the License.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the amendment, Nordic may assume responsibility for commercializing the methotrexate products in the U.S. after June 30, 2023. We will continue to distribute and support the RediTrex product line during a transition period until then. Following the return of the License, Nordic will provide us with a royalty on their future sales of the products through April 2035. The companies will continue to collaborate on any transition and the ongoing commercialization of the product line.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has transferred the marketing authorization associated with the RediTrex product line to Nordic. Nordic has returned the 180,000 shares we issued to them associated with the original License and has refunded the $1 million we paid following the brand&#8217;s approval in the U.S. Nordic has also issued a credit note in favor of Cumberland in the amount of $1 million for the unpaid milestone payment due from us which was associated with our launch of the product line.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sancuso Acquisition and Promotion</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In early 2022, Cumberland acquired the U.S. rights to the FDA-approved oncology-supportive care medicine Sancuso from Kyowa Kirin, Inc., the U.S. affiliate of Japan-based Kyowa Kirin Co., Ltd. In early 2022, Cumberland assumed commercial responsibility for the product in the U.S. &#8211; including its marketing, promotion, distribution, manufacturing and medical support activities. During 2022 we largely completed the transition of Sancuso to Cumberland. In late 2022, the FDA approved moving the product&#8217;s manufacturer to a new facility, which will be a source of future product supplies. </span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sancuso is the first and only FDA-approved prescription patch for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment. The active drug in Sancuso, granisetron, slowly dissolves in the thin layer of adhesive that sticks to the patient&#8217;s skin and is released into their bloodstream over several days, working continuously to prevent chemotherapy-induced nausea and vomiting (&#8220;CINV&#8221;). It is applied 24 to 48 hours before receiving chemotherapy and can prevent CINV for up to five consecutive days. Alternative oral treatments must be taken several times (day and night) to deliver the same therapeutic doses.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In early 2022, we formed a new sales division, Cumberland Oncology, to support the brand. The division was comprised of both field-based and inside sales representatives that were formerly associated with Kyowa Kirin. In April 2022, we entered into an agreement with Verity Pharmaceuticals International Limited (&#8220;Verity&#8221;) for the national co-promotion of Sancuso. Verity is a specialty pharmaceutical company that agreed to utilize its established oncology commercial organization to co-promote Sancuso throughout the United States. Verity was to provide sales representation in the U.S. market for an initial three-year term, with an option to extend for an additional two years. In January 2023, we sent a 30-day notice of default to Verity due to failure of the parties to reach agreement regarding fundamental elements of the agreement, including targets and detailing obligations, among other items. As a result, the agreement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:line-through">t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">erminated effective February 25, 2023. The agreement provides for arbitration of any unresolved issues and we are in agreement with Verity that such arbitration should proceed. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ifetroban Clinical Studies</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been evaluating our ifetroban product candidate, a selective thromboxane-prostanoid receptor (&#8220;TPr&#8221;) antagonist, in a series of clinical studies. It has been dosed in nearly 1,400 subjects and has been found to be safe and well tolerated in healthy volunteers and various patient populations. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland is currently sponsoring three Phase II clinical programs to evaluate ifetroban in patients with:</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1) Aspirin-Exacerbated Respiratory Disease, ("AERD") a severe form of asthma; </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2) Systemic Sclerosis or scleroderma, a debilitating autoimmune disorder characterized by diffuse fibrosis of the skin and internal organs; and </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3) patients with cardiomyopathy associated with Duchenne Muscular Dystrophy, a genetic neuromuscular disease that results in deterioration of the skeletal, heart and lung muscles.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also designing a fourth Phase II program to evaluate the use of ifetroban to treat patients with Progressive Fibrosing Interstitial Lung Diseases, and we have submitted an application to the FDA to support the new program, which we expect to launch in 2023.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In late 2022, we closed enrollment in our Phase II study in patients with AERD. We then conducted a quality review of the data and clinical sites, closed the database for the study and are awaiting the initial results.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also completed Phase II clinical programs with ifetroban in patients with Hepatorenal Syndrome (&#8220;HRS&#8221;) and patients with Portal Hypertension (&#8220;PH&#8221;). Additional preclinical and pilot clinical studies of ifetroban are underway, including several investigator-initiated trials.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our plan going forward is to complete each of our Company-sponsored studies, analyze their final data, announce top-line results and decide on the best development path for the registration of ifetroban, which we continue to believe has the potential to benefit many patients with orphan diseases that represent unmet medical needs.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our Company-sponsored studies, researchers at Brigham and Women&#8217;s Hospital have completed an investigator-initiated study evaluating the impact of ifetroban on the aspirin desensitization process in patients with AERD. This single center study closed early due to poor patient accrual and exhausted funding. The researchers found no statistical difference in the dose of aspirin needed to provide an increase in an extended version of the patient&#8217;s total nasal symptom score. A publication by the researchers with the full study results will be forthcoming. It should be noted that the results from this investigator study were inconsistent with the previously published preclinical findings that demonstrated ifetroban blockade inhibited all features of aspirin reactions in a model of AERD.</span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vaprisol Supply Update</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Demand for the product increased in 2020 during the pandemic, and we worked to support the expanded use of the product in hospitals and clinics during the health care crisis. During 2021, we shipped all remaining inventory of the product and have notified the FDA that supplies of the product are not currently available. We have since transferred the manufacturing of the product to a new facility. Our new manufacturing partner is working with the FDA to address several Form 483 and warning letter issues in a timely manner. Meanwhile, we are working with them to support a special, interim supply of compounded product for critically ill patients, while awaiting the needed facility approval to relaunch Vaprisol.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Omeclamox-Pak Supply Update</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The packager for Omeclamox-Pak encountered financial difficulties in 2020 due to the impact of COVID-19, and their operations were suspended. As a result, we depleted our inventory of the product and notified the FDA that it is currently unavailable. We are awaiting resumption of those operations, while also exploring other alternatives to restart the product&#8217;s packaging.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sustainability Report </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earlier this year we provided updated sustainability metrics, which cover company activities pertaining to environmental, social and governance issues. Highlights for 2022 include:  </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Providing 2.2 million doses of our products to patients;  </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Safely disposing of over 2,750 pounds of expired and damaged products; and </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Having no product recalls or terminated clinical trials due to failure to practice good clinical standards.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the largest biopharmaceutical company founded and headquartered in the Mid-South, we hold ourselves to the highest standards of ethical practices and understand the importance of recognizing and addressing our impact on our constituents, the community and the environment. Through our sustainability initiatives, we will continue to identify and address critical industry issues, monitor relevant guidelines and utilize best practices.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FDA Fee Waiver</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, the FDA informed us that it had granted a barrier-to-innovation waiver, which will result in a refund of approximately $1.8 million that we previously paid for prescription drug program fees associated with the RediTrex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product line.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA granted the barrier-to-innovation waiver after concluding that the Company met the statutory criteria, based on the innovation associated with Cumberland&#8217;s ifetroban clinical development programs, as the funds could be better used to advance those studies which are designed to address a series of unmet medical needs.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA&#8217;s decision was in response to a request for reconsideration that Cumberland provided on November 28, 2021, after the agency had initially denied Cumberland&#8217;s submission for a waiver in a decision dated November 1, 2021. Cumberland paid the FDA the fiscal year 2022 RediTrex prescription drug program fees in the amount of approximately $1.8 million on or about October 4, 2021. The fees were assessed under the Prescription Drug User Fee Act. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA informed Cumberland on March 30, 2023, that the agency&#8217;s Office of Financial Management had been asked to provide a refund of the fees, which is expected within 45 days. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Federal NOPAIN Act</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, Cumberland announced that it expects that its Caldolor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">injection product should be eligible for special Medicare reimbursement under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Opioids Prevent Addiction in the Nation Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;NOPAIN Act&#8221;), which was enacted as part of the Consolidated Appropriations Act of 2023. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NOPAIN Act requires Medicare to provide separate reimbursement for non-opioid products that are used to manage pain during surgeries conducted in outpatient hospital departments or in ambulatory surgical centers. The NOPAIN Act applies, in part, to products that are indicated to provide analgesia without acting upon the body&#8217;s opioid receptors. As a result, the Company expects that the NOPAIN Act will affect Medicare reimbursement for Caldolor, Cumberland&#8217;s non-opioid analgesic injection product.</span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The methodology for reimbursement for non-opioid pain alternatives under the NOPAIN Act will apply to those products that are furnished between January 1, 2025 and January 1, 2028. It is anticipated that in 2024, the Centers for Medicare &amp; Medicaid Services (CMS) will issue regulations implementing the NOPAIN Act and detailing the conditions for, and amount of, the separate reimbursement.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caldolor is approved by the U.S. Food and Drug Administration (FDA) for use in adults and pediatric patients six months and older, for the management of mild to moderate pain as a sole therapy, and for the management of moderate to severe pain as an adjunct to an opioid. A series of published clinical studies have demonstrated that Caldolor significantly reduces patient pain, while also significantly reducing patients&#8217; need for opioids. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland remains committed to our mission of providing innovative products that improve the quality of care for patients and address poorly met medical needs. We are working to fulfill this mission by building a portfolio of innovative and differentiated products through a multifaceted strategy that includes the development of new candidates as well as the acquisition of established brands. Our resulting, diversified product line has enabled us to weather external challenges while our team remains responsive to the evolving medical market. We are prepared for and look forward to future opportunities to carry out our mission throughout the remainder of the year.</span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i04c341cdfaf14da59111ae7d8142fa3a_67"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING POLICIES AND SIGNIFICANT JUDGMENTS AND ESTIMATES</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see a discussion of our critical accounting policies and significant judgments and estimates in Note 1 to the Company's Condensed Consolidated Financial Statements accompanying this report and the section entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our 2022 Annual Report on Form 10-K.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Estimates and Judgments</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. We base our estimates on past experience and on other factors we deem reasonable given the circumstances. Past results help form the basis of our judgments about the carrying value of assets and liabilities that cannot be determined from other sources. Actual results could differ from these estimates. The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of contingent consideration liabilities associated with business combinations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="i04c341cdfaf14da59111ae7d8142fa3a_70"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three months ended March 31, 2023 compared to the three months ended March 31, 2022 </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the unaudited interim statements of operations for continuing operations for the three months ended March 31, 2023 and 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,224,638&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,175,045&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,950,407)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250,264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,211,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(961,621)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and marketing</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,277,318&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,614,429&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(337,111)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,745,136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(245,466)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,498,993&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,302,349&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,644&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,230,071&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,593,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(363,174)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,756,316&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,467,044&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,710,728)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,531,678)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,291,999)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(239,679)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,190&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,041&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,149&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,847,065&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,847,065&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(186,353)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119,575)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,778)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,224&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,395,533)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,574,757&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,938)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,900)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,402,433)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,574,719&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes net revenues by product for the periods presented: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,315,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,945,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sancuso</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,886,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,397,209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,510,416)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,848,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,501,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(653,247)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">935,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959,634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,591)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,090&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,518)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,255)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141,045)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(200,271)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98,432)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,224,638&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,175,045&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,950,407)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Net revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Net revenues for the three months ended March 31, 2023, were $9.2 million compared to $11.2 million for the three months ended March 31, 2022.  As noted in the table above, net revenue increased during the quarter for two of our marketed products: Kristalose and Acetadote.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kristalose revenue of $4.3 million for the first quarter of 2023, represented an increase of $0.4 million when compared to the prior year period.  The increase was primarily the result of increased shipments of the product.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acetadote revenue includes net sales of our Acetadote brand and our share of net sales from our Authorized Generic. During the first quarter of 2023, there was an increase of $0.1 million in the branded product's revenue when compared to the prior year period due to increased shipments of the product.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no Vaprisol revenue for the first quarter of 2023, an increase of $0.1 million compared to the same period last year. This increase is primarily due to normal adjustments to expired product reserves.  We await FDA approval on a new manufacturer. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caldolor revenue was $0.9 million for the first quarter of 2023, similar to the first quarter of 2022.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vibativ revenue was $1.8 million for the three months ended March 31, 2023, which declined $0.7 million from the same prior year period.  The decrease in net revenue of the product was the result of lower unit shipments.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sancuso revenue was $1.9 million for the first quarter of 2023, which was $1.5 million lower than the first quarter of 2022.  The decline resulted from larger product returns associated with the inventory acquired at the acquisition of the product and lower sales.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Omeclamox-Pak had no sales for the first quarter of 2023, as Cumberland is currently out of commercial inventory of this product. The packager for our Omeclamox-Pak product encountered financial difficulties in 2020.  Net revenue for the three months ended March 31, 2023, reflects sales deduction adjustments.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of products sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Co</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">st of products sold for the first quarter of 2023 and 2022 were $1.3 million and $2.2 million, respectively. Cost of products sold, as a percentage of net revenues, were 13.6% during the three months ended March 31, 2023, compared to 19.8% during the three months ended March 31, 2022.  The improvement in cost of products sold is primarily due to the availability of new lower cost inventory and less inventory write-offs.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling and marketing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Selling and marketing expense for the first quarter of 2023 decreased $0.3 million compared to the same period last year.  This decrease is primarily attributable to lower royalty expenses.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Research and development costs for the first quarter of 2023 and 2022 were $1.5 million and $1.7 million, respectively.  A portion of our research and development costs is variable based on the number of trials, study sites, number of patients and the cost per patient in each of our clinical programs. We continue to fund our ongoing clinical initiatives associated with our pipeline product candidates.  The decrease in costs for the first quarter of 2023 results from lower FDA fees in 2023.   </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  General and administrative expense increased to $2.5 million for the first quarter of 2023, compared to $2.3 million for the first quarter of 2022, an increase of  $0.2 million. The increase was primarily attributable to increases in deferred compensation expenses.</span></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the statements of operations discussed above reflect the following impacts from Vibativ:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Impact of Vibativ</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,848,187&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,651,434&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,742&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">927,160&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty and operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519,608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">681,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ contribution</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081,837&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,042,957&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> 2022 net revenue includes a $150,000 payment to Cumberland required under the terms of a new licensee agreement.</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The Vibativ inventory included in the costs of product sold during the period was acquired and paid for by Cumberland as part of the acquisition of the brand during 2018.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the statements of operations discussed above reflect the following impacts from Sancuso:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Impact of Sancuso</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,886,793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,397,209&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,478&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388,264&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty and operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415,707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sancuso contribution</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,181,608&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,098,845&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The Sancuso inventory included in the costs of product sold during the period was acquired and paid for by Cumberland as part of the acquisition of the brand during 2022.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Amortization expense is the ratable use of our capitalized intangible assets including product and license rights, patents, trademarks and patent defense costs.  Amortization for the three months ended March 31, 2023 and 2022, totaled approximately $1.2 million and $1.6 million, respectively.  The decline in amortization expense resulted from adjustments to the useful life of Sancuso during the valuation of the product in December 2022.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Income tax expense for the three months ended March 31, 2023, was comparable to the income tax expense for the three months ended March 31, 2022.  </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, we had approximately $57.8 million in federal net operating loss carryforwards including approximately  $44 million of net operating loss carryforwards resulting from the exercise of nonqualified stock options that have historically been used to significantly offset income tax obligations.  We expect to continue to pay minimal income taxes during 2023 and beyond, through the continued utilization of these net operating loss carryforwards, on any taxable income generated from our operations. </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span><br/></span></div><div id="i04c341cdfaf14da59111ae7d8142fa3a_76"></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Working Capital</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of liquidity are cash equivalents, cash flows from operations and the amounts borrowed under our line of credit. We believe that our internally generated cash flows, existing working capital and our line of credit will be adequate to finance internal growth, finance business development initiatives, and fund capital expenditures for the foreseeable future. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our liquidity and working capital as of March 31, 2023 and December 31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:58.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.461%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:7pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,386,166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,757,970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital (current assets less current liabilities)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,103,385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,290,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current ratio (multiple of current assets to current liabilities)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving line of credit availability</span></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,927,714&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,800,000&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:11pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our net changes in cash and cash equivalents for the three months ended March 31, 2023 and March 31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:58.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.461%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,418,209)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150,498)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(174,453)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,541,898)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,779,142)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,918,365&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,371,804)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,774,031)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net $3.4 million decrease in cash and cash equivalents for the three months ended March 31, 2023, was primarily attributable to cash used in operating and financing activities.  A decrease of cash used in operating activities of $1.4 million was primarily the result of an increase of accounts receivable of $1.4 million (which includes a $1.8 million receivable for the approved PDUFA fee refund), a decrease of net accounts payable and other current liabilities of $1.1 million and the offsetting positive impact from the add backs of non-cash expenses of depreciation, amortization and share-based compensation expense totaling $1.3 million.  Cash used in investing activities of $0.2 million was the result of additions to property and equipment and intangibles. Financing activities use of cash was $1.8 million and include the repayments on our line of credit of $0.1 million, the $0.2 million in cash used to repurchase shares of our common stock as well as the $1.5 million used for the payment of a Sancuso milestone, plus royalties on sales of Vibativ and Sancuso.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net $9.8 million decrease in cash and cash equivalents for the three months ended March 31, 2022, was primarily attributable to cash used in investing and partially offset by cash provided by financing activities.  Cash used in operating activities of $0.2 million was primarily the result of accounts receivable increasing by $7.8 million mainly from Sancuso sales, positively impacted by decreases in inventory of $2.3 million and increases in accounts payable and other liabilities of $4.4 million, as well as the add back of non-cash expenses of depreciation, amortization and share-based compensation expense totaling $1.8 million.  Cash used in investing activities was the result of the acquisition of Sancuso.  Our financing activities included the increase in our line of credit of $5.0 million partially offset by the $0.6 million in cash used to repurchase shares of our common stock as well as the $0.5 million used for the payment of royalties for sales of Vibativ and Sancuso.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt Agreement</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 29, 2022, the Company entered into the Ninth Amendment to the Revolving Credit Loan Agreement with Pinnacle Bank (as amended, the "Pinnacle Agreement") to update the Funded Debt Ratio to mean the ratio of (i) Funded Debt less the amount of Unrestricted Cash in excess of $8,500,000, to (ii) EBITDA, as determined at the end of each fiscal quarter on a rolling four (4) quarter basis.  For the quarter ended March 31, 2023, we were in compliance with the Funded Debt Ratio financial covenant.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 30, 2022, the Company entered into the Eighth Amendment to the Revolving Credit Loan Agreement with Pinnacle Bank permitting the Maximum Funded Debt Ratio to be calculated on a rolling four-quarter basis to be no more than 3.00 to 1.00 for the second and third quarters of 2022 and 2.50 to 1.00 for each quarter thereafter.   </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2022, the Company and Pinnacle Bank entered into a Seventh Amendment to the Revolving Credit Loan Agreement to revise and update the Maximum Funded Debt Ratio financial covenant and to delete from the Pinnacle Agreement the Funded Debt to Tangible Capital Ratio financial covenant. These changes were made to more appropriately reflect the impact from the Sancuso acquisition. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2021, the Company and Pinnacle Bank entered into the Fifth Amendment to the Revolving Credit Note and the Sixth Amendment to the Revolving Credit Loan Agreement in order to increase the principal amount of the Note from $15 million to $20 million.  On October 28, 2021, the Company entered into a Fourth Amendment to the Revolving Credit Note and Fifth Amendment to Revolving Credit Loan Agreement with Pinnacle Bank. Among other terms, the Fourth Amendment extended the maturity date to October 1, 2024.</span></div><div id="i04c341cdfaf14da59111ae7d8142fa3a_79"></div><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OFF-BALANCE SHEET ARRANGEMENTS</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023 and 2022, we did not engage in any off-balance sheet arrangements.</span></div><div id="i04c341cdfaf14da59111ae7d8142fa3a_82"></div><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3. Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk related to changes in interest rates on our cash on deposit in highly-liquid money market accounts and our revolving credit facility. We do not utilize derivative financial instruments or other market risk-sensitive instruments to manage exposure to interest rate changes. The main objective of our cash investment activities is to preserve principal while maximizing interest income through low-risk investments. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our interest rate risk related to our cash and cash equivalents is not material. The risk related to interest rates for these accounts would produce less income than expected if market interest rates fall. Based on current interest rates, we do not believe we are exposed to significant downside risk related to a change in interest on our money market accounts at March 31, 2023.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate risk related to borrowings under our line of credit is based on LIBOR plus an interest rate spread.  The current pricing under the Pinnacle Agreement provides for an interest rate spread of 1.75% to 2.75% above LIBOR with a minimum LIBOR of 0.90%. The applicable interest rate under the Pinnacle Agreement was 7.375% at March 31, 2023.   As of March 31, 2023, we had $16.1 million in borrowings outstanding under our revolving credit facility. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exchange Rate Risk</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we operate primarily in the United States, we are exposed to foreign currency risk.  Currently, we do not utilize financial instruments to hedge exposure to foreign currency fluctuations.  We believe our exposure to foreign currency fluctuation is minimal as our purchases in foreign currency have a maximum exposure of 90 days based on invoice terms with a portion of the exposure being limited to 30 days based on the due date of the invoice.  Foreign currency exchange gains and losses were immaterial for the three months ended March 31, 2023 and 2022.  Neither a five percent increase nor decrease from current exchange rates would have a material effect on our operating results or financial condition.</span></div><div id="i04c341cdfaf14da59111ae7d8142fa3a_85"></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4. Controls and Procedures</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management, with the participation of the Company&#8217;s Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, the Company&#8217;s Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of such period, the Company&#8217;s disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms and is accumulated and communicated to the Company&#8217;s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, there has not been any change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="i04c341cdfaf14da59111ae7d8142fa3a_88"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II &#8211; OTHER INFORMATION</span></div><div id="i04c341cdfaf14da59111ae7d8142fa3a_91"></div><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. Legal Proceedings</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference from Part I, Item 1. Financial Statements, Notes to Unaudited Condensed Consolidated Financial Statements, Note 10.</span></div><div id="i04c341cdfaf14da59111ae7d8142fa3a_94"></div><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A. Risk Factors</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the other information set forth in this quarterly report, an investor should consider the risk factors included in the Company's Annual Report on Form 10-K for the year ended December 31, 2022.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations are subject to the effects of a rising rate of inflation.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflation rates have increased recently to levels not seen in decades.  If our costs, in particular costs related to clinical trial expenses and/or employee-related expenses, were to become subject to significant inflationary pressures, it may adversely impact our business, operating results and financial condition. In addition, the United States Federal Reserve has raised, and is expected to continue to raise, interest rates in response to concerns about inflation. Increases in interest rates, especially if coupled with reduced government spending and volatility in financial markets, may further increase economic uncertainty and heighten these risks.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we do not believe that inflation has had a material impact on our financial position or results of operations to date, we may experience increases in the near future (especially if inflation rates continue to rise) on our operating costs, including our labor costs and research and development costs, due to supply chain constraints, consequences associated with COVID-19 and the ongoing conflict between Russia and Ukraine, and employee availability and wage increases.</span></div><div id="i04c341cdfaf14da59111ae7d8142fa3a_97"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have a share repurchase program to purchase up to $10 million of our common stock pursuant to Rule 10b-18 of the Exchange Act. In January 2019, our Board of Directors established the current $10 million repurchase program to replace the prior authorizations for repurchases of our outstanding common stock.  </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity, by month, during the three months ended March 31, 2023:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:37.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.574%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.598%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.577%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares or Units</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchased, which were also Part of the Publicly Announced Plans or Programs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price&#160;Paid</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">per&#160;Share</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(or Unit)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum&#160;Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(or Approximate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollar Value) of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares that May Yet Be</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchased&#160;Under</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">the Plans or</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Programs</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,122</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,706,634&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,663</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,678,628&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,044</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,565,836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,829</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i04c341cdfaf14da59111ae7d8142fa3a_100"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6. Exhibits</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.968%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.265%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="ajkazimiemploymentagreemen.htm">Employment Agreement dated March 9, 2023, effective as of January 1, 2023, by and between A.J. Kazimi and Cumberland Pharmaceuticals Inc. (incorporated by reference to Exhibit 10.11 of the Company&#8217;s Current Report on Form 8-K, File No. 001-33637, filed with the Securities and Exchange Commission on March 15, 2023).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="jameshermanemploymentagree.htm">Employment Agreement dated March 9, 2023, effective as of January 1, 2023, by and between Jim Herman and Cumberland Pharmaceuticals Inc. (incorporated by reference to Exhibit 10.12 of the Company&#8217;s Current Report on Form 8-K, File No. 001-33637, filed with the Securities and Exchange Commission on March 15, 2023).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="toddanthony-employmentagre.htm">Employment Agreement dated March 9, 2023, effective as of January 1, 2023, by and between Todd Anthony and Cumberland Pharmaceuticals Inc. (incorporated by reference to Exhibit 10.13 of the Company&#8217;s Current Report on Form 8-K, File No. 001-33637, filed with the Securities and Exchange Commission on March 15, 2023).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="chrisbittermanemploymentag.htm">Employment Agreement dated March 9, 2023, effective as of January 1, 2023, by and between Chris Bitterman and Cumberland Pharmaceuticals Inc. (incorporated by reference to Exhibit 10.14 of the Company&#8217;s Current Report on Form 8-K, File No. 001-33637, filed with the Securities and Exchange Commission on March 15, 2023).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="johnhammemploymentagreemen.htm">Employment Agreement dated March 9, 2023, effective as of January 1, 2023, by and between John M. Hamm and Cumberland Pharmaceuticals Inc. (incorporated by reference to Exhibit 10.15 of the Company&#8217;s Current Report on Form 8-K, File No. 001-33637, filed with the Securities and Exchange Commission on March 15, 2023).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023q1-exhibit311.htm">Certification of Chief Executive Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023q1-exhibit312.htm">Certification of Chief Financial Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023q1-exhibit321.htm">Certification of Chief Executive and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL INSTANCE DOCUMENT - THE INSTANCE DOCUMENT DOES NOT APPEAR IN THE INTERACTIVE DATA FILE BECAUSE ITS XBRL TAGS ARE EMBEDDED WITHIN THE INLINE XBRL DOCUMENT.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVER PAGE INTERACTIVE DATA FILE (FORMATTED AS INLINE XBRL AND CONTAINED IN EXHIBIT 101)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furnished herewith.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="i04c341cdfaf14da59111ae7d8142fa3a_103"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:8.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.184%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.669%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.072%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.184%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.416%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumberland Pharmaceuticals Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 12, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ John Hamm</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Hamm</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Duly Authorized Officer</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ajkazimiemploymentagreemen.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i506476fa67154df1b840737594e55713_1"></div><div style="min-height:153.36pt;width:100%"><div style="text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:90px;margin-bottom:5pt;vertical-align:text-bottom;width:394px"></div><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 9, 2023</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Mr. A.J. Kazimi </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1600 West End Avenue, Suite 1300</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Nashville, TN  37203</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Re&#58;&#160;&#160;&#160;&#160;Employment of AJ Kazimi as Chief Executive Officer by Cumberland Pharmaceuticals Inc.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dear AJ, </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Effective January 1, 2023, this letter agreement (the &#8220;Agreement&#8221;) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;) In consideration of your appointment as Chief Executive Officer of the Company, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Compensation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Company agrees to compensate you as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;The Company agrees to pay you on a salary basis for services performed based on an annual rate of six hundred thirty-five thousand dollars ($675,000.00), payable in arrears in equal monthly installments on the 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day of each calendar month of 2023.  For each year, thereafter, you will be paid on a salary basis for services performed based on an annual rate determined by the Company in its sole discretion&#59; provided, however, that any obligation to make payments under this Section 1(a) will cease upon termination of your employment for any reason.  Notwithstanding the foregoing, nothing in this Section 1(a) alters or is intended to alter the at-will nature of your employment as described in Section 3 of this Agreement.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;You will be eligible to participate in any Company-wide employee benefits as approved by the Board of Directors.  The terms of your eligibility and participation will be governed by the provisions of the employee benefit plans, as such plans may be amended from time to time in the discretion of the Company's Board of Directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;You may be eligible for any Company bonus program, based upon performance in meeting your individual objectives and the Company&#8217;s overall performance, both as determined and approved by the Board of Directors of the Company.  Any such bonus will be discretionary and will be subject to the terms of the applicable bonus program, the terms of which program may be modified from year to year in the sole discretion of the Company&#8217;s Board of Directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:153.36pt;width:100%"><div><font><br></font></div></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;You will receive a grant of Cumberland Pharmaceuticals common stock, pursuant to a stock options agreement (SOA).  Such shares will be subject to the SOA and the terms set forth in the incentive compensation plan under which they are awarded.  You may, at the Company&#8217;s sole discretion, receive additional awards of Company equity, which will be subject to their designated agreements and the incentive compensation plans under which they are awarded.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;Except as set forth in Section 2, the Company shall not be liable to you for any expense incurred by you unless you receive the Company's prior written consent to reimburse you for such expense.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Additional Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During the term hereof, you shall be entitled to receive prompt reimbursement for all reasonable and documented expenses incurred in the performance of services in accordance with the expense reimbursement policy of the Company.  Such reimbursement policy shall require adequate documentation by you of the expenses and payment by the Company of such amounts shall be made within a reasonable period after the close of the year in which the expenses were incurred.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employment at Will</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   This Agreement is not intended to and shall not be understood in any manner as affecting or modifying the at-will status of your employment with the Company.  As an at-will employee either you or the Company may terminate the employment relationship at any time with or without cause or notice.  The obligations of Sections 4, 5, 6, 7, 8, 10, 11 and 12 herein shall survive the termination of the employment relationship or of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All knowledge and information, not already available to the public, which you acquire, have acquired, or will acquire in the course of your employment with the Company with respect to the Company&#8217;s business, work methods, or pending regulatory matters, or other Company matters that are treated by the Company as confidential, shall be regarded by you as trade secrets, whether or not they are classifiable legally as trade secrets, and shall be treated by you as strictly confidential.  Such knowledge and information shall not either directly or indirectly be used, disclosed, or made accessible to anyone by you for any purpose, except in the ordinary course of the Company&#8217;s business under circumstances in which you are authorized to use or disclose such information.  No disclosures of such confidential information shall be made outside of those you are authorized to make in the regular and ordinary course of your duties unless and until you receive prior written permission of the Board of Directors of the Company to make such disclosure.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Discoveries and Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the time that you are employed by the Company, all confidential information, trade secrets, or proprietary information and all other discoveries, inventions, software programs, processes, methods and improvements that are conceived, developed, or otherwise made by you , alone or with others, that relate in any way to the Company&#8217;s present or planned business or products (collectively the &#8220;Developments&#8221;), whether or not patentable or subject to copyright protection and whether or not reduced to tangible form or reduced to practice, shall be the sole property of the Company.  You agree to disclose all Developments promptly, fully and in writing to the Company.  You agree to keep and maintain </font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:153.36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">adequate and current dated and witnessed written records of all such Developments, in the form of notes, sketches, drawings, or reports, which records shall  be promptly submitted to the Company and shall be and remain the property of the Company at all times.  You agree to assign, and hereby do assign, to, the Company all your right, title and interest throughout the world in and to all Developments.  You agree that all Developments shall constitute &#8220;Works for Hire&#8221; (as such are defined under the U.S. Copyright Laws) and hereby assign to the Company all copyrights, patents and other proprietary rights you may have in any Developments without any obligation on the part of the Company to pay royalties or any other consideration to you for such Developments.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All documents and other writings produced by you during the period of your employment, which relate to work you are doing or have done for the Company or to the business of the Company or its affiliates, shall belong to the Company.  You will not publish outside of the Company any such writing without the prior written consent of the Board of Directors of the Company.  You will, without further compensation, execute at any time (whether or not you are still employed by the Company) all documents requested of you relating to the protection of such rights, including the assignment of such rights to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You shall notify the Company within three business days if no longer employed and immediately if still employed by the Company if you are contacted by any person relating to any claim or litigation against the Company.  You shall not communicate in any manner with any person related to any claim or litigation against the Company without the prior consent of the Board of Directors of the Company unless compelled to do so by law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   For so long as you are employed by the Company or any Affiliate (as defined below) and for a period of one year after you cease to be employed by the Company or any Affiliate, you shall not, directly or indirectly, engage in any work or other activity--whether as owner, stockholder, partner, officer, consultant, or otherwise--involving a trademark, product, or process that, in the opinion of the Company&#8217;s Chief Executive Officer, is  similar to a trademark, product or process on which you worked for the Company (or any Affiliate) or obtained knowledge about while working for the Company at any time during the period of employment, if such work or other activity is then, or reasonably expected to become, competitive with that of the Company (or any Affiliate).  The restriction in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such work or activity and have received a release in writing from the Board of Directors of the Company allowing you to engage in such work or activity. The Company&#8217;s Chief Executive Officer shall have sole discretion to determine whether your work or activity for another employer involves trademarks, products, or processes that are similar to trademarks, products, or processes that you worked on for the Company. Ownership by you of five percent (5%) or less of the outstanding shares of stock of any company either (i) listed on a national securities exchange, or (ii) having at least one hundred (100) stockholders shall not make you a &#8220;stockholder&#8221; within the meaning of that term as used in this paragraph.  For one year after you cease to work for the Company, you will not engage in any work or activity that will cause you to inevitably disclose to anyone not employed by the Company (or an Affiliate) any trade secret </font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:153.36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or confidential information that belongs to the Company or one of its Affiliates.   Nothing in this paragraph shall limit the rights or remedies of the Company arising, directly or indirectly, from such competitive employment, including, without limitation, claims based upon breach of fiduciary duty, misappropriation, or theft of confidential information.  The term &#8220;Affiliate&#8221; shall mean the Company and any entity controlling, controlled by, or under common control with the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Conflicting Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You represent and warrant that you are not now under any obligation resulting from any contract or arrangement, to any person, firm, or corporation, which is inconsistent or in conflict with this Agreement.  Likewise you represent and warrant that you are not now under any obligation resulting from any contract or arrangement to any person, firm, or corporation which would prevent, limit, or impair in any way the performance by you of your obligations to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  After you cease to be employed by the Company (or a Company affiliate)&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;You agree not to solicit, directly or indirectly, business related to the development or sales of pharmaceutical products from any entity, organization, or person which is contracted with the Company, which has been doing business with the Company or from which the Company was soliciting at the time of your termination, or a firm which you knew or had reason to know that the Company was going to solicit business at the time you ceased to be employed by the Company.&#160; The restriction set forth in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such solicitation and have received a release in writing from the Board of Directors of the Company to engage in such solicitation.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;You agree not to solicit, recruit, hire, or assist in the hiring of any employee of the Company to work for you or another person, firm, corporation, or business.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Return of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon termination of your employment for any reason, you shall immediately return to the Company all documents and things belonging to the Company.  This includes, but is not limited to, trade secrets, confidential information, knowledge, data or know-how, and software containing such information, whether or not the documents are marked &#8220;Confidential.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge that in the event of breach of this Agreement by you, actual damages to the Company will be impossible to calculate, the Company&#8217;s remedies at law will be inadequate, and the Company will suffer irreparable harm.  Therefore, you agree that any of the covenants contained in this Agreement may be specifically enforced through injunctive relief, but such right to injunctive relief shall not preclude the Company from other remedies which may be available to it.  You further agree that should you fail to keep any of the promises made by you in this Agreement, or any way violate this Agreement, the Company shall be entitled to recover all monies the Company is required to spend, including attorneys&#8217; fees, to enforce the provisions of this Agreement.</font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:153.36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Best Efforts and Conflicts of Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;  You are hired with the understanding that Cumberland is your sole employer and you will provide a full-time work effort. You agree to devote your entire professional and business-related time and best efforts t&#92;o the services required of you by the express and implicit terms of this Agreement, to the reasonable satisfaction of Cumberland in its sole and complete discretion.  Engaging in activities outside of work that create a conflict of interest, or detract from your ability to perform your assigned responsibilities or meet your defined goals and objectives with Cumberland, is a problem and may lead to disciplinary action up to and including termination of employment.  If you believe that you are potentially involved in a situation that could create a conflict of interest and affect your ability to adequately perform your job with&#160;Cumberland, you should inform your direct supervisor and Cumberland&#8217;s Human Resources Department immediately.</font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i506476fa67154df1b840737594e55713_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Standards of Business Conduct and Ethics.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Cumberland&#8217;s commitment to a culture of integrity, ethics and compliance with the law is comprised in this policy, which will be provided to you as part of the conditions of your employment. You will have the opportunity to read, discuss and understand this policy prior to accepting and signing its Letter of Agreement.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Debarment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You represent and warrant that you have not been debarred and will notify the Company immediately if you are debarred, pursuant to subsection 306(a) or 306(b) of the Federal Food, Drug, and Cosmetic Act.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notice required or permitted to be given under this Agreement shall be sufficient if in writing and if sent by registered or certified mail to your residence or to the Company&#8217;s principal office in the case of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 17&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The waiver by either party of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement contains the entire agreement of the parties and may not be changed orally, but only by an agreement in writing signed by the party against whom enforcement of any waiver, change, modification, extension, or discharge is sought.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement shall be governed by the laws of the State of Tennessee.  Any dispute arising out of this Agreement shall be resolved, at the Company&#8217;s sole option, by courts sitting in Nashville, Tennessee, and you waive any objection to such venue.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Enforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that any provision of this Agreement shall be held by a court to be unenforceable, such provision will be enforced to the maximum extent permissible, and the remaining portions of this Agreement shall remain in full force and effect.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any termination of your employment, this Agreement shall survive and remain in effect in accordance with its terms.</font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font><br></font></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font><br></font></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font><br></font></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font><br></font></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">#   #   #   #</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This letter agreement may be signed in one or more counterparts, each of which shall be an original and all of which will constitute one and the same instrument.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Sincerely yours,</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> CUMBERLAND PHARMACEUTICALS INC.</font></div><div style="padding-left:108pt;padding-right:108pt;text-align:center"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">_____</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline"> Stephanie Smith</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">_________&#160;&#160;&#160;&#160;        </font></div><div style="padding-left:144pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160; By&#58;  &#160;&#160;&#160;&#160;Stephanie Smith, MBA, HRM</font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">HR Manager</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accepted as to all terms and conditions.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> as of the 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day of March 2023&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">______</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; A.J. Kazimi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">_______________</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.J. Kazimi </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>jameshermanemploymentagree.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i1a8d03c550a843f08f09724887d9c8b7_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 9, 2023</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">James &#8220;Jim&#8221; Herman</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">430 Brentwood Oaks Dr</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Nashville, TN 37221</font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Re&#58;&#160;&#160;&#160;&#160;Employment of Jim Herman Executive Vice President National Accounts &#38; Chief Compliance Officer as by Cumberland Pharmaceuticals Inc.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dear Jim, </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Effective January 1, 2023, this letter agreement (the &#8220;Agreement&#8221;) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;) In consideration of your appointment as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Executive Vice President National Accounts &#38; Chief Compliance Officer </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Company, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Compensation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Company agrees to compensate you as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;The Company agrees to pay you on a salary basis for services performed based on an annual rate of three hundred ten thousand ($310,000) payable in arrears in equal monthly installments on the 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day of each calendar month of 2023.  For each year, thereafter, you will be paid on a salary basis for services performed based on an annual rate determined by the Company in its sole discretion&#59; provided, however, that any obligation to make payments under this Section 1(a) will cease upon termination of your employment for any reason.  Notwithstanding the foregoing, nothing in this Section 1(a) alters or is intended to alter the at-will nature of your employment as described in Section 3 of this Agreement.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;You will be eligible to participate in any Company-wide employee benefits as approved by the Board of Directors.  The terms of your eligibility and participation will be governed by the provisions of the employee benefit plans, as such plans may be amended from time to time in the discretion of the Company's Board of Directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;You may be eligible for any Company bonus program, based upon performance in meeting your individual objectives and the Company&#8217;s overall performance, both as determined and approved by the Board of Directors of the Company.  Any such bonus will be discretionary and will be subject to the terms of the applicable bonus program, the terms of which program may be modified from year to year in the sole discretion of the Company&#8217;s Board of Directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;You will receive a grant of Cumberland Pharmaceuticals common stock, pursuant to a stock options agreement (SOA).  Such shares will be subject to the SOA and the terms set forth in the incentive compensation plan under which they are awarded.  You may, at the Company&#8217;s sole discretion, receive additional awards of Company equity, which will be subject to their designated agreements and the incentive compensation plans under which they are awarded.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;Except as set forth in Section 2, the Company shall not be liable to you for any expense incurred by you unless you receive the Company's prior written consent to reimburse you for such expense.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Additional Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During the term hereof, you shall be entitled to receive prompt reimbursement for all reasonable and documented expenses incurred in the performance of services in accordance with the expense reimbursement policy of the Company.  Such reimbursement policy shall require adequate documentation by you of the expenses and payment by the Company of such amounts shall be made within a reasonable period after the close of the year in which the expenses were incurred.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employment at Will</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   This Agreement is not intended to and shall not be understood in any manner as affecting or modifying the at-will status of your employment with the Company.  As an at-will employee either you or the Company may terminate the employment relationship at any time with or without cause or notice.  The obligations of Sections 4, 5, 6, 7, 8, 10, 11 and 12 herein shall survive the termination of the employment relationship or of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All knowledge and information, not already available to the public, which you acquire, have acquired, or will acquire in the course of your employment with the Company with respect to the Company&#8217;s business, work methods, or pending regulatory matters, or other Company matters that are treated by the Company as confidential, shall be regarded by you as trade secrets, whether or not they are classifiable legally as trade secrets, and shall be treated by you as strictly confidential.  Such knowledge and information shall not either directly or indirectly be used, disclosed, or made accessible to anyone by you for any purpose, except in the ordinary course of the Company&#8217;s business when you are authorized to use or disclose such information.  No disclosures of such confidential information shall be made outside of those you are authorized to make in the regular and ordinary course of your duties unless and until you receive prior written permission of the Board of Directors of the Company to make such disclosure.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Discoveries and Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the time that you are employed by the Company, all confidential information, trade secrets, or proprietary information and all other discoveries, inventions, software programs, processes, methods and improvements that are conceived, developed, or otherwise made by you , alone or with others, that relate in any way to the Company&#8217;s present or planned business or products (collectively the &#8220;Developments&#8221;), whether or not patentable or subject to copyright protection and whether or not reduced to tangible form or reduced to practice, shall be the sole property of the Company.  You agree to disclose all Developments promptly, fully and in writing to the Company.  You agree to keep and maintain adequate and current dated and witnessed written records of all such Developments, in the form of notes, sketches, drawings, or reports, which records shall be promptly submitted to the Company and shall be always and remain the property of the Company.  You agree to assign, and hereby do assign, to, the Company all your right, title, and interest throughout the world in and to all Developments.  You agree that all Developments shall constitute &#8220;Works for Hire&#8221; (as such are defined under the U.S. Copyright Laws) and hereby assign to the Company all copyrights, patents, and other proprietary rights you may have in any Developments without any obligation on the part of the Company to pay royalties or any other consideration to you for such Developments.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All documents and other writings produced by you during the period of your employment, which relate to work you are doing or have done for the Company or to the business of the Company or its affiliates, shall belong to the Company.  You will not publish outside of the Company any such writing without the prior written consent of the Board of Directors of the Company.  You will, without further compensation, execute at any time (whether or not you are still employed by the Company) all documents requested of you relating to the protection of such rights, including the assignment of such rights to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You shall notify the Company within three business days if no longer employed and immediately if still employed by the Company if you are contacted by any person </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">relating to any claim or litigation against the Company.  You shall not communicate in any manner with any person related to any claim or litigation against the Company without the prior consent of the Board of Directors of the Company unless compelled to do so by law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   For so long as you are employed by the Company or any Affiliate (as defined below) and for a period of one year after you cease to be employed by the Company or any Affiliate, you shall not, directly or indirectly, engage in any work or other activity--whether as owner, stockholder, partner, officer, consultant, or otherwise--involving a trademark, product, or process that, in the opinion of the Company&#8217;s President, is  similar to a trademark, product or process on which you worked for the Company (or any Affiliate) or obtained knowledge about while working for the Company at any time during the period of employment, if such work or other activity is then, or reasonably expected to become, competitive with that of the Company (or any Affiliate).  The restriction in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such work or activity and have received a release in writing from the Board of Directors of the Company allowing you to engage in such work or activity. The Company&#8217;s President shall have sole discretion to determine whether your work or activity for another employer involves trademarks, products, or processes that are similar to trademarks, products, or processes that you worked on for the Company. Ownership by you of five percent (5%) or less of the outstanding shares of stock of any company either (i) listed on a national securities exchange, or (ii) having at least one hundred (100) stockholders shall not make you a &#8220;stockholder&#8221; within the meaning of that term as used in this paragraph.  For one year after you cease to work for the Company, you will not engage in any work or activity that will cause you to inevitably disclose to anyone not employed by the Company (or an Affiliate) any trade secret or confidential information that belongs to the Company or one of its Affiliates.   Nothing in this paragraph shall limit the rights or remedies of the Company arising, directly or indirectly, from such competitive employment, including, without limitation, claims based upon breach of fiduciary duty, misappropriation, or theft of confidential information.  The term &#8220;Affiliate&#8221; shall mean the Company and any entity controlling, controlled by, or under common control with the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Conflicting Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You represent and warrant that you are not now under any obligation resulting from any contract or arrangement to any person, firm, or corporation, which is inconsistent or in conflict with this Agreement.  Likewise, you represent and warrant that you are not now under any obligation resulting from any contract or arrangement to any person, firm, or corporation which would prevent, limit, or impair in any way the performance by you of your obligations to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  For a period of one year after you cease to be employed by the Company (or a Company affiliate)&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;You agree not to solicit, directly or indirectly, business related to the development or sales of pharmaceutical products from any entity, organization, or person which is contracted with the Company, which has been doing business with the Company or from which the Company was soliciting at the time of your termination, or a firm which you knew or had reason to know that the Company was going to solicit business at the time you ceased to be employed by the Company.  The restriction set forth in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such solicitation and have received a release in writing from the Board of Directors of the Company to engage in such solicitation.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;You agree not to solicit, recruit, hire, or assist in the hiring of any employee of the Company to work for you or another person, firm, corporation, or business in competition with, or reasonably likely to become in competition with, the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Return of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon termination of your employment for any reason, you shall immediately return to the Company all documents and things belonging to the Company.  This includes, but is not limited to, trade secrets, confidential information, knowledge, data or know-how, and software containing such information, whether or not the documents are marked &#8220;Confidential.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge that in the event of breach of this Agreement by you, actual damages to the Company will be impossible to calculate, the Company&#8217;s remedies at law will be inadequate, and the Company will suffer irreparable harm.  Therefore, you agree that any of the covenants contained in this Agreement may be specifically enforced through injunctive relief, but such right to injunctive relief shall not preclude the Company from other remedies which may be available to it.  You further agree that should you fail to keep any of the promises made by you in this Agreement, or any way violate this Agreement, the Company shall be entitled to recover all monies the Company is required to spend, including attorneys&#8217; fees, to enforce the provisions of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Best Efforts and Conflicts of Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;  You are hired with the understanding that Cumberland is your sole employer, and you will provide a full-time work effort. You agree to devote your entire professional and business-related time and best efforts to the services required of you by the express and implicit terms of this Agreement, to the reasonable satisfaction of Cumberland in its sole and complete discretion.  Engaging in activities outside of work that create a conflict of interest or detract from your ability to perform your assigned responsibilities or meet your defined goals and objectives with Cumberland, is a problem and may lead to disciplinary action up to and including termination of employment.  If you believe that you are potentially involved in a situation that could create a conflict of interest and affect your ability to adequately perform your job with&#160;Cumberland, you should inform your direct supervisor and Cumberland&#8217;s Human Resources Department immediately.</font></div><div id="i1a8d03c550a843f08f09724887d9c8b7_4"></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Debarment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You represent and warrant that you have not been debarred and will notify the Company immediately if you are debarred, pursuant to subsection 306(a) or 306(b) of the Federal Food, Drug, and Cosmetic Act.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notice required or permitted to be given under this Agreement shall be sufficient if in writing and if sent by registered or certified mail to your residence or to the Company&#8217;s principal office in the case of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The waiver by either party of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement contains the entire agreement of the parties and may not be changed orally, but only by an agreement in writing signed by the party against whom enforcement of any waiver, change, modification, extension, or discharge is sought.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement shall be governed by the laws of the State of Tennessee.  Any dispute arising out of this Agreement shall be resolved, at the Company&#8217;s sole option, by courts sitting in Nashville, Tennessee, and you waive any objection to such venue.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Enforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If any provision of this Agreement shall be held by a court to be unenforceable, such provision will be enforced to the maximum extent permissible, and the remaining portions of this Agreement shall remain in full force and effect.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any termination of your employment, this Agreement shall survive and remain in effect in accordance with its terms.</font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">#   #   #   #</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This letter agreement may be signed in one or more counterparts, each of which shall be an original and all of which will constitute one and the same instrument.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sincerely yours,</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> CUMBERLAND PHARMACEUTICALS INC.</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">_______________________________________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; By&#58;  &#160;&#160;&#160;&#160;A.J. Kazimi</font></div><div style="padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Executive Officer</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accepted as to all terms and conditions.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as of the 9th of March 2023&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">____________</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Jim Herman</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">_____________</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">James &#8220;Jim&#8221; Herman    </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>toddanthony-employmentagre.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i948cd6629d6e40e8bea0cae6137ef94c_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 9, 2023</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Todd Anthony</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">702 Meeting Street</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Franklin, TN 37064</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Re&#58;&#160;&#160;&#160;&#160;Employment of Todd Anthony Vice President of Organizational Development as by Cumberland Pharmaceuticals Inc.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dear Todd, </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Effective January 1, 2023, this letter agreement (the &#8220;Agreement&#8221;) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;) In consideration of your appointment as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Vice President of Organizational Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> the Company, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Compensation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Company agrees to compensate you as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;The Company agrees to pay you on a salary basis for services performed based on an annual rate of two hundred fifty-two thousand five hundred ($272,500.00), payable in arrears in equal monthly installments on the 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day of each calendar month of 2023.  For each year, thereafter, you will be paid on a salary basis for services performed based on an annual rate determined by the Company in its sole discretion&#59; provided, however, that any obligation to make payments under this Section 1(a) will cease upon termination of your employment for any reason.  Notwithstanding the foregoing, nothing in this Section 1(a) alters or is intended to alter the at-will nature of your employment as described in Section 3 of this Agreement.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;You will be eligible to participate in any Company-wide employee benefits as approved by the Board of Directors.  The terms of your eligibility and participation will be governed by the provisions of the employee benefit plans, as such plans may be amended from time to time in the discretion of the Company's Board of Directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;You may be eligible for any Company bonus program, based upon performance in meeting your individual objectives and the Company&#8217;s overall performance, both as determined and approved by the Board of Directors of the Company.  Any such bonus will be discretionary and will be subject to the terms of the applicable bonus program, the terms of which program may be modified from year to year in the sole discretion of the Company&#8217;s Board of Directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;You will receive a grant of Cumberland Pharmaceuticals common stock, pursuant to a stock options agreement (SOA).  Such shares will be subject to the SOA and the terms set forth in the incentive compensation plan under which they are awarded.  You may, at the Company&#8217;s sole discretion, receive additional awards of Company equity, which will be subject to their designated agreements and the incentive compensation plans under which they are awarded.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;Except as set forth in Section 2, the Company shall not be liable to you for any expense incurred by you unless you receive the Company's prior written consent to reimburse you for such expense.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Additional Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During the term hereof, you shall be entitled to receive prompt reimbursement for all reasonable and documented expenses incurred in the performance of services in accordance with the expense reimbursement policy of the Company.  Such reimbursement policy shall require adequate documentation by you of the expenses and payment by the Company of such amounts shall be made within a reasonable period after the close of the year in which the expenses were incurred.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employment at Will</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   This Agreement is not intended to and shall not be understood in any manner as affecting or modifying the at-will status of your employment with the Company.  As an at-will employee either you or the Company may terminate the employment relationship at any time with or without cause or notice.  The obligations of Sections 4, 5, 6, 7, 8, 10, 11 and 12 herein shall survive the termination of the employment relationship or of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All knowledge and information, not already available to the public, which you acquire, have acquired, or will acquire in the course of your employment with the Company with respect to the Company&#8217;s business, work methods, or pending regulatory matters, or other Company matters that are treated by the Company as confidential, shall be regarded by you as trade secrets, whether or not they are classifiable legally as trade secrets, and shall be treated by you as strictly confidential.  Such knowledge and information shall not either directly or indirectly be used, disclosed, or made accessible to anyone by you for any purpose, except in the ordinary course of the Company&#8217;s business when you are authorized to use or disclose such information.  No disclosures of such confidential information shall be made outside of those you are authorized to make in the regular and ordinary course of your duties unless and until you receive prior written permission of the Board of Directors of the Company to make such disclosure.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Discoveries and Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the time that you are employed by the Company, all confidential information, trade secrets, or proprietary information and all other discoveries, inventions, software programs, processes, methods and improvements that are conceived, developed, or otherwise made by you , alone or with others, that relate in any way to the Company&#8217;s present or planned business or products (collectively the &#8220;Developments&#8221;), whether or not patentable or subject to copyright protection and whether or not reduced to tangible form or reduced to practice, shall be the sole property of the Company.  You agree to disclose all Developments promptly, fully and in writing to the Company.  You agree to keep and maintain adequate and current dated and witnessed written records of all such Developments, in the form of notes, sketches, drawings, or reports, which records shall be promptly submitted to the Company and shall be always and remain the property of the Company.  You agree to assign, and hereby do assign, to, the Company all your right, title, and interest throughout the world in and to all Developments.  You agree that all Developments shall constitute &#8220;Works for Hire&#8221; (as such are defined under the U.S. Copyright Laws) and hereby assign to the Company all copyrights, patents, and other proprietary rights you may have in any Developments without any obligation on the part of the Company to pay royalties or any other consideration to you for such Developments.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All documents and other writings produced by you during the period of your employment, which relate to work you are doing or have done for the Company or to the business of the Company or its affiliates, shall belong to the Company.  You will not publish outside of the Company any such writing without the prior written consent of the Board of Directors of the Company.  You will, without further compensation, execute at any time (whether or not you are still employed by the Company) all documents requested of you relating to the protection of such rights, including the assignment of such rights to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You shall notify the Company within three business days if no longer employed and immediately if still employed by the Company if you are contacted by any person </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">relating to any claim or litigation against the Company.  You shall not communicate in any manner with any person related to any claim or litigation against the Company without the prior consent of the Board of Directors of the Company unless compelled to do so by law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   For so long as you are employed by the Company or any Affiliate (as defined below) and for a period of one year after you cease to be employed by the Company or any Affiliate, you shall not, directly or indirectly, engage in any work or other activity--whether as owner, stockholder, partner, officer, consultant, or otherwise--involving a trademark, product, or process that, in the opinion of the Company&#8217;s President, is  similar to a trademark, product or process on which you worked for the Company (or any Affiliate) or obtained knowledge about while working for the Company at any time during the period of employment, if such work or other activity is then, or reasonably expected to become, competitive with that of the Company (or any Affiliate).  The restriction in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such work or activity and have received a release in writing from the Board of Directors of the Company allowing you to engage in such work or activity. The Company&#8217;s President shall have sole discretion to determine whether your work or activity for another employer involves trademarks, products, or processes that are similar to trademarks, products, or processes that you worked on for the Company. Ownership by you of five percent (5%) or less of the outstanding shares of stock of any company either (i) listed on a national securities exchange, or (ii) having at least one hundred (100) stockholders shall not make you a &#8220;stockholder&#8221; within the meaning of that term as used in this paragraph.  For one year after you cease to work for the Company, you will not engage in any work or activity that will cause you to inevitably disclose to anyone not employed by the Company (or an Affiliate) any trade secret or confidential information that belongs to the Company or one of its Affiliates.   Nothing in this paragraph shall limit the rights or remedies of the Company arising, directly or indirectly, from such competitive employment, including, without limitation, claims based upon breach of fiduciary duty, misappropriation, or theft of confidential information.  The term &#8220;Affiliate&#8221; shall mean the Company and any entity controlling, controlled by, or under common control with the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Conflicting Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You represent and warrant that you are not now under any obligation resulting from any contract or arrangement to any person, firm, or corporation, which is inconsistent or in conflict with this Agreement.  Likewise, you represent and warrant that you are not now under any obligation resulting from any contract or arrangement to any person, firm, or corporation which would prevent, limit, or impair in any way the performance by you of your obligations to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  For a period of one year after you cease to be employed by the Company (or a Company affiliate)&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;You agree not to solicit, directly or indirectly, business related to the development or sales of pharmaceutical products from any entity, organization, or person which is contracted with the Company, which has been doing business with the Company or from which the Company was soliciting at the time of your termination, or a firm which you knew or had reason to know that the Company was going to solicit business at the time you ceased to be employed by the Company.  The restriction set forth in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such solicitation and have received a release in writing from the Board of Directors of the Company to engage in such solicitation.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;You agree not to solicit, recruit, hire, or assist in the hiring of any employee of the Company to work for you or another person, firm, corporation, or business in competition with, or reasonably likely to become in competition with, the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Return of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon termination of your employment for any reason, you shall immediately return to the Company all documents and things belonging to the Company.  This includes, but is not limited to, trade secrets, confidential information, knowledge, data or know-how, and software containing such information, whether or not the documents are marked &#8220;Confidential.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge that in the event of breach of this Agreement by you, actual damages to the Company will be impossible to calculate, the Company&#8217;s remedies at law will be inadequate, and the Company will suffer irreparable harm.  Therefore, you agree that any of the covenants contained in this Agreement may be specifically enforced through injunctive relief, but such right to injunctive relief shall not preclude the Company from other remedies which may be available to it.  You further agree that should you fail to keep any of the promises made by you in this Agreement, or any way violate this Agreement, the Company shall be entitled to recover all monies the Company is required to spend, including attorneys&#8217; fees, to enforce the provisions of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Best Efforts and Conflicts of Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;  You are hired with the understanding that Cumberland is your sole employer, and you will provide a full-time work effort. You agree to devote your entire professional and business-related time and best efforts to the services required of you by the express and implicit terms of this Agreement, to the reasonable satisfaction of Cumberland in its sole and complete discretion.  Engaging in activities outside of work that create a conflict of interest or detract from your ability to perform your assigned responsibilities or meet your defined goals and objectives with Cumberland, is a problem and may lead to disciplinary action up to and including termination of employment.  If you believe that you are potentially involved in a situation that could create a conflict of interest and affect your ability to adequately perform your job with&#160;Cumberland, you should inform your direct supervisor and Cumberland&#8217;s Human Resources Department immediately.</font></div><div id="i948cd6629d6e40e8bea0cae6137ef94c_4"></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Debarment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You represent and warrant that you have not been debarred and will notify the Company immediately if you are debarred, pursuant to subsection 306(a) or 306(b) of the Federal Food, Drug, and Cosmetic Act.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notice required or permitted to be given under this Agreement shall be sufficient if in writing and if sent by registered or certified mail to your residence or to the Company&#8217;s principal office in the case of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The waiver by either party of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement contains the entire agreement of the parties and may not be changed orally, but only by an agreement in writing signed by the party against whom enforcement of any waiver, change, modification, extension, or discharge is sought.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement shall be governed by the laws of the State of Tennessee.  Any dispute arising out of this Agreement shall be resolved, at the Company&#8217;s sole option, by courts sitting in Nashville, Tennessee, and you waive any objection to such venue.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Enforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If any provision of this Agreement shall be held by a court to be unenforceable, such provision will be enforced to the maximum extent permissible, and the remaining portions of this Agreement shall remain in full force and effect.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any termination of your employment, this Agreement shall survive and remain in effect in accordance with its terms.</font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">#   #   #   #</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This letter agreement may be signed in one or more counterparts, each of which shall be an original and all of which will constitute one and the same instrument.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sincerely yours,</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> CUMBERLAND PHARMACEUTICALS INC.</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">_______________________________________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; By&#58;  &#160;&#160;&#160;&#160;A.J. Kazimi</font></div><div style="padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Executive Officer</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accepted as to all terms and conditions.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as of the 9th of March 2023&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">____________</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Todd Anthony</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">___________</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Todd Anthony   </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>5
<FILENAME>chrisbittermanemploymentag.htm
<DESCRIPTION>EX-10.4
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ia326ba55958e4e0782f7ded7cc1db8ee_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 9, 2023</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chris Bitterman </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6440 Halcyon Garden Drive</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Alpharetta, GA 37090</font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Re&#58;&#160;&#160;&#160;&#160;Employment of Chris Bitterman, Vice President of Sales and Marketing as by Cumberland Pharmaceuticals Inc.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dear Chris, </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Effective January 1, 2023, this letter agreement (the &#8220;Agreement&#8221;) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;) In consideration of your appointment as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Vice President of Sales and Marketing </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Company, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Compensation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Company agrees to compensate you as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;The Company agrees to pay you on a salary basis for services performed based on an annual rate of two hundred fifty-eight thousand five hundred ($258,500.00) payable in arrears in equal monthly installments on the 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day of each calendar month of 2023.  For each year, thereafter, you will be paid on a salary basis for services performed based on an annual rate determined by the Company in its sole discretion&#59; provided, however, that any obligation to make payments under this Section 1(a) will cease upon termination of your employment for any reason.  Notwithstanding the foregoing, nothing in this Section 1(a) alters or is intended to alter the at-will nature of your employment as described in Section 3 of this Agreement.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;You will be eligible to participate in any Company-wide employee benefits as approved by the Board of Directors.  The terms of your eligibility and participation will be governed by the provisions of the employee benefit plans, as such plans may be amended from time to time in the discretion of the Company's Board of Directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;You may be eligible for any Company bonus program, based upon performance in meeting your individual objectives and the Company&#8217;s overall performance, both as determined and approved by the Board of Directors of the Company.  Any such bonus will be discretionary and will be subject to the terms of the applicable bonus program, the terms of which program may be modified from year to year in the sole discretion of the Company&#8217;s Board of Directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;You will receive a grant of Cumberland Pharmaceuticals common stock, pursuant to a stock options agreement (SOA).  Such shares will be subject to the SOA and the terms set forth in the incentive compensation plan under which they are awarded.  You may, at the Company&#8217;s sole discretion, receive additional awards of Company equity, which will be subject to their designated agreements and the incentive compensation plans under which they are awarded.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;Except as set forth in Section 2, the Company shall not be liable to you for any expense incurred by you unless you receive the Company's prior written consent to reimburse you for such expense.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Additional Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During the term hereof, you shall be entitled to receive prompt reimbursement for all reasonable and documented expenses incurred in the performance of services in accordance with the expense reimbursement policy of the Company.  Such reimbursement policy shall require adequate documentation by you of the expenses and payment by the Company of such amounts shall be made within a reasonable period after the close of the year in which the expenses were incurred.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employment at Will</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   This Agreement is not intended to and shall not be understood in any manner as affecting or modifying the at-will status of your employment with the Company.  As an at-will employee either you or the Company may terminate the employment relationship at any time with or without cause or notice.  The obligations of Sections 4, 5, 6, 7, 8, 10, 11 and 12 herein shall survive the termination of the employment relationship or of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All knowledge and information, not already available to the public, which you acquire, have acquired, or will acquire in the course of your employment with the Company with respect to the Company&#8217;s business, work methods, or pending regulatory matters, or other Company matters that are treated by the Company as confidential, shall be regarded by you as trade secrets, whether or not they are classifiable legally as trade secrets, and shall be treated by you as strictly confidential.  Such knowledge and information shall not either directly or indirectly be used, disclosed, or made accessible to anyone by you for any purpose, except in the ordinary course of the Company&#8217;s business when you are authorized to use or disclose such information.  No disclosures of such confidential information shall be made outside of those you are authorized to make in the regular and ordinary course of your duties unless and until you receive prior written permission of the Board of Directors of the Company to make such disclosure.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Discoveries and Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the time that you are employed by the Company, all confidential information, trade secrets, or proprietary information and all other discoveries, inventions, software programs, processes, methods and improvements that are conceived, developed, or otherwise made by you , alone or with others, that relate in any way to the Company&#8217;s present or planned business or products (collectively the &#8220;Developments&#8221;), whether or not patentable or subject to copyright protection and whether or not reduced to tangible form or reduced to practice, shall be the sole property of the Company.  You agree to disclose all Developments promptly, fully and in writing to the Company.  You agree to keep and maintain adequate and current dated and witnessed written records of all such Developments, in the form of notes, sketches, drawings, or reports, which records shall be promptly submitted to the Company and shall be always and remain the property of the Company.  You agree to assign, and hereby do assign, to, the Company all your right, title, and interest throughout the world in and to all Developments.  You agree that all Developments shall constitute &#8220;Works for Hire&#8221; (as such are defined under the U.S. Copyright Laws) and hereby assign to the Company all copyrights, patents, and other proprietary rights you may have in any Developments without any obligation on the part of the Company to pay royalties or any other consideration to you for such Developments.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All documents and other writings produced by you during the period of your employment, which relate to work you are doing or have done for the Company or to the business of the Company or its affiliates, shall belong to the Company.  You will not publish outside of the Company any such writing without the prior written consent of the Board of Directors of the Company.  You will, without further compensation, execute at any time (whether or not you are still employed by the Company) all documents requested of you relating to the protection of such rights, including the assignment of such rights to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You shall notify the Company within three business days if no longer employed and immediately if still employed by the Company if you are contacted by any person </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">relating to any claim or litigation against the Company.  You shall not communicate in any manner with any person related to any claim or litigation against the Company without the prior consent of the Board of Directors of the Company unless compelled to do so by law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   For so long as you are employed by the Company or any Affiliate (as defined below) and for a period of one year after you cease to be employed by the Company or any Affiliate, you shall not, directly or indirectly, engage in any work or other activity--whether as owner, stockholder, partner, officer, consultant, or otherwise--involving a trademark, product, or process that, in the opinion of the Company&#8217;s President, is  similar to a trademark, product or process on which you worked for the Company (or any Affiliate) or obtained knowledge about while working for the Company at any time during the period of employment, if such work or other activity is then, or reasonably expected to become, competitive with that of the Company (or any Affiliate).  The restriction in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such work or activity and have received a release in writing from the Board of Directors of the Company allowing you to engage in such work or activity. The Company&#8217;s President shall have sole discretion to determine whether your work or activity for another employer involves trademarks, products, or processes that are similar to trademarks, products, or processes that you worked on for the Company. Ownership by you of five percent (5%) or less of the outstanding shares of stock of any company either (i) listed on a national securities exchange, or (ii) having at least one hundred (100) stockholders shall not make you a &#8220;stockholder&#8221; within the meaning of that term as used in this paragraph.  For one year after you cease to work for the Company, you will not engage in any work or activity that will cause you to inevitably disclose to anyone not employed by the Company (or an Affiliate) any trade secret or confidential information that belongs to the Company or one of its Affiliates.   Nothing in this paragraph shall limit the rights or remedies of the Company arising, directly or indirectly, from such competitive employment, including, without limitation, claims based upon breach of fiduciary duty, misappropriation, or theft of confidential information.  The term &#8220;Affiliate&#8221; shall mean the Company and any entity controlling, controlled by, or under common control with the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Conflicting Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You represent and warrant that you are not now under any obligation resulting from any contract or arrangement to any person, firm, or corporation, which is inconsistent or in conflict with this Agreement.  Likewise, you represent and warrant that you are not now under any obligation resulting from any contract or arrangement to any person, firm, or corporation which would prevent, limit, or impair in any way the performance by you of your obligations to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  For a period of one year after you cease to be employed by the Company (or a Company affiliate)&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;You agree not to solicit, directly or indirectly, business related to the development or sales of pharmaceutical products from any entity, organization, or person which is contracted with the Company, which has been doing business with the Company or from which the Company was soliciting at the time of your termination, or a firm which you knew or had reason to know that the Company was going to solicit business at the time you ceased to be employed by the Company.  The restriction set forth in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such solicitation and have received a release in writing from the Board of Directors of the Company to engage in such solicitation.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;You agree not to solicit, recruit, hire, or assist in the hiring of any employee of the Company to work for you or another person, firm, corporation, or business in competition with, or reasonably likely to become in competition with, the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Return of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon termination of your employment for any reason, you shall immediately return to the Company all documents and things belonging to the Company.  This includes, but is not limited to, trade secrets, confidential information, knowledge, data or know-how, and software containing such information, whether or not the documents are marked &#8220;Confidential.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge that in the event of breach of this Agreement by you, actual damages to the Company will be impossible to calculate, the Company&#8217;s remedies at law will be inadequate, and the Company will suffer irreparable harm.  Therefore, you agree that any of the covenants contained in this Agreement may be specifically enforced through injunctive relief, but such right to injunctive relief shall not preclude the Company from other remedies which may be available to it.  You further agree that should you fail to keep any of the promises made by you in this Agreement, or any way violate this Agreement, the Company shall be entitled to recover all monies the Company is required to spend, including attorneys&#8217; fees, to enforce the provisions of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Best Efforts and Conflicts of Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;  You are hired with the understanding that Cumberland is your sole employer, and you will provide a full-time work effort. You agree to devote your entire professional and business-related time and best efforts to the services required of you by the express and implicit terms of this Agreement, to the reasonable satisfaction of Cumberland in its sole and complete discretion.  Engaging in activities outside of work that create a conflict of interest or detract from your ability to perform your assigned responsibilities or meet your defined goals and objectives with Cumberland, is a problem and may lead to disciplinary action up to and including termination of employment.  If you believe that you are potentially involved in a situation that could create a conflict of interest and affect your ability to adequately perform your job with&#160;Cumberland, you should inform your direct supervisor and Cumberland&#8217;s Human Resources Department immediately.</font></div><div id="ia326ba55958e4e0782f7ded7cc1db8ee_4"></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Debarment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You represent and warrant that you have not been debarred and will notify the Company immediately if you are debarred, pursuant to subsection 306(a) or 306(b) of the Federal Food, Drug, and Cosmetic Act.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notice required or permitted to be given under this Agreement shall be sufficient if in writing and if sent by registered or certified mail to your residence or to the Company&#8217;s principal office in the case of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The waiver by either party of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement contains the entire agreement of the parties and may not be changed orally, but only by an agreement in writing signed by the party against whom enforcement of any waiver, change, modification, extension, or discharge is sought.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement shall be governed by the laws of the State of Tennessee.  Any dispute arising out of this Agreement shall be resolved, at the Company&#8217;s sole option, by courts sitting in Nashville, Tennessee, and you waive any objection to such venue.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Enforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If any provision of this Agreement shall be held by a court to be unenforceable, such provision will be enforced to the maximum extent permissible, and the remaining portions of this Agreement shall remain in full force and effect.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any termination of your employment, this Agreement shall survive and remain in effect in accordance with its terms.</font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">#   #   #   #</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This letter agreement may be signed in one or more counterparts, each of which shall be an original and all of which will constitute one and the same instrument.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sincerely yours,</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> CUMBERLAND PHARMACEUTICALS INC.</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">_______________________________________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; By&#58;  &#160;&#160;&#160;&#160;A.J. Kazimi</font></div><div style="padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Executive Officer</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accepted as to all terms and conditions.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as of the 9th of March 2023&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">_________</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Chris Bitterman</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">_____________</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chris Bitterman     </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>6
<FILENAME>johnhammemploymentagreemen.htm
<DESCRIPTION>EX-10.5
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i84bae12c0a43449a9560fe6bce00e9bd_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 9, 2023</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">John Hamm</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1659 Kirkwood Place</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Brentwood, TN 37216</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Re&#58;&#160;&#160;&#160;&#160;Employment of John Hamm Chief Financial Officer as by Cumberland Pharmaceuticals Inc.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dear John, </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Effective January 1, 2023, this letter agreement (the &#8220;Agreement&#8221;) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;) In consideration of your appointment as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Company, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Compensation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Company agrees to compensate you as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;The Company agrees to pay you on a salary basis for services performed based on an annual rate of two hundred and twenty-eight thousand ($228,000.00) payable in arrears in equal monthly installments on the 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day of each calendar month of 2023.  For each year, thereafter, you will be paid on a salary basis for services performed based on an annual rate determined by the Company in its sole discretion&#59; provided, however, that any obligation to make payments under this Section 1(a) will cease upon termination of your employment for any reason.  Notwithstanding the foregoing, nothing in this Section 1(a) alters or is intended to alter the at-will nature of your employment as described in Section 3 of this Agreement.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;You will be eligible to participate in any Company-wide employee benefits as approved by the Board of Directors.  The terms of your eligibility and participation will be governed by the provisions of the employee benefit plans, as such plans may be amended from time to time in the discretion of the Company's Board of Directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;You may be eligible for any Company bonus program, based upon performance in meeting your individual objectives and the Company&#8217;s overall performance, both as determined and approved by the Board of Directors of the Company.  Any such bonus will be discretionary and will be subject to the terms of the applicable bonus program, the terms of which program may be modified from year to year in the sole discretion of the Company&#8217;s Board of Directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;You will receive a grant of Cumberland Pharmaceuticals common stock, pursuant to a stock options agreement (SOA).  Such shares will be subject to the SOA and the terms set forth in the incentive compensation plan under which they are awarded.  You may, at the Company&#8217;s sole discretion, receive additional awards of Company equity, which will be subject to their designated agreements and the incentive compensation plans under which they are awarded.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;Except as set forth in Section 2, the Company shall not be liable to you for any expense incurred by you unless you receive the Company's prior written consent to reimburse you for such expense.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Additional Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During the term hereof, you shall be entitled to receive prompt reimbursement for all reasonable and documented expenses incurred in the performance of services in accordance with the expense reimbursement policy of the Company.  Such reimbursement policy shall require adequate documentation by you of the expenses and payment by the Company of such amounts shall be made within a reasonable period after the close of the year in which the expenses were incurred.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employment at Will</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   This Agreement is not intended to and shall not be understood in any manner as affecting or modifying the at-will status of your employment with the Company.  As an at-will employee either you or the Company may terminate the employment relationship at any time with or without cause or notice.  The obligations of Sections 4, 5, 6, 7, 8, 10, 11 and 12 herein shall survive the termination of the employment relationship or of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All knowledge and information, not already available to the public, which you acquire, have acquired, or will acquire in the course of your employment with the Company with respect to the Company&#8217;s business, work methods, or pending regulatory matters, or other Company matters that are treated by the Company as confidential, shall be regarded by you as trade secrets, whether or not they are classifiable legally as trade secrets, and shall be treated by you as strictly confidential.  Such knowledge and information shall not either directly or indirectly be used, disclosed, or made accessible to anyone by you for any purpose, except in the ordinary course of the Company&#8217;s business when you are authorized to use or disclose such information.  No disclosures of such confidential information shall be made outside of those you are authorized to make in the regular and ordinary course of your duties unless and until you receive prior written permission of the Board of Directors of the Company to make such disclosure.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Discoveries and Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the time that you are employed by the Company, all confidential information, trade secrets, or proprietary information and all other discoveries, inventions, software programs, processes, methods and improvements that are conceived, developed, or otherwise made by you , alone or with others, that relate in any way to the Company&#8217;s present or planned business or products (collectively the &#8220;Developments&#8221;), whether or not patentable or subject to copyright protection and whether or not reduced to tangible form or reduced to practice, shall be the sole property of the Company.  You agree to disclose all Developments promptly, fully and in writing to the Company.  You agree to keep and maintain adequate and current dated and witnessed written records of all such Developments, in the form of notes, sketches, drawings, or reports, which records shall be promptly submitted to the Company and shall be always and remain the property of the Company.  You agree to assign, and hereby do assign, to, the Company all your right, title, and interest throughout the world in and to all Developments.  You agree that all Developments shall constitute &#8220;Works for Hire&#8221; (as such are defined under the U.S. Copyright Laws) and hereby assign to the Company all copyrights, patents, and other proprietary rights you may have in any Developments without any obligation on the part of the Company to pay royalties or any other consideration to you for such Developments.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All documents and other writings produced by you during the period of your employment, which relate to work you are doing or have done for the Company or to the business of the Company or its affiliates, shall belong to the Company.  You will not publish outside of the Company any such writing without the prior written consent of the Board of Directors of the Company.  You will, without further compensation, execute at any time (whether or not you are still employed by the Company) all documents requested of you relating to the protection of such rights, including the assignment of such rights to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You shall notify the Company within three business days if no longer employed and immediately if still employed by the Company if you are contacted by any person </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">relating to any claim or litigation against the Company.  You shall not communicate in any manner with any person related to any claim or litigation against the Company without the prior consent of the Board of Directors of the Company unless compelled to do so by law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   For so long as you are employed by the Company or any Affiliate (as defined below) and for a period of one year after you cease to be employed by the Company or any Affiliate, you shall not, directly or indirectly, engage in any work or other activity--whether as owner, stockholder, partner, officer, consultant, or otherwise--involving a trademark, product, or process that, in the opinion of the Company&#8217;s President, is  similar to a trademark, product or process on which you worked for the Company (or any Affiliate) or obtained knowledge about while working for the Company at any time during the period of employment, if such work or other activity is then, or reasonably expected to become, competitive with that of the Company (or any Affiliate).  The restriction in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such work or activity and have received a release in writing from the Board of Directors of the Company allowing you to engage in such work or activity. The Company&#8217;s President shall have sole discretion to determine whether your work or activity for another employer involves trademarks, products, or processes that are similar to trademarks, products, or processes that you worked on for the Company. Ownership by you of five percent (5%) or less of the outstanding shares of stock of any company either (i) listed on a national securities exchange, or (ii) having at least one hundred (100) stockholders shall not make you a &#8220;stockholder&#8221; within the meaning of that term as used in this paragraph.  For one year after you cease to work for the Company, you will not engage in any work or activity that will cause you to inevitably disclose to anyone not employed by the Company (or an Affiliate) any trade secret or confidential information that belongs to the Company or one of its Affiliates.   Nothing in this paragraph shall limit the rights or remedies of the Company arising, directly or indirectly, from such competitive employment, including, without limitation, claims based upon breach of fiduciary duty, misappropriation, or theft of confidential information.  The term &#8220;Affiliate&#8221; shall mean the Company and any entity controlling, controlled by, or under common control with the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Conflicting Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You represent and warrant that you are not now under any obligation resulting from any contract or arrangement to any person, firm, or corporation, which is inconsistent or in conflict with this Agreement.  Likewise, you represent and warrant that you are not now under any obligation resulting from any contract or arrangement to any person, firm, or corporation which would prevent, limit, or impair in any way the performance by you of your obligations to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  For a period of one year after you cease to be employed by the Company (or a Company affiliate)&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;You agree not to solicit, directly or indirectly, business related to the development or sales of pharmaceutical products from any entity, organization, or person which is contracted with the Company, which has been doing business with the Company or from which the Company was soliciting at the time of your termination, or a firm which you knew or had reason to know that the Company was going to solicit business at the time you ceased to be employed by the Company.  The restriction set forth in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such solicitation and have received a release in writing from the Board of Directors of the Company to engage in such solicitation.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;You agree not to solicit, recruit, hire, or assist in the hiring of any employee of the Company to work for you or another person, firm, corporation, or business in competition with, or reasonably likely to become in competition with, the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Return of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon termination of your employment for any reason, you shall immediately return to the Company all documents and things belonging to the Company.  This includes, but is not limited to, trade secrets, confidential information, knowledge, data or know-how, and software containing such information, whether or not the documents are marked &#8220;Confidential.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge that in the event of breach of this Agreement by you, actual damages to the Company will be impossible to calculate, the Company&#8217;s remedies at law will be inadequate, and the Company will suffer irreparable harm.  Therefore, you agree that any of the covenants contained in this Agreement may be specifically enforced through injunctive relief, but such right to injunctive relief shall not preclude the Company from other remedies which may be available to it.  You further agree that should you fail to keep any of the promises made by you in this Agreement, or any way violate this Agreement, the Company shall be entitled to recover all monies the Company is required to spend, including attorneys&#8217; fees, to enforce the provisions of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Best Efforts and Conflicts of Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;  You are hired with the understanding that Cumberland is your sole employer, and you will provide a full-time work effort. You agree to devote your entire professional and business-related time and best efforts to the services required of you by the express and implicit terms of this Agreement, to the reasonable satisfaction of Cumberland in its sole and complete discretion.  Engaging in activities outside of work that create a conflict of interest or detract from your ability to perform your assigned responsibilities or meet your defined goals and objectives with Cumberland, is a problem and may lead to disciplinary action up to and including termination of employment.  If you believe that you are potentially involved in a situation that could create a conflict of interest and affect your ability to adequately perform your job with&#160;Cumberland, you should inform your direct supervisor and Cumberland&#8217;s Human Resources Department immediately.</font></div><div id="i84bae12c0a43449a9560fe6bce00e9bd_4"></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Debarment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You represent and warrant that you have not been debarred and will notify the Company immediately if you are debarred, pursuant to subsection 306(a) or 306(b) of the Federal Food, Drug, and Cosmetic Act.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notice required or permitted to be given under this Agreement shall be sufficient if in writing and if sent by registered or certified mail to your residence or to the Company&#8217;s principal office in the case of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The waiver by either party of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement contains the entire agreement of the parties and may not be changed orally, but only by an agreement in writing signed by the party against whom enforcement of any waiver, change, modification, extension, or discharge is sought.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement shall be governed by the laws of the State of Tennessee.  Any dispute arising out of this Agreement shall be resolved, at the Company&#8217;s sole option, by courts sitting in Nashville, Tennessee, and you waive any objection to such venue.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Enforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If any provision of this Agreement shall be held by a court to be unenforceable, such provision will be enforced to the maximum extent permissible, and the remaining portions of this Agreement shall remain in full force and effect.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any termination of your employment, this Agreement shall survive and remain in effect in accordance with its terms.</font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">#   #   #   #</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This letter agreement may be signed in one or more counterparts, each of which shall be an original and all of which will constitute one and the same instrument.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sincerely yours,</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> CUMBERLAND PHARMACEUTICALS INC.</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">_______________________________________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; By&#58;  &#160;&#160;&#160;&#160;A.J. Kazimi</font></div><div style="padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Executive Officer</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accepted as to all terms and conditions.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as of the 9th of March 2023&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">____________</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; John Hamm</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">____________</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">John Hamm, CFO</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>a2023q1-exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="if27dd143c574412396b16f6633575376_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, A.J. Kazimi, certify that&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I have reviewed this Form 10-Q of Cumberland Pharmaceuticals Inc.&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div></td></tr></table></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:50.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.164%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 12, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; A.J. Kazimi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A.J. Kazimi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>a2023q1-exhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ie52cddef9c4b45579a805911faa4db2a_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, John Hamm, certify that&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I have reviewed this Form 10-Q of Cumberland Pharmaceuticals Inc.&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div></td></tr></table></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:50.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.158%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.164%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 12, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John Hamm</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Hamm</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>a2023q1-exhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="icc19ceb7c0fc4f3fbec9c54a26b922ff_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE AND</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION&#160;1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION&#160;906</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form&#160;10-Q for the fiscal quarter ended March 31, 2023 of Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;), as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, A.J. Kazimi, Chief Executive Officer and John Hamm, Chief Financial Officer of the Company, certify, pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. section 1350), that&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934&#59; and</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:38.888%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; A. J. Kazimi</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A.J. Kazimi</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 12, 2023</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John Hamm</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Hamm</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 12, 2023</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:right"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>cpix-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:918a0a89-5dad-4ed0-b568-e96d686f2112,g:1ebee0a3-fb1a-41df-91cd-eb248c2cddb5-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cpix="http://www.cumberlandpharma.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cumberlandpharma.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.cumberlandpharma.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofEquity" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity">
        <link:definition>0000006 - Statement - Condensed Consolidated Statement of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentation" roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation">
        <link:definition>0000007 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShare" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare">
        <link:definition>0000008 - Disclosure - Earnings (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.cumberlandpharma.com/role/Revenues">
        <link:definition>0000009 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.cumberlandpharma.com/role/Inventories">
        <link:definition>0000010 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.cumberlandpharma.com/role/Leases">
        <link:definition>0000011 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityandDebt" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt">
        <link:definition>0000012 - Disclosure - Shareholders' Equity and Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes">
        <link:definition>0000013 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncome" roleURI="http://www.cumberlandpharma.com/role/OtherIncome">
        <link:definition>0000014 - Disclosure - Other Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreements" roleURI="http://www.cumberlandpharma.com/role/CollaborativeAgreements">
        <link:definition>0000015 - Disclosure - Collaborative Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRights" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights">
        <link:definition>0000016 - Disclosure - Additions and Returns of Product Rights</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.cumberlandpharma.com/role/CommitmentsandContingencies">
        <link:definition>0000017 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationPolicies" roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies">
        <link:definition>0000018 - Disclosure - Organization and Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareTables" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables">
        <link:definition>0000019 - Disclosure - Earnings (Loss) Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.cumberlandpharma.com/role/RevenuesTables">
        <link:definition>0000020 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.cumberlandpharma.com/role/InventoriesTables">
        <link:definition>0000021 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.cumberlandpharma.com/role/LeasesTables">
        <link:definition>0000022 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRightsTables" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables">
        <link:definition>0000023 - Disclosure - Additions and Returns of Product Rights (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationOrganizationDetails" roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails">
        <link:definition>0000024 - Disclosure - Organization and Basis of Presentation Organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareDetails" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails">
        <link:definition>0000025 - Disclosure - Earnings (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareDetailsTextual" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual">
        <link:definition>0000026 - Disclosure - Earnings (Loss) Per Share (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesScheduleofRevenueDetails" roleURI="http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails">
        <link:definition>0000027 - Disclosure - Revenues - Schedule of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesAdditionalInformationDetails" roleURI="http://www.cumberlandpharma.com/role/RevenuesAdditionalInformationDetails">
        <link:definition>0000028 - Disclosure - Revenues - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails">
        <link:definition>0000029 - Disclosure - Inventories (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesScheduleofInventoriesDetails" roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails">
        <link:definition>0000030 - Disclosure - Inventories (Schedule of Inventories) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails">
        <link:definition>0000031 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeasePositionDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails">
        <link:definition>0000032 - Disclosure - Leases - Lease Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails">
        <link:definition>0000033 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1">
        <link:definition>0000033 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesRentExpenseDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails">
        <link:definition>0000034 - Disclosure - Leases - Rent Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityandDebtShareholdersEquityDetails" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails">
        <link:definition>0000035 - Disclosure - Shareholders' Equity and Debt - Shareholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetailsTextual" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual">
        <link:definition>0000036 - Disclosure - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeDetails" roleURI="http://www.cumberlandpharma.com/role/OtherIncomeDetails">
        <link:definition>0000037 - Disclosure - Other Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRightsNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails">
        <link:definition>0000038 - Disclosure - Additions and Returns of Product Rights - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRightsChangeinConsiderationVibativDetails" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationVibativDetails">
        <link:definition>0000039 - Disclosure - Additions and Returns of Product Rights - Change in Consideration, Vibativ (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRightsChangeinConsiderationSancusoAcquisitionDetails" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationSancusoAcquisitionDetails">
        <link:definition>0000040 - Disclosure - Additions and Returns of Product Rights - Change in Consideration, Sancuso Acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="cpix_VIBATIVMember" abstract="true" name="VIBATIVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_CaldolorMember" abstract="true" name="CaldolorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_CETMember" abstract="true" name="CETMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected" abstract="false" name="CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_DebtInstrumentCovenantEvaluationFrequency" abstract="false" name="DebtInstrumentCovenantEvaluationFrequency" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsSalesMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue" abstract="false" name="CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" abstract="false" name="CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" abstract="false" name="IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_LineOfCreditFacilityAdditionalBorrowingCapacity" abstract="false" name="LineOfCreditFacilityAdditionalBorrowingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_TieredRoyaltyPaymentsThreshold" abstract="false" name="TieredRoyaltyPaymentsThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_EightAmendmentMember" abstract="true" name="EightAmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_IfetrobanClinicalMember" abstract="true" name="IfetrobanClinicalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_MethotrexateMember" abstract="true" name="MethotrexateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_EquityAndDebtAbstract" abstract="true" name="EquityAndDebtAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_PinnacleBankMember" abstract="true" name="PinnacleBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_DebtInstrumentCovenantFundedDebtRatioMaximum" abstract="false" name="DebtInstrumentCovenantFundedDebtRatioMaximum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="cpix_DebtInstrumentCovenantUnrestrictedCashThreshold" abstract="false" name="DebtInstrumentCovenantUnrestrictedCashThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_WinHealthInvestmentSingaporeLtdMember" abstract="true" name="WinHealthInvestmentSingaporeLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment" abstract="false" name="CollaborativeArrangementRightsAndObligationsUpfrontPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities" abstract="false" name="StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_KyowaKirinMember" abstract="true" name="KyowaKirinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_TradeAndNoteReceivablesPolicyTextBlock" abstract="false" name="TradeAndNoteReceivablesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" abstract="false" name="CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_KristaloseMember" abstract="true" name="KristaloseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_OtherProductsMember" abstract="true" name="OtherProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" abstract="false" name="BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_NordicGroupBVMember" abstract="true" name="NordicGroupBVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_RediTrexMember" abstract="true" name="RediTrexMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable" abstract="false" name="CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_NinthAmemdmentMember" abstract="true" name="NinthAmemdmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_A1600WestEndAvenuePartnersLLCMember" abstract="true" name="A1600WestEndAvenuePartnersLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_LesseeOperatingLeaseNumberOfRenewalTerms" abstract="false" name="LesseeOperatingLeaseNumberOfRenewalTerms" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cpix_LesseeOperatingLeaseRentIncrease" abstract="false" name="LesseeOperatingLeaseRentIncrease" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cpix_LesseeOperatingLeaseLeasedArea" abstract="false" name="LesseeOperatingLeaseLeasedArea" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="cpix_OmeclamoxPakMember" abstract="true" name="OmeclamoxPakMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_LesseeOperatingLeaseBaseRent" abstract="false" name="LesseeOperatingLeaseBaseRent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:monetaryPerAreaItemType"/>
  <xs:element id="cpix_SancusoMember" abstract="true" name="SancusoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_NumeratorAbstract" abstract="true" name="NumeratorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_SixthAmendmentMember" abstract="true" name="SixthAmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" abstract="false" name="ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cpix_AcetadoteMember" abstract="true" name="AcetadoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable" abstract="false" name="CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cpix_DenominatorAbstract" abstract="true" name="DenominatorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_BroadwestLeaseFiveYearRenewalOptionMember" abstract="true" name="BroadwestLeaseFiveYearRenewalOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_LeaseLiability" abstract="false" name="LeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_TieredRoyaltyPaymentsPercentage" abstract="false" name="TieredRoyaltyPaymentsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cpix_IncentiveStockOptionsMember" abstract="true" name="IncentiveStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_VaprisolMember" abstract="true" name="VaprisolMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_ProductsAbstract" abstract="true" name="ProductsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>cpix-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:918a0a89-5dad-4ed0-b568-e96d686f2112,g:1ebee0a3-fb1a-41df-91cd-eb248c2cddb5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cpix-20230331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5bfd297f-8265-4efc-a0e2-981899d994f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2273a3ad-501f-42a8-9ceb-704d7925364b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5bfd297f-8265-4efc-a0e2-981899d994f4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2273a3ad-501f-42a8-9ceb-704d7925364b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_71c652a8-6294-4ddb-a156-d466763bee34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5bfd297f-8265-4efc-a0e2-981899d994f4" xlink:to="loc_us-gaap_Goodwill_71c652a8-6294-4ddb-a156-d466763bee34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_82973e41-3c1c-4510-8e23-516c6b042e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5bfd297f-8265-4efc-a0e2-981899d994f4" xlink:to="loc_us-gaap_InventoryNoncurrent_82973e41-3c1c-4510-8e23-516c6b042e3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_781cdf5e-8791-4913-b2f2-bb03edd49ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5bfd297f-8265-4efc-a0e2-981899d994f4" xlink:to="loc_us-gaap_AssetsCurrent_781cdf5e-8791-4913-b2f2-bb03edd49ea0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_a5ff90c2-f708-41ec-8d16-854182e82e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5bfd297f-8265-4efc-a0e2-981899d994f4" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_a5ff90c2-f708-41ec-8d16-854182e82e5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d1a45755-ace6-4612-8fd3-440d2e12f797" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5bfd297f-8265-4efc-a0e2-981899d994f4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d1a45755-ace6-4612-8fd3-440d2e12f797" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_0e3b9282-aab9-4d62-9874-0dca4798ad34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5bfd297f-8265-4efc-a0e2-981899d994f4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_0e3b9282-aab9-4d62-9874-0dca4798ad34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_60073e76-a897-4ed9-a95f-a0b3cdcb434b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_dfc92b45-8bf3-46d9-8e9d-423c38afaee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_60073e76-a897-4ed9-a95f-a0b3cdcb434b" xlink:to="loc_us-gaap_Liabilities_dfc92b45-8bf3-46d9-8e9d-423c38afaee0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_31be310e-42a4-4288-b2c2-71ecad2f394d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_60073e76-a897-4ed9-a95f-a0b3cdcb434b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_31be310e-42a4-4288-b2c2-71ecad2f394d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_046ffec8-9cb1-4375-b40a-275dc5c825f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_60073e76-a897-4ed9-a95f-a0b3cdcb434b" xlink:to="loc_us-gaap_CommitmentsAndContingencies_046ffec8-9cb1-4375-b40a-275dc5c825f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c73b80a2-c35a-41a5-b3e0-1ef99440c5fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4dd5f849-e346-4840-93f2-94957a0d2f89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c73b80a2-c35a-41a5-b3e0-1ef99440c5fd" xlink:to="loc_us-gaap_StockholdersEquity_4dd5f849-e346-4840-93f2-94957a0d2f89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_25b0f216-7e6c-4748-9489-6dc162772587" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c73b80a2-c35a-41a5-b3e0-1ef99440c5fd" xlink:to="loc_us-gaap_MinorityInterest_25b0f216-7e6c-4748-9489-6dc162772587" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f9c38cad-ced2-41da-9b99-28b3ae642c40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_42d93a55-2b6e-446d-a0e8-9cd48e4d9c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f9c38cad-ced2-41da-9b99-28b3ae642c40" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_42d93a55-2b6e-446d-a0e8-9cd48e4d9c6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7a9843e4-d0bd-4163-9561-47190573f80c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f9c38cad-ced2-41da-9b99-28b3ae642c40" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7a9843e4-d0bd-4163-9561-47190573f80c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_2b6df2b9-03b3-4e9f-9ae3-af7c9e98ccb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f9c38cad-ced2-41da-9b99-28b3ae642c40" xlink:to="loc_us-gaap_OtherAssetsCurrent_2b6df2b9-03b3-4e9f-9ae3-af7c9e98ccb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_a806700c-3110-4026-b692-6f5393840948" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f9c38cad-ced2-41da-9b99-28b3ae642c40" xlink:to="loc_us-gaap_InventoryNet_a806700c-3110-4026-b692-6f5393840948" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a92fbc01-bafd-4d97-92eb-6f7872c33728" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_1819e335-a545-4dc8-aacd-d28a42efb25b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a92fbc01-bafd-4d97-92eb-6f7872c33728" xlink:to="loc_us-gaap_CommonStockValue_1819e335-a545-4dc8-aacd-d28a42efb25b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c103b0a4-3131-4b0c-83b2-21afaab672f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a92fbc01-bafd-4d97-92eb-6f7872c33728" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c103b0a4-3131-4b0c-83b2-21afaab672f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_063c97cc-766e-424f-9455-44d101d31b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_ca6c8e36-79b9-448f-a549-367eb7ec275b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_063c97cc-766e-424f-9455-44d101d31b4b" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_ca6c8e36-79b9-448f-a549-367eb7ec275b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_77257857-baed-473e-afc9-812e5b716374" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_063c97cc-766e-424f-9455-44d101d31b4b" xlink:to="loc_us-gaap_AccountsPayableCurrent_77257857-baed-473e-afc9-812e5b716374" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_fbba8bfe-eeef-480e-a607-b3aef56292e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_063c97cc-766e-424f-9455-44d101d31b4b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_fbba8bfe-eeef-480e-a607-b3aef56292e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c05862b9-ca33-4815-be73-92cd0875ee05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a6fdd7fd-cb8a-4f15-85c2-c9875ba0fa7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c05862b9-ca33-4815-be73-92cd0875ee05" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a6fdd7fd-cb8a-4f15-85c2-c9875ba0fa7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_3b66e5c8-b934-472d-91e1-0f85ca2f0ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c05862b9-ca33-4815-be73-92cd0875ee05" xlink:to="loc_us-gaap_LongTermLineOfCredit_3b66e5c8-b934-472d-91e1-0f85ca2f0ee3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_20a9cc4d-4993-4718-aa6c-9fb5dc2be415" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c05862b9-ca33-4815-be73-92cd0875ee05" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_20a9cc4d-4993-4718-aa6c-9fb5dc2be415" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c5a0d725-0305-4882-b6f3-1d2984ea4645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c05862b9-ca33-4815-be73-92cd0875ee05" xlink:to="loc_us-gaap_LiabilitiesCurrent_c5a0d725-0305-4882-b6f3-1d2984ea4645" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="cpix-20230331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7d918e12-fff4-4ad1-9b94-685e51367fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5d0d441e-5bfc-497f-8aca-dc23d2e477b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7d918e12-fff4-4ad1-9b94-685e51367fb2" xlink:to="loc_us-gaap_OperatingIncomeLoss_5d0d441e-5bfc-497f-8aca-dc23d2e477b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_3f195d21-d260-4169-9566-2ec21697aca6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7d918e12-fff4-4ad1-9b94-685e51367fb2" xlink:to="loc_us-gaap_InterestExpense_3f195d21-d260-4169-9566-2ec21697aca6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_5b448ccc-d672-4587-9294-0fd8f140fb12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7d918e12-fff4-4ad1-9b94-685e51367fb2" xlink:to="loc_us-gaap_OtherIncome_5b448ccc-d672-4587-9294-0fd8f140fb12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_14100a3a-5c8c-4c31-b6e3-23bf0a83bcc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7d918e12-fff4-4ad1-9b94-685e51367fb2" xlink:to="loc_us-gaap_InvestmentIncomeInterest_14100a3a-5c8c-4c31-b6e3-23bf0a83bcc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e75db0be-8c66-48e8-8cd8-df3e54ce239e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_822f7272-7830-4444-a2c4-6de7ce5bfd9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_e75db0be-8c66-48e8-8cd8-df3e54ce239e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_822f7272-7830-4444-a2c4-6de7ce5bfd9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8fe36cb0-faf6-477c-96f4-8c54528ca9fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_e75db0be-8c66-48e8-8cd8-df3e54ce239e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8fe36cb0-faf6-477c-96f4-8c54528ca9fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_128978f4-fa4a-449c-ac9b-17a6ad4c7919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_249a6f54-24ed-4881-9077-1cbaeaad9729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_128978f4-fa4a-449c-ac9b-17a6ad4c7919" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_249a6f54-24ed-4881-9077-1cbaeaad9729" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_e3d9f160-e645-4196-a38b-94c27891eb3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_128978f4-fa4a-449c-ac9b-17a6ad4c7919" xlink:to="loc_us-gaap_CostsAndExpenses_e3d9f160-e645-4196-a38b-94c27891eb3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_18112cdf-5cc6-47ee-81ee-bd8d1e531647" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_b74c1779-4cd6-4f0a-9e82-09a97f2ec57b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_18112cdf-5cc6-47ee-81ee-bd8d1e531647" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_b74c1779-4cd6-4f0a-9e82-09a97f2ec57b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_5554b20e-f233-4310-a875-d651227f2c94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_18112cdf-5cc6-47ee-81ee-bd8d1e531647" xlink:to="loc_us-gaap_SellingAndMarketingExpense_5554b20e-f233-4310-a875-d651227f2c94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a65b21f0-e10c-4a85-bdb4-026c855f427b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_18112cdf-5cc6-47ee-81ee-bd8d1e531647" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a65b21f0-e10c-4a85-bdb4-026c855f427b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_50feee1d-8ffe-4f82-ad1f-a3ae5b1d4583" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_18112cdf-5cc6-47ee-81ee-bd8d1e531647" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_50feee1d-8ffe-4f82-ad1f-a3ae5b1d4583" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_006bfa88-1b5c-4366-b95b-c437890ba54b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_18112cdf-5cc6-47ee-81ee-bd8d1e531647" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_006bfa88-1b5c-4366-b95b-c437890ba54b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_016af150-7cc5-4d03-8652-1c7a86246725" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5bbaf16e-0ff5-456a-bcba-26af620fb877" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_016af150-7cc5-4d03-8652-1c7a86246725" xlink:to="loc_us-gaap_ProfitLoss_5bbaf16e-0ff5-456a-bcba-26af620fb877" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c16e9204-fbef-4972-b654-9ed250cddbca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_016af150-7cc5-4d03-8652-1c7a86246725" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c16e9204-fbef-4972-b654-9ed250cddbca" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cpix-20230331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_801349b2-43d7-4886-911e-b594d936fa6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_950315ad-4d17-44f5-a2a3-1c007598a5f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_801349b2-43d7-4886-911e-b594d936fa6c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_950315ad-4d17-44f5-a2a3-1c007598a5f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_226fd9da-61f7-4c2f-af97-78c8995a54cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_801349b2-43d7-4886-911e-b594d936fa6c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_226fd9da-61f7-4c2f-af97-78c8995a54cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4bc8a615-2e8c-4ef8-91f7-8342800af079" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_801349b2-43d7-4886-911e-b594d936fa6c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4bc8a615-2e8c-4ef8-91f7-8342800af079" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9c555bcb-4814-44c9-be1e-1f596774a5b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_69bf1aaf-de11-4e64-a52c-8a6e5eb87084" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9c555bcb-4814-44c9-be1e-1f596774a5b6" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_69bf1aaf-de11-4e64-a52c-8a6e5eb87084" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_984a96ec-caaa-4f34-bc2d-644495c90606" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9c555bcb-4814-44c9-be1e-1f596774a5b6" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_984a96ec-caaa-4f34-bc2d-644495c90606" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_5905d2eb-62f8-44a6-9676-b166aea8507a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9c555bcb-4814-44c9-be1e-1f596774a5b6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_5905d2eb-62f8-44a6-9676-b166aea8507a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_cb249fbb-93f7-4458-8bcb-49585b02cdfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9c555bcb-4814-44c9-be1e-1f596774a5b6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_cb249fbb-93f7-4458-8bcb-49585b02cdfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuredEventGainLoss_232de294-0059-42c6-83cc-1c20502629e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuredEventGainLoss"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9c555bcb-4814-44c9-be1e-1f596774a5b6" xlink:to="loc_us-gaap_InsuredEventGainLoss_232de294-0059-42c6-83cc-1c20502629e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_0977826e-d045-4740-8538-8e6ef0dfa3c2" xlink:href="cpix-20230331.xsd#cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9c555bcb-4814-44c9-be1e-1f596774a5b6" xlink:to="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_0977826e-d045-4740-8538-8e6ef0dfa3c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_e9dd90c3-1ef5-45dd-9c2f-e5654334ef1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9c555bcb-4814-44c9-be1e-1f596774a5b6" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_e9dd90c3-1ef5-45dd-9c2f-e5654334ef1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_ed67a7e0-64ee-4a7f-91a6-39d328b9f273" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9c555bcb-4814-44c9-be1e-1f596774a5b6" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_ed67a7e0-64ee-4a7f-91a6-39d328b9f273" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_b2c92d7b-d251-4b74-9e89-9c806ccd71e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9c555bcb-4814-44c9-be1e-1f596774a5b6" xlink:to="loc_us-gaap_ShareBasedCompensation_b2c92d7b-d251-4b74-9e89-9c806ccd71e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_871980fe-0a75-4597-9ffd-c7f26e3ee8dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9c555bcb-4814-44c9-be1e-1f596774a5b6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_871980fe-0a75-4597-9ffd-c7f26e3ee8dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_5b416f59-a706-407c-80f4-f5f59e8b05b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9c555bcb-4814-44c9-be1e-1f596774a5b6" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_5b416f59-a706-407c-80f4-f5f59e8b05b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_76a84544-881f-4ebc-8e2a-ffbe6e510e51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9c555bcb-4814-44c9-be1e-1f596774a5b6" xlink:to="loc_us-gaap_ProfitLoss_76a84544-881f-4ebc-8e2a-ffbe6e510e51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e3a7effb-7876-4d1f-b65b-4e4e31629978" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_7d507f5e-d7a9-4005-8ce5-b866b30cf457" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e3a7effb-7876-4d1f-b65b-4e4e31629978" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_7d507f5e-d7a9-4005-8ce5-b866b30cf457" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_3fdcd7d4-ef81-4469-8d9f-a83b71188f63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e3a7effb-7876-4d1f-b65b-4e4e31629978" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_3fdcd7d4-ef81-4469-8d9f-a83b71188f63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_506ab614-8abb-419d-9052-0e6c0eae5ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e3a7effb-7876-4d1f-b65b-4e4e31629978" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_506ab614-8abb-419d-9052-0e6c0eae5ef4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_cd455fb5-30f2-4c22-9161-9d7f804ba18a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e3a7effb-7876-4d1f-b65b-4e4e31629978" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_cd455fb5-30f2-4c22-9161-9d7f804ba18a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_11219006-2793-424d-aaa7-a3223662cd88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_c68ff01c-2f7c-48a6-b274-171e16a92eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_11219006-2793-424d-aaa7-a3223662cd88" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_c68ff01c-2f7c-48a6-b274-171e16a92eb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_a6e10dfc-4809-4594-918c-220ec5f1f801" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_11219006-2793-424d-aaa7-a3223662cd88" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_a6e10dfc-4809-4594-918c-220ec5f1f801" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fb19ffa7-b259-4f1d-bf3e-9121db1a07e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_11219006-2793-424d-aaa7-a3223662cd88" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fb19ffa7-b259-4f1d-bf3e-9121db1a07e4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="simple" xlink:href="cpix-20230331.xsd#EarningsLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9505dab2-777a-427f-8aab-d002c397c3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5fbc9296-7681-4853-b0a4-a435b6a5c83c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9505dab2-777a-427f-8aab-d002c397c3f1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5fbc9296-7681-4853-b0a4-a435b6a5c83c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_b4ad04e5-b7b9-48c7-8413-08eda38d2309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9505dab2-777a-427f-8aab-d002c397c3f1" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_b4ad04e5-b7b9-48c7-8413-08eda38d2309" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="cpix-20230331.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_6f10e6c8-a892-4800-b3c3-f133d446be70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_4b806d76-ffde-4da0-9ad5-b0b7946e5164" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_6f10e6c8-a892-4800-b3c3-f133d446be70" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_4b806d76-ffde-4da0-9ad5-b0b7946e5164" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_56547454-7489-4b75-b433-dbf5d3d2419a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_6f10e6c8-a892-4800-b3c3-f133d446be70" xlink:to="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_56547454-7489-4b75-b433-dbf5d3d2419a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_cdd4cf79-fcc4-4ac6-b28c-bba2090922a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_6f10e6c8-a892-4800-b3c3-f133d446be70" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_cdd4cf79-fcc4-4ac6-b28c-bba2090922a0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="simple" xlink:href="cpix-20230331.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f32b0618-2faf-4f05-86f5-b4a36ba93eee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5958072b-49c3-453f-b62c-06ac1f12a33d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f32b0618-2faf-4f05-86f5-b4a36ba93eee" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5958072b-49c3-453f-b62c-06ac1f12a33d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_3fee884c-2db0-4505-adff-f481139eb97e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f32b0618-2faf-4f05-86f5-b4a36ba93eee" xlink:to="loc_us-gaap_OperatingLeaseLiability_3fee884c-2db0-4505-adff-f481139eb97e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" xlink:type="simple" xlink:href="cpix-20230331.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_976942e7-58d5-4cbb-b1d2-4f8a73ca52b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_953606ee-9260-44f9-823f-c76a7ed866e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_976942e7-58d5-4cbb-b1d2-4f8a73ca52b0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_953606ee-9260-44f9-823f-c76a7ed866e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_289f78cd-6838-41d8-a188-a41ebd42bf33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_976942e7-58d5-4cbb-b1d2-4f8a73ca52b0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_289f78cd-6838-41d8-a188-a41ebd42bf33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_f3df7c83-be11-4f69-853a-4e7e268324d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_976942e7-58d5-4cbb-b1d2-4f8a73ca52b0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_f3df7c83-be11-4f69-853a-4e7e268324d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_864c483b-b342-461c-ac2e-d3f5a22628a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_976942e7-58d5-4cbb-b1d2-4f8a73ca52b0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_864c483b-b342-461c-ac2e-d3f5a22628a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a3388100-fe2a-4fef-be1a-fa9df5657f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_976942e7-58d5-4cbb-b1d2-4f8a73ca52b0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a3388100-fe2a-4fef-be1a-fa9df5657f1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_23a39e47-d416-487e-93cf-91db95c5652b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_976942e7-58d5-4cbb-b1d2-4f8a73ca52b0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_23a39e47-d416-487e-93cf-91db95c5652b" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>cpix-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:918a0a89-5dad-4ed0-b568-e96d686f2112,g:1ebee0a3-fb1a-41df-91cd-eb248c2cddb5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="simple" xlink:href="cpix-20230331.xsd#CondensedConsolidatedStatementofEquity"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="extended" id="i3f985d62fc8a4932ba43de707dd15cd6_CondensedConsolidatedStatementofEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ff89d359-663f-4bee-8616-3fdf0cc22cff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_edd696dd-95c6-4e21-bb81-91e671ede81c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ff89d359-663f-4bee-8616-3fdf0cc22cff" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_edd696dd-95c6-4e21-bb81-91e671ede81c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0d8436c8-984b-4da3-95ca-2dc58587cffe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_edd696dd-95c6-4e21-bb81-91e671ede81c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0d8436c8-984b-4da3-95ca-2dc58587cffe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8b15e28a-368f-48bc-9444-a6ccec5855d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_edd696dd-95c6-4e21-bb81-91e671ede81c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8b15e28a-368f-48bc-9444-a6ccec5855d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_f05413d6-c867-4690-8fb2-761eee06aa52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_edd696dd-95c6-4e21-bb81-91e671ede81c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_f05413d6-c867-4690-8fb2-761eee06aa52" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_b5354398-d7df-4d49-b8c3-26ceb5911159" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_edd696dd-95c6-4e21-bb81-91e671ede81c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_b5354398-d7df-4d49-b8c3-26ceb5911159" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_791fc9b7-ca94-4875-b005-9655f2a4879d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_edd696dd-95c6-4e21-bb81-91e671ede81c" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_791fc9b7-ca94-4875-b005-9655f2a4879d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_274c3f81-199a-449d-a32b-09e29b8de7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_edd696dd-95c6-4e21-bb81-91e671ede81c" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_274c3f81-199a-449d-a32b-09e29b8de7d3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5587e126-b087-42b7-90b0-168aaa51892c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_edd696dd-95c6-4e21-bb81-91e671ede81c" xlink:to="loc_us-gaap_ProfitLoss_5587e126-b087-42b7-90b0-168aaa51892c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1115857d-0c3f-426b-9973-6dbcdcb4d2a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_088c725c-0c8e-4c0a-a2d8-65585dea64e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_bc72cf6c-3eb5-40cc-9beb-7518f97e333c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_ff89d359-663f-4bee-8616-3fdf0cc22cff" xlink:to="loc_us-gaap_StatementTable_bc72cf6c-3eb5-40cc-9beb-7518f97e333c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a4a67d3a-cc20-4139-be51-23616adea4aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_bc72cf6c-3eb5-40cc-9beb-7518f97e333c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a4a67d3a-cc20-4139-be51-23616adea4aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a4a67d3a-cc20-4139-be51-23616adea4aa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a4a67d3a-cc20-4139-be51-23616adea4aa" xlink:to="loc_us-gaap_EquityComponentDomain_a4a67d3a-cc20-4139-be51-23616adea4aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_613bd5bc-f71b-4891-b9d2-b7b75995c8f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a4a67d3a-cc20-4139-be51-23616adea4aa" xlink:to="loc_us-gaap_EquityComponentDomain_613bd5bc-f71b-4891-b9d2-b7b75995c8f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3196a245-73cf-44c4-88af-acabd191d83d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_613bd5bc-f71b-4891-b9d2-b7b75995c8f3" xlink:to="loc_us-gaap_CommonStockMember_3196a245-73cf-44c4-88af-acabd191d83d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_55b72f2c-afea-4bb1-9a64-146692dcf398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_613bd5bc-f71b-4891-b9d2-b7b75995c8f3" xlink:to="loc_us-gaap_RetainedEarningsMember_55b72f2c-afea-4bb1-9a64-146692dcf398" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_990e32b8-64c0-4a0e-b088-0a150b644fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_613bd5bc-f71b-4891-b9d2-b7b75995c8f3" xlink:to="loc_us-gaap_NoncontrollingInterestMember_990e32b8-64c0-4a0e-b088-0a150b644fa3" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails" xlink:type="simple" xlink:href="cpix-20230331.xsd#RevenuesScheduleofRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails" xlink:type="extended" id="i9f76ab2842da4cc6ae864b1e749ab782_RevenuesScheduleofRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_a4d0c684-1086-4367-9163-09d4e7ca1853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_1d04dbd9-c994-48fb-8de5-95b14e82b6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_a4d0c684-1086-4367-9163-09d4e7ca1853" xlink:to="loc_us-gaap_RevenuesAbstract_1d04dbd9-c994-48fb-8de5-95b14e82b6ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductsAbstract_5aa848d6-102c-4d29-a843-541da6b23185" xlink:href="cpix-20230331.xsd#cpix_ProductsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_1d04dbd9-c994-48fb-8de5-95b14e82b6ff" xlink:to="loc_cpix_ProductsAbstract_5aa848d6-102c-4d29-a843-541da6b23185" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_90d24a63-4134-41e6-b850-5e2fb787cda6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ProductsAbstract_5aa848d6-102c-4d29-a843-541da6b23185" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_90d24a63-4134-41e6-b850-5e2fb787cda6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_6d7580a2-5f0a-4b5a-bc46-a652a836c56c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_a4d0c684-1086-4367-9163-09d4e7ca1853" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_6d7580a2-5f0a-4b5a-bc46-a652a836c56c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6aaabb2f-b2d9-4d72-9eae-f68612c33b8f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_6d7580a2-5f0a-4b5a-bc46-a652a836c56c" xlink:to="loc_srt_ProductOrServiceAxis_6aaabb2f-b2d9-4d72-9eae-f68612c33b8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6aaabb2f-b2d9-4d72-9eae-f68612c33b8f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_6aaabb2f-b2d9-4d72-9eae-f68612c33b8f" xlink:to="loc_srt_ProductsAndServicesDomain_6aaabb2f-b2d9-4d72-9eae-f68612c33b8f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b976ba88-17a5-410f-92c7-8548d7abc5c8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_6aaabb2f-b2d9-4d72-9eae-f68612c33b8f" xlink:to="loc_srt_ProductsAndServicesDomain_b976ba88-17a5-410f-92c7-8548d7abc5c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember_22a31496-508b-49b0-9155-6c18e3bd44a4" xlink:href="cpix-20230331.xsd#cpix_KristaloseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b976ba88-17a5-410f-92c7-8548d7abc5c8" xlink:to="loc_cpix_KristaloseMember_22a31496-508b-49b0-9155-6c18e3bd44a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SancusoMember_223cc7cc-2f14-45b5-ab17-61be8238d6e2" xlink:href="cpix-20230331.xsd#cpix_SancusoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b976ba88-17a5-410f-92c7-8548d7abc5c8" xlink:to="loc_cpix_SancusoMember_223cc7cc-2f14-45b5-ab17-61be8238d6e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_7153bed2-1333-465d-83bd-5a9d5a35f0cd" xlink:href="cpix-20230331.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b976ba88-17a5-410f-92c7-8548d7abc5c8" xlink:to="loc_cpix_VIBATIVMember_7153bed2-1333-465d-83bd-5a9d5a35f0cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember_c7ccd30a-495f-4400-b6fa-81a528f85985" xlink:href="cpix-20230331.xsd#cpix_CaldolorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b976ba88-17a5-410f-92c7-8548d7abc5c8" xlink:to="loc_cpix_CaldolorMember_c7ccd30a-495f-4400-b6fa-81a528f85985" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember_eaae0d98-81ea-4955-b76c-40e5d12bee46" xlink:href="cpix-20230331.xsd#cpix_AcetadoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b976ba88-17a5-410f-92c7-8548d7abc5c8" xlink:to="loc_cpix_AcetadoteMember_eaae0d98-81ea-4955-b76c-40e5d12bee46" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember_f2dd9497-beb1-4711-8867-f04f2433ea0e" xlink:href="cpix-20230331.xsd#cpix_VaprisolMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b976ba88-17a5-410f-92c7-8548d7abc5c8" xlink:to="loc_cpix_VaprisolMember_f2dd9497-beb1-4711-8867-f04f2433ea0e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember_f5cea72f-6438-4c16-858e-5d8fb3c2382e" xlink:href="cpix-20230331.xsd#cpix_OmeclamoxPakMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b976ba88-17a5-410f-92c7-8548d7abc5c8" xlink:to="loc_cpix_OmeclamoxPakMember_f5cea72f-6438-4c16-858e-5d8fb3c2382e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RediTrexMember_cc795c46-92e0-4a6c-91f2-efe0fba65800" xlink:href="cpix-20230331.xsd#cpix_RediTrexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b976ba88-17a5-410f-92c7-8548d7abc5c8" xlink:to="loc_cpix_RediTrexMember_cc795c46-92e0-4a6c-91f2-efe0fba65800" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherProductsMember_129e85a6-491d-4347-b34a-2b7a23de70f8" xlink:href="cpix-20230331.xsd#cpix_OtherProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b976ba88-17a5-410f-92c7-8548d7abc5c8" xlink:to="loc_cpix_OtherProductsMember_129e85a6-491d-4347-b34a-2b7a23de70f8" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesAdditionalInformationDetails" xlink:type="simple" xlink:href="cpix-20230331.xsd#RevenuesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesAdditionalInformationDetails" xlink:type="extended" id="i1a60f91a7b814eedb648a428885bc70b_RevenuesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_f2825675-6498-4a69-840a-c8376cbf83d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5c7d6137-f827-445f-b1a7-13182b72849c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_f2825675-6498-4a69-840a-c8376cbf83d1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5c7d6137-f827-445f-b1a7-13182b72849c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_ccff3845-87eb-4d50-864b-2906904df0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_f2825675-6498-4a69-840a-c8376cbf83d1" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_ccff3845-87eb-4d50-864b-2906904df0f8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ce662f2a-a2af-4ae8-ac1a-59527a577b68" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_ccff3845-87eb-4d50-864b-2906904df0f8" xlink:to="loc_srt_ProductOrServiceAxis_ce662f2a-a2af-4ae8-ac1a-59527a577b68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ce662f2a-a2af-4ae8-ac1a-59527a577b68_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ce662f2a-a2af-4ae8-ac1a-59527a577b68" xlink:to="loc_srt_ProductsAndServicesDomain_ce662f2a-a2af-4ae8-ac1a-59527a577b68_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_739762cb-66d3-4301-b242-25a8f207a173" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ce662f2a-a2af-4ae8-ac1a-59527a577b68" xlink:to="loc_srt_ProductsAndServicesDomain_739762cb-66d3-4301-b242-25a8f207a173" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_e7a6bbf4-6233-40a1-8769-2a4a900120da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_739762cb-66d3-4301-b242-25a8f207a173" xlink:to="loc_us-gaap_GrantMember_e7a6bbf4-6233-40a1-8769-2a4a900120da" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20230331.xsd#InventoriesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="extended" id="ic2325902a0604dcdbe6b37dd7e406a58_InventoriesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_db593aac-e98e-4e6c-b921-48343d1657b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_a364bc5f-0476-4c92-bc64-b1cf75edd76d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_db593aac-e98e-4e6c-b921-48343d1657b3" xlink:to="loc_us-gaap_InventoryValuationReserves_a364bc5f-0476-4c92-bc64-b1cf75edd76d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_88de891f-82cd-459c-9b3e-c3c9eb03af6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_db593aac-e98e-4e6c-b921-48343d1657b3" xlink:to="loc_us-gaap_InventoryNoncurrent_88de891f-82cd-459c-9b3e-c3c9eb03af6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_5405f74e-793c-421f-9999-3484b9d55612" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_db593aac-e98e-4e6c-b921-48343d1657b3" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_5405f74e-793c-421f-9999-3484b9d55612" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_31cd6905-0a90-48b5-a1fc-d92ccdaf6e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_db593aac-e98e-4e6c-b921-48343d1657b3" xlink:to="loc_us-gaap_InventoryCurrentTable_31cd6905-0a90-48b5-a1fc-d92ccdaf6e3d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_da5d85d3-31c2-49ed-9b91-ba0bea321733" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_31cd6905-0a90-48b5-a1fc-d92ccdaf6e3d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_da5d85d3-31c2-49ed-9b91-ba0bea321733" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_da5d85d3-31c2-49ed-9b91-ba0bea321733_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_da5d85d3-31c2-49ed-9b91-ba0bea321733" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_da5d85d3-31c2-49ed-9b91-ba0bea321733_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d7c9869e-c9e8-4dee-a085-e013921b6900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_da5d85d3-31c2-49ed-9b91-ba0bea321733" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d7c9869e-c9e8-4dee-a085-e013921b6900" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_cb6f0686-0220-4e7c-82ad-f930d82b846d" xlink:href="cpix-20230331.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d7c9869e-c9e8-4dee-a085-e013921b6900" xlink:to="loc_cpix_VIBATIVMember_cb6f0686-0220-4e7c-82ad-f930d82b846d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_17b9cb11-56e1-49fc-8dfe-ec60384c285b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_31cd6905-0a90-48b5-a1fc-d92ccdaf6e3d" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_17b9cb11-56e1-49fc-8dfe-ec60384c285b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_17b9cb11-56e1-49fc-8dfe-ec60384c285b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_17b9cb11-56e1-49fc-8dfe-ec60384c285b" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_17b9cb11-56e1-49fc-8dfe-ec60384c285b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_c64fbb6d-e306-469e-a48f-23736f86fa12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_17b9cb11-56e1-49fc-8dfe-ec60384c285b" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_c64fbb6d-e306-469e-a48f-23736f86fa12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember_50ab516c-2146-4f3c-ae28-d7c8ccdc409d" xlink:href="cpix-20230331.xsd#cpix_IfetrobanClinicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_c64fbb6d-e306-469e-a48f-23736f86fa12" xlink:to="loc_cpix_IfetrobanClinicalMember_50ab516c-2146-4f3c-ae28-d7c8ccdc409d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20230331.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i1521d8f9c50d41d586a8ea0548858d90_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3a40569-a413-4486-87c2-843bb58d046a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseLeasedArea_cb4d8ae5-66a3-4aac-8b67-4d419b840e33" xlink:href="cpix-20230331.xsd#cpix_LesseeOperatingLeaseLeasedArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3a40569-a413-4486-87c2-843bb58d046a" xlink:to="loc_cpix_LesseeOperatingLeaseLeasedArea_cb4d8ae5-66a3-4aac-8b67-4d419b840e33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_2ad45642-0327-4fb1-b246-e931ac46d2eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3a40569-a413-4486-87c2-843bb58d046a" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_2ad45642-0327-4fb1-b246-e931ac46d2eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseNumberOfRenewalTerms_bfe1e5a9-7a02-4fd7-b248-b327c44fe3c3" xlink:href="cpix-20230331.xsd#cpix_LesseeOperatingLeaseNumberOfRenewalTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3a40569-a413-4486-87c2-843bb58d046a" xlink:to="loc_cpix_LesseeOperatingLeaseNumberOfRenewalTerms_bfe1e5a9-7a02-4fd7-b248-b327c44fe3c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_2adfb778-e3b7-41f8-a8b6-fd886b901d29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3a40569-a413-4486-87c2-843bb58d046a" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_2adfb778-e3b7-41f8-a8b6-fd886b901d29" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseBaseRent_b6d0adda-4176-408a-9c8a-102224f68c8d" xlink:href="cpix-20230331.xsd#cpix_LesseeOperatingLeaseBaseRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3a40569-a413-4486-87c2-843bb58d046a" xlink:to="loc_cpix_LesseeOperatingLeaseBaseRent_b6d0adda-4176-408a-9c8a-102224f68c8d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseRentIncrease_ce4e272f-1869-481d-868b-b145dfae3f83" xlink:href="cpix-20230331.xsd#cpix_LesseeOperatingLeaseRentIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3a40569-a413-4486-87c2-843bb58d046a" xlink:to="loc_cpix_LesseeOperatingLeaseRentIncrease_ce4e272f-1869-481d-868b-b145dfae3f83" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_cc7b3e01-2534-48a9-9d43-5221232164eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3a40569-a413-4486-87c2-843bb58d046a" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_cc7b3e01-2534-48a9-9d43-5221232164eb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_621a1a64-3129-4eb8-ba5f-ba90a28a9774" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3a40569-a413-4486-87c2-843bb58d046a" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_621a1a64-3129-4eb8-ba5f-ba90a28a9774" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_b9eb8d8a-6671-4328-9aa2-16686a5a5594" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3a40569-a413-4486-87c2-843bb58d046a" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_b9eb8d8a-6671-4328-9aa2-16686a5a5594" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_4bb39bfa-796b-4c95-95cc-ef710e2d7824" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3a40569-a413-4486-87c2-843bb58d046a" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_4bb39bfa-796b-4c95-95cc-ef710e2d7824" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_7af848bb-431b-4b13-b102-53723f68dad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3a40569-a413-4486-87c2-843bb58d046a" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_7af848bb-431b-4b13-b102-53723f68dad5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_df274af1-77b6-45a5-8322-bf8a9c396d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_7af848bb-431b-4b13-b102-53723f68dad5" xlink:to="loc_us-gaap_LeaseContractualTermAxis_df274af1-77b6-45a5-8322-bf8a9c396d6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_df274af1-77b6-45a5-8322-bf8a9c396d6b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_df274af1-77b6-45a5-8322-bf8a9c396d6b" xlink:to="loc_us-gaap_LeaseContractualTermDomain_df274af1-77b6-45a5-8322-bf8a9c396d6b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_3304c86f-9d77-4610-a630-eec3a3b7fa74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_df274af1-77b6-45a5-8322-bf8a9c396d6b" xlink:to="loc_us-gaap_LeaseContractualTermDomain_3304c86f-9d77-4610-a630-eec3a3b7fa74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BroadwestLeaseFiveYearRenewalOptionMember_18087868-8c6e-4358-97d9-69d7b0077c1f" xlink:href="cpix-20230331.xsd#cpix_BroadwestLeaseFiveYearRenewalOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_3304c86f-9d77-4610-a630-eec3a3b7fa74" xlink:to="loc_cpix_BroadwestLeaseFiveYearRenewalOptionMember_18087868-8c6e-4358-97d9-69d7b0077c1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8518fb82-232e-4e83-8f9e-b84ccfb27f90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_7af848bb-431b-4b13-b102-53723f68dad5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8518fb82-232e-4e83-8f9e-b84ccfb27f90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8518fb82-232e-4e83-8f9e-b84ccfb27f90_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8518fb82-232e-4e83-8f9e-b84ccfb27f90" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8518fb82-232e-4e83-8f9e-b84ccfb27f90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0194ad4e-ecf5-43ed-b51f-016f06405bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8518fb82-232e-4e83-8f9e-b84ccfb27f90" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0194ad4e-ecf5-43ed-b51f-016f06405bc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficeBuildingMember_0dc4e88b-60e6-4e32-b77f-215ab70ad0b7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OfficeBuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0194ad4e-ecf5-43ed-b51f-016f06405bc2" xlink:to="loc_srt_OfficeBuildingMember_0dc4e88b-60e6-4e32-b77f-215ab70ad0b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d64da85f-c5f4-4b35-afda-10b97786a91e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_7af848bb-431b-4b13-b102-53723f68dad5" xlink:to="loc_srt_CounterpartyNameAxis_d64da85f-c5f4-4b35-afda-10b97786a91e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d64da85f-c5f4-4b35-afda-10b97786a91e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d64da85f-c5f4-4b35-afda-10b97786a91e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d64da85f-c5f4-4b35-afda-10b97786a91e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a9ecb72c-c75f-463f-b89b-271927f9f61f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d64da85f-c5f4-4b35-afda-10b97786a91e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a9ecb72c-c75f-463f-b89b-271927f9f61f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_A1600WestEndAvenuePartnersLLCMember_b31f714b-ae7b-4964-8592-3d31a6f47076" xlink:href="cpix-20230331.xsd#cpix_A1600WestEndAvenuePartnersLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a9ecb72c-c75f-463f-b89b-271927f9f61f" xlink:to="loc_cpix_A1600WestEndAvenuePartnersLLCMember_b31f714b-ae7b-4964-8592-3d31a6f47076" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CETMember_e349dc2f-f6d7-450c-9e60-fc8c62cecd2a" xlink:href="cpix-20230331.xsd#cpix_CETMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a9ecb72c-c75f-463f-b89b-271927f9f61f" xlink:to="loc_cpix_CETMember_e349dc2f-f6d7-450c-9e60-fc8c62cecd2a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="simple" xlink:href="cpix-20230331.xsd#ShareholdersEquityandDebtShareholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="extended" id="i940ef9e5c0aa46e1a523e119e9a7c055_ShareholdersEquityandDebtShareholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c29cfda4-84de-4fb8-b53a-cb5dd6b9ea80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_7036e372-ba5d-4641-89f3-c35ed78becfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c29cfda4-84de-4fb8-b53a-cb5dd6b9ea80" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_7036e372-ba5d-4641-89f3-c35ed78becfe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_0bcb89cc-a14f-4cab-aabe-84e19ec0489b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c29cfda4-84de-4fb8-b53a-cb5dd6b9ea80" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_0bcb89cc-a14f-4cab-aabe-84e19ec0489b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_2912aed3-57bb-4b65-8771-8eac7baca662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c29cfda4-84de-4fb8-b53a-cb5dd6b9ea80" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_2912aed3-57bb-4b65-8771-8eac7baca662" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_da6af174-f78f-456a-8390-75d367da7dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c29cfda4-84de-4fb8-b53a-cb5dd6b9ea80" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_da6af174-f78f-456a-8390-75d367da7dfa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities_7a753891-daa3-4357-8636-23a9106c637b" xlink:href="cpix-20230331.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c29cfda4-84de-4fb8-b53a-cb5dd6b9ea80" xlink:to="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities_7a753891-daa3-4357-8636-23a9106c637b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8ed1f624-157a-48b4-983a-96fb936bef1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c29cfda4-84de-4fb8-b53a-cb5dd6b9ea80" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8ed1f624-157a-48b4-983a-96fb936bef1f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b4b1c7bc-0adc-409f-896f-825d05d95efb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c29cfda4-84de-4fb8-b53a-cb5dd6b9ea80" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b4b1c7bc-0adc-409f-896f-825d05d95efb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_8951c018-15de-4ac7-8818-238b31136167" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c29cfda4-84de-4fb8-b53a-cb5dd6b9ea80" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_8951c018-15de-4ac7-8818-238b31136167" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity_b6c381a5-e34a-4d3c-a2d1-612a1e067063" xlink:href="cpix-20230331.xsd#cpix_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c29cfda4-84de-4fb8-b53a-cb5dd6b9ea80" xlink:to="loc_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity_b6c381a5-e34a-4d3c-a2d1-612a1e067063" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_0d0309a3-87a2-42ca-b972-fdff66962546" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c29cfda4-84de-4fb8-b53a-cb5dd6b9ea80" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_0d0309a3-87a2-42ca-b972-fdff66962546" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DebtInstrumentCovenantFundedDebtRatioMaximum_da58f443-ba09-41df-8ed8-9c685721d3b3" xlink:href="cpix-20230331.xsd#cpix_DebtInstrumentCovenantFundedDebtRatioMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c29cfda4-84de-4fb8-b53a-cb5dd6b9ea80" xlink:to="loc_cpix_DebtInstrumentCovenantFundedDebtRatioMaximum_da58f443-ba09-41df-8ed8-9c685721d3b3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold_0d1cbd87-b95d-4096-9038-cacf7875b671" xlink:href="cpix-20230331.xsd#cpix_DebtInstrumentCovenantUnrestrictedCashThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c29cfda4-84de-4fb8-b53a-cb5dd6b9ea80" xlink:to="loc_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold_0d1cbd87-b95d-4096-9038-cacf7875b671" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DebtInstrumentCovenantEvaluationFrequency_dd453129-7efd-4ab2-8bc8-847b95cd1a62" xlink:href="cpix-20230331.xsd#cpix_DebtInstrumentCovenantEvaluationFrequency"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c29cfda4-84de-4fb8-b53a-cb5dd6b9ea80" xlink:to="loc_cpix_DebtInstrumentCovenantEvaluationFrequency_dd453129-7efd-4ab2-8bc8-847b95cd1a62" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_49e68e9c-3131-47a9-9e9e-1b5b3a7d5936" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c29cfda4-84de-4fb8-b53a-cb5dd6b9ea80" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_49e68e9c-3131-47a9-9e9e-1b5b3a7d5936" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bae119ba-11a0-4223-bfab-dcf164d4251f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c29cfda4-84de-4fb8-b53a-cb5dd6b9ea80" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bae119ba-11a0-4223-bfab-dcf164d4251f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_368f6dfd-6aee-42d3-9912-7783f40788e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c29cfda4-84de-4fb8-b53a-cb5dd6b9ea80" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_368f6dfd-6aee-42d3-9912-7783f40788e3" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_70021682-e571-4e09-9e28-7f8bc15347ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c29cfda4-84de-4fb8-b53a-cb5dd6b9ea80" xlink:to="loc_us-gaap_LongTermLineOfCredit_70021682-e571-4e09-9e28-7f8bc15347ae" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_0b9b0766-f31e-4036-8feb-d9fbb071ee48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c29cfda4-84de-4fb8-b53a-cb5dd6b9ea80" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_0b9b0766-f31e-4036-8feb-d9fbb071ee48" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_c99af6c1-b447-4147-b90f-630546e6b217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c29cfda4-84de-4fb8-b53a-cb5dd6b9ea80" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_c99af6c1-b447-4147-b90f-630546e6b217" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40505492-c341-4e11-af24-2086f0f0739d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c29cfda4-84de-4fb8-b53a-cb5dd6b9ea80" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40505492-c341-4e11-af24-2086f0f0739d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2e552e24-58f5-47cc-92fd-d567c04dd146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40505492-c341-4e11-af24-2086f0f0739d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2e552e24-58f5-47cc-92fd-d567c04dd146" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2e552e24-58f5-47cc-92fd-d567c04dd146_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2e552e24-58f5-47cc-92fd-d567c04dd146" xlink:to="loc_us-gaap_EquityComponentDomain_2e552e24-58f5-47cc-92fd-d567c04dd146_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a26b3578-521f-48b1-a6e4-3abbed180558" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2e552e24-58f5-47cc-92fd-d567c04dd146" xlink:to="loc_us-gaap_EquityComponentDomain_a26b3578-521f-48b1-a6e4-3abbed180558" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_baf9d43f-00aa-4894-a2f5-d2830934000e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a26b3578-521f-48b1-a6e4-3abbed180558" xlink:to="loc_us-gaap_CommonStockMember_baf9d43f-00aa-4894-a2f5-d2830934000e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_56e26098-e284-41a5-b50c-8c558c776ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40505492-c341-4e11-af24-2086f0f0739d" xlink:to="loc_us-gaap_AwardTypeAxis_56e26098-e284-41a5-b50c-8c558c776ec8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56e26098-e284-41a5-b50c-8c558c776ec8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_56e26098-e284-41a5-b50c-8c558c776ec8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56e26098-e284-41a5-b50c-8c558c776ec8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_050fe6e2-7ad4-4ed3-a462-7bbd5be5892a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_56e26098-e284-41a5-b50c-8c558c776ec8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_050fe6e2-7ad4-4ed3-a462-7bbd5be5892a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_bc324789-8255-4c7a-84d7-51a17dd86f51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_050fe6e2-7ad4-4ed3-a462-7bbd5be5892a" xlink:to="loc_us-gaap_RestrictedStockMember_bc324789-8255-4c7a-84d7-51a17dd86f51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncentiveStockOptionsMember_3fb55f74-d4d2-45c7-a0d4-b2a85388a86c" xlink:href="cpix-20230331.xsd#cpix_IncentiveStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_050fe6e2-7ad4-4ed3-a462-7bbd5be5892a" xlink:to="loc_cpix_IncentiveStockOptionsMember_3fb55f74-d4d2-45c7-a0d4-b2a85388a86c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_7929045e-3449-4ae5-8182-f722998ddd96" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40505492-c341-4e11-af24-2086f0f0739d" xlink:to="loc_srt_TitleOfIndividualAxis_7929045e-3449-4ae5-8182-f722998ddd96" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7929045e-3449-4ae5-8182-f722998ddd96_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_7929045e-3449-4ae5-8182-f722998ddd96" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7929045e-3449-4ae5-8182-f722998ddd96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b978f897-4923-4ccc-a088-1a894f70a616" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_7929045e-3449-4ae5-8182-f722998ddd96" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b978f897-4923-4ccc-a088-1a894f70a616" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_ea39041e-117e-44ef-a051-b9230ca9a9fd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b978f897-4923-4ccc-a088-1a894f70a616" xlink:to="loc_srt_DirectorMember_ea39041e-117e-44ef-a051-b9230ca9a9fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_8c954a3b-1020-4de3-9ba5-ab33f662c424" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40505492-c341-4e11-af24-2086f0f0739d" xlink:to="loc_us-gaap_CreditFacilityAxis_8c954a3b-1020-4de3-9ba5-ab33f662c424" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_8c954a3b-1020-4de3-9ba5-ab33f662c424_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_8c954a3b-1020-4de3-9ba5-ab33f662c424" xlink:to="loc_us-gaap_CreditFacilityDomain_8c954a3b-1020-4de3-9ba5-ab33f662c424_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_b56c4ff3-e46f-4abb-8e9f-65cbe90e7fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_8c954a3b-1020-4de3-9ba5-ab33f662c424" xlink:to="loc_us-gaap_CreditFacilityDomain_b56c4ff3-e46f-4abb-8e9f-65cbe90e7fa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_4ac7e108-5b4f-4aab-a77b-89a58295c205" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_b56c4ff3-e46f-4abb-8e9f-65cbe90e7fa5" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_4ac7e108-5b4f-4aab-a77b-89a58295c205" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a30790dd-a70c-4fa2-a1ee-400dd32bfe70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40505492-c341-4e11-af24-2086f0f0739d" xlink:to="loc_us-gaap_DebtInstrumentAxis_a30790dd-a70c-4fa2-a1ee-400dd32bfe70" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a30790dd-a70c-4fa2-a1ee-400dd32bfe70_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_a30790dd-a70c-4fa2-a1ee-400dd32bfe70" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a30790dd-a70c-4fa2-a1ee-400dd32bfe70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_cf695c1d-af54-4a9d-b10b-227082782ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_a30790dd-a70c-4fa2-a1ee-400dd32bfe70" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_cf695c1d-af54-4a9d-b10b-227082782ecf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SixthAmendmentMember_fec8d36c-bdae-4597-887e-0c68c6b38699" xlink:href="cpix-20230331.xsd#cpix_SixthAmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf695c1d-af54-4a9d-b10b-227082782ecf" xlink:to="loc_cpix_SixthAmendmentMember_fec8d36c-bdae-4597-887e-0c68c6b38699" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EightAmendmentMember_e1ca71ea-64e9-4843-94e5-4c1f5f2b6681" xlink:href="cpix-20230331.xsd#cpix_EightAmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf695c1d-af54-4a9d-b10b-227082782ecf" xlink:to="loc_cpix_EightAmendmentMember_e1ca71ea-64e9-4843-94e5-4c1f5f2b6681" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NinthAmemdmentMember_b9f1d811-dc89-4b06-babc-272a3205f2a7" xlink:href="cpix-20230331.xsd#cpix_NinthAmemdmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf695c1d-af54-4a9d-b10b-227082782ecf" xlink:to="loc_cpix_NinthAmemdmentMember_b9f1d811-dc89-4b06-babc-272a3205f2a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_334ed5ac-9854-4b24-8410-a77b1ff5fd21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf695c1d-af54-4a9d-b10b-227082782ecf" xlink:to="loc_us-gaap_LineOfCreditMember_334ed5ac-9854-4b24-8410-a77b1ff5fd21" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_81e8d474-53b3-46f9-bdd5-542723329eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40505492-c341-4e11-af24-2086f0f0739d" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_81e8d474-53b3-46f9-bdd5-542723329eb7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_81e8d474-53b3-46f9-bdd5-542723329eb7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_81e8d474-53b3-46f9-bdd5-542723329eb7" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_81e8d474-53b3-46f9-bdd5-542723329eb7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_20cd299c-a96f-44ea-849a-5f354e677512" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_81e8d474-53b3-46f9-bdd5-542723329eb7" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_20cd299c-a96f-44ea-849a-5f354e677512" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember_28b0b352-f2ce-48d7-a1b9-141e91b9715c" xlink:href="cpix-20230331.xsd#cpix_PinnacleBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_20cd299c-a96f-44ea-849a-5f354e677512" xlink:to="loc_cpix_PinnacleBankMember_28b0b352-f2ce-48d7-a1b9-141e91b9715c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8f6fd65a-c3bd-46c2-a8ff-41b8406f0881" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40505492-c341-4e11-af24-2086f0f0739d" xlink:to="loc_srt_RangeAxis_8f6fd65a-c3bd-46c2-a8ff-41b8406f0881" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8f6fd65a-c3bd-46c2-a8ff-41b8406f0881_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8f6fd65a-c3bd-46c2-a8ff-41b8406f0881" xlink:to="loc_srt_RangeMember_8f6fd65a-c3bd-46c2-a8ff-41b8406f0881_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d4e15c0c-e378-44e6-b8bc-98c7a53800e0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8f6fd65a-c3bd-46c2-a8ff-41b8406f0881" xlink:to="loc_srt_RangeMember_d4e15c0c-e378-44e6-b8bc-98c7a53800e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_814e85dc-403a-4034-9240-056b4d46f6b0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d4e15c0c-e378-44e6-b8bc-98c7a53800e0" xlink:to="loc_srt_MinimumMember_814e85dc-403a-4034-9240-056b4d46f6b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8fba5a5c-fc24-41c1-9ed2-e916dc8319a2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d4e15c0c-e378-44e6-b8bc-98c7a53800e0" xlink:to="loc_srt_MaximumMember_8fba5a5c-fc24-41c1-9ed2-e916dc8319a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_4dc6b361-3a7b-4e21-97ac-fababd879510" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40505492-c341-4e11-af24-2086f0f0739d" xlink:to="loc_us-gaap_VariableRateAxis_4dc6b361-3a7b-4e21-97ac-fababd879510" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_4dc6b361-3a7b-4e21-97ac-fababd879510_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_4dc6b361-3a7b-4e21-97ac-fababd879510" xlink:to="loc_us-gaap_VariableRateDomain_4dc6b361-3a7b-4e21-97ac-fababd879510_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_a3ec130c-6b38-46ef-8191-c0b1b914d06e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_4dc6b361-3a7b-4e21-97ac-fababd879510" xlink:to="loc_us-gaap_VariableRateDomain_a3ec130c-6b38-46ef-8191-c0b1b914d06e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_ade4f390-d055-494f-8115-56d75a826605" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_a3ec130c-6b38-46ef-8191-c0b1b914d06e" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_ade4f390-d055-494f-8115-56d75a826605" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4f96dcc5-1981-4655-8737-e5210890ba15" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40505492-c341-4e11-af24-2086f0f0739d" xlink:to="loc_srt_CounterpartyNameAxis_4f96dcc5-1981-4655-8737-e5210890ba15" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4f96dcc5-1981-4655-8737-e5210890ba15_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_4f96dcc5-1981-4655-8737-e5210890ba15" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4f96dcc5-1981-4655-8737-e5210890ba15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d85a37a1-208b-46e2-8b84-c08df9c1db2f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_4f96dcc5-1981-4655-8737-e5210890ba15" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d85a37a1-208b-46e2-8b84-c08df9c1db2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_WinHealthInvestmentSingaporeLtdMember_cc0decd9-7d6e-4393-afd1-bbb5cc14052e" xlink:href="cpix-20230331.xsd#cpix_WinHealthInvestmentSingaporeLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d85a37a1-208b-46e2-8b84-c08df9c1db2f" xlink:to="loc_cpix_WinHealthInvestmentSingaporeLtdMember_cc0decd9-7d6e-4393-afd1-bbb5cc14052e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f91871df-d2b5-43b5-b460-8e7ee0bdc119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40505492-c341-4e11-af24-2086f0f0739d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f91871df-d2b5-43b5-b460-8e7ee0bdc119" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f91871df-d2b5-43b5-b460-8e7ee0bdc119_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f91871df-d2b5-43b5-b460-8e7ee0bdc119" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f91871df-d2b5-43b5-b460-8e7ee0bdc119_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_657379b6-e30a-431f-85d5-3e9516a73df7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f91871df-d2b5-43b5-b460-8e7ee0bdc119" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_657379b6-e30a-431f-85d5-3e9516a73df7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_49db64d1-cff0-4d2e-b461-cbd039edd74a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_657379b6-e30a-431f-85d5-3e9516a73df7" xlink:to="loc_us-gaap_ConvertibleDebtMember_49db64d1-cff0-4d2e-b461-cbd039edd74a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="cpix-20230331.xsd#IncomeTaxesDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="extended" id="i7380ed728f1e41df8ddb79fa9183ed18_IncomeTaxesDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_2cd0a034-b362-48bd-97ee-7cbc13068ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_8e38e84f-3407-485d-b971-255307952ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2cd0a034-b362-48bd-97ee-7cbc13068ca0" xlink:to="loc_us-gaap_OperatingLossCarryforwards_8e38e84f-3407-485d-b971-255307952ea1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_0882bcc0-d154-47b1-91cd-989f684a81f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2cd0a034-b362-48bd-97ee-7cbc13068ca0" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_0882bcc0-d154-47b1-91cd-989f684a81f2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_40a3a527-df44-4c44-8914-591287171ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_0882bcc0-d154-47b1-91cd-989f684a81f2" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_40a3a527-df44-4c44-8914-591287171ffd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_40a3a527-df44-4c44-8914-591287171ffd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_40a3a527-df44-4c44-8914-591287171ffd" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_40a3a527-df44-4c44-8914-591287171ffd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_4e46ac1a-39d3-4eb8-be99-cb6e31947433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_40a3a527-df44-4c44-8914-591287171ffd" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_4e46ac1a-39d3-4eb8-be99-cb6e31947433" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_81d993b6-54ce-42ca-9c63-b88ecf6ac169" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_4e46ac1a-39d3-4eb8-be99-cb6e31947433" xlink:to="loc_us-gaap_DomesticCountryMember_81d993b6-54ce-42ca-9c63-b88ecf6ac169" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20230331.xsd#AdditionsandReturnsofProductRightsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="extended" id="i93299dccc534478b9aed0523f9198e7f_AdditionsandReturnsofProductRightsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_dccbb44d-914a-4803-95c4-f99b13440312" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_dccbb44d-914a-4803-95c4-f99b13440312" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_8b5ebda0-589f-43cc-bc77-f6e6733e2033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_8b5ebda0-589f-43cc-bc77-f6e6733e2033" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsPercentage_9dc7b2cf-8163-4dd0-ad11-33a7e2292055" xlink:href="cpix-20230331.xsd#cpix_TieredRoyaltyPaymentsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_cpix_TieredRoyaltyPaymentsPercentage_9dc7b2cf-8163-4dd0-ad11-33a7e2292055" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsThreshold_148ed4ea-efdb-453f-880a-33daee537322" xlink:href="cpix-20230331.xsd#cpix_TieredRoyaltyPaymentsThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_cpix_TieredRoyaltyPaymentsThreshold_148ed4ea-efdb-453f-880a-33daee537322" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_dc9f2abd-93e6-42bd-9a08-4aa98dac6b31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_dc9f2abd-93e6-42bd-9a08-4aa98dac6b31" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_aa88e358-b4fd-444c-9e4e-f1ac17e26fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_aa88e358-b4fd-444c-9e4e-f1ac17e26fe2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_bb87a88a-43a0-4cf9-bb61-cbcbb3a2e051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_bb87a88a-43a0-4cf9-bb61-cbcbb3a2e051" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_09f6b83a-4307-42bf-9786-5cc40d0a97b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_09f6b83a-4307-42bf-9786-5cc40d0a97b3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_defd6a03-bae3-4da2-924c-efc09ac51be4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_defd6a03-bae3-4da2-924c-efc09ac51be4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_a1f3eef6-e2c6-4a68-b441-58f06f6d19da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_a1f3eef6-e2c6-4a68-b441-58f06f6d19da" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable_46a63492-ae8d-4a32-b5f0-ac5b0ae5d1df" xlink:href="cpix-20230331.xsd#cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable_46a63492-ae8d-4a32-b5f0-ac5b0ae5d1df" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable_ee3bc96e-21e3-48c2-bcd7-b5da1b9b0eca" xlink:href="cpix-20230331.xsd#cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable_ee3bc96e-21e3-48c2-bcd7-b5da1b9b0eca" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue_7e8e2c7d-8f5e-4e65-a7f2-90e0c7ac82af" xlink:href="cpix-20230331.xsd#cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue_7e8e2c7d-8f5e-4e65-a7f2-90e0c7ac82af" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment_07bc3f14-74b4-4780-8556-a52363693ac4" xlink:href="cpix-20230331.xsd#cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment_07bc3f14-74b4-4780-8556-a52363693ac4" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_885676c4-dda5-4b9e-ae7f-9dd61e550da4" xlink:href="cpix-20230331.xsd#cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_885676c4-dda5-4b9e-ae7f-9dd61e550da4" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected_d257fd0d-2ee5-4076-98eb-e35839002ba8" xlink:href="cpix-20230331.xsd#cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected_d257fd0d-2ee5-4076-98eb-e35839002ba8" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePayments_fef48a5f-9567-40c1-ad2b-6c2079da608f" xlink:href="cpix-20230331.xsd#cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePayments_fef48a5f-9567-40c1-ad2b-6c2079da608f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_9ebc69ab-122b-4ee9-8448-4937b2fd1c14" xlink:href="cpix-20230331.xsd#cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_9ebc69ab-122b-4ee9-8448-4937b2fd1c14" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_478b73e6-1c63-4451-90be-28adfa0de0de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_478b73e6-1c63-4451-90be-28adfa0de0de" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_cb6efb0b-915d-4676-9e8b-d97f63afb0fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_cb6efb0b-915d-4676-9e8b-d97f63afb0fa" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2d1e6dd1-bbff-438f-ad9b-fb5675d475c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_us-gaap_Goodwill_2d1e6dd1-bbff-438f-ad9b-fb5675d475c0" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_aaad2df7-5939-451d-86e2-5e84f3e1a8ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_aaad2df7-5939-451d-86e2-5e84f3e1a8ac" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_844f4bf1-ec64-4c63-a9a4-d19dd51362ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_844f4bf1-ec64-4c63-a9a4-d19dd51362ac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f29b59de-90a1-4ef7-a679-b20d7a518702" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_844f4bf1-ec64-4c63-a9a4-d19dd51362ac" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f29b59de-90a1-4ef7-a679-b20d7a518702" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f29b59de-90a1-4ef7-a679-b20d7a518702_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f29b59de-90a1-4ef7-a679-b20d7a518702" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f29b59de-90a1-4ef7-a679-b20d7a518702_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3c5e3058-d170-4744-8a16-e18933576b27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f29b59de-90a1-4ef7-a679-b20d7a518702" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3c5e3058-d170-4744-8a16-e18933576b27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_f8b517c7-d763-4ab6-b46d-3ea48b974498" xlink:href="cpix-20230331.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3c5e3058-d170-4744-8a16-e18933576b27" xlink:to="loc_cpix_VIBATIVMember_f8b517c7-d763-4ab6-b46d-3ea48b974498" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MethotrexateMember_50d0d88e-a114-424c-978c-b4ad5c052487" xlink:href="cpix-20230331.xsd#cpix_MethotrexateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3c5e3058-d170-4744-8a16-e18933576b27" xlink:to="loc_cpix_MethotrexateMember_50d0d88e-a114-424c-978c-b4ad5c052487" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SancusoMember_07e32cb7-ebc5-4a3a-b8ac-1f6a12c4aacc" xlink:href="cpix-20230331.xsd#cpix_SancusoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3c5e3058-d170-4744-8a16-e18933576b27" xlink:to="loc_cpix_SancusoMember_07e32cb7-ebc5-4a3a-b8ac-1f6a12c4aacc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a0e3a3f4-94d9-40fc-90ba-694c7cae0bf5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_844f4bf1-ec64-4c63-a9a4-d19dd51362ac" xlink:to="loc_srt_CounterpartyNameAxis_a0e3a3f4-94d9-40fc-90ba-694c7cae0bf5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a0e3a3f4-94d9-40fc-90ba-694c7cae0bf5_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a0e3a3f4-94d9-40fc-90ba-694c7cae0bf5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a0e3a3f4-94d9-40fc-90ba-694c7cae0bf5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2e5db722-182d-4341-a6db-23fd971707b4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a0e3a3f4-94d9-40fc-90ba-694c7cae0bf5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2e5db722-182d-4341-a6db-23fd971707b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KyowaKirinMember_947436dd-214d-4251-8484-42cd1a306470" xlink:href="cpix-20230331.xsd#cpix_KyowaKirinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2e5db722-182d-4341-a6db-23fd971707b4" xlink:to="loc_cpix_KyowaKirinMember_947436dd-214d-4251-8484-42cd1a306470" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NordicGroupBVMember_6adda529-aeb7-4b5a-8f32-9baa41b0da01" xlink:href="cpix-20230331.xsd#cpix_NordicGroupBVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2e5db722-182d-4341-a6db-23fd971707b4" xlink:to="loc_cpix_NordicGroupBVMember_6adda529-aeb7-4b5a-8f32-9baa41b0da01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0520917b-2357-4944-bb9c-b5df02bf6b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_844f4bf1-ec64-4c63-a9a4-d19dd51362ac" xlink:to="loc_us-gaap_AwardTypeAxis_0520917b-2357-4944-bb9c-b5df02bf6b6b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0520917b-2357-4944-bb9c-b5df02bf6b6b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0520917b-2357-4944-bb9c-b5df02bf6b6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0520917b-2357-4944-bb9c-b5df02bf6b6b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f16f14b-2a48-44eb-a7c7-bb562403e8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0520917b-2357-4944-bb9c-b5df02bf6b6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f16f14b-2a48-44eb-a7c7-bb562403e8a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_b736b969-6bd7-4bf2-8db7-2381866fabea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f16f14b-2a48-44eb-a7c7-bb562403e8a0" xlink:to="loc_us-gaap_RestrictedStockMember_b736b969-6bd7-4bf2-8db7-2381866fabea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8b218066-0422-45cf-b561-208bd6cd9e90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_844f4bf1-ec64-4c63-a9a4-d19dd51362ac" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8b218066-0422-45cf-b561-208bd6cd9e90" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8b218066-0422-45cf-b561-208bd6cd9e90_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8b218066-0422-45cf-b561-208bd6cd9e90" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8b218066-0422-45cf-b561-208bd6cd9e90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7fe07d2e-ec33-451e-9110-26cdfd4dde5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8b218066-0422-45cf-b561-208bd6cd9e90" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7fe07d2e-ec33-451e-9110-26cdfd4dde5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_d744ff78-3f5c-487c-b42c-dca9c7e56423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7fe07d2e-ec33-451e-9110-26cdfd4dde5a" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_d744ff78-3f5c-487c-b42c-dca9c7e56423" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_50ad0d70-3cad-4075-a89e-4a02f860c27d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_844f4bf1-ec64-4c63-a9a4-d19dd51362ac" xlink:to="loc_srt_RangeAxis_50ad0d70-3cad-4075-a89e-4a02f860c27d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_50ad0d70-3cad-4075-a89e-4a02f860c27d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_50ad0d70-3cad-4075-a89e-4a02f860c27d" xlink:to="loc_srt_RangeMember_50ad0d70-3cad-4075-a89e-4a02f860c27d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2d4e513f-d2dd-4bb6-9c18-3e507f4562f9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_50ad0d70-3cad-4075-a89e-4a02f860c27d" xlink:to="loc_srt_RangeMember_2d4e513f-d2dd-4bb6-9c18-3e507f4562f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d138ceeb-9ad3-4210-9ebb-05f264b64e5d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2d4e513f-d2dd-4bb6-9c18-3e507f4562f9" xlink:to="loc_srt_MaximumMember_d138ceeb-9ad3-4210-9ebb-05f264b64e5d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationVibativDetails" xlink:type="simple" xlink:href="cpix-20230331.xsd#AdditionsandReturnsofProductRightsChangeinConsiderationVibativDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationVibativDetails" xlink:type="extended" id="ief4efe1ffcc349bca57e48bf7c21ff9d_AdditionsandReturnsofProductRightsChangeinConsiderationVibativDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_6c203208-826c-4791-8995-1dee47cb5f66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualRollForward_80abc321-a244-47da-b060-12a8b7bd55ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6c203208-826c-4791-8995-1dee47cb5f66" xlink:to="loc_us-gaap_LossContingencyAccrualRollForward_80abc321-a244-47da-b060-12a8b7bd55ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2ad8c9d3-e316-455e-a2ee-006138c45d69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_80abc321-a244-47da-b060-12a8b7bd55ab" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2ad8c9d3-e316-455e-a2ee-006138c45d69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_f39a0e2d-9a70-4308-937d-bd8e087ad771" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_80abc321-a244-47da-b060-12a8b7bd55ab" xlink:to="loc_us-gaap_PaymentsForRoyalties_f39a0e2d-9a70-4308-937d-bd8e087ad771" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_bc5c914d-7323-41ea-8891-039ff831aeb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_80abc321-a244-47da-b060-12a8b7bd55ab" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_bc5c914d-7323-41ea-8891-039ff831aeb4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_3780ac99-1403-4a27-83e4-3d23b85fc8bc" xlink:href="cpix-20230331.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_80abc321-a244-47da-b060-12a8b7bd55ab" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_3780ac99-1403-4a27-83e4-3d23b85fc8bc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f6a0427d-a988-4b9d-a884-580162c5c5e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d81a35c0-16fb-4e35-b5b7-d6ba57e0fde6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6c203208-826c-4791-8995-1dee47cb5f66" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d81a35c0-16fb-4e35-b5b7-d6ba57e0fde6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6baf8072-c66c-4b8f-9a23-574c9e8d8077" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d81a35c0-16fb-4e35-b5b7-d6ba57e0fde6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6baf8072-c66c-4b8f-9a23-574c9e8d8077" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6baf8072-c66c-4b8f-9a23-574c9e8d8077_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6baf8072-c66c-4b8f-9a23-574c9e8d8077" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6baf8072-c66c-4b8f-9a23-574c9e8d8077_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_500a33e6-9613-4f03-bcab-f6736aff5ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6baf8072-c66c-4b8f-9a23-574c9e8d8077" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_500a33e6-9613-4f03-bcab-f6736aff5ba2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_7a49b183-680f-4b96-95e8-893fe4c06e04" xlink:href="cpix-20230331.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_500a33e6-9613-4f03-bcab-f6736aff5ba2" xlink:to="loc_cpix_VIBATIVMember_7a49b183-680f-4b96-95e8-893fe4c06e04" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationSancusoAcquisitionDetails" xlink:type="simple" xlink:href="cpix-20230331.xsd#AdditionsandReturnsofProductRightsChangeinConsiderationSancusoAcquisitionDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationSancusoAcquisitionDetails" xlink:type="extended" id="i19ecff2702864df4b49412f6e9b0a72b_AdditionsandReturnsofProductRightsChangeinConsiderationSancusoAcquisitionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_825f019a-b1b8-4521-8d17-c896d59a5392" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualRollForward_d1029688-ff4f-4cc5-9289-9468365c9674" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_825f019a-b1b8-4521-8d17-c896d59a5392" xlink:to="loc_us-gaap_LossContingencyAccrualRollForward_d1029688-ff4f-4cc5-9289-9468365c9674" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_59db5143-6c67-4591-95c4-eaa425f6dac4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_d1029688-ff4f-4cc5-9289-9468365c9674" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_59db5143-6c67-4591-95c4-eaa425f6dac4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_4b7a0fd2-b6fb-4d8e-ac72-a89143365a55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_d1029688-ff4f-4cc5-9289-9468365c9674" xlink:to="loc_us-gaap_PaymentsForRoyalties_4b7a0fd2-b6fb-4d8e-ac72-a89143365a55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1eb621ec-31ac-47d5-a9e0-735c936b2c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_d1029688-ff4f-4cc5-9289-9468365c9674" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1eb621ec-31ac-47d5-a9e0-735c936b2c5b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_ddf65e8b-7012-4a25-98ed-5b0d78224129" xlink:href="cpix-20230331.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_d1029688-ff4f-4cc5-9289-9468365c9674" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_ddf65e8b-7012-4a25-98ed-5b0d78224129" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d39badca-4535-400f-9980-e67430a7300a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8f6ebe41-f280-4728-8d98-e04d365a2907" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_825f019a-b1b8-4521-8d17-c896d59a5392" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8f6ebe41-f280-4728-8d98-e04d365a2907" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5e13a0eb-9902-485e-a78a-dec229755212" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8f6ebe41-f280-4728-8d98-e04d365a2907" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5e13a0eb-9902-485e-a78a-dec229755212" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5e13a0eb-9902-485e-a78a-dec229755212_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5e13a0eb-9902-485e-a78a-dec229755212" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5e13a0eb-9902-485e-a78a-dec229755212_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ac976e51-4e6f-482a-95e2-0090bd0dc272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5e13a0eb-9902-485e-a78a-dec229755212" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ac976e51-4e6f-482a-95e2-0090bd0dc272" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SancusoMember_ff1cca6e-8765-486b-9e1a-15d1f9671856" xlink:href="cpix-20230331.xsd#cpix_SancusoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ac976e51-4e6f-482a-95e2-0090bd0dc272" xlink:to="loc_cpix_SancusoMember_ff1cca6e-8765-486b-9e1a-15d1f9671856" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>cpix-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:918a0a89-5dad-4ed0-b568-e96d686f2112,g:1ebee0a3-fb1a-41df-91cd-eb248c2cddb5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5db03d07-86b0-425a-b8b6-b45f9570f195_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_8df2ea07-c7d1-44e8-b803-54a70ec69189_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_0c6e1186-dddc-4bc8-8a29-0eb9cf220e61_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_d7822a51-d202-44f7-b9b1-e58833df047a_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IfetrobanClinicalMember_ba579b8f-68f6-430f-acf6-30b89774cf58_terseLabel_en-US" xlink:label="lab_cpix_IfetrobanClinicalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ifetroban Clinical</link:label>
    <link:label id="lab_cpix_IfetrobanClinicalMember_label_en-US" xlink:label="lab_cpix_IfetrobanClinicalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ifetroban Clinical [Member]</link:label>
    <link:label id="lab_cpix_IfetrobanClinicalMember_documentation_en-US" xlink:label="lab_cpix_IfetrobanClinicalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ifetroban Clinical</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember" xlink:href="cpix-20230331.xsd#cpix_IfetrobanClinicalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IfetrobanClinicalMember" xlink:to="lab_cpix_IfetrobanClinicalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_da862a78-799c-467b-b9b5-2c0e3a707edb_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:to="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81f352e1-87bd-4bda-9613-d42481c18a08_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_44a02147-daa1-4cd0-ae9d-1232c9f9d302_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_96d640b0-9403-4918-be46-2dba19abea58_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_fe8bb0ac-a5cb-411e-b56f-01be70c2896b_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_ff6edea4-3a87-4766-86f6-62f21163e303_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_03f5550d-949f-4cad-8593-73c85e108c1a_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_70373711-2ccf-4857-ba3b-97ec75f5d2b7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_ba1ecc86-2a6d-42f9-9902-3d0e9016bd9d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6c3ba1c9-84f7-4703-9f2c-23ad56e10a18_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_0e9fc37c-0687-47de-996a-9737ca9bcd4f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_b0ac7d56-5331-42ab-9eca-53f511fc62c2_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_a4b18567-33be-4bfe-ad15-93e0a21e009f_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Square feet of office space</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_170f4edd-7aaa-408d-a3c5-528c44675678_negatedTerseLabel_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease (increase) in cash surrender value of life insurance policies over premiums paid</link:label>
    <link:label id="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_label_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy</link:label>
    <link:label id="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_documentation_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:href="cpix-20230331.xsd#cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:to="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_7cde17af-e79d-4a86-8b08-a704723a43ff_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_45f9086e-07ff-4978-95c0-78804ce39fa3_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">- diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_430f6db7-a22d-4f19-8ddf-6aecfe420307_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding &#8211; diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_c95e035e-a148-45e3-a1f4-9a0823491843_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_3433f3ad-0c41-4c4f-acba-c376771752a5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AcetadoteMember_d1362eb2-b394-4364-a976-0e3eb82f7006_terseLabel_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote</link:label>
    <link:label id="lab_cpix_AcetadoteMember_label_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote [Member]</link:label>
    <link:label id="lab_cpix_AcetadoteMember_documentation_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember" xlink:href="cpix-20230331.xsd#cpix_AcetadoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AcetadoteMember" xlink:to="lab_cpix_AcetadoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NumeratorAbstract_ebab5f3c-2f57-4cc2-af4a-47c554d3e818_verboseLabel_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_cpix_NumeratorAbstract_label_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator [Abstract]</link:label>
    <link:label id="lab_cpix_NumeratorAbstract_documentation_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NumeratorAbstract" xlink:href="cpix-20230331.xsd#cpix_NumeratorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NumeratorAbstract" xlink:to="lab_cpix_NumeratorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_16626916-f804-4b3a-9773-1a11cf3fe98a_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_c5922845-ad81-4a8e-b0e6-2f32c9041d78_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPaymentsToAcquireBusinesses_ef3b0fd9-b2c8-4993-8333-47385afa2ccb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Payments to Acquire Businesses</link:label>
    <link:label id="lab_us-gaap_OtherPaymentsToAcquireBusinesses_label_en-US" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Payments to Acquire Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:to="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_ea1995be-b37d-44e9-93a2-6af8f03a7aae_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock&#8212;no par value; 100,000,000 shares authorized; 15,555,865 and 15,723,075 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NordicGroupBVMember_a0d5071d-834e-4d19-951c-c113d4c7ba52_terseLabel_en-US" xlink:label="lab_cpix_NordicGroupBVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nordic Group B.V.</link:label>
    <link:label id="lab_cpix_NordicGroupBVMember_label_en-US" xlink:label="lab_cpix_NordicGroupBVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nordic Group B.V. [Member]</link:label>
    <link:label id="lab_cpix_NordicGroupBVMember_documentation_en-US" xlink:label="lab_cpix_NordicGroupBVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nordic Group B.V.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NordicGroupBVMember" xlink:href="cpix-20230331.xsd#cpix_NordicGroupBVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NordicGroupBVMember" xlink:to="lab_cpix_NordicGroupBVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_a7df2734-dc0f-4db4-85ac-e4b62ff61c9c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_2c02819e-f33c-4f43-83c7-7765faddb321_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_32022d8f-3645-484a-9eda-4660e813eff1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity_9277e638-2e7d-4c32-9374-1e51aa1e2547_terseLabel_en-US" xlink:label="lab_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional borrowing capacity</link:label>
    <link:label id="lab_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity_label_en-US" xlink:label="lab_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Additional Borrowing Capacity</link:label>
    <link:label id="lab_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity_documentation_en-US" xlink:label="lab_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Additional Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:href="cpix-20230331.xsd#cpix_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:to="lab_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_fc333cbb-d275-428a-b930-d021f3adc87e_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_f5835c3d-0c1f-40ee-9bf8-88816d6984e7_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_379f7cf7-a885-4d6c-9838-cb45c44ff5a9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate spread</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2ae24c2b-5ac8-4a27-9a34-2904e1f11bb1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of remaining lease payments, percent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProductsAbstract_b442df7e-c154-4a9c-9c54-bbb246815768_verboseLabel_en-US" xlink:label="lab_cpix_ProductsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products:</link:label>
    <link:label id="lab_cpix_ProductsAbstract_label_en-US" xlink:label="lab_cpix_ProductsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products [Abstract]</link:label>
    <link:label id="lab_cpix_ProductsAbstract_documentation_en-US" xlink:label="lab_cpix_ProductsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductsAbstract" xlink:href="cpix-20230331.xsd#cpix_ProductsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProductsAbstract" xlink:to="lab_cpix_ProductsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_95abcf30-cb0b-4060-bd6b-f932287c10af_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncome_70f49010-a0f4-4ef4-9f76-b504687df4ff_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherIncome_7787bd5d-0972-4619-bae9-2378be9a2ba2_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherIncome" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refund</link:label>
    <link:label id="lab_us-gaap_OtherIncome_label_en-US" xlink:label="lab_us-gaap_OtherIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncome" xlink:to="lab_us-gaap_OtherIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LesseeOperatingLeaseBaseRent_9f299c0a-c01b-40ef-9079-cb8303175ce0_terseLabel_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseBaseRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base rent per square foot</link:label>
    <link:label id="lab_cpix_LesseeOperatingLeaseBaseRent_label_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseBaseRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Base Rent</link:label>
    <link:label id="lab_cpix_LesseeOperatingLeaseBaseRent_documentation_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseBaseRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Base Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseBaseRent" xlink:href="cpix-20230331.xsd#cpix_LesseeOperatingLeaseBaseRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LesseeOperatingLeaseBaseRent" xlink:to="lab_cpix_LesseeOperatingLeaseBaseRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4e842c22-4c68-4f6b-9378-1dd7c86e5c89_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_22bf6ab2-f720-4432-8256-d58578fccb22_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_26f04625-997b-4462-9c84-8a5bbafc19f8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TextBlockAbstract_label_en-US" xlink:label="lab_us-gaap_TextBlockAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Text Block [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TextBlockAbstract" xlink:to="lab_us-gaap_TextBlockAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_cc6f7657-b684-492f-b89e-1bf0bd701e9e_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c1b49d5d-3cfd-43f3-8beb-88cd35fb3b49_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss at subsidiary attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9223603e-d3d4-4d9b-866c-ff75bd4d7d8b_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_6c3fde19-cf94-4677-a41e-4b87b7b049bf_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_77ed43cc-1e16-419c-9f3b-70f373046439_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsThreshold_7512ecdd-15a8-495b-b734-80edfb6ff589_terseLabel_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered royalty payment, threshold</link:label>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsThreshold_label_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered Royalty Payments, Threshold</link:label>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsThreshold_documentation_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered Royalty Payments, Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsThreshold" xlink:href="cpix-20230331.xsd#cpix_TieredRoyaltyPaymentsThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_TieredRoyaltyPaymentsThreshold" xlink:to="lab_cpix_TieredRoyaltyPaymentsThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_ab5dba26-b1df-4603-8d5c-81e195a3d6ce_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_51b88cb9-1f57-49f9-9edd-5d1023aace6f_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_11a41c20-df68-4064-aafe-daa9342cab76_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_TradeAndNoteReceivablesPolicyTextBlock_830fd3e4-38b8-4315-a1ed-409c41cef121_terseLabel_en-US" xlink:label="lab_cpix_TradeAndNoteReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade and Note Receivables Policy</link:label>
    <link:label id="lab_cpix_TradeAndNoteReceivablesPolicyTextBlock_label_en-US" xlink:label="lab_cpix_TradeAndNoteReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade and Note Receivables [Policy Text Block]</link:label>
    <link:label id="lab_cpix_TradeAndNoteReceivablesPolicyTextBlock_documentation_en-US" xlink:label="lab_cpix_TradeAndNoteReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade and Note Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TradeAndNoteReceivablesPolicyTextBlock" xlink:href="cpix-20230331.xsd#cpix_TradeAndNoteReceivablesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_TradeAndNoteReceivablesPolicyTextBlock" xlink:to="lab_cpix_TradeAndNoteReceivablesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4fa425a1-1cb7-4d95-ba47-e37bb50fa7bd_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock available for purchase through restricted stock awards and options (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_VIBATIVMember_169a0f0b-f9f3-45ed-9ada-c76a93d15281_terseLabel_en-US" xlink:label="lab_cpix_VIBATIVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vibativ</link:label>
    <link:label id="lab_cpix_VIBATIVMember_label_en-US" xlink:label="lab_cpix_VIBATIVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIBATIV [Member]</link:label>
    <link:label id="lab_cpix_VIBATIVMember_documentation_en-US" xlink:label="lab_cpix_VIBATIVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIBATIV</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember" xlink:href="cpix-20230331.xsd#cpix_VIBATIVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_VIBATIVMember" xlink:to="lab_cpix_VIBATIVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_EightAmendmentMember_00c3abd5-9990-413d-9188-beec679db2e6_terseLabel_en-US" xlink:label="lab_cpix_EightAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eight Amendment</link:label>
    <link:label id="lab_cpix_EightAmendmentMember_label_en-US" xlink:label="lab_cpix_EightAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eight Amendment [Member]</link:label>
    <link:label id="lab_cpix_EightAmendmentMember_documentation_en-US" xlink:label="lab_cpix_EightAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eight Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EightAmendmentMember" xlink:href="cpix-20230331.xsd#cpix_EightAmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_EightAmendmentMember" xlink:to="lab_cpix_EightAmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_350328eb-c17f-4ce0-bc50-7d2ba385647a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity of Lease Liabilities at March 31, 2023</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_435585d4-2373-4989-be28-c23c4ea00c2c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After 2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DenominatorAbstract_b91d1a1e-49e1-40f1-9c1a-c4d3e7073cd4_verboseLabel_en-US" xlink:label="lab_cpix_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_cpix_DenominatorAbstract_label_en-US" xlink:label="lab_cpix_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator [Abstract]</link:label>
    <link:label id="lab_cpix_DenominatorAbstract_documentation_en-US" xlink:label="lab_cpix_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DenominatorAbstract" xlink:href="cpix-20230331.xsd#cpix_DenominatorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DenominatorAbstract" xlink:to="lab_cpix_DenominatorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_67798cf8-e128-4912-80ba-4b04a5f0be06_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_8687037a-4705-446e-b84c-cc45a8607823_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_e2680692-38f9-4071-8337-1ca4a37ff575_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_7181df48-917b-4b03-b9df-37d6c9d3eeb8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible note</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_df700b04-11b2-4746-8757-118903b65f87_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_9584f2af-bbce-41c0-b29d-bf5ae6275ae0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_05a13aa2-106d-49bf-aef9-8da7ea93a8c7_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_3353af2c-c239-4c29-9b51-2f917b74ffe2_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_e204acc5-b70f-4f20-8c6f-aa6de92225ff_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_f4f70fda-9f79-436d-a46b-8b83511e2433_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - Continuing operations - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_9abeb39f-d344-401e-9368-7e5aa63f5977_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_04bba2aa-1aae-4782-a847-4a34ce26ea03_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_7b96f33c-57d8-48d3-9348-3e9e9e2c9ab0_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit, unused capacity, commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_06f25488-5d7b-463d-873b-346b270c3080_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered royalty, percent</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Tiered Royalty, Percent</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Tiered Royalty, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" xlink:href="cpix-20230331.xsd#cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" xlink:to="lab_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_0b5cf793-6a8c-4e1b-9dd9-9619792ebfa1_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_b22bdbd4-5c2c-46ad-99f1-6ef418cdd70e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments on line of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_c72990f2-430d-4179-a6ec-6afe7390e12b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_9597c3de-44a0-453e-bba0-87a8a024f6d3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LeaseLiability_d7621baf-1b0b-4af3-b479-9cfda01f3d44_terseLabel_en-US" xlink:label="lab_cpix_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_cpix_LeaseLiability_label_en-US" xlink:label="lab_cpix_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:label id="lab_cpix_LeaseLiability_documentation_en-US" xlink:label="lab_cpix_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LeaseLiability" xlink:href="cpix-20230331.xsd#cpix_LeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LeaseLiability" xlink:to="lab_cpix_LeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_6011c69b-c0c9-41de-8f6d-88b8b871600e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BroadwestLeaseFiveYearRenewalOptionMember_bc2a52b3-28a0-4849-b41c-c20774f8e757_terseLabel_en-US" xlink:label="lab_cpix_BroadwestLeaseFiveYearRenewalOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Broadwest Lease, Five Year Renewal Option</link:label>
    <link:label id="lab_cpix_BroadwestLeaseFiveYearRenewalOptionMember_label_en-US" xlink:label="lab_cpix_BroadwestLeaseFiveYearRenewalOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Broadwest Lease, Five Year Renewal Option [Member]</link:label>
    <link:label id="lab_cpix_BroadwestLeaseFiveYearRenewalOptionMember_documentation_en-US" xlink:label="lab_cpix_BroadwestLeaseFiveYearRenewalOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Broadwest Lease, Five Year Renewal Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BroadwestLeaseFiveYearRenewalOptionMember" xlink:href="cpix-20230331.xsd#cpix_BroadwestLeaseFiveYearRenewalOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BroadwestLeaseFiveYearRenewalOptionMember" xlink:to="lab_cpix_BroadwestLeaseFiveYearRenewalOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_164f3d73-1443-4ece-8d02-0a6676cc55f2_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NinthAmemdmentMember_6620392f-da25-4110-91cd-3b0468c75cef_terseLabel_en-US" xlink:label="lab_cpix_NinthAmemdmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ninth Amemdment</link:label>
    <link:label id="lab_cpix_NinthAmemdmentMember_label_en-US" xlink:label="lab_cpix_NinthAmemdmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ninth Amemdment [Member]</link:label>
    <link:label id="lab_cpix_NinthAmemdmentMember_documentation_en-US" xlink:label="lab_cpix_NinthAmemdmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ninth Amemdment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NinthAmemdmentMember" xlink:href="cpix-20230331.xsd#cpix_NinthAmemdmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NinthAmemdmentMember" xlink:to="lab_cpix_NinthAmemdmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_OtherProductsMember_074ad158-f458-422d-97b0-bba2ab61e5b8_terseLabel_en-US" xlink:label="lab_cpix_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenue</link:label>
    <link:label id="lab_cpix_OtherProductsMember_label_en-US" xlink:label="lab_cpix_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products [Member]</link:label>
    <link:label id="lab_cpix_OtherProductsMember_documentation_en-US" xlink:label="lab_cpix_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherProductsMember" xlink:href="cpix-20230331.xsd#cpix_OtherProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OtherProductsMember" xlink:to="lab_cpix_OtherProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_61176948-0f97-47d2-82ec-94a003f30820_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_VaprisolMember_589074e5-64e1-4ac1-800d-71184b157ba3_terseLabel_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol</link:label>
    <link:label id="lab_cpix_VaprisolMember_label_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol [Member]</link:label>
    <link:label id="lab_cpix_VaprisolMember_documentation_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember" xlink:href="cpix-20230331.xsd#cpix_VaprisolMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_VaprisolMember" xlink:to="lab_cpix_VaprisolMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_c805ff1e-1035-4b99-ba60-a60c887337f5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_6adf125b-4356-47cc-8d15-c7f21e330dc0_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_13989a9d-9313-4568-b573-449f34263304_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_196b362f-318c-4f40-bdc8-31e230a9930a_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_3bf57f14-5dde-4373-ba05-ce6fcad9a4d2_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_347d5ff9-4171-4c68-94df-bd6748f34408_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_8ff8c6e0-3055-41d9-b28a-7c63223bc615_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Other Expense Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_9f1565ef-8810-487f-9e16-4e364ea9f190_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DebtInstrumentCovenantEvaluationFrequency_89a50b94-e9d0-4638-8749-f57118e96f9b_terseLabel_en-US" xlink:label="lab_cpix_DebtInstrumentCovenantEvaluationFrequency" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Covenant evaluation frequency</link:label>
    <link:label id="lab_cpix_DebtInstrumentCovenantEvaluationFrequency_label_en-US" xlink:label="lab_cpix_DebtInstrumentCovenantEvaluationFrequency" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Evaluation Frequency</link:label>
    <link:label id="lab_cpix_DebtInstrumentCovenantEvaluationFrequency_documentation_en-US" xlink:label="lab_cpix_DebtInstrumentCovenantEvaluationFrequency" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Evaluation Frequency</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DebtInstrumentCovenantEvaluationFrequency" xlink:href="cpix-20230331.xsd#cpix_DebtInstrumentCovenantEvaluationFrequency"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DebtInstrumentCovenantEvaluationFrequency" xlink:to="lab_cpix_DebtInstrumentCovenantEvaluationFrequency" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_11b85b90-75a2-4f7e-b0e5-dc2ea1c5e3bb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent portion of the contingent consideration liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IncentiveStockOptionsMember_02bc9ba0-26a8-46e2-81fd-3174064036b2_terseLabel_en-US" xlink:label="lab_cpix_IncentiveStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options</link:label>
    <link:label id="lab_cpix_IncentiveStockOptionsMember_label_en-US" xlink:label="lab_cpix_IncentiveStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options [Member]</link:label>
    <link:label id="lab_cpix_IncentiveStockOptionsMember_documentation_en-US" xlink:label="lab_cpix_IncentiveStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncentiveStockOptionsMember" xlink:href="cpix-20230331.xsd#cpix_IncentiveStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IncentiveStockOptionsMember" xlink:to="lab_cpix_IncentiveStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_81dd31f8-f521-43d5-bb5f-1384aab4b0ef_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_040a420c-fb4b-430b-8492-e006e660679d_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_d0a8bc72-87d3-4b15-9204-c44af487e2d0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bd648c1f-05fc-4be1-bae8-a9f32155aa43_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_69a1980d-40fb-42d9-82b5-65a47a61a8aa_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_aba93bd2-bd8c-47f0-99eb-63f9eb937462_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_d2010944-61c0-445a-9064-4d75c7fd5015_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of net revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantMember_e851902a-7617-4e84-8fde-56963cc29587_terseLabel_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant</link:label>
    <link:label id="lab_us-gaap_GrantMember_label_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember" xlink:to="lab_us-gaap_GrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_OmeclamoxPakMember_619351fa-134a-4bbc-95fa-96af46c33e08_terseLabel_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak</link:label>
    <link:label id="lab_cpix_OmeclamoxPakMember_label_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak [Member]</link:label>
    <link:label id="lab_cpix_OmeclamoxPakMember_documentation_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember" xlink:href="cpix-20230331.xsd#cpix_OmeclamoxPakMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OmeclamoxPakMember" xlink:to="lab_cpix_OmeclamoxPakMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_671e8a8c-3c7f-47ea-a08c-888f3ccc2e54_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_98d53692-7afa-4f9f-8a9c-6a77ff69b5c2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_45eb8df5-1298-4183-8139-fc213c74eecd_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_da1c0bb9-7b16-4086-9baf-7434190ec5e6_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_29c717c9-3d37-489c-8465-d17982ba1c2a_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_ab59995c-60f6-432a-921e-a23a016319d7_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_ae41bf8b-468f-423e-b9c8-b3b288e44524_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_42f69d49-c768-40ff-99c9-a9293f0c4fcf_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities_76a7222c-57dc-4498-b6e9-76353bdd040d_terseLabel_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration, sale of corporate securities (up to)</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities_label_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shelf Registration, Proceeds From Sale of Corporate Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities" xlink:href="cpix-20230331.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities" xlink:to="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_0f8d2683-76a6-4fc6-9410-b52d03a4bd7d_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_92fa958a-f1ce-4e2e-a6b1-6a1a8a6b7f0a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_430d3985-b7b2-42e4-980a-7b566c71b93b_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_4d29ba36-abb1-4bac-ad6a-8c9af311fe45_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_5175aec5-ebef-471a-923c-be40dfc4cae1_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHAREHOLDERS' EQUITY AND DEBT</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_c702feb6-c1c1-4c9a-8bb4-179c1648af7b_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Revenues</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_446c81d9-58f4-49ba-b574-f7b22bf995f0_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_e5d5a5ab-a0b1-418d-8de6-619e7040ed71_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePayments_0cbb1876-fbae-47bf-989b-8e6b5b2e756a_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales milestone payments</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePayments_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePayments_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePayments" xlink:href="cpix-20230331.xsd#cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePayments" xlink:to="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_88c0bbd9-6ad4-4c56-b357-8f57239c03a7_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_96638c74-c492-419c-8964-434e8314be9a_terseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7d400fc6-ba43-48cd-8fd0-c3fc17392976_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_6b13f23d-df4a-4dad-b98f-fe1f051cef2a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_RediTrexMember_d3cf566e-9f65-4072-90ce-180ca60967cc_terseLabel_en-US" xlink:label="lab_cpix_RediTrexMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RediTrex</link:label>
    <link:label id="lab_cpix_RediTrexMember_label_en-US" xlink:label="lab_cpix_RediTrexMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RediTrex [Member]</link:label>
    <link:label id="lab_cpix_RediTrexMember_documentation_en-US" xlink:label="lab_cpix_RediTrexMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RediTrex</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RediTrexMember" xlink:href="cpix-20230331.xsd#cpix_RediTrexMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_RediTrexMember" xlink:to="lab_cpix_RediTrexMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_44f9f6c4-3cf6-4a39-9742-657daab68c27_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_4c2c6b12-afd9-44d1-a995-f3422a91f0e1_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_fc16efe4-8b0c-4114-bbbe-3e40eeca6f68_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORGANIZATION AND BASIS OF PRESENTATION</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LesseeOperatingLeaseNumberOfRenewalTerms_235c3a4a-b209-4a0f-8621-89757ab5acc7_terseLabel_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of renewal terms</link:label>
    <link:label id="lab_cpix_LesseeOperatingLeaseNumberOfRenewalTerms_label_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Terms</link:label>
    <link:label id="lab_cpix_LesseeOperatingLeaseNumberOfRenewalTerms_documentation_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:href="cpix-20230331.xsd#cpix_LesseeOperatingLeaseNumberOfRenewalTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:to="lab_cpix_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_3681ed0c-b226-44a9-a2b7-2a3e50bf7469_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_cd103675-b50b-4c2b-a27f-42ab93e59ec7_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsPercentage_5ffca295-fc40-4a7b-8753-d7414a391fa3_terseLabel_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of tiered royalty payments (up to)</link:label>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsPercentage_label_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered Royalty Payments, Percentage</link:label>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsPercentage_documentation_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered Royalty Payments, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsPercentage" xlink:href="cpix-20230331.xsd#cpix_TieredRoyaltyPaymentsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_TieredRoyaltyPaymentsPercentage" xlink:to="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_537bbc0e-f6f6-4b0d-9b16-16cacb427ad4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SixthAmendmentMember_144ce4a6-957a-4425-a53f-c1844ead81a8_terseLabel_en-US" xlink:label="lab_cpix_SixthAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sixth Amendment</link:label>
    <link:label id="lab_cpix_SixthAmendmentMember_label_en-US" xlink:label="lab_cpix_SixthAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sixth Amendment [Member]</link:label>
    <link:label id="lab_cpix_SixthAmendmentMember_documentation_en-US" xlink:label="lab_cpix_SixthAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sixth Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SixthAmendmentMember" xlink:href="cpix-20230331.xsd#cpix_SixthAmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SixthAmendmentMember" xlink:to="lab_cpix_SixthAmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_b7185ab0-e465-462f-b06d-8b87d3f9493f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DebtInstrumentCovenantFundedDebtRatioMaximum_42755e70-9975-4cdb-b54d-14be5c022cd3_terseLabel_en-US" xlink:label="lab_cpix_DebtInstrumentCovenantFundedDebtRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum funded debt ratio</link:label>
    <link:label id="lab_cpix_DebtInstrumentCovenantFundedDebtRatioMaximum_label_en-US" xlink:label="lab_cpix_DebtInstrumentCovenantFundedDebtRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Funded Debt Ratio, Maximum</link:label>
    <link:label id="lab_cpix_DebtInstrumentCovenantFundedDebtRatioMaximum_documentation_en-US" xlink:label="lab_cpix_DebtInstrumentCovenantFundedDebtRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Funded Debt Ratio, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DebtInstrumentCovenantFundedDebtRatioMaximum" xlink:href="cpix-20230331.xsd#cpix_DebtInstrumentCovenantFundedDebtRatioMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DebtInstrumentCovenantFundedDebtRatioMaximum" xlink:to="lab_cpix_DebtInstrumentCovenantFundedDebtRatioMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_dd8c8f04-5f21-40ff-bcf2-3365bd8af4e5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_bdc88572-79f5-4c6c-ae0d-1f91306c0459_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_7fb9ba3b-6fe6-4f37-a100-ad16f5fe7350_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUES</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_b05e18ab-958f-448d-bd95-08bc6d3f19fe_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_ac59bee8-d904-4c81-9749-d80d466f58f8_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future minimum sublease income under noncancelable operating subleases</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bb16c893-4eb5-4ea9-aa75-febb5bccb2c9_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_2b6544d0-b9d6-4d51-b53e-0124dc892a45_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_6f9a9a10-022b-42d2-84d1-b0e91f7045c3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c76ee944-f1ad-4c6b-8ad3-86282980bae5_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_1bc68728-402a-4d74-b733-8a0fb9015dde_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PinnacleBankMember_8adb2078-c1ee-43da-8fcd-4c4c3aca1ff6_terseLabel_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank</link:label>
    <link:label id="lab_cpix_PinnacleBankMember_label_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank [Member]</link:label>
    <link:label id="lab_cpix_PinnacleBankMember_documentation_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember" xlink:href="cpix-20230331.xsd#cpix_PinnacleBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PinnacleBankMember" xlink:to="lab_cpix_PinnacleBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment_40152b29-df89-45f1-8c25-e06d29afad6e_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Upfront Payment</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:href="cpix-20230331.xsd#cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:to="lab_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_7a0c2f5a-b3ed-498c-8cc6-76e241f2e4c0_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_5f2e31a8-7f2d-481b-b6ea-2ead7a844fa7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories classified as current</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_4d749175-d146-4a0f-b63a-8b322c253fd1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings on line of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_44469df1-cf23-4b09-ba33-937ae2cb5d70_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_032be5ce-4863-41c1-9269-7d0ae88346a8_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_98be7bf7-a472-475e-ab2c-5d476b858327_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_08c21d69-b00c-4ab1-8524-07f56737f520_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_b31dc677-c7ee-40e1-bd8a-1ff57bb344cc_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_3a5fd20d-9a51-4415-a900-31d5516b8111_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_3466f548-35af-4f43-be4f-2ea43b958d36_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_ec480941-54a4-4180-8bfe-dcc49f7b2e50_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - Continuing operations - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_KristaloseMember_c6a32c34-cf21-4568-a940-730dd1e22321_terseLabel_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose</link:label>
    <link:label id="lab_cpix_KristaloseMember_label_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose [Member]</link:label>
    <link:label id="lab_cpix_KristaloseMember_documentation_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember" xlink:href="cpix-20230331.xsd#cpix_KristaloseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_KristaloseMember" xlink:to="lab_cpix_KristaloseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_421814b2-354d-429a-807b-7b40dcb83d21_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CETMember_fe50eaeb-3a7d-4708-88e4-c84c8e48050c_terseLabel_en-US" xlink:label="lab_cpix_CETMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CET</link:label>
    <link:label id="lab_cpix_CETMember_label_en-US" xlink:label="lab_cpix_CETMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CET [Member]</link:label>
    <link:label id="lab_cpix_CETMember_documentation_en-US" xlink:label="lab_cpix_CETMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CET</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CETMember" xlink:href="cpix-20230331.xsd#cpix_CETMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CETMember" xlink:to="lab_cpix_CETMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8b3ec1f9-32bc-41a4-9903-e34c6bebfd8e_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">- basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a73c1f3d-0c0b-449a-ae04-9a055888d132_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding &#8211; basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_35835476-e174-495e-8bb5-c5ed066206eb_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ab374f0-9598-4c70-9360-90f69dbc6990_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_1e7b740f-8834-4d3e-a933-564d170c465d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable_2d98b54e-2bf6-4133-b626-1671647d239a_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted shares receivable (in shares)</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Restricted Shares Receivable</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Restricted Shares Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable" xlink:href="cpix-20230331.xsd#cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable" xlink:to="lab_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_9c70bc2b-91dc-4de9-900d-8e3cc8bba16c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for acquisitions</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_9b689b37-1a8a-456d-99e2-70a210c8f489_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment to acquire business upon closing</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualRollForward_3238eeb7-01c7-4b7d-8a64-8cb08300710a_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualRollForward_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward" xlink:to="lab_us-gaap_LossContingencyAccrualRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_044b43c0-ae0a-4457-aa04-b06589fff0e0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation credit</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_aef55ae9-8417-4d8b-84e4-e66e333941c2_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_58a515e5-98bb-404b-bcb4-71e484e8ca84_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_e8c0d226-2dfc-4e29-bb79-0a2603340e8b_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_4eebe126-7b1c-4d55-a70d-e1a3c99cc3ad_terseLabel_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Position</link:label>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="cpix-20230331.xsd#cpix_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_491f26cb-ba6c-4449-97cc-9b4896d33bad_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consigned inventory</link:label>
    <link:label id="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_label_en-US" xlink:label="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:to="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermLineOfCredit_a95d6945-5eca-4f05-9b9a-2af99ac8f1bc_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermLineOfCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving line of credit</link:label>
    <link:label id="lab_us-gaap_LongTermLineOfCredit_label_en-US" xlink:label="lab_us-gaap_LongTermLineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Line of Credit, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermLineOfCredit" xlink:to="lab_us-gaap_LongTermLineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_2ba3d9d9-7891-450b-8b22-e613a0feb379_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_A1600WestEndAvenuePartnersLLCMember_64e870af-3d66-40bc-88c0-2a1e1fcb0886_terseLabel_en-US" xlink:label="lab_cpix_A1600WestEndAvenuePartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1600 West End Avenue Partners, LLC</link:label>
    <link:label id="lab_cpix_A1600WestEndAvenuePartnersLLCMember_label_en-US" xlink:label="lab_cpix_A1600WestEndAvenuePartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1600 West End Avenue Partners, LLC [Member]</link:label>
    <link:label id="lab_cpix_A1600WestEndAvenuePartnersLLCMember_documentation_en-US" xlink:label="lab_cpix_A1600WestEndAvenuePartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1600 West End Avenue Partners, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_A1600WestEndAvenuePartnersLLCMember" xlink:href="cpix-20230331.xsd#cpix_A1600WestEndAvenuePartnersLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_A1600WestEndAvenuePartnersLLCMember" xlink:to="lab_cpix_A1600WestEndAvenuePartnersLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_2fdfcb5d-ee76-460d-8772-6b4ee9d28a45_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OfficeBuildingMember_c555eecc-7ebb-485a-9732-d8fa65bcbcec_terseLabel_en-US" xlink:label="lab_srt_OfficeBuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wet Laboratory and Office Space</link:label>
    <link:label id="lab_srt_OfficeBuildingMember_label_en-US" xlink:label="lab_srt_OfficeBuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficeBuildingMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OfficeBuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OfficeBuildingMember" xlink:to="lab_srt_OfficeBuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e4b129a9-2af6-48f7-a8d6-a6782c0a662b_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_73ed0380-01ac-40f6-8dc5-b29eaa2be7fe_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_ae845a2b-e776-47f8-9ab3-e48338a111bd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7d0711d8-3152-4fc7-bf34-5c37360ec58d_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_60f588f8-4b21-4df7-b47a-9c7ccfd7e19f_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, Beginning of Period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_255a7433-df7c-410a-8e72-93a5507b20d5_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, End of Period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_WinHealthInvestmentSingaporeLtdMember_9e2585ab-801b-452d-9030-c221ff4842e1_terseLabel_en-US" xlink:label="lab_cpix_WinHealthInvestmentSingaporeLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WinHealth</link:label>
    <link:label id="lab_cpix_WinHealthInvestmentSingaporeLtdMember_label_en-US" xlink:label="lab_cpix_WinHealthInvestmentSingaporeLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WinHealth Investment (Singapore) Ltd [Member]</link:label>
    <link:label id="lab_cpix_WinHealthInvestmentSingaporeLtdMember_documentation_en-US" xlink:label="lab_cpix_WinHealthInvestmentSingaporeLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WinHealth Investment (Singapore) Ltd</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_WinHealthInvestmentSingaporeLtdMember" xlink:href="cpix-20230331.xsd#cpix_WinHealthInvestmentSingaporeLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_WinHealthInvestmentSingaporeLtdMember" xlink:to="lab_cpix_WinHealthInvestmentSingaporeLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_e140b360-fd4c-4443-a688-23a71c26399c_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_f772f056-72ec-4358-b58b-644a4d8838fd_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_d679592d-becd-4ded-84d4-3ffbf42ed8d3_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_18a77307-fd50-4008-be39-a79ad1d37420_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials and work in process</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_1fee97e2-9c7a-4a13-858c-d64a6c3dfc36_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_25d38051-9890-40c6-92cf-fe164ed0c659_terseLabel_en-US" xlink:label="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Rent Expense and Sublease Income</link:label>
    <link:label id="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_label_en-US" xlink:label="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Rent Expense and Sublease Income [Table Text Block]</link:label>
    <link:label id="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_documentation_en-US" xlink:label="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Rent Expense and Sublease Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:href="cpix-20230331.xsd#cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:to="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_0accf8f7-072a-4de8-ae8e-6944dcee60f7_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_5e28ab9b-45b1-4b12-ad88-5020f9aab79d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_2c560358-ce98-4141-b3a5-7e1645818a02_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_6d3a9d0d-6853-48f4-8e01-5e5fde9ccad3_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_87f71d7e-d605-451e-ba64-40485cadae67_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_dcb772b5-8e37-47bf-a9e6-b82fc2d2aa1d_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold_91df4dec-3bef-4173-a136-976d5b2c697c_terseLabel_en-US" xlink:label="lab_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrestricted cash threshold</link:label>
    <link:label id="lab_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold_label_en-US" xlink:label="lab_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Unrestricted Cash Threshold</link:label>
    <link:label id="lab_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold_documentation_en-US" xlink:label="lab_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Unrestricted Cash Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold" xlink:href="cpix-20230331.xsd#cpix_DebtInstrumentCovenantUnrestrictedCashThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold" xlink:to="lab_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_dae25d03-592c-4b12-b81e-2e69c08dd7c9_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_6933a9a3-9784-48ce-87f9-737f69c2787f_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in noncash interest expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_37a609cc-aeff-4d30-b47b-58169997c5c1_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LesseeOperatingLeaseLeasedArea_73b45f4f-d8cc-4984-b7a1-15f8f46a8739_terseLabel_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseLeasedArea" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leased area</link:label>
    <link:label id="lab_cpix_LesseeOperatingLeaseLeasedArea_label_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseLeasedArea" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Leased Area</link:label>
    <link:label id="lab_cpix_LesseeOperatingLeaseLeasedArea_documentation_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseLeasedArea" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Leased Area</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseLeasedArea" xlink:href="cpix-20230331.xsd#cpix_LesseeOperatingLeaseLeasedArea"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LesseeOperatingLeaseLeasedArea" xlink:to="lab_cpix_LesseeOperatingLeaseLeasedArea" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_c9010385-a12d-46fb-845c-81ebc6a7aa5f_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares left to repurchase</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuredEventGainLoss_8a411a1a-9287-48ed-aff4-09c46fc8cb39_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InsuredEventGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on receivable of FDA fees</link:label>
    <link:label id="lab_us-gaap_InsuredEventGainLoss_d5f6dba6-3bdb-4242-a9a3-81fd7b79826f_terseLabel_en-US" xlink:label="lab_us-gaap_InsuredEventGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on receivable of FDA fees</link:label>
    <link:label id="lab_us-gaap_InsuredEventGainLoss_label_en-US" xlink:label="lab_us-gaap_InsuredEventGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insured Event, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuredEventGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuredEventGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuredEventGainLoss" xlink:to="lab_us-gaap_InsuredEventGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_8fa5b351-38e2-4b86-9dff-2b3cb85d4873_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_8a21da80-71b7-44d7-ab20-97b20db4d966_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_94dae3ed-ad45-47bb-852c-9471aebdb907_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock granted in period, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_d1103e45-6314-4bde-8711-6675248727a5_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f40a72bf-e7c7-4721-ae9b-d0960249e3a4_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_19639156-e951-4cff-a905-f7c6c2b962a9_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SancusoMember_897a3063-2dc6-4b6f-92e1-5864d4eba220_terseLabel_en-US" xlink:label="lab_cpix_SancusoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sancuso</link:label>
    <link:label id="lab_cpix_SancusoMember_label_en-US" xlink:label="lab_cpix_SancusoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sancuso [Member]</link:label>
    <link:label id="lab_cpix_SancusoMember_documentation_en-US" xlink:label="lab_cpix_SancusoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sancuso</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SancusoMember" xlink:href="cpix-20230331.xsd#cpix_SancusoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SancusoMember" xlink:to="lab_cpix_SancusoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_99659ca7-4d11-4571-8ca1-4bfd746b7c1e_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_c15e7154-f35e-4049-a300-54003362eb82_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADDITIONS AND RETURN OF PRODUCT RIGHTS</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LesseeOperatingLeaseRentIncrease_46ed7d10-4786-45c5-80e1-185511ea451d_terseLabel_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseRentIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent increase</link:label>
    <link:label id="lab_cpix_LesseeOperatingLeaseRentIncrease_label_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseRentIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Rent Increase</link:label>
    <link:label id="lab_cpix_LesseeOperatingLeaseRentIncrease_documentation_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseRentIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Rent Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseRentIncrease" xlink:href="cpix-20230331.xsd#cpix_LesseeOperatingLeaseRentIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LesseeOperatingLeaseRentIncrease" xlink:to="lab_cpix_LesseeOperatingLeaseRentIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6d9e5287-b8fa-4e86-bf02-2290f4721591_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards, vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_e754a4d7-02a2-4233-b76e-afa365b3cfff_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_18caf76d-05af-4ba8-8d4d-a0734a2c4edd_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_d9fe0508-3f9e-4c2b-8f6a-7d5b0daaeef3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability recorded</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_92719c3b-ff4f-4a7c-84ac-5cda570c9270_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_ac9d3f69-e136-4914-9b67-165522e53c16_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_8130e425-21e4-42a8-8bfb-190e6e117d9f_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_28adec3b-b949-472b-91a9-a8fbaaf949e4_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_55615126-c7b1-43a3-85f6-d62de8e3ac1a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_23e296a7-28a3-45d5-a306-8bb18cd8ec14_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods, net of reserve</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_e24ac854-7799-41fd-91fe-bc36015c5a1c_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_f10d0c18-1de2-47f5-868c-d0cda3683628_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_537dc323-6834-4cf7-bfbb-0ad3e7674c0f_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0a751f13-de2a-4cce-a1f7-3d20b9867367_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_3cd3138f-ff40-4c56-91e2-e67f9114e6ee_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturity of Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_b9771f92-d43a-440e-a702-0faf5ee5f27a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_0ec79c7f-6cc9-4ea2-9254-2b1001dc79d3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue_603dc168-ce9e-4e88-90dd-9da25db26842_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment credit due</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Milestone Payment Credit Due</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Milestone Payment Credit Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue" xlink:href="cpix-20230331.xsd#cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue" xlink:to="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_e50690e3-07ea-4cce-8bd0-6e18d092daea_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_f7394e0d-4987-46d2-9a41-7322313509b3_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_c60a5b23-b18b-45bb-8696-fecf6a39e7b5_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_fbe8f2c3-59d5-458b-979b-e140e648385a_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_KyowaKirinMember_619ef28e-93e9-4b46-b98a-9bab48483336_terseLabel_en-US" xlink:label="lab_cpix_KyowaKirinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kyowa Kirin</link:label>
    <link:label id="lab_cpix_KyowaKirinMember_label_en-US" xlink:label="lab_cpix_KyowaKirinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kyowa Kirin [Member]</link:label>
    <link:label id="lab_cpix_KyowaKirinMember_documentation_en-US" xlink:label="lab_cpix_KyowaKirinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kyowa Kirin</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KyowaKirinMember" xlink:href="cpix-20230331.xsd#cpix_KyowaKirinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_KyowaKirinMember" xlink:to="lab_cpix_KyowaKirinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_eddbe66f-55bc-4ad7-ae2d-b6c9f9643923_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_cc440481-8f6a-4a9a-a041-12c41d81c662_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_0cff7034-4316-45a4-ba0b-c4404f38c197_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_bdb86ed0-9fb3-4e1e-84ad-f2608be955ff_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration earned and accrued in operating expenses</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_label_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:href="cpix-20230331.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:to="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_32dde92d-eb63-45af-a27b-eb614a81f44a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment of royalty during the period</link:label>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_b1c2ad64-f5b5-4d32-adc4-2e03347bf666_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment of royalty during the period</link:label>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_label_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRoyalties" xlink:to="lab_us-gaap_PaymentsForRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_MethotrexateMember_91e9c36c-4229-4867-a554-71052bf18185_terseLabel_en-US" xlink:label="lab_cpix_MethotrexateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Methotrexate</link:label>
    <link:label id="lab_cpix_MethotrexateMember_label_en-US" xlink:label="lab_cpix_MethotrexateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Methotrexate [Member]</link:label>
    <link:label id="lab_cpix_MethotrexateMember_documentation_en-US" xlink:label="lab_cpix_MethotrexateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Methotrexate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MethotrexateMember" xlink:href="cpix-20230331.xsd#cpix_MethotrexateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_MethotrexateMember" xlink:to="lab_cpix_MethotrexateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_9d12ea89-aa9f-4e7f-b69b-99e82be6ec47_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_3dfe0d21-4814-4324-bc63-5fc4c877fb55_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_dc02ec2d-8206-46cf-8348-2b7366e7ca7c_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_e3234bca-6f16-41a0-b589-6ddbb38ec36e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_a6b62a24-2c71-4fe0-b289-28d1f69fd298_negatedLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">less non-current inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ff79d9f6-8015-475e-82ab-1d00792f4678_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net changes in assets and liabilities affecting operating activities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_43699336-bf8e-45a9-98f2-017a78963223_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obsolescence and discontinuance losses</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_b229a1e5-8514-4176-9bc1-810f70983f5b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVENTORIES</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_7f7b23a0-afa3-4f3a-8d02-934b09deb952_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings (deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_4cfdceb7-bad8-458b-aa07-f0f798ae5ec4_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_51e63d99-e16a-4677-992a-ad788aabd95e_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_131676cb-5089-4a76-aea4-9aeb5c6c6410_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected_897a55cd-d324-419d-a6e4-2c5fac738c83_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales milestone payments, expected</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Expected</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Expected</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected" xlink:href="cpix-20230331.xsd#cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected" xlink:to="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ed17eb55-6914-4ce7-bb23-263ebf66269c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_e8724387-8a73-4034-ab74-ec3aa2629c8f_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales milestone payments, maximum</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Maximum</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" xlink:href="cpix-20230331.xsd#cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" xlink:to="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_0f430442-f3ad-4448-b34a-487f1f91bbf7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common shares</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_5e710346-decb-4a92-a3e1-2a9e4056ea53_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_d8ff36ed-4403-4af4-98ac-73a595d49a79_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_9368b99c-6465-4286-9d09-b183c8b7a264_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_f55486e2-b0c2-4b2a-af3e-f07af7bb4fcb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_a17f156c-07f6-493f-8229-eddb3e412c81_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested common stock, value</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_4beac9f8-58de-4ef7-a55b-a7752549cca2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_63c88837-ed52-4755-b7c0-0ef50b36100c_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_ff044efa-e8dd-4eed-99c0-dac74bcd120b_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_dd2c34a8-b584-4292-846f-9165f8e34290_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_EquityAndDebtAbstract_label_en-US" xlink:label="lab_cpix_EquityAndDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity and Debt [Abstract]</link:label>
    <link:label id="lab_cpix_EquityAndDebtAbstract_documentation_en-US" xlink:label="lab_cpix_EquityAndDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity and Debt [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract" xlink:href="cpix-20230331.xsd#cpix_EquityAndDebtAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_EquityAndDebtAbstract" xlink:to="lab_cpix_EquityAndDebtAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNoParValue_987fbc5e-7f44-4303-a402-9d4a243b60a5_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNoParValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockNoParValue_label_en-US" xlink:label="lab_us-gaap_CommonStockNoParValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, No Par Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNoParValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNoParValue" xlink:to="lab_us-gaap_CommonStockNoParValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable_f5834f25-b9f4-4991-b710-1cdee007e6f7_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment receivable</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Milestone Payment Receivable</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Milestone Payment Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable" xlink:href="cpix-20230331.xsd#cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable" xlink:to="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_ef0f4851-bb59-43d6-933d-cbfce856f4bb_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5dec740e-4190-4034-872c-0a09912178f7_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_a536057d-d546-4883-b9fa-307a432c9295_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment of contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_ab913fb4-0653-46b9-85e5-b580f3a4de60_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_365b45ef-87d3-4094-a644-180da07574ef_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive effect of other securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_d4be96c9-5994-4927-ae35-56ee73016ef7_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings (deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_cab7099a-734e-465c-864c-36bfe2aa2bb1_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_b1ad19fe-23ed-496b-bbd8-9ecd766e0f36_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_008897d5-c01a-4661-9cf0-6c315ed58682_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_b2d4b406-7c7b-4db1-a0ff-a30b0f3765ad_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_25dc8533-cb16-43e7-9040-6247f8b7aad4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_a8fb33cb-6218-4c30-b249-af4e6ff8b18a_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_a52ebfe1-5fe7-4a9a-ae5d-c220392f10d3_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_2b2136e1-ed8d-4dcb-b4df-6fe798c5d265_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9ee1e6fb-a741-4d71-bfc8-d719a012f306_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_fe5cc19f-995a-48d9-8298-0a2320aacc01_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_f0241f48-18ab-458a-b0ba-e50e37ff6b38_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_2f50fc30-a66f-437d-a170-2f59a0d2a0cb_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_0a9e4a71-95f3-48f3-9933-d0b1340a5227_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_da79cf8a-6624-4e19-8b01-8a031ef86363_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_e587c3f9-87fd-4d72-8d12-d06da3b2764c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of the contingent consideration liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_67792f23-dbf9-424a-aad7-f787c4dc6529_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f9320a4d-18c4-4cc9-874e-7064b281d7dc_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in non-cash contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_0831ac37-0307-4c77-a0b8-aecb2bd352ec_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration included in operating expenses</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b3cc8c2d-acec-460e-9926-0de11e8a6644_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_29dbf0e4-600a-4a72-959f-e2294feb60ea_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_9faf2634-cd3a-493b-8577-88ba1ca7d56d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_4b9f8127-2a8e-45dd-83dc-8fc61a50963b_verboseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_274e95d8-754a-44b3-860a-40a169b1b7ac_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net, Items Net of Reserve Alternative [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:to="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_431d5f66-7874-4d19-9615-a0bc7ab4c765_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_61ebf95a-30ea-4225-9420-790ebfbd8c87_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CaldolorMember_c952aff8-69c7-483f-8329-4bdde277ae10_terseLabel_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor</link:label>
    <link:label id="lab_cpix_CaldolorMember_label_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor [Member]</link:label>
    <link:label id="lab_cpix_CaldolorMember_documentation_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember" xlink:href="cpix-20230331.xsd#cpix_CaldolorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CaldolorMember" xlink:to="lab_cpix_CaldolorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_255940e3-87c2-4d14-b4c0-d72021e3acd1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_29e1374a-ecc2-4b8c-8c04-4306f7cd7686_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_a3cb3186-762c-4118-8868-7cd339665881_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_1c17d4e2-b892-439f-9f43-1959ecfbff25_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7aa460ff-af1a-4ae5-a5d2-aae319c29a7c_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_17e38b46-a97e-4cee-a091-27e418774612_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_7b058827-4015-4df8-bfae-0d3b55dee656_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fc456cd7-5980-4298-84ce-4a94293e1dc0_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Guidance</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_123f2463-8d61-412c-b58c-0fee114c828d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of numerator and denominator</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_dc554fae-1cb6-47cc-b234-fe489502b5e1_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Current Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_880ce6f1-fd27-4e46-b1dd-9656569d5aab_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_a94708e0-1334-4aa9-89dd-483dd0fa59c4_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, Beginning of Period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_15836d44-e1e7-4668-a14d-3c91ea669895_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, End of Period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_cc1c313e-2c85-45a7-9207-f0cb0e368e1b_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial investment in joint ventures</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_e0b7e66e-664c-42d2-9ad3-e2bf511d1cc4_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_891d63ee-1ee1-4751-8a70-4bd027366c82_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>cpix-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:918a0a89-5dad-4ed0-b568-e96d686f2112,g:1ebee0a3-fb1a-41df-91cd-eb248c2cddb5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="simple" xlink:href="cpix-20230331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_40481e78-de74-4820-8992-a0a9f59147de" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_43059820-73cd-416c-9493-f4f6b3ad64c8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40481e78-de74-4820-8992-a0a9f59147de" xlink:to="loc_dei_DocumentType_43059820-73cd-416c-9493-f4f6b3ad64c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_e5c1d2e3-e8e4-45ad-b094-8db6bd84a52a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40481e78-de74-4820-8992-a0a9f59147de" xlink:to="loc_dei_DocumentQuarterlyReport_e5c1d2e3-e8e4-45ad-b094-8db6bd84a52a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_6a602535-316f-4815-83c8-4282d2b54c32" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40481e78-de74-4820-8992-a0a9f59147de" xlink:to="loc_dei_DocumentPeriodEndDate_6a602535-316f-4815-83c8-4282d2b54c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_d3a826e1-a327-4026-a2bf-acca0acca144" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40481e78-de74-4820-8992-a0a9f59147de" xlink:to="loc_dei_DocumentTransitionReport_d3a826e1-a327-4026-a2bf-acca0acca144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_d11b74bb-531e-4e94-b13e-0b9cbfa1e07d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40481e78-de74-4820-8992-a0a9f59147de" xlink:to="loc_dei_EntityFileNumber_d11b74bb-531e-4e94-b13e-0b9cbfa1e07d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_3992f96d-ae7a-451e-ad63-45aaeb4243da" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40481e78-de74-4820-8992-a0a9f59147de" xlink:to="loc_dei_EntityRegistrantName_3992f96d-ae7a-451e-ad63-45aaeb4243da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_92c925d4-b460-48fa-b282-3eae71d84d92" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40481e78-de74-4820-8992-a0a9f59147de" xlink:to="loc_dei_EntityIncorporationStateCountryCode_92c925d4-b460-48fa-b282-3eae71d84d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_67d88a52-1d2e-46bd-961a-64e790d046fa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40481e78-de74-4820-8992-a0a9f59147de" xlink:to="loc_dei_EntityTaxIdentificationNumber_67d88a52-1d2e-46bd-961a-64e790d046fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_36696ce7-e3a7-4f53-b99e-82aa84ce34cc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40481e78-de74-4820-8992-a0a9f59147de" xlink:to="loc_dei_EntityAddressAddressLine1_36696ce7-e3a7-4f53-b99e-82aa84ce34cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_24018f67-7028-41e5-840b-4160044e3fe4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40481e78-de74-4820-8992-a0a9f59147de" xlink:to="loc_dei_EntityAddressAddressLine2_24018f67-7028-41e5-840b-4160044e3fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_89cfb19e-3ea7-42eb-958a-fb0914876155" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40481e78-de74-4820-8992-a0a9f59147de" xlink:to="loc_dei_EntityAddressCityOrTown_89cfb19e-3ea7-42eb-958a-fb0914876155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_8d61640a-dd1a-4d4c-8d9d-d9e264b5f134" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40481e78-de74-4820-8992-a0a9f59147de" xlink:to="loc_dei_EntityAddressStateOrProvince_8d61640a-dd1a-4d4c-8d9d-d9e264b5f134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_19867e22-1cc6-41c2-886c-2802e3861c81" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40481e78-de74-4820-8992-a0a9f59147de" xlink:to="loc_dei_EntityAddressPostalZipCode_19867e22-1cc6-41c2-886c-2802e3861c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_7bc89d2e-a82a-490f-a819-c9a2c8ab9057" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40481e78-de74-4820-8992-a0a9f59147de" xlink:to="loc_dei_CityAreaCode_7bc89d2e-a82a-490f-a819-c9a2c8ab9057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_065de8b6-540a-457d-abdc-d28e6a4610e7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40481e78-de74-4820-8992-a0a9f59147de" xlink:to="loc_dei_LocalPhoneNumber_065de8b6-540a-457d-abdc-d28e6a4610e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_f3e38f01-0f6c-4f9e-be65-dadf1751fa9c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40481e78-de74-4820-8992-a0a9f59147de" xlink:to="loc_dei_Security12bTitle_f3e38f01-0f6c-4f9e-be65-dadf1751fa9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_c645cb9d-7afc-4520-a733-5b1beab03ad2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40481e78-de74-4820-8992-a0a9f59147de" xlink:to="loc_dei_TradingSymbol_c645cb9d-7afc-4520-a733-5b1beab03ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_b6486013-74d6-4f71-8a7b-9c25ced4c6f7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40481e78-de74-4820-8992-a0a9f59147de" xlink:to="loc_dei_SecurityExchangeName_b6486013-74d6-4f71-8a7b-9c25ced4c6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_d5bee5bd-8be0-49de-8385-a90dbc27ccad" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40481e78-de74-4820-8992-a0a9f59147de" xlink:to="loc_dei_EntityCurrentReportingStatus_d5bee5bd-8be0-49de-8385-a90dbc27ccad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_f301163c-dde8-452a-bebd-854a15e0db56" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40481e78-de74-4820-8992-a0a9f59147de" xlink:to="loc_dei_EntityInteractiveDataCurrent_f301163c-dde8-452a-bebd-854a15e0db56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_1f908124-22a4-4063-94f1-98325c29c99f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40481e78-de74-4820-8992-a0a9f59147de" xlink:to="loc_dei_EntityFilerCategory_1f908124-22a4-4063-94f1-98325c29c99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_9963171a-65eb-42a2-9014-ce3ec659939b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40481e78-de74-4820-8992-a0a9f59147de" xlink:to="loc_dei_EntitySmallBusiness_9963171a-65eb-42a2-9014-ce3ec659939b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_ea61cb78-3817-4d16-b586-ff32393f0103" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40481e78-de74-4820-8992-a0a9f59147de" xlink:to="loc_dei_EntityEmergingGrowthCompany_ea61cb78-3817-4d16-b586-ff32393f0103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_6bd44a12-c545-4f86-ba03-c51a4eec8f21" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40481e78-de74-4820-8992-a0a9f59147de" xlink:to="loc_dei_EntityShellCompany_6bd44a12-c545-4f86-ba03-c51a4eec8f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_5f8950db-a107-4947-9b2d-92af5406aa3a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40481e78-de74-4820-8992-a0a9f59147de" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_5f8950db-a107-4947-9b2d-92af5406aa3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_c1d73c91-04cd-4c58-86a3-f6516a773135" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40481e78-de74-4820-8992-a0a9f59147de" xlink:to="loc_dei_DocumentFiscalYearFocus_c1d73c91-04cd-4c58-86a3-f6516a773135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_ca70979c-d526-4383-9b65-341d8c687cdc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40481e78-de74-4820-8992-a0a9f59147de" xlink:to="loc_dei_DocumentFiscalPeriodFocus_ca70979c-d526-4383-9b65-341d8c687cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_292c5d53-a6c5-4532-a16c-0b4719128108" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40481e78-de74-4820-8992-a0a9f59147de" xlink:to="loc_dei_AmendmentFlag_292c5d53-a6c5-4532-a16c-0b4719128108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_27702c19-4c7a-476a-84ba-32cdb0f632d8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40481e78-de74-4820-8992-a0a9f59147de" xlink:to="loc_dei_EntityCentralIndexKey_27702c19-4c7a-476a-84ba-32cdb0f632d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_d4859c06-0199-474a-b69f-ca9509ee6648" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40481e78-de74-4820-8992-a0a9f59147de" xlink:to="loc_dei_CurrentFiscalYearEndDate_d4859c06-0199-474a-b69f-ca9509ee6648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cpix-20230331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2a66c582-0f3f-4149-bceb-524eb32b66c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_1ffcdd86-99aa-4b68-9ac5-6cf6bc982573" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2a66c582-0f3f-4149-bceb-524eb32b66c1" xlink:to="loc_us-gaap_AssetsAbstract_1ffcdd86-99aa-4b68-9ac5-6cf6bc982573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_d3e6dd5e-4873-4781-a8f8-1a5d4315a9be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1ffcdd86-99aa-4b68-9ac5-6cf6bc982573" xlink:to="loc_us-gaap_AssetsCurrentAbstract_d3e6dd5e-4873-4781-a8f8-1a5d4315a9be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5df7be62-6fb4-4e10-8ffa-0f663e710b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d3e6dd5e-4873-4781-a8f8-1a5d4315a9be" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5df7be62-6fb4-4e10-8ffa-0f663e710b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_283891cb-22a4-4f96-8f71-e05a815e3c45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d3e6dd5e-4873-4781-a8f8-1a5d4315a9be" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_283891cb-22a4-4f96-8f71-e05a815e3c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_66a8bfa9-ef8f-49a4-b715-7c25f8ba1010" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d3e6dd5e-4873-4781-a8f8-1a5d4315a9be" xlink:to="loc_us-gaap_InventoryNet_66a8bfa9-ef8f-49a4-b715-7c25f8ba1010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_51f297a5-ea60-4af9-b35f-ed12831fe5f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d3e6dd5e-4873-4781-a8f8-1a5d4315a9be" xlink:to="loc_us-gaap_OtherAssetsCurrent_51f297a5-ea60-4af9-b35f-ed12831fe5f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d0587a8d-3769-4550-ae27-fd1d510b12bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d3e6dd5e-4873-4781-a8f8-1a5d4315a9be" xlink:to="loc_us-gaap_AssetsCurrent_d0587a8d-3769-4550-ae27-fd1d510b12bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_e32fea2f-297b-45d4-90dd-14e0faf600f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1ffcdd86-99aa-4b68-9ac5-6cf6bc982573" xlink:to="loc_us-gaap_InventoryNoncurrent_e32fea2f-297b-45d4-90dd-14e0faf600f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_07d9b269-bc60-402b-9438-7d71681369de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1ffcdd86-99aa-4b68-9ac5-6cf6bc982573" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_07d9b269-bc60-402b-9438-7d71681369de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c52b50ab-b83b-40f8-8bac-f5d3d7e3794a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1ffcdd86-99aa-4b68-9ac5-6cf6bc982573" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c52b50ab-b83b-40f8-8bac-f5d3d7e3794a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_6c7a92b9-8a4e-4a7c-9bc5-b7a51595e757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1ffcdd86-99aa-4b68-9ac5-6cf6bc982573" xlink:to="loc_us-gaap_Goodwill_6c7a92b9-8a4e-4a7c-9bc5-b7a51595e757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_98860ebf-04f0-426b-bc53-79924af34292" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1ffcdd86-99aa-4b68-9ac5-6cf6bc982573" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_98860ebf-04f0-426b-bc53-79924af34292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_609225ec-b4bb-471d-863a-9dff10b92f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1ffcdd86-99aa-4b68-9ac5-6cf6bc982573" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_609225ec-b4bb-471d-863a-9dff10b92f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_3a1e5d6c-8a59-4fb8-9614-ecb3d6594f00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1ffcdd86-99aa-4b68-9ac5-6cf6bc982573" xlink:to="loc_us-gaap_Assets_3a1e5d6c-8a59-4fb8-9614-ecb3d6594f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9789d39a-ed5b-441f-bb26-eba571db2d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2a66c582-0f3f-4149-bceb-524eb32b66c1" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9789d39a-ed5b-441f-bb26-eba571db2d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_10cfc598-7d7c-4462-86a2-6310ad2e7814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9789d39a-ed5b-441f-bb26-eba571db2d2d" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_10cfc598-7d7c-4462-86a2-6310ad2e7814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_18eaffba-8f21-45cc-be76-91b44a7507af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_10cfc598-7d7c-4462-86a2-6310ad2e7814" xlink:to="loc_us-gaap_AccountsPayableCurrent_18eaffba-8f21-45cc-be76-91b44a7507af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_befa07bb-61c0-4fa5-a7d2-027ca25a6212" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_10cfc598-7d7c-4462-86a2-6310ad2e7814" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_befa07bb-61c0-4fa5-a7d2-027ca25a6212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_c660b79a-d561-495d-96e0-5169c55dd581" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_10cfc598-7d7c-4462-86a2-6310ad2e7814" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_c660b79a-d561-495d-96e0-5169c55dd581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2dd4755c-3e0c-424c-a930-761252af61c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_10cfc598-7d7c-4462-86a2-6310ad2e7814" xlink:to="loc_us-gaap_LiabilitiesCurrent_2dd4755c-3e0c-424c-a930-761252af61c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_224bfcdd-2bca-48e5-bdb7-337d3c8ef681" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9789d39a-ed5b-441f-bb26-eba571db2d2d" xlink:to="loc_us-gaap_LongTermLineOfCredit_224bfcdd-2bca-48e5-bdb7-337d3c8ef681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0586dae8-3e24-4cf7-b563-a55fde956b70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9789d39a-ed5b-441f-bb26-eba571db2d2d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0586dae8-3e24-4cf7-b563-a55fde956b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_704b73b7-5175-448c-836b-ef1c518cef65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9789d39a-ed5b-441f-bb26-eba571db2d2d" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_704b73b7-5175-448c-836b-ef1c518cef65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_dd683984-beaa-4a58-94df-9f9a0efb5dff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9789d39a-ed5b-441f-bb26-eba571db2d2d" xlink:to="loc_us-gaap_Liabilities_dd683984-beaa-4a58-94df-9f9a0efb5dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_e19c28e4-7650-427a-bc16-004b7428541c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9789d39a-ed5b-441f-bb26-eba571db2d2d" xlink:to="loc_us-gaap_CommitmentsAndContingencies_e19c28e4-7650-427a-bc16-004b7428541c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e6c8be60-497b-4ed2-bac8-1fee6807dfe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9789d39a-ed5b-441f-bb26-eba571db2d2d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e6c8be60-497b-4ed2-bac8-1fee6807dfe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_8aa9317b-f82a-4a87-98b2-4796975ba9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e6c8be60-497b-4ed2-bac8-1fee6807dfe9" xlink:to="loc_us-gaap_StockholdersEquityAbstract_8aa9317b-f82a-4a87-98b2-4796975ba9ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_5ca01183-0498-4f92-b50f-5475678d51ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8aa9317b-f82a-4a87-98b2-4796975ba9ed" xlink:to="loc_us-gaap_CommonStockValue_5ca01183-0498-4f92-b50f-5475678d51ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c3065923-062c-4224-a675-fbbc1c0014b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8aa9317b-f82a-4a87-98b2-4796975ba9ed" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c3065923-062c-4224-a675-fbbc1c0014b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9cc1e95d-376e-42ef-9681-c35842f78470" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8aa9317b-f82a-4a87-98b2-4796975ba9ed" xlink:to="loc_us-gaap_StockholdersEquity_9cc1e95d-376e-42ef-9681-c35842f78470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_9d4fee91-b54c-4ff9-9674-c2ac636aeb8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e6c8be60-497b-4ed2-bac8-1fee6807dfe9" xlink:to="loc_us-gaap_MinorityInterest_9d4fee91-b54c-4ff9-9674-c2ac636aeb8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_83fa63e7-bc6f-49be-8c30-d1943b386a09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e6c8be60-497b-4ed2-bac8-1fee6807dfe9" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_83fa63e7-bc6f-49be-8c30-d1943b386a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_0d9c5619-64a8-4cd3-94f9-f49388ed6d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9789d39a-ed5b-441f-bb26-eba571db2d2d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_0d9c5619-64a8-4cd3-94f9-f49388ed6d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cpix-20230331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_bdc93223-b9f1-44e9-92ea-76b01c22558b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNoParValue_0ee84ad6-d0af-4f0e-b511-8e1da0a0a670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bdc93223-b9f1-44e9-92ea-76b01c22558b" xlink:to="loc_us-gaap_CommonStockNoParValue_0ee84ad6-d0af-4f0e-b511-8e1da0a0a670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1a2218a7-b062-4184-96ac-d2a8383dae64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bdc93223-b9f1-44e9-92ea-76b01c22558b" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1a2218a7-b062-4184-96ac-d2a8383dae64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_58a47a1c-3753-4654-a538-94375f83fe98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bdc93223-b9f1-44e9-92ea-76b01c22558b" xlink:to="loc_us-gaap_CommonStockSharesIssued_58a47a1c-3753-4654-a538-94375f83fe98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_51ee1141-0201-4281-88ce-349be04ab9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bdc93223-b9f1-44e9-92ea-76b01c22558b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_51ee1141-0201-4281-88ce-349be04ab9eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="cpix-20230331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_5532b1e0-7213-4d43-8e39-753e52100d14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_196c5648-313a-4a4d-9ccf-6bf640fce3ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5532b1e0-7213-4d43-8e39-753e52100d14" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_196c5648-313a-4a4d-9ccf-6bf640fce3ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_d20df7b2-58bf-4b93-84a1-cd3e16b04790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5532b1e0-7213-4d43-8e39-753e52100d14" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_d20df7b2-58bf-4b93-84a1-cd3e16b04790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_009ea7a0-a8fc-45a9-a3fc-6da332153855" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d20df7b2-58bf-4b93-84a1-cd3e16b04790" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_009ea7a0-a8fc-45a9-a3fc-6da332153855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_91ed942e-8a0a-49c9-9dc3-bb14b1efe516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d20df7b2-58bf-4b93-84a1-cd3e16b04790" xlink:to="loc_us-gaap_SellingAndMarketingExpense_91ed942e-8a0a-49c9-9dc3-bb14b1efe516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7c5d924a-fe69-4ac0-962e-47b3b590755f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d20df7b2-58bf-4b93-84a1-cd3e16b04790" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7c5d924a-fe69-4ac0-962e-47b3b590755f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_6de81d0e-118e-4d21-bd02-c9c903072cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d20df7b2-58bf-4b93-84a1-cd3e16b04790" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_6de81d0e-118e-4d21-bd02-c9c903072cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_26324494-a16e-4028-9c5d-6d9fc6052787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d20df7b2-58bf-4b93-84a1-cd3e16b04790" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_26324494-a16e-4028-9c5d-6d9fc6052787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_994e3bd2-6030-4c49-a881-0f1a3bc18eab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d20df7b2-58bf-4b93-84a1-cd3e16b04790" xlink:to="loc_us-gaap_CostsAndExpenses_994e3bd2-6030-4c49-a881-0f1a3bc18eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1a9f16aa-78e1-4abb-a691-c5de359188bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d20df7b2-58bf-4b93-84a1-cd3e16b04790" xlink:to="loc_us-gaap_OperatingIncomeLoss_1a9f16aa-78e1-4abb-a691-c5de359188bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_e15420bd-49e2-48ff-82d3-af4ab01ac79b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5532b1e0-7213-4d43-8e39-753e52100d14" xlink:to="loc_us-gaap_InvestmentIncomeInterest_e15420bd-49e2-48ff-82d3-af4ab01ac79b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_1e50dab9-bd56-40a1-b543-1f0861c586b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5532b1e0-7213-4d43-8e39-753e52100d14" xlink:to="loc_us-gaap_OtherIncome_1e50dab9-bd56-40a1-b543-1f0861c586b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_5ed86733-0cf7-45b2-8806-4e5b8b2d979f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5532b1e0-7213-4d43-8e39-753e52100d14" xlink:to="loc_us-gaap_InterestExpense_5ed86733-0cf7-45b2-8806-4e5b8b2d979f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c6731b83-6f30-458c-be58-c22cd20ce500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5532b1e0-7213-4d43-8e39-753e52100d14" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c6731b83-6f30-458c-be58-c22cd20ce500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9e7ceb51-1516-4ffb-88aa-5ec08e48f00d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5532b1e0-7213-4d43-8e39-753e52100d14" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9e7ceb51-1516-4ffb-88aa-5ec08e48f00d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e8628b9f-d2b7-478e-910b-5d0e3b649f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5532b1e0-7213-4d43-8e39-753e52100d14" xlink:to="loc_us-gaap_ProfitLoss_e8628b9f-d2b7-478e-910b-5d0e3b649f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_974e51aa-2756-4324-9349-6bfb7f4a7fba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5532b1e0-7213-4d43-8e39-753e52100d14" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_974e51aa-2756-4324-9349-6bfb7f4a7fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_73037e37-9d99-4761-b0b5-93f1d8b5e859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5532b1e0-7213-4d43-8e39-753e52100d14" xlink:to="loc_us-gaap_NetIncomeLoss_73037e37-9d99-4761-b0b5-93f1d8b5e859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b6871614-8726-4f00-a940-dca3e3f39cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5532b1e0-7213-4d43-8e39-753e52100d14" xlink:to="loc_us-gaap_EarningsPerShareAbstract_b6871614-8726-4f00-a940-dca3e3f39cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_eb63b875-6d44-4048-b9f1-dec39298bf07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b6871614-8726-4f00-a940-dca3e3f39cf1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_eb63b875-6d44-4048-b9f1-dec39298bf07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_188034d0-9e9d-4688-b8e9-903d5e57b79a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b6871614-8726-4f00-a940-dca3e3f39cf1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_188034d0-9e9d-4688-b8e9-903d5e57b79a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_a5769e65-7b5c-4ec5-97ce-5ac97a65da0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5532b1e0-7213-4d43-8e39-753e52100d14" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_a5769e65-7b5c-4ec5-97ce-5ac97a65da0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2436cd15-d4ae-4295-9192-48b134d150f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_a5769e65-7b5c-4ec5-97ce-5ac97a65da0f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2436cd15-d4ae-4295-9192-48b134d150f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fc82333d-118b-421e-9b1d-c71c119d6f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_a5769e65-7b5c-4ec5-97ce-5ac97a65da0f" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fc82333d-118b-421e-9b1d-c71c119d6f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cpix-20230331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_231443b2-0813-4d38-9d4d-3abcf924d38e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b4d27156-6d65-4d29-a303-fca4f933f6bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_231443b2-0813-4d38-9d4d-3abcf924d38e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b4d27156-6d65-4d29-a303-fca4f933f6bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_117a504f-a650-44c2-8d0d-101c04078c03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b4d27156-6d65-4d29-a303-fca4f933f6bd" xlink:to="loc_us-gaap_ProfitLoss_117a504f-a650-44c2-8d0d-101c04078c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_00e3ab77-3a84-4167-8909-5b04eb080fef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b4d27156-6d65-4d29-a303-fca4f933f6bd" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_00e3ab77-3a84-4167-8909-5b04eb080fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4aff8c5e-cc1f-4ec8-8db7-1273c3e54542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_00e3ab77-3a84-4167-8909-5b04eb080fef" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_4aff8c5e-cc1f-4ec8-8db7-1273c3e54542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_1a74ffa2-9aec-4e1b-ad73-e4b4f783aed2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_00e3ab77-3a84-4167-8909-5b04eb080fef" xlink:to="loc_us-gaap_ShareBasedCompensation_1a74ffa2-9aec-4e1b-ad73-e4b4f783aed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_11d9a51e-d322-4b49-bd8c-e84f881cee22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_00e3ab77-3a84-4167-8909-5b04eb080fef" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_11d9a51e-d322-4b49-bd8c-e84f881cee22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_0bffbb29-2611-437e-96f5-988919ffaa74" xlink:href="cpix-20230331.xsd#cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_00e3ab77-3a84-4167-8909-5b04eb080fef" xlink:to="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_0bffbb29-2611-437e-96f5-988919ffaa74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_c2ef2fc2-b489-46a6-a1c7-5b3ea1ebb0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_00e3ab77-3a84-4167-8909-5b04eb080fef" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_c2ef2fc2-b489-46a6-a1c7-5b3ea1ebb0f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuredEventGainLoss_d9c5c36d-bb61-443b-84f9-aebb4caa0032" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuredEventGainLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_00e3ab77-3a84-4167-8909-5b04eb080fef" xlink:to="loc_us-gaap_InsuredEventGainLoss_d9c5c36d-bb61-443b-84f9-aebb4caa0032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_591b0e8f-c8fd-402b-b246-e87092ea83b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_00e3ab77-3a84-4167-8909-5b04eb080fef" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_591b0e8f-c8fd-402b-b246-e87092ea83b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_038123a6-3659-4280-83f7-0046a33936ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_591b0e8f-c8fd-402b-b246-e87092ea83b5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_038123a6-3659-4280-83f7-0046a33936ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_37820715-002c-4a09-bd44-d3f6386f8bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_591b0e8f-c8fd-402b-b246-e87092ea83b5" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_37820715-002c-4a09-bd44-d3f6386f8bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_6414bf2a-b5cc-4b82-b17a-aaecfa23a9f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_591b0e8f-c8fd-402b-b246-e87092ea83b5" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_6414bf2a-b5cc-4b82-b17a-aaecfa23a9f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7ab2f22c-d158-4759-b966-1151ecbdb9f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_591b0e8f-c8fd-402b-b246-e87092ea83b5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7ab2f22c-d158-4759-b966-1151ecbdb9f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_c1a6d931-755e-4b8d-be5a-3f4015cba5a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_591b0e8f-c8fd-402b-b246-e87092ea83b5" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_c1a6d931-755e-4b8d-be5a-3f4015cba5a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6b19da2d-bd6e-49b7-94d1-26649eb7d558" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b4d27156-6d65-4d29-a303-fca4f933f6bd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6b19da2d-bd6e-49b7-94d1-26649eb7d558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a3f0271e-b535-4749-b891-d461e108af9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_231443b2-0813-4d38-9d4d-3abcf924d38e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a3f0271e-b535-4749-b891-d461e108af9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3b782532-4198-443b-99b7-90bcbbee597f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a3f0271e-b535-4749-b891-d461e108af9d" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3b782532-4198-443b-99b7-90bcbbee597f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_924a2b62-20e1-45a2-974a-7f0accee806e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a3f0271e-b535-4749-b891-d461e108af9d" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_924a2b62-20e1-45a2-974a-7f0accee806e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_2033586c-dafd-4ad5-806f-e5a9f46e2b13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a3f0271e-b535-4749-b891-d461e108af9d" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_2033586c-dafd-4ad5-806f-e5a9f46e2b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5d3d436f-f980-4a6e-88f4-9544ee3f7636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a3f0271e-b535-4749-b891-d461e108af9d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5d3d436f-f980-4a6e-88f4-9544ee3f7636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7ce33402-6192-4255-bc74-cb6e9a1b69cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_231443b2-0813-4d38-9d4d-3abcf924d38e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7ce33402-6192-4255-bc74-cb6e9a1b69cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_a40df221-526c-40f0-8642-9e20b1e6a8de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7ce33402-6192-4255-bc74-cb6e9a1b69cb" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_a40df221-526c-40f0-8642-9e20b1e6a8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_b84039c4-4d5d-4da4-88bc-7174ef11f693" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7ce33402-6192-4255-bc74-cb6e9a1b69cb" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_b84039c4-4d5d-4da4-88bc-7174ef11f693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_14344590-c96f-4f0b-a240-a464d1edbeff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7ce33402-6192-4255-bc74-cb6e9a1b69cb" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_14344590-c96f-4f0b-a240-a464d1edbeff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_542e7957-ab8d-4f9f-b36d-7987ecc18b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7ce33402-6192-4255-bc74-cb6e9a1b69cb" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_542e7957-ab8d-4f9f-b36d-7987ecc18b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_29f4a2b3-60e9-4d8f-9317-65f71158ffa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7ce33402-6192-4255-bc74-cb6e9a1b69cb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_29f4a2b3-60e9-4d8f-9317-65f71158ffa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_12cf2fb8-c7ac-4eb1-9258-81908e88bb52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7ce33402-6192-4255-bc74-cb6e9a1b69cb" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_12cf2fb8-c7ac-4eb1-9258-81908e88bb52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_db5fd225-46cd-48b5-8144-5b130f04f05f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7ce33402-6192-4255-bc74-cb6e9a1b69cb" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_db5fd225-46cd-48b5-8144-5b130f04f05f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_094f009f-b388-4a1e-8ff5-469b3c8ded19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7ce33402-6192-4255-bc74-cb6e9a1b69cb" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_094f009f-b388-4a1e-8ff5-469b3c8ded19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="simple" xlink:href="cpix-20230331.xsd#CondensedConsolidatedStatementofEquity"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_5fef002f-4cc9-41b1-9282-a42583fe8ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_bc72cf6c-3eb5-40cc-9beb-7518f97e333c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_5fef002f-4cc9-41b1-9282-a42583fe8ac9" xlink:to="loc_us-gaap_StatementTable_bc72cf6c-3eb5-40cc-9beb-7518f97e333c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a4a67d3a-cc20-4139-be51-23616adea4aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_bc72cf6c-3eb5-40cc-9beb-7518f97e333c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a4a67d3a-cc20-4139-be51-23616adea4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_613bd5bc-f71b-4891-b9d2-b7b75995c8f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a4a67d3a-cc20-4139-be51-23616adea4aa" xlink:to="loc_us-gaap_EquityComponentDomain_613bd5bc-f71b-4891-b9d2-b7b75995c8f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3196a245-73cf-44c4-88af-acabd191d83d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_613bd5bc-f71b-4891-b9d2-b7b75995c8f3" xlink:to="loc_us-gaap_CommonStockMember_3196a245-73cf-44c4-88af-acabd191d83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_55b72f2c-afea-4bb1-9a64-146692dcf398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_613bd5bc-f71b-4891-b9d2-b7b75995c8f3" xlink:to="loc_us-gaap_RetainedEarningsMember_55b72f2c-afea-4bb1-9a64-146692dcf398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_990e32b8-64c0-4a0e-b088-0a150b644fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_613bd5bc-f71b-4891-b9d2-b7b75995c8f3" xlink:to="loc_us-gaap_NoncontrollingInterestMember_990e32b8-64c0-4a0e-b088-0a150b644fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ff89d359-663f-4bee-8616-3fdf0cc22cff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_bc72cf6c-3eb5-40cc-9beb-7518f97e333c" xlink:to="loc_us-gaap_StatementLineItems_ff89d359-663f-4bee-8616-3fdf0cc22cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_edd696dd-95c6-4e21-bb81-91e671ede81c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ff89d359-663f-4bee-8616-3fdf0cc22cff" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_edd696dd-95c6-4e21-bb81-91e671ede81c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0d8436c8-984b-4da3-95ca-2dc58587cffe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_edd696dd-95c6-4e21-bb81-91e671ede81c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0d8436c8-984b-4da3-95ca-2dc58587cffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8b15e28a-368f-48bc-9444-a6ccec5855d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_edd696dd-95c6-4e21-bb81-91e671ede81c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8b15e28a-368f-48bc-9444-a6ccec5855d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_f05413d6-c867-4690-8fb2-761eee06aa52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_edd696dd-95c6-4e21-bb81-91e671ede81c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_f05413d6-c867-4690-8fb2-761eee06aa52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_b5354398-d7df-4d49-b8c3-26ceb5911159" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_edd696dd-95c6-4e21-bb81-91e671ede81c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_b5354398-d7df-4d49-b8c3-26ceb5911159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_791fc9b7-ca94-4875-b005-9655f2a4879d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_edd696dd-95c6-4e21-bb81-91e671ede81c" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_791fc9b7-ca94-4875-b005-9655f2a4879d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_274c3f81-199a-449d-a32b-09e29b8de7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_edd696dd-95c6-4e21-bb81-91e671ede81c" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_274c3f81-199a-449d-a32b-09e29b8de7d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5587e126-b087-42b7-90b0-168aaa51892c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_edd696dd-95c6-4e21-bb81-91e671ede81c" xlink:to="loc_us-gaap_ProfitLoss_5587e126-b087-42b7-90b0-168aaa51892c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1115857d-0c3f-426b-9973-6dbcdcb4d2a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_edd696dd-95c6-4e21-bb81-91e671ede81c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1115857d-0c3f-426b-9973-6dbcdcb4d2a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_088c725c-0c8e-4c0a-a2d8-65585dea64e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_edd696dd-95c6-4e21-bb81-91e671ede81c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_088c725c-0c8e-4c0a-a2d8-65585dea64e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="cpix-20230331.xsd#OrganizationandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f8e2ef8b-b20b-4cdc-a430-2a824998ec12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_a0d97363-b319-4c4d-8852-5b8712ad98a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f8e2ef8b-b20b-4cdc-a430-2a824998ec12" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_a0d97363-b319-4c4d-8852-5b8712ad98a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="simple" xlink:href="cpix-20230331.xsd#EarningsLossPerShare"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_458e5bf9-a552-48c7-8d11-76dee6ed2e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_7f32e7f6-d2d4-48c0-9ed9-1b5f2215fc18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_458e5bf9-a552-48c7-8d11-76dee6ed2e1d" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_7f32e7f6-d2d4-48c0-9ed9-1b5f2215fc18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Revenues" xlink:type="simple" xlink:href="cpix-20230331.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_2a849e08-3291-46cb-bb84-13c82dee53a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_eca3b5b7-8b8e-4d8b-8b64-34bfbffe5cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2a849e08-3291-46cb-bb84-13c82dee53a1" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_eca3b5b7-8b8e-4d8b-8b64-34bfbffe5cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Inventories" xlink:type="simple" xlink:href="cpix-20230331.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_8a601d4b-0fbf-43a2-88f6-a17abb06f74d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_6b143539-e4ed-4142-843c-7b81c37a23ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8a601d4b-0fbf-43a2-88f6-a17abb06f74d" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_6b143539-e4ed-4142-843c-7b81c37a23ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Leases" xlink:type="simple" xlink:href="cpix-20230331.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c527c105-166e-41dd-9724-63ed4b304e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_e32f51fd-37a9-4798-be1a-ba927a47f49d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c527c105-166e-41dd-9724-63ed4b304e1c" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_e32f51fd-37a9-4798-be1a-ba927a47f49d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="simple" xlink:href="cpix-20230331.xsd#ShareholdersEquityandDebt"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract_e54095a5-1068-414b-b40e-091f2629a4de" xlink:href="cpix-20230331.xsd#cpix_EquityAndDebtAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_879a7f21-998d-4226-8c2c-be3796b9ba19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_EquityAndDebtAbstract_e54095a5-1068-414b-b40e-091f2629a4de" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_879a7f21-998d-4226-8c2c-be3796b9ba19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cpix-20230331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_52d04694-081e-4efe-a6d6-d29fc3f800d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_615e7860-5209-427e-9ec8-4f03e5eea0e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_52d04694-081e-4efe-a6d6-d29fc3f800d1" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_615e7860-5209-427e-9ec8-4f03e5eea0e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OtherIncome" xlink:type="simple" xlink:href="cpix-20230331.xsd#OtherIncome"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OtherIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_92fc1b4e-e278-4ee1-88d5-abf59bfe9b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_da3fdb0c-9605-4238-b42d-2570aa7d31c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_92fc1b4e-e278-4ee1-88d5-abf59bfe9b4e" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_da3fdb0c-9605-4238-b42d-2570aa7d31c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="cpix-20230331.xsd#CollaborativeAgreements"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a0496b79-c8fb-4986-bb31-bf405283545b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_964bcb3b-ac4e-4f5f-bfdb-3f7eb5998c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a0496b79-c8fb-4986-bb31-bf405283545b" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_964bcb3b-ac4e-4f5f-bfdb-3f7eb5998c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights" xlink:type="simple" xlink:href="cpix-20230331.xsd#AdditionsandReturnsofProductRights"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_f8b6f9d8-0274-4ee0-a9aa-9428cdf9a733" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_4126368b-91e2-48f9-a0e1-74eab51b174a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_f8b6f9d8-0274-4ee0-a9aa-9428cdf9a733" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_4126368b-91e2-48f9-a0e1-74eab51b174a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="cpix-20230331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a1159b09-14a9-4f27-b764-4e78cb17a72b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a40f6993-15ab-4292-b620-67d63a97aa7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a1159b09-14a9-4f27-b764-4e78cb17a72b" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a40f6993-15ab-4292-b620-67d63a97aa7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="simple" xlink:href="cpix-20230331.xsd#OrganizationandBasisofPresentationPolicies"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_766a6f64-f2f7-43f4-8b3c-e2e65a19bf06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2349b57d-ebd8-4dec-b56b-989400058cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_766a6f64-f2f7-43f4-8b3c-e2e65a19bf06" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2349b57d-ebd8-4dec-b56b-989400058cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_ad878b28-ede1-4e18-b404-ca645ed9acb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_766a6f64-f2f7-43f4-8b3c-e2e65a19bf06" xlink:to="loc_us-gaap_UseOfEstimates_ad878b28-ede1-4e18-b404-ca645ed9acb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_93f2bf18-5115-4903-a2db-a06915a7d64c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_766a6f64-f2f7-43f4-8b3c-e2e65a19bf06" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_93f2bf18-5115-4903-a2db-a06915a7d64c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TradeAndNoteReceivablesPolicyTextBlock_dc168b00-a2d5-40d6-85f6-dff24a33909c" xlink:href="cpix-20230331.xsd#cpix_TradeAndNoteReceivablesPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_766a6f64-f2f7-43f4-8b3c-e2e65a19bf06" xlink:to="loc_cpix_TradeAndNoteReceivablesPolicyTextBlock_dc168b00-a2d5-40d6-85f6-dff24a33909c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="simple" xlink:href="cpix-20230331.xsd#EarningsLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d103a6ad-30b0-4f1e-818b-a9f03b854443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_e20f9970-4571-4aec-b391-4f0f8e237794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d103a6ad-30b0-4f1e-818b-a9f03b854443" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_e20f9970-4571-4aec-b391-4f0f8e237794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="simple" xlink:href="cpix-20230331.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_9ac073d0-4668-4c0b-9d2c-add46f13de2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_303c5c86-cfb3-4184-89fe-2d6b9879b177" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_9ac073d0-4668-4c0b-9d2c-add46f13de2a" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_303c5c86-cfb3-4184-89fe-2d6b9879b177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="simple" xlink:href="cpix-20230331.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_a4b6bdb1-7a38-4db7-acca-a6e4acffec78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_95fe83fc-89ba-45f9-b706-2c9e6ae355d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a4b6bdb1-7a38-4db7-acca-a6e4acffec78" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_95fe83fc-89ba-45f9-b706-2c9e6ae355d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="simple" xlink:href="cpix-20230331.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5bd9a4f2-649c-4767-90c9-8d57dc5286e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_cbe46986-5ea3-4b32-b198-6556160ee48c" xlink:href="cpix-20230331.xsd#cpix_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5bd9a4f2-649c-4767-90c9-8d57dc5286e7" xlink:to="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_cbe46986-5ea3-4b32-b198-6556160ee48c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d8fa95ef-b4f7-4d63-8f8b-8c7cbcbb94fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5bd9a4f2-649c-4767-90c9-8d57dc5286e7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d8fa95ef-b4f7-4d63-8f8b-8c7cbcbb94fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_0da757fc-6afa-48f9-a5b6-a58994b84b36" xlink:href="cpix-20230331.xsd#cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5bd9a4f2-649c-4767-90c9-8d57dc5286e7" xlink:to="loc_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_0da757fc-6afa-48f9-a5b6-a58994b84b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables" xlink:type="simple" xlink:href="cpix-20230331.xsd#AdditionsandReturnsofProductRightsTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_3fc2fcef-0c5c-4de2-b9bd-4a8fcd9bc561" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_5b9dfdfd-e458-4a2b-8f06-0a885765ba3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_3fc2fcef-0c5c-4de2-b9bd-4a8fcd9bc561" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_5b9dfdfd-e458-4a2b-8f06-0a885765ba3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="simple" xlink:href="cpix-20230331.xsd#OrganizationandBasisofPresentationOrganizationDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4df00048-89a8-41bb-a0f8-0aae36dcee57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_186eafea-432a-4947-a28d-bf7b027a327b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4df00048-89a8-41bb-a0f8-0aae36dcee57" xlink:to="loc_us-gaap_NumberOfOperatingSegments_186eafea-432a-4947-a28d-bf7b027a327b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="simple" xlink:href="cpix-20230331.xsd#EarningsLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_aeb4611b-6fba-4ab7-b7db-b8a747e2405f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NumeratorAbstract_70f0417a-206c-4763-9289-15dc2b0d5176" xlink:href="cpix-20230331.xsd#cpix_NumeratorAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_aeb4611b-6fba-4ab7-b7db-b8a747e2405f" xlink:to="loc_cpix_NumeratorAbstract_70f0417a-206c-4763-9289-15dc2b0d5176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_139a9ca9-81a7-497e-a7e9-bdc3fc47579f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_70f0417a-206c-4763-9289-15dc2b0d5176" xlink:to="loc_us-gaap_ProfitLoss_139a9ca9-81a7-497e-a7e9-bdc3fc47579f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e887b285-cd58-4001-bf99-64c6761996d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_70f0417a-206c-4763-9289-15dc2b0d5176" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e887b285-cd58-4001-bf99-64c6761996d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e894e365-b17e-4347-989a-709a99d34f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_70f0417a-206c-4763-9289-15dc2b0d5176" xlink:to="loc_us-gaap_NetIncomeLoss_e894e365-b17e-4347-989a-709a99d34f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DenominatorAbstract_013d9eed-b8ef-41af-8a57-c928605d4903" xlink:href="cpix-20230331.xsd#cpix_DenominatorAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_aeb4611b-6fba-4ab7-b7db-b8a747e2405f" xlink:to="loc_cpix_DenominatorAbstract_013d9eed-b8ef-41af-8a57-c928605d4903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_36318476-132a-4364-84c9-5e227ada24db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DenominatorAbstract_013d9eed-b8ef-41af-8a57-c928605d4903" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_36318476-132a-4364-84c9-5e227ada24db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_287b7dac-3f6c-4be3-bca0-75c87dfc5740" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DenominatorAbstract_013d9eed-b8ef-41af-8a57-c928605d4903" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_287b7dac-3f6c-4be3-bca0-75c87dfc5740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ecce6c2f-5910-4632-b89f-00dd43216922" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DenominatorAbstract_013d9eed-b8ef-41af-8a57-c928605d4903" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ecce6c2f-5910-4632-b89f-00dd43216922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="simple" xlink:href="cpix-20230331.xsd#EarningsLossPerShareDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_166079db-c9e7-4749-8625-7959f3c1d6e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_34716dc8-aace-4b95-b0ca-f0754de3f70f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_166079db-c9e7-4749-8625-7959f3c1d6e8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_34716dc8-aace-4b95-b0ca-f0754de3f70f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails" xlink:type="simple" xlink:href="cpix-20230331.xsd#RevenuesScheduleofRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_b9b2b4b0-7cfb-405b-99fe-ab640a104949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_6d7580a2-5f0a-4b5a-bc46-a652a836c56c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b9b2b4b0-7cfb-405b-99fe-ab640a104949" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_6d7580a2-5f0a-4b5a-bc46-a652a836c56c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6aaabb2f-b2d9-4d72-9eae-f68612c33b8f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_6d7580a2-5f0a-4b5a-bc46-a652a836c56c" xlink:to="loc_srt_ProductOrServiceAxis_6aaabb2f-b2d9-4d72-9eae-f68612c33b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b976ba88-17a5-410f-92c7-8548d7abc5c8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_6aaabb2f-b2d9-4d72-9eae-f68612c33b8f" xlink:to="loc_srt_ProductsAndServicesDomain_b976ba88-17a5-410f-92c7-8548d7abc5c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember_22a31496-508b-49b0-9155-6c18e3bd44a4" xlink:href="cpix-20230331.xsd#cpix_KristaloseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b976ba88-17a5-410f-92c7-8548d7abc5c8" xlink:to="loc_cpix_KristaloseMember_22a31496-508b-49b0-9155-6c18e3bd44a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SancusoMember_223cc7cc-2f14-45b5-ab17-61be8238d6e2" xlink:href="cpix-20230331.xsd#cpix_SancusoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b976ba88-17a5-410f-92c7-8548d7abc5c8" xlink:to="loc_cpix_SancusoMember_223cc7cc-2f14-45b5-ab17-61be8238d6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_7153bed2-1333-465d-83bd-5a9d5a35f0cd" xlink:href="cpix-20230331.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b976ba88-17a5-410f-92c7-8548d7abc5c8" xlink:to="loc_cpix_VIBATIVMember_7153bed2-1333-465d-83bd-5a9d5a35f0cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember_c7ccd30a-495f-4400-b6fa-81a528f85985" xlink:href="cpix-20230331.xsd#cpix_CaldolorMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b976ba88-17a5-410f-92c7-8548d7abc5c8" xlink:to="loc_cpix_CaldolorMember_c7ccd30a-495f-4400-b6fa-81a528f85985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember_eaae0d98-81ea-4955-b76c-40e5d12bee46" xlink:href="cpix-20230331.xsd#cpix_AcetadoteMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b976ba88-17a5-410f-92c7-8548d7abc5c8" xlink:to="loc_cpix_AcetadoteMember_eaae0d98-81ea-4955-b76c-40e5d12bee46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember_f2dd9497-beb1-4711-8867-f04f2433ea0e" xlink:href="cpix-20230331.xsd#cpix_VaprisolMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b976ba88-17a5-410f-92c7-8548d7abc5c8" xlink:to="loc_cpix_VaprisolMember_f2dd9497-beb1-4711-8867-f04f2433ea0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember_f5cea72f-6438-4c16-858e-5d8fb3c2382e" xlink:href="cpix-20230331.xsd#cpix_OmeclamoxPakMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b976ba88-17a5-410f-92c7-8548d7abc5c8" xlink:to="loc_cpix_OmeclamoxPakMember_f5cea72f-6438-4c16-858e-5d8fb3c2382e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RediTrexMember_cc795c46-92e0-4a6c-91f2-efe0fba65800" xlink:href="cpix-20230331.xsd#cpix_RediTrexMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b976ba88-17a5-410f-92c7-8548d7abc5c8" xlink:to="loc_cpix_RediTrexMember_cc795c46-92e0-4a6c-91f2-efe0fba65800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherProductsMember_129e85a6-491d-4347-b34a-2b7a23de70f8" xlink:href="cpix-20230331.xsd#cpix_OtherProductsMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b976ba88-17a5-410f-92c7-8548d7abc5c8" xlink:to="loc_cpix_OtherProductsMember_129e85a6-491d-4347-b34a-2b7a23de70f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_a4d0c684-1086-4367-9163-09d4e7ca1853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_6d7580a2-5f0a-4b5a-bc46-a652a836c56c" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_a4d0c684-1086-4367-9163-09d4e7ca1853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_1d04dbd9-c994-48fb-8de5-95b14e82b6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_a4d0c684-1086-4367-9163-09d4e7ca1853" xlink:to="loc_us-gaap_RevenuesAbstract_1d04dbd9-c994-48fb-8de5-95b14e82b6ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductsAbstract_5aa848d6-102c-4d29-a843-541da6b23185" xlink:href="cpix-20230331.xsd#cpix_ProductsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_1d04dbd9-c994-48fb-8de5-95b14e82b6ff" xlink:to="loc_cpix_ProductsAbstract_5aa848d6-102c-4d29-a843-541da6b23185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_90d24a63-4134-41e6-b850-5e2fb787cda6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ProductsAbstract_5aa848d6-102c-4d29-a843-541da6b23185" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_90d24a63-4134-41e6-b850-5e2fb787cda6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesAdditionalInformationDetails" xlink:type="simple" xlink:href="cpix-20230331.xsd#RevenuesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TextBlockAbstract_fab50fca-024b-4bbf-b6d1-fd6b814bf0ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_ccff3845-87eb-4d50-864b-2906904df0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_fab50fca-024b-4bbf-b6d1-fd6b814bf0ff" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_ccff3845-87eb-4d50-864b-2906904df0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ce662f2a-a2af-4ae8-ac1a-59527a577b68" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_ccff3845-87eb-4d50-864b-2906904df0f8" xlink:to="loc_srt_ProductOrServiceAxis_ce662f2a-a2af-4ae8-ac1a-59527a577b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_739762cb-66d3-4301-b242-25a8f207a173" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ce662f2a-a2af-4ae8-ac1a-59527a577b68" xlink:to="loc_srt_ProductsAndServicesDomain_739762cb-66d3-4301-b242-25a8f207a173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_e7a6bbf4-6233-40a1-8769-2a4a900120da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_739762cb-66d3-4301-b242-25a8f207a173" xlink:to="loc_us-gaap_GrantMember_e7a6bbf4-6233-40a1-8769-2a4a900120da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_f2825675-6498-4a69-840a-c8376cbf83d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_ccff3845-87eb-4d50-864b-2906904df0f8" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_f2825675-6498-4a69-840a-c8376cbf83d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5c7d6137-f827-445f-b1a7-13182b72849c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_f2825675-6498-4a69-840a-c8376cbf83d1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5c7d6137-f827-445f-b1a7-13182b72849c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20230331.xsd#InventoriesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_17e8425a-9f7a-4544-8101-12f1b6f5d138" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_31cd6905-0a90-48b5-a1fc-d92ccdaf6e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_17e8425a-9f7a-4544-8101-12f1b6f5d138" xlink:to="loc_us-gaap_InventoryCurrentTable_31cd6905-0a90-48b5-a1fc-d92ccdaf6e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_da5d85d3-31c2-49ed-9b91-ba0bea321733" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_31cd6905-0a90-48b5-a1fc-d92ccdaf6e3d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_da5d85d3-31c2-49ed-9b91-ba0bea321733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d7c9869e-c9e8-4dee-a085-e013921b6900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_da5d85d3-31c2-49ed-9b91-ba0bea321733" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d7c9869e-c9e8-4dee-a085-e013921b6900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_cb6f0686-0220-4e7c-82ad-f930d82b846d" xlink:href="cpix-20230331.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d7c9869e-c9e8-4dee-a085-e013921b6900" xlink:to="loc_cpix_VIBATIVMember_cb6f0686-0220-4e7c-82ad-f930d82b846d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_17b9cb11-56e1-49fc-8dfe-ec60384c285b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_31cd6905-0a90-48b5-a1fc-d92ccdaf6e3d" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_17b9cb11-56e1-49fc-8dfe-ec60384c285b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_c64fbb6d-e306-469e-a48f-23736f86fa12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_17b9cb11-56e1-49fc-8dfe-ec60384c285b" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_c64fbb6d-e306-469e-a48f-23736f86fa12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember_50ab516c-2146-4f3c-ae28-d7c8ccdc409d" xlink:href="cpix-20230331.xsd#cpix_IfetrobanClinicalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_c64fbb6d-e306-469e-a48f-23736f86fa12" xlink:to="loc_cpix_IfetrobanClinicalMember_50ab516c-2146-4f3c-ae28-d7c8ccdc409d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_db593aac-e98e-4e6c-b921-48343d1657b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_31cd6905-0a90-48b5-a1fc-d92ccdaf6e3d" xlink:to="loc_us-gaap_InventoryLineItems_db593aac-e98e-4e6c-b921-48343d1657b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_a364bc5f-0476-4c92-bc64-b1cf75edd76d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_db593aac-e98e-4e6c-b921-48343d1657b3" xlink:to="loc_us-gaap_InventoryValuationReserves_a364bc5f-0476-4c92-bc64-b1cf75edd76d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_88de891f-82cd-459c-9b3e-c3c9eb03af6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_db593aac-e98e-4e6c-b921-48343d1657b3" xlink:to="loc_us-gaap_InventoryNoncurrent_88de891f-82cd-459c-9b3e-c3c9eb03af6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_5405f74e-793c-421f-9999-3484b9d55612" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_db593aac-e98e-4e6c-b921-48343d1657b3" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_5405f74e-793c-421f-9999-3484b9d55612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="cpix-20230331.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_1685abd2-4aac-40c3-9d48-7f7a7b62dc62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_c749e3c4-aecc-4854-bb17-0ba9e28fb124" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1685abd2-4aac-40c3-9d48-7f7a7b62dc62" xlink:to="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_c749e3c4-aecc-4854-bb17-0ba9e28fb124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_15bd2cde-0874-4896-84e2-e4ed2f1d55a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_c749e3c4-aecc-4854-bb17-0ba9e28fb124" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_15bd2cde-0874-4896-84e2-e4ed2f1d55a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_251b58cd-77be-4383-bbb2-047b4aaa566d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_c749e3c4-aecc-4854-bb17-0ba9e28fb124" xlink:to="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_251b58cd-77be-4383-bbb2-047b4aaa566d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_74181405-50b5-4d73-a839-e03f82ce84d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_c749e3c4-aecc-4854-bb17-0ba9e28fb124" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_74181405-50b5-4d73-a839-e03f82ce84d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_1775bfe3-3c16-4692-88f3-36fb300f468e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_c749e3c4-aecc-4854-bb17-0ba9e28fb124" xlink:to="loc_us-gaap_InventoryGross_1775bfe3-3c16-4692-88f3-36fb300f468e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_af4f5182-bc8c-4996-985b-5c15160de4d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_c749e3c4-aecc-4854-bb17-0ba9e28fb124" xlink:to="loc_us-gaap_InventoryNoncurrent_af4f5182-bc8c-4996-985b-5c15160de4d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_6a9d7746-ae96-438c-a5ca-cfea92495c93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_c749e3c4-aecc-4854-bb17-0ba9e28fb124" xlink:to="loc_us-gaap_InventoryNet_6a9d7746-ae96-438c-a5ca-cfea92495c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20230331.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5dcc9750-5012-4495-81b3-9fbaf5a0abc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_7af848bb-431b-4b13-b102-53723f68dad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5dcc9750-5012-4495-81b3-9fbaf5a0abc4" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_7af848bb-431b-4b13-b102-53723f68dad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_df274af1-77b6-45a5-8322-bf8a9c396d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_7af848bb-431b-4b13-b102-53723f68dad5" xlink:to="loc_us-gaap_LeaseContractualTermAxis_df274af1-77b6-45a5-8322-bf8a9c396d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_3304c86f-9d77-4610-a630-eec3a3b7fa74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_df274af1-77b6-45a5-8322-bf8a9c396d6b" xlink:to="loc_us-gaap_LeaseContractualTermDomain_3304c86f-9d77-4610-a630-eec3a3b7fa74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BroadwestLeaseFiveYearRenewalOptionMember_18087868-8c6e-4358-97d9-69d7b0077c1f" xlink:href="cpix-20230331.xsd#cpix_BroadwestLeaseFiveYearRenewalOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_3304c86f-9d77-4610-a630-eec3a3b7fa74" xlink:to="loc_cpix_BroadwestLeaseFiveYearRenewalOptionMember_18087868-8c6e-4358-97d9-69d7b0077c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8518fb82-232e-4e83-8f9e-b84ccfb27f90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_7af848bb-431b-4b13-b102-53723f68dad5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8518fb82-232e-4e83-8f9e-b84ccfb27f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0194ad4e-ecf5-43ed-b51f-016f06405bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8518fb82-232e-4e83-8f9e-b84ccfb27f90" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0194ad4e-ecf5-43ed-b51f-016f06405bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficeBuildingMember_0dc4e88b-60e6-4e32-b77f-215ab70ad0b7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OfficeBuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0194ad4e-ecf5-43ed-b51f-016f06405bc2" xlink:to="loc_srt_OfficeBuildingMember_0dc4e88b-60e6-4e32-b77f-215ab70ad0b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d64da85f-c5f4-4b35-afda-10b97786a91e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_7af848bb-431b-4b13-b102-53723f68dad5" xlink:to="loc_srt_CounterpartyNameAxis_d64da85f-c5f4-4b35-afda-10b97786a91e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a9ecb72c-c75f-463f-b89b-271927f9f61f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d64da85f-c5f4-4b35-afda-10b97786a91e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a9ecb72c-c75f-463f-b89b-271927f9f61f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_A1600WestEndAvenuePartnersLLCMember_b31f714b-ae7b-4964-8592-3d31a6f47076" xlink:href="cpix-20230331.xsd#cpix_A1600WestEndAvenuePartnersLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a9ecb72c-c75f-463f-b89b-271927f9f61f" xlink:to="loc_cpix_A1600WestEndAvenuePartnersLLCMember_b31f714b-ae7b-4964-8592-3d31a6f47076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CETMember_e349dc2f-f6d7-450c-9e60-fc8c62cecd2a" xlink:href="cpix-20230331.xsd#cpix_CETMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a9ecb72c-c75f-463f-b89b-271927f9f61f" xlink:to="loc_cpix_CETMember_e349dc2f-f6d7-450c-9e60-fc8c62cecd2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3a40569-a413-4486-87c2-843bb58d046a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_7af848bb-431b-4b13-b102-53723f68dad5" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3a40569-a413-4486-87c2-843bb58d046a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseLeasedArea_cb4d8ae5-66a3-4aac-8b67-4d419b840e33" xlink:href="cpix-20230331.xsd#cpix_LesseeOperatingLeaseLeasedArea"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3a40569-a413-4486-87c2-843bb58d046a" xlink:to="loc_cpix_LesseeOperatingLeaseLeasedArea_cb4d8ae5-66a3-4aac-8b67-4d419b840e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_2ad45642-0327-4fb1-b246-e931ac46d2eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3a40569-a413-4486-87c2-843bb58d046a" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_2ad45642-0327-4fb1-b246-e931ac46d2eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseNumberOfRenewalTerms_bfe1e5a9-7a02-4fd7-b248-b327c44fe3c3" xlink:href="cpix-20230331.xsd#cpix_LesseeOperatingLeaseNumberOfRenewalTerms"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3a40569-a413-4486-87c2-843bb58d046a" xlink:to="loc_cpix_LesseeOperatingLeaseNumberOfRenewalTerms_bfe1e5a9-7a02-4fd7-b248-b327c44fe3c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_2adfb778-e3b7-41f8-a8b6-fd886b901d29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3a40569-a413-4486-87c2-843bb58d046a" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_2adfb778-e3b7-41f8-a8b6-fd886b901d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseBaseRent_b6d0adda-4176-408a-9c8a-102224f68c8d" xlink:href="cpix-20230331.xsd#cpix_LesseeOperatingLeaseBaseRent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3a40569-a413-4486-87c2-843bb58d046a" xlink:to="loc_cpix_LesseeOperatingLeaseBaseRent_b6d0adda-4176-408a-9c8a-102224f68c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseRentIncrease_ce4e272f-1869-481d-868b-b145dfae3f83" xlink:href="cpix-20230331.xsd#cpix_LesseeOperatingLeaseRentIncrease"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3a40569-a413-4486-87c2-843bb58d046a" xlink:to="loc_cpix_LesseeOperatingLeaseRentIncrease_ce4e272f-1869-481d-868b-b145dfae3f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_cc7b3e01-2534-48a9-9d43-5221232164eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3a40569-a413-4486-87c2-843bb58d046a" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_cc7b3e01-2534-48a9-9d43-5221232164eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_621a1a64-3129-4eb8-ba5f-ba90a28a9774" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3a40569-a413-4486-87c2-843bb58d046a" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_621a1a64-3129-4eb8-ba5f-ba90a28a9774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_b9eb8d8a-6671-4328-9aa2-16686a5a5594" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3a40569-a413-4486-87c2-843bb58d046a" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_b9eb8d8a-6671-4328-9aa2-16686a5a5594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_4bb39bfa-796b-4c95-95cc-ef710e2d7824" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3a40569-a413-4486-87c2-843bb58d046a" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_4bb39bfa-796b-4c95-95cc-ef710e2d7824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="simple" xlink:href="cpix-20230331.xsd#LeasesLeasePositionDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_93828ee8-aaca-4a7d-adfa-4197c5304b03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8b737907-bfc3-47a6-a4fc-8ee5a07ef146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_93828ee8-aaca-4a7d-adfa-4197c5304b03" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8b737907-bfc3-47a6-a4fc-8ee5a07ef146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_eb108b8d-818a-4cd8-bc2b-3a8bf38ceb70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_93828ee8-aaca-4a7d-adfa-4197c5304b03" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_eb108b8d-818a-4cd8-bc2b-3a8bf38ceb70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_181c2abc-5586-411d-9698-ac20239fbe93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_93828ee8-aaca-4a7d-adfa-4197c5304b03" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_181c2abc-5586-411d-9698-ac20239fbe93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LeaseLiability_0f3adeff-c1d7-445d-be16-118f2ecd1698" xlink:href="cpix-20230331.xsd#cpix_LeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_93828ee8-aaca-4a7d-adfa-4197c5304b03" xlink:to="loc_cpix_LeaseLiability_0f3adeff-c1d7-445d-be16-118f2ecd1698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="simple" xlink:href="cpix-20230331.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1967d371-17d8-4c49-bde3-6473c62a7e88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_70656f07-09e4-4687-b0a0-ddea39485f76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1967d371-17d8-4c49-bde3-6473c62a7e88" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_70656f07-09e4-4687-b0a0-ddea39485f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_339c0cba-3ba6-41b1-bda2-b3b2b6b67932" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_70656f07-09e4-4687-b0a0-ddea39485f76" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_339c0cba-3ba6-41b1-bda2-b3b2b6b67932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e23199af-8ec4-4d57-a83b-7a87884da862" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_70656f07-09e4-4687-b0a0-ddea39485f76" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e23199af-8ec4-4d57-a83b-7a87884da862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6659a8be-17d0-475a-ab1f-21d3994f3914" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_70656f07-09e4-4687-b0a0-ddea39485f76" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6659a8be-17d0-475a-ab1f-21d3994f3914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_291f2c3c-ad62-4ac1-b476-cd9450732176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_70656f07-09e4-4687-b0a0-ddea39485f76" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_291f2c3c-ad62-4ac1-b476-cd9450732176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b4a8549f-234a-4114-838b-8ae6ab731143" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_70656f07-09e4-4687-b0a0-ddea39485f76" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b4a8549f-234a-4114-838b-8ae6ab731143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_0d5a18f9-5953-46dc-bebe-a1b8d80730d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_70656f07-09e4-4687-b0a0-ddea39485f76" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_0d5a18f9-5953-46dc-bebe-a1b8d80730d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d0639b94-68a5-4b18-85cb-539519bb6bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_70656f07-09e4-4687-b0a0-ddea39485f76" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d0639b94-68a5-4b18-85cb-539519bb6bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5a3f1dca-cd57-4f21-b264-b1afdfd003e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_70656f07-09e4-4687-b0a0-ddea39485f76" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5a3f1dca-cd57-4f21-b264-b1afdfd003e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_c7dbb514-5503-425d-af8f-79863ee31755" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_70656f07-09e4-4687-b0a0-ddea39485f76" xlink:to="loc_us-gaap_OperatingLeaseLiability_c7dbb514-5503-425d-af8f-79863ee31755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" xlink:type="simple" xlink:href="cpix-20230331.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails" xlink:type="simple" xlink:href="cpix-20230331.xsd#LeasesRentExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_adcea6e1-8935-479b-857d-972841e9e063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_3fba229f-fb47-4d7b-8d66-a738c160898e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_adcea6e1-8935-479b-857d-972841e9e063" xlink:to="loc_us-gaap_OperatingLeaseExpense_3fba229f-fb47-4d7b-8d66-a738c160898e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_58cf6635-b8b4-4596-8db6-fd474450eaf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_adcea6e1-8935-479b-857d-972841e9e063" xlink:to="loc_us-gaap_SubleaseIncome_58cf6635-b8b4-4596-8db6-fd474450eaf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="simple" xlink:href="cpix-20230331.xsd#ShareholdersEquityandDebtShareholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract_5a2fd804-f389-4090-9c25-066325ca61a7" xlink:href="cpix-20230331.xsd#cpix_EquityAndDebtAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40505492-c341-4e11-af24-2086f0f0739d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_EquityAndDebtAbstract_5a2fd804-f389-4090-9c25-066325ca61a7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40505492-c341-4e11-af24-2086f0f0739d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2e552e24-58f5-47cc-92fd-d567c04dd146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40505492-c341-4e11-af24-2086f0f0739d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2e552e24-58f5-47cc-92fd-d567c04dd146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a26b3578-521f-48b1-a6e4-3abbed180558" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2e552e24-58f5-47cc-92fd-d567c04dd146" xlink:to="loc_us-gaap_EquityComponentDomain_a26b3578-521f-48b1-a6e4-3abbed180558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_baf9d43f-00aa-4894-a2f5-d2830934000e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a26b3578-521f-48b1-a6e4-3abbed180558" xlink:to="loc_us-gaap_CommonStockMember_baf9d43f-00aa-4894-a2f5-d2830934000e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_56e26098-e284-41a5-b50c-8c558c776ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40505492-c341-4e11-af24-2086f0f0739d" xlink:to="loc_us-gaap_AwardTypeAxis_56e26098-e284-41a5-b50c-8c558c776ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_050fe6e2-7ad4-4ed3-a462-7bbd5be5892a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_56e26098-e284-41a5-b50c-8c558c776ec8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_050fe6e2-7ad4-4ed3-a462-7bbd5be5892a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_bc324789-8255-4c7a-84d7-51a17dd86f51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_050fe6e2-7ad4-4ed3-a462-7bbd5be5892a" xlink:to="loc_us-gaap_RestrictedStockMember_bc324789-8255-4c7a-84d7-51a17dd86f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncentiveStockOptionsMember_3fb55f74-d4d2-45c7-a0d4-b2a85388a86c" xlink:href="cpix-20230331.xsd#cpix_IncentiveStockOptionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_050fe6e2-7ad4-4ed3-a462-7bbd5be5892a" xlink:to="loc_cpix_IncentiveStockOptionsMember_3fb55f74-d4d2-45c7-a0d4-b2a85388a86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_7929045e-3449-4ae5-8182-f722998ddd96" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40505492-c341-4e11-af24-2086f0f0739d" xlink:to="loc_srt_TitleOfIndividualAxis_7929045e-3449-4ae5-8182-f722998ddd96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b978f897-4923-4ccc-a088-1a894f70a616" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_7929045e-3449-4ae5-8182-f722998ddd96" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b978f897-4923-4ccc-a088-1a894f70a616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_ea39041e-117e-44ef-a051-b9230ca9a9fd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b978f897-4923-4ccc-a088-1a894f70a616" xlink:to="loc_srt_DirectorMember_ea39041e-117e-44ef-a051-b9230ca9a9fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_8c954a3b-1020-4de3-9ba5-ab33f662c424" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40505492-c341-4e11-af24-2086f0f0739d" xlink:to="loc_us-gaap_CreditFacilityAxis_8c954a3b-1020-4de3-9ba5-ab33f662c424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_b56c4ff3-e46f-4abb-8e9f-65cbe90e7fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_8c954a3b-1020-4de3-9ba5-ab33f662c424" xlink:to="loc_us-gaap_CreditFacilityDomain_b56c4ff3-e46f-4abb-8e9f-65cbe90e7fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_4ac7e108-5b4f-4aab-a77b-89a58295c205" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_b56c4ff3-e46f-4abb-8e9f-65cbe90e7fa5" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_4ac7e108-5b4f-4aab-a77b-89a58295c205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a30790dd-a70c-4fa2-a1ee-400dd32bfe70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40505492-c341-4e11-af24-2086f0f0739d" xlink:to="loc_us-gaap_DebtInstrumentAxis_a30790dd-a70c-4fa2-a1ee-400dd32bfe70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_cf695c1d-af54-4a9d-b10b-227082782ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_a30790dd-a70c-4fa2-a1ee-400dd32bfe70" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_cf695c1d-af54-4a9d-b10b-227082782ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SixthAmendmentMember_fec8d36c-bdae-4597-887e-0c68c6b38699" xlink:href="cpix-20230331.xsd#cpix_SixthAmendmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf695c1d-af54-4a9d-b10b-227082782ecf" xlink:to="loc_cpix_SixthAmendmentMember_fec8d36c-bdae-4597-887e-0c68c6b38699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EightAmendmentMember_e1ca71ea-64e9-4843-94e5-4c1f5f2b6681" xlink:href="cpix-20230331.xsd#cpix_EightAmendmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf695c1d-af54-4a9d-b10b-227082782ecf" xlink:to="loc_cpix_EightAmendmentMember_e1ca71ea-64e9-4843-94e5-4c1f5f2b6681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NinthAmemdmentMember_b9f1d811-dc89-4b06-babc-272a3205f2a7" xlink:href="cpix-20230331.xsd#cpix_NinthAmemdmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf695c1d-af54-4a9d-b10b-227082782ecf" xlink:to="loc_cpix_NinthAmemdmentMember_b9f1d811-dc89-4b06-babc-272a3205f2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_334ed5ac-9854-4b24-8410-a77b1ff5fd21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf695c1d-af54-4a9d-b10b-227082782ecf" xlink:to="loc_us-gaap_LineOfCreditMember_334ed5ac-9854-4b24-8410-a77b1ff5fd21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_81e8d474-53b3-46f9-bdd5-542723329eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40505492-c341-4e11-af24-2086f0f0739d" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_81e8d474-53b3-46f9-bdd5-542723329eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_20cd299c-a96f-44ea-849a-5f354e677512" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_81e8d474-53b3-46f9-bdd5-542723329eb7" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_20cd299c-a96f-44ea-849a-5f354e677512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember_28b0b352-f2ce-48d7-a1b9-141e91b9715c" xlink:href="cpix-20230331.xsd#cpix_PinnacleBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_20cd299c-a96f-44ea-849a-5f354e677512" xlink:to="loc_cpix_PinnacleBankMember_28b0b352-f2ce-48d7-a1b9-141e91b9715c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8f6fd65a-c3bd-46c2-a8ff-41b8406f0881" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40505492-c341-4e11-af24-2086f0f0739d" xlink:to="loc_srt_RangeAxis_8f6fd65a-c3bd-46c2-a8ff-41b8406f0881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d4e15c0c-e378-44e6-b8bc-98c7a53800e0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8f6fd65a-c3bd-46c2-a8ff-41b8406f0881" xlink:to="loc_srt_RangeMember_d4e15c0c-e378-44e6-b8bc-98c7a53800e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_814e85dc-403a-4034-9240-056b4d46f6b0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d4e15c0c-e378-44e6-b8bc-98c7a53800e0" xlink:to="loc_srt_MinimumMember_814e85dc-403a-4034-9240-056b4d46f6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8fba5a5c-fc24-41c1-9ed2-e916dc8319a2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d4e15c0c-e378-44e6-b8bc-98c7a53800e0" xlink:to="loc_srt_MaximumMember_8fba5a5c-fc24-41c1-9ed2-e916dc8319a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_4dc6b361-3a7b-4e21-97ac-fababd879510" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40505492-c341-4e11-af24-2086f0f0739d" xlink:to="loc_us-gaap_VariableRateAxis_4dc6b361-3a7b-4e21-97ac-fababd879510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_a3ec130c-6b38-46ef-8191-c0b1b914d06e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_4dc6b361-3a7b-4e21-97ac-fababd879510" xlink:to="loc_us-gaap_VariableRateDomain_a3ec130c-6b38-46ef-8191-c0b1b914d06e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_ade4f390-d055-494f-8115-56d75a826605" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_a3ec130c-6b38-46ef-8191-c0b1b914d06e" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_ade4f390-d055-494f-8115-56d75a826605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4f96dcc5-1981-4655-8737-e5210890ba15" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40505492-c341-4e11-af24-2086f0f0739d" xlink:to="loc_srt_CounterpartyNameAxis_4f96dcc5-1981-4655-8737-e5210890ba15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d85a37a1-208b-46e2-8b84-c08df9c1db2f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_4f96dcc5-1981-4655-8737-e5210890ba15" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d85a37a1-208b-46e2-8b84-c08df9c1db2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_WinHealthInvestmentSingaporeLtdMember_cc0decd9-7d6e-4393-afd1-bbb5cc14052e" xlink:href="cpix-20230331.xsd#cpix_WinHealthInvestmentSingaporeLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d85a37a1-208b-46e2-8b84-c08df9c1db2f" xlink:to="loc_cpix_WinHealthInvestmentSingaporeLtdMember_cc0decd9-7d6e-4393-afd1-bbb5cc14052e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f91871df-d2b5-43b5-b460-8e7ee0bdc119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40505492-c341-4e11-af24-2086f0f0739d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f91871df-d2b5-43b5-b460-8e7ee0bdc119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_657379b6-e30a-431f-85d5-3e9516a73df7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f91871df-d2b5-43b5-b460-8e7ee0bdc119" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_657379b6-e30a-431f-85d5-3e9516a73df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_49db64d1-cff0-4d2e-b461-cbd039edd74a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_657379b6-e30a-431f-85d5-3e9516a73df7" xlink:to="loc_us-gaap_ConvertibleDebtMember_49db64d1-cff0-4d2e-b461-cbd039edd74a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c29cfda4-84de-4fb8-b53a-cb5dd6b9ea80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40505492-c341-4e11-af24-2086f0f0739d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c29cfda4-84de-4fb8-b53a-cb5dd6b9ea80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_7036e372-ba5d-4641-89f3-c35ed78becfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c29cfda4-84de-4fb8-b53a-cb5dd6b9ea80" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_7036e372-ba5d-4641-89f3-c35ed78becfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_0bcb89cc-a14f-4cab-aabe-84e19ec0489b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c29cfda4-84de-4fb8-b53a-cb5dd6b9ea80" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_0bcb89cc-a14f-4cab-aabe-84e19ec0489b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_2912aed3-57bb-4b65-8771-8eac7baca662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c29cfda4-84de-4fb8-b53a-cb5dd6b9ea80" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_2912aed3-57bb-4b65-8771-8eac7baca662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_da6af174-f78f-456a-8390-75d367da7dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c29cfda4-84de-4fb8-b53a-cb5dd6b9ea80" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_da6af174-f78f-456a-8390-75d367da7dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities_7a753891-daa3-4357-8636-23a9106c637b" xlink:href="cpix-20230331.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c29cfda4-84de-4fb8-b53a-cb5dd6b9ea80" xlink:to="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities_7a753891-daa3-4357-8636-23a9106c637b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8ed1f624-157a-48b4-983a-96fb936bef1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c29cfda4-84de-4fb8-b53a-cb5dd6b9ea80" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8ed1f624-157a-48b4-983a-96fb936bef1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b4b1c7bc-0adc-409f-896f-825d05d95efb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c29cfda4-84de-4fb8-b53a-cb5dd6b9ea80" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b4b1c7bc-0adc-409f-896f-825d05d95efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_8951c018-15de-4ac7-8818-238b31136167" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c29cfda4-84de-4fb8-b53a-cb5dd6b9ea80" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_8951c018-15de-4ac7-8818-238b31136167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity_b6c381a5-e34a-4d3c-a2d1-612a1e067063" xlink:href="cpix-20230331.xsd#cpix_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c29cfda4-84de-4fb8-b53a-cb5dd6b9ea80" xlink:to="loc_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity_b6c381a5-e34a-4d3c-a2d1-612a1e067063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_0d0309a3-87a2-42ca-b972-fdff66962546" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c29cfda4-84de-4fb8-b53a-cb5dd6b9ea80" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_0d0309a3-87a2-42ca-b972-fdff66962546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DebtInstrumentCovenantFundedDebtRatioMaximum_da58f443-ba09-41df-8ed8-9c685721d3b3" xlink:href="cpix-20230331.xsd#cpix_DebtInstrumentCovenantFundedDebtRatioMaximum"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c29cfda4-84de-4fb8-b53a-cb5dd6b9ea80" xlink:to="loc_cpix_DebtInstrumentCovenantFundedDebtRatioMaximum_da58f443-ba09-41df-8ed8-9c685721d3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold_0d1cbd87-b95d-4096-9038-cacf7875b671" xlink:href="cpix-20230331.xsd#cpix_DebtInstrumentCovenantUnrestrictedCashThreshold"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c29cfda4-84de-4fb8-b53a-cb5dd6b9ea80" xlink:to="loc_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold_0d1cbd87-b95d-4096-9038-cacf7875b671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DebtInstrumentCovenantEvaluationFrequency_dd453129-7efd-4ab2-8bc8-847b95cd1a62" xlink:href="cpix-20230331.xsd#cpix_DebtInstrumentCovenantEvaluationFrequency"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c29cfda4-84de-4fb8-b53a-cb5dd6b9ea80" xlink:to="loc_cpix_DebtInstrumentCovenantEvaluationFrequency_dd453129-7efd-4ab2-8bc8-847b95cd1a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_49e68e9c-3131-47a9-9e9e-1b5b3a7d5936" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c29cfda4-84de-4fb8-b53a-cb5dd6b9ea80" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_49e68e9c-3131-47a9-9e9e-1b5b3a7d5936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bae119ba-11a0-4223-bfab-dcf164d4251f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c29cfda4-84de-4fb8-b53a-cb5dd6b9ea80" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bae119ba-11a0-4223-bfab-dcf164d4251f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_368f6dfd-6aee-42d3-9912-7783f40788e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c29cfda4-84de-4fb8-b53a-cb5dd6b9ea80" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_368f6dfd-6aee-42d3-9912-7783f40788e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_70021682-e571-4e09-9e28-7f8bc15347ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c29cfda4-84de-4fb8-b53a-cb5dd6b9ea80" xlink:to="loc_us-gaap_LongTermLineOfCredit_70021682-e571-4e09-9e28-7f8bc15347ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_0b9b0766-f31e-4036-8feb-d9fbb071ee48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c29cfda4-84de-4fb8-b53a-cb5dd6b9ea80" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_0b9b0766-f31e-4036-8feb-d9fbb071ee48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_c99af6c1-b447-4147-b90f-630546e6b217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c29cfda4-84de-4fb8-b53a-cb5dd6b9ea80" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_c99af6c1-b447-4147-b90f-630546e6b217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="cpix-20230331.xsd#IncomeTaxesDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e5fa8b47-21dd-4732-9065-b62c12a004d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_0882bcc0-d154-47b1-91cd-989f684a81f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e5fa8b47-21dd-4732-9065-b62c12a004d9" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_0882bcc0-d154-47b1-91cd-989f684a81f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_40a3a527-df44-4c44-8914-591287171ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_0882bcc0-d154-47b1-91cd-989f684a81f2" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_40a3a527-df44-4c44-8914-591287171ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_4e46ac1a-39d3-4eb8-be99-cb6e31947433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_40a3a527-df44-4c44-8914-591287171ffd" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_4e46ac1a-39d3-4eb8-be99-cb6e31947433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_81d993b6-54ce-42ca-9c63-b88ecf6ac169" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_4e46ac1a-39d3-4eb8-be99-cb6e31947433" xlink:to="loc_us-gaap_DomesticCountryMember_81d993b6-54ce-42ca-9c63-b88ecf6ac169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_2cd0a034-b362-48bd-97ee-7cbc13068ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_0882bcc0-d154-47b1-91cd-989f684a81f2" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_2cd0a034-b362-48bd-97ee-7cbc13068ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_8e38e84f-3407-485d-b971-255307952ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2cd0a034-b362-48bd-97ee-7cbc13068ca0" xlink:to="loc_us-gaap_OperatingLossCarryforwards_8e38e84f-3407-485d-b971-255307952ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OtherIncomeDetails" xlink:type="simple" xlink:href="cpix-20230331.xsd#OtherIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OtherIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_00a3bd98-69aa-4dde-aba0-8898e59f3576" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuredEventGainLoss_2bcb4067-eabe-45d7-8833-e5b20a54bdd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuredEventGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_00a3bd98-69aa-4dde-aba0-8898e59f3576" xlink:to="loc_us-gaap_InsuredEventGainLoss_2bcb4067-eabe-45d7-8833-e5b20a54bdd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_e83ca833-4a47-4696-b7aa-95c04518b7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_00a3bd98-69aa-4dde-aba0-8898e59f3576" xlink:to="loc_us-gaap_OtherIncome_e83ca833-4a47-4696-b7aa-95c04518b7a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20230331.xsd#AdditionsandReturnsofProductRightsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_10991b07-7dd5-4e1a-abdc-b84f642ed658" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_844f4bf1-ec64-4c63-a9a4-d19dd51362ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_10991b07-7dd5-4e1a-abdc-b84f642ed658" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_844f4bf1-ec64-4c63-a9a4-d19dd51362ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f29b59de-90a1-4ef7-a679-b20d7a518702" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_844f4bf1-ec64-4c63-a9a4-d19dd51362ac" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f29b59de-90a1-4ef7-a679-b20d7a518702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3c5e3058-d170-4744-8a16-e18933576b27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f29b59de-90a1-4ef7-a679-b20d7a518702" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3c5e3058-d170-4744-8a16-e18933576b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_f8b517c7-d763-4ab6-b46d-3ea48b974498" xlink:href="cpix-20230331.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3c5e3058-d170-4744-8a16-e18933576b27" xlink:to="loc_cpix_VIBATIVMember_f8b517c7-d763-4ab6-b46d-3ea48b974498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MethotrexateMember_50d0d88e-a114-424c-978c-b4ad5c052487" xlink:href="cpix-20230331.xsd#cpix_MethotrexateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3c5e3058-d170-4744-8a16-e18933576b27" xlink:to="loc_cpix_MethotrexateMember_50d0d88e-a114-424c-978c-b4ad5c052487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SancusoMember_07e32cb7-ebc5-4a3a-b8ac-1f6a12c4aacc" xlink:href="cpix-20230331.xsd#cpix_SancusoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3c5e3058-d170-4744-8a16-e18933576b27" xlink:to="loc_cpix_SancusoMember_07e32cb7-ebc5-4a3a-b8ac-1f6a12c4aacc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a0e3a3f4-94d9-40fc-90ba-694c7cae0bf5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_844f4bf1-ec64-4c63-a9a4-d19dd51362ac" xlink:to="loc_srt_CounterpartyNameAxis_a0e3a3f4-94d9-40fc-90ba-694c7cae0bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2e5db722-182d-4341-a6db-23fd971707b4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a0e3a3f4-94d9-40fc-90ba-694c7cae0bf5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2e5db722-182d-4341-a6db-23fd971707b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KyowaKirinMember_947436dd-214d-4251-8484-42cd1a306470" xlink:href="cpix-20230331.xsd#cpix_KyowaKirinMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2e5db722-182d-4341-a6db-23fd971707b4" xlink:to="loc_cpix_KyowaKirinMember_947436dd-214d-4251-8484-42cd1a306470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NordicGroupBVMember_6adda529-aeb7-4b5a-8f32-9baa41b0da01" xlink:href="cpix-20230331.xsd#cpix_NordicGroupBVMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2e5db722-182d-4341-a6db-23fd971707b4" xlink:to="loc_cpix_NordicGroupBVMember_6adda529-aeb7-4b5a-8f32-9baa41b0da01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0520917b-2357-4944-bb9c-b5df02bf6b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_844f4bf1-ec64-4c63-a9a4-d19dd51362ac" xlink:to="loc_us-gaap_AwardTypeAxis_0520917b-2357-4944-bb9c-b5df02bf6b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f16f14b-2a48-44eb-a7c7-bb562403e8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0520917b-2357-4944-bb9c-b5df02bf6b6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f16f14b-2a48-44eb-a7c7-bb562403e8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_b736b969-6bd7-4bf2-8db7-2381866fabea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f16f14b-2a48-44eb-a7c7-bb562403e8a0" xlink:to="loc_us-gaap_RestrictedStockMember_b736b969-6bd7-4bf2-8db7-2381866fabea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8b218066-0422-45cf-b561-208bd6cd9e90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_844f4bf1-ec64-4c63-a9a4-d19dd51362ac" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8b218066-0422-45cf-b561-208bd6cd9e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7fe07d2e-ec33-451e-9110-26cdfd4dde5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8b218066-0422-45cf-b561-208bd6cd9e90" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7fe07d2e-ec33-451e-9110-26cdfd4dde5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_d744ff78-3f5c-487c-b42c-dca9c7e56423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7fe07d2e-ec33-451e-9110-26cdfd4dde5a" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_d744ff78-3f5c-487c-b42c-dca9c7e56423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_50ad0d70-3cad-4075-a89e-4a02f860c27d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_844f4bf1-ec64-4c63-a9a4-d19dd51362ac" xlink:to="loc_srt_RangeAxis_50ad0d70-3cad-4075-a89e-4a02f860c27d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2d4e513f-d2dd-4bb6-9c18-3e507f4562f9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_50ad0d70-3cad-4075-a89e-4a02f860c27d" xlink:to="loc_srt_RangeMember_2d4e513f-d2dd-4bb6-9c18-3e507f4562f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d138ceeb-9ad3-4210-9ebb-05f264b64e5d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2d4e513f-d2dd-4bb6-9c18-3e507f4562f9" xlink:to="loc_srt_MaximumMember_d138ceeb-9ad3-4210-9ebb-05f264b64e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_844f4bf1-ec64-4c63-a9a4-d19dd51362ac" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_dccbb44d-914a-4803-95c4-f99b13440312" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_dccbb44d-914a-4803-95c4-f99b13440312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_8b5ebda0-589f-43cc-bc77-f6e6733e2033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_8b5ebda0-589f-43cc-bc77-f6e6733e2033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsPercentage_9dc7b2cf-8163-4dd0-ad11-33a7e2292055" xlink:href="cpix-20230331.xsd#cpix_TieredRoyaltyPaymentsPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_cpix_TieredRoyaltyPaymentsPercentage_9dc7b2cf-8163-4dd0-ad11-33a7e2292055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsThreshold_148ed4ea-efdb-453f-880a-33daee537322" xlink:href="cpix-20230331.xsd#cpix_TieredRoyaltyPaymentsThreshold"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_cpix_TieredRoyaltyPaymentsThreshold_148ed4ea-efdb-453f-880a-33daee537322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_dc9f2abd-93e6-42bd-9a08-4aa98dac6b31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_dc9f2abd-93e6-42bd-9a08-4aa98dac6b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_aa88e358-b4fd-444c-9e4e-f1ac17e26fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_aa88e358-b4fd-444c-9e4e-f1ac17e26fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_bb87a88a-43a0-4cf9-bb61-cbcbb3a2e051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_bb87a88a-43a0-4cf9-bb61-cbcbb3a2e051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_09f6b83a-4307-42bf-9786-5cc40d0a97b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_09f6b83a-4307-42bf-9786-5cc40d0a97b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_defd6a03-bae3-4da2-924c-efc09ac51be4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_defd6a03-bae3-4da2-924c-efc09ac51be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_a1f3eef6-e2c6-4a68-b441-58f06f6d19da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_a1f3eef6-e2c6-4a68-b441-58f06f6d19da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable_46a63492-ae8d-4a32-b5f0-ac5b0ae5d1df" xlink:href="cpix-20230331.xsd#cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable_46a63492-ae8d-4a32-b5f0-ac5b0ae5d1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable_ee3bc96e-21e3-48c2-bcd7-b5da1b9b0eca" xlink:href="cpix-20230331.xsd#cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable_ee3bc96e-21e3-48c2-bcd7-b5da1b9b0eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue_7e8e2c7d-8f5e-4e65-a7f2-90e0c7ac82af" xlink:href="cpix-20230331.xsd#cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue_7e8e2c7d-8f5e-4e65-a7f2-90e0c7ac82af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment_07bc3f14-74b4-4780-8556-a52363693ac4" xlink:href="cpix-20230331.xsd#cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment_07bc3f14-74b4-4780-8556-a52363693ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_885676c4-dda5-4b9e-ae7f-9dd61e550da4" xlink:href="cpix-20230331.xsd#cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_885676c4-dda5-4b9e-ae7f-9dd61e550da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected_d257fd0d-2ee5-4076-98eb-e35839002ba8" xlink:href="cpix-20230331.xsd#cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected_d257fd0d-2ee5-4076-98eb-e35839002ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePayments_fef48a5f-9567-40c1-ad2b-6c2079da608f" xlink:href="cpix-20230331.xsd#cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePayments"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePayments_fef48a5f-9567-40c1-ad2b-6c2079da608f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_9ebc69ab-122b-4ee9-8448-4937b2fd1c14" xlink:href="cpix-20230331.xsd#cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_9ebc69ab-122b-4ee9-8448-4937b2fd1c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_478b73e6-1c63-4451-90be-28adfa0de0de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_478b73e6-1c63-4451-90be-28adfa0de0de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_cb6efb0b-915d-4676-9e8b-d97f63afb0fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_cb6efb0b-915d-4676-9e8b-d97f63afb0fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2d1e6dd1-bbff-438f-ad9b-fb5675d475c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_us-gaap_Goodwill_2d1e6dd1-bbff-438f-ad9b-fb5675d475c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_aaad2df7-5939-451d-86e2-5e84f3e1a8ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9ab9244a-9b66-4487-bbb1-00ff83c7466e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_aaad2df7-5939-451d-86e2-5e84f3e1a8ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationVibativDetails" xlink:type="simple" xlink:href="cpix-20230331.xsd#AdditionsandReturnsofProductRightsChangeinConsiderationVibativDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationVibativDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_404c1c34-e52b-4b03-99bf-15c84fde05ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d81a35c0-16fb-4e35-b5b7-d6ba57e0fde6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_404c1c34-e52b-4b03-99bf-15c84fde05ff" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d81a35c0-16fb-4e35-b5b7-d6ba57e0fde6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6baf8072-c66c-4b8f-9a23-574c9e8d8077" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d81a35c0-16fb-4e35-b5b7-d6ba57e0fde6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6baf8072-c66c-4b8f-9a23-574c9e8d8077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_500a33e6-9613-4f03-bcab-f6736aff5ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6baf8072-c66c-4b8f-9a23-574c9e8d8077" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_500a33e6-9613-4f03-bcab-f6736aff5ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_7a49b183-680f-4b96-95e8-893fe4c06e04" xlink:href="cpix-20230331.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_500a33e6-9613-4f03-bcab-f6736aff5ba2" xlink:to="loc_cpix_VIBATIVMember_7a49b183-680f-4b96-95e8-893fe4c06e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_6c203208-826c-4791-8995-1dee47cb5f66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d81a35c0-16fb-4e35-b5b7-d6ba57e0fde6" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_6c203208-826c-4791-8995-1dee47cb5f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualRollForward_80abc321-a244-47da-b060-12a8b7bd55ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6c203208-826c-4791-8995-1dee47cb5f66" xlink:to="loc_us-gaap_LossContingencyAccrualRollForward_80abc321-a244-47da-b060-12a8b7bd55ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2ad8c9d3-e316-455e-a2ee-006138c45d69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_80abc321-a244-47da-b060-12a8b7bd55ab" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2ad8c9d3-e316-455e-a2ee-006138c45d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_f39a0e2d-9a70-4308-937d-bd8e087ad771" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_80abc321-a244-47da-b060-12a8b7bd55ab" xlink:to="loc_us-gaap_PaymentsForRoyalties_f39a0e2d-9a70-4308-937d-bd8e087ad771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_bc5c914d-7323-41ea-8891-039ff831aeb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_80abc321-a244-47da-b060-12a8b7bd55ab" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_bc5c914d-7323-41ea-8891-039ff831aeb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_3780ac99-1403-4a27-83e4-3d23b85fc8bc" xlink:href="cpix-20230331.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_80abc321-a244-47da-b060-12a8b7bd55ab" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_3780ac99-1403-4a27-83e4-3d23b85fc8bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f6a0427d-a988-4b9d-a884-580162c5c5e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_80abc321-a244-47da-b060-12a8b7bd55ab" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f6a0427d-a988-4b9d-a884-580162c5c5e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationSancusoAcquisitionDetails" xlink:type="simple" xlink:href="cpix-20230331.xsd#AdditionsandReturnsofProductRightsChangeinConsiderationSancusoAcquisitionDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationSancusoAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_7d025244-1e12-41cd-9ced-a7173181fee1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8f6ebe41-f280-4728-8d98-e04d365a2907" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_7d025244-1e12-41cd-9ced-a7173181fee1" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8f6ebe41-f280-4728-8d98-e04d365a2907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5e13a0eb-9902-485e-a78a-dec229755212" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8f6ebe41-f280-4728-8d98-e04d365a2907" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5e13a0eb-9902-485e-a78a-dec229755212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ac976e51-4e6f-482a-95e2-0090bd0dc272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5e13a0eb-9902-485e-a78a-dec229755212" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ac976e51-4e6f-482a-95e2-0090bd0dc272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SancusoMember_ff1cca6e-8765-486b-9e1a-15d1f9671856" xlink:href="cpix-20230331.xsd#cpix_SancusoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ac976e51-4e6f-482a-95e2-0090bd0dc272" xlink:to="loc_cpix_SancusoMember_ff1cca6e-8765-486b-9e1a-15d1f9671856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_825f019a-b1b8-4521-8d17-c896d59a5392" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8f6ebe41-f280-4728-8d98-e04d365a2907" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_825f019a-b1b8-4521-8d17-c896d59a5392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualRollForward_d1029688-ff4f-4cc5-9289-9468365c9674" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_825f019a-b1b8-4521-8d17-c896d59a5392" xlink:to="loc_us-gaap_LossContingencyAccrualRollForward_d1029688-ff4f-4cc5-9289-9468365c9674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_59db5143-6c67-4591-95c4-eaa425f6dac4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_d1029688-ff4f-4cc5-9289-9468365c9674" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_59db5143-6c67-4591-95c4-eaa425f6dac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_4b7a0fd2-b6fb-4d8e-ac72-a89143365a55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_d1029688-ff4f-4cc5-9289-9468365c9674" xlink:to="loc_us-gaap_PaymentsForRoyalties_4b7a0fd2-b6fb-4d8e-ac72-a89143365a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1eb621ec-31ac-47d5-a9e0-735c936b2c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_d1029688-ff4f-4cc5-9289-9468365c9674" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1eb621ec-31ac-47d5-a9e0-735c936b2c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_ddf65e8b-7012-4a25-98ed-5b0d78224129" xlink:href="cpix-20230331.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_d1029688-ff4f-4cc5-9289-9468365c9674" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_ddf65e8b-7012-4a25-98ed-5b0d78224129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d39badca-4535-400f-9980-e67430a7300a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_d1029688-ff4f-4cc5-9289-9468365c9674" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d39badca-4535-400f-9980-e67430a7300a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
MB5!.1PT*&@H    -24A$4@  !G(   %W" (    >L$)N  "  $E$051X7NS=
M"5Q55YXO^GWO^WQNO_OI3[_J[O?Z];VWNKHK7?6I[GZWATJE*DFE*HF55,4A
ME4DSF<3,B<:H<4 $$51DD$%F05 0!!%0!%3 651$Q1E%!2<T<< Y1HE$Q+=D
MMZ=.UH+-6OOLO?8Z^_R^G__'3P*LL_][G;777OM_]CE'NP<           ""
M-/H'            T!^4U0           (2AK 8          " ,934
M      !A**L!           (0UD-          ! &,IJ            PE!6
M P          $(:R&@          @#"4U0           (2AK 8
M " ,934           !A**L!           (0UD-          ! &,IJ
M        PE!6 UIW=_>,F*IQDXOH7P          P ,HJP&MJ^ONIV/S1X[+
MIW\!           /H*P&M,[;=WXQ*.*S"07T+P          X &4U8#6WG[C
MSQ\=\_G$0OH7          #P ,IJ0*NHW/=?'OX$934           ,HJP%M
M\K0R[>>?C$%9#0        "@;RBK >VW+T3]EX<_'1.$;P(%         .@3
MRFKP/0</GOW;WTSXKP^/1%D-         ,  RFKP/=.CJ_[LD<_^#Y35
M       ,H:P&?W+K5N?@UQ+^VR]&H:P&         & ,937XDZJ5^__ZU^/^
MSU^.1ED-         , 8RFKP)Q^/R?MOOQCUWW^%LAH         0#]05H/_
MM&??Z7]^=NJ?_VHTRFH          /U"60WNZ^[NCIA5^6>_'/T7CX[!FT !
M         /J%LAK<MZWA^#_^;LH/'AV#LAH           ^4U>#^K6IC)A7]
M]U^._JO'QZ*L!@        #  V4UN+=TV>Z_>'3,7_]ZW%\]/NXO'OT<934
M        @'ZAK!;HVB_<>'A0Q%\]/O9OGQC_E_?O5D-9#0        "@?RBK
M!;3.VW<^'I/WYX]^_L/?3OR;7W^!LAH          ">4U0):Y.R5?_;(9S]Z
M<N+__,T$E-4          /BAK!:@NKN[8^)6_>7C8W_T5-"/GYJ$LAH
M    @!"4U0)48O+J_^NQ,3]^.NBG X)_]"3*:@          8E!6"S@W;MR>
M/JOBKQ\?]Y,!P?_T3,A/!DQ&60T         0!3*:H'ER.'SPS_*_,%C8_[E
MF9!_^T/8SWX7C+(:         ( )**L%D/D+-C_U8M0/GYSXBX'3'AD8_K]_
M'XJR&@        " .2BK!80M6X^]\7[&__SMQ'_[0]@3ST]_='#$?SP7AK(:
M         (!I**NYW)DS5\=,*OK)[Z;\TS,AOWTA<L"+LYYX?OHO!X>CK 8
M        X N4U=RIN[O[S.FKD3$K?O9,R#\\%33@Q5D#A\8^^W+4DR]$/HZR
M&@        " SU!6<YM;MSKW[CL]=4;YWST9]..G@P8.C7WAC83!K\Y^[I68
M9UY"60T         P!HHJ[G'\1.7EB_?,VI\P8^>G/1/SX0,?C5NV#O)+PY/
M?/[U^$$HJP$         6 IE-;_7WGYCQ<K]P5-+AKR6\-,!P4^^$/G*VW.&
M?YC^VGLIK[PUYX4W$U!6 P        "P',IJ_NKXL8L%B^I'CLT;\GKBHT.F
M#W@A\N6WYKS[:>;[([/>^BCC]?=2AKV3C+(:         (!-4%;S)S=NW*ZN
M/3@CNO*U=].>>C'J-R_,'/QJ[.OOI7PP*OO3<0L^'I,SXI/,MSY,'_YA.LIJ
M          "V0EE-:5U==Z]=ZZBHW!LQJV+H.ZG_W^^G/C(H8N#0V'<^R?QT
M[/S/Q^>.G91/8M07N1]]EOW!J'GOH*P&         " %RFIJZ;Q]Y_*EFX</
MG5NZ=-?$T))!P^)_\KO@_W@N[(4W$]X;F34IM"@D;/&4L,4ATXJ#IB[^(GC1
MF EYH[[(_63L?)35          !D0EG->5U==\]^=7W?OM-+2G9."%DRY/7$
M?QPP^8GGI[_Q7NJ8B0MGQ93'QE?.BBV?&5T>$;DT;'I)2'CQI-"B"5,*QTW.
M1UD-         , 1**LYYORYZW6;6Q;F;9D04C+LO?0GGI\^Z-78#T9E3YM1
MFCZW-BM[35I&35+JJKC$JIB>LMKT64O)KZ9&+ F9AK(:         (##4%:3
M[>B1"XL6U8=&E U[-^VY5V*'OCUG]/C<R.CR^;GKR\L;"@HWY^2NGYM5FYI>
MDY1:G9"T(BX!934          .6@K";)KMUM\8DU;W^<^?+;R:^\DS3JBP71
MLY?/RUZ[:M7.E2MWEBW;5KAX2]["#=D+UF5FK\G(1%D-         $!I**O9
M:W_35Q&1RY]_(W'P:_'#/TR/2ZA:D+N^HG+'N@W[UJ[;MV+ESK*E]8N+MQ0N
MWI*_J YE-0          ?X&RFO6^^^[.T2,7HN)6#7HU_ND7HSX9,W]^[OH5
M*W:N7;-GV[9#FS<WK5FS9\7*G165.Y8MVU9:AK(:         (#_05G-,IVW
M[YPY?;6PJ.&5MY)_.3C\@U'S%B[<4%?7M&W;H<;&HPW;F^OJ#JQ=MV_UZCW5
MU;M6K$!9#0        # CZ&L9H$SIZ]65>X=$U3TZ."(U]]+24Q:L7/GD</-
M)_?O.[9K=TO#]N;Z^D-UFYLV;-R/LAH         @#N@K.:3#1L.SYRU_)5W
M4EYX(WY6;/GF+0?;V]N/'SO==/#XOGW'=N]JV;GS2,,VE-4          -P&
M934SKE_OR%^X]=,QN4->C1L[*7])R=;3;5^UM[>?:ONJN?D$B::F8RBK 0
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M-935          "LX[:RVJJ:IN=>B7UI^)SL^>N6E&Q=5+BEJ!AE-935
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M5D-9#0        ! #K\LJW5W=P=/+?G)[X(GAA9E9*Z9DU*=G%J-LAK*:@
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MK_=18_<KUC:6U0H*M_UX0/ S+\<.?G"WVLMO)P]Y+?Z'OYWXP6<+;MRX33<
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M3;W*&O^4I0?=/N )W:I&_I@<[^J': 5!VJ@66G_2C1UE;L8@AR?G$2IMZC/
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MV:.XN'C>O'F1D9&)B8GD5Y<O7Z:W!!#8OOGFFYDS9\;&QN[=NY?^'0
M  !81%Y9[=Z#&]96KUZ]>_=N$V6UY<N7+UNVK+R\G/Q;7%R<FYL;%Q<7%165
MEY>W?__^[[[[CMX>0* BQ\[$B1/)H43_ @         L(K6L1E165F9G9^L?
MKV:NK+9TZ=+2TM*RLK*2DI+BXN*%"Q<F)R=/GSY]]NS9Y"\O7+AP^_9M>JL
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M4UF-/'A65E9F9N;<'NGIZ<G)R7%Q<;-FS8J(B(B.CDY+2R,/M6?/'MS"!@
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M3",@$$3HBX!1:?+?I"[YI_>NG)RAJLZN<[Z?M9<+D\JIVKMVU=[UJSKG (@
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M:H:$^R;6,[;0D'Q?XY\;&Y]83_Q<_-=XS<8:,CMU2PQB@T4+R[L'
M]^D5JPDU-349&1D+%R[<O'DSL5KC6*TA*5/SM:3[$9NH0DH]49TI]QEU;"PU
M-36M$=$4F?=EU1.OL&+%"GG?        X#[M8C7ATT\_34I*JJBHV+AQ([&:
MO[&:P4C6#$:X-K61OPW9_B9E2Z\G7HI8#0      P L=8[6[=^_NW+ESTJ1)
MRY<OKZJJ(E8C5@,      -"-CK%:77VRMG[]^BE3IJQ8L6+=NG7$:L1J
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M/7OV)"8FSIHURWA@C5B-6"V2_?G,U:<[3?UMVXGM>V3^^(FH\B7[Y"4
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MM)=ZYW3LF=6A1^9SG5-_^E3TF=-7Y44! (@,556?BI*6M3XN>;E4C%_)?P
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MYX"9KP^?-VAX8?\A^>:Q6M\93[\TM>4+*>?.7Y-?16/6#DOBQ*T^<&[3A7H
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M%GN+U?KE=ND[X[=M$OL/+I!?47MV#$OJO$>3*TEIJ^R;^SJV(ILT&Q;4F3W
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M%7[':J^]W;G/C!\^-NK=C6X]E5LX+'VP^XSZ@0Z>H*,*"TD;9M_LP;$562N
ML*#.[.K++5\';FVLUE3_UV<RU.S!KB[@?4;NA2]]25U=P"<?AZEY4[,]1YTK
MZY.W-D7=@\U6,[RYM\<&0#VQRTM8(3R:5*J"6T9\B<[[0GV$Q_L-O\ATPNQ;
MFYN=PJFW?-SR2++./388ZAXQBIAX-+LW44>LYJ,[=^Z</7NVO+P\,3%Q].C1
MQ&KPQ7???7_IXE]6KCK08^"L?WT^KEW7M-$Q[TQ+6YF6M3HC:TU*:F7RU!6)
M*4L#B]7ZO#ZG1?ND?H,+;MRHE5?L$I8,2^(26KR..IQ[-'NZ0=HV^^:^CJW(
M6H&]#5 -I]SR78?JE@>6&GCI_UI-_9L]V$VSL,"^AD)=E]J7U&4"./DX[X39
MY]#YTN'5N;+.5R_J]\-Z NT,8<.E/38PQ&J^DZK@EA%?HO.^D#;,XYZ[=TY2
M[_?X\CY9=2(DABI?1K20T[G'!D/=(XV+V,OA44W[$*OYY_+ER^O7KY\Z=6K4
M_?>$$JM!=?[\]:JJ3\;%5?RQ0_+#;1,&#,E/RUH](V]#=NZZS.EKQ+^GI:]*
M25T1<*S6Y_4YG?OD_/3)L;MWGY;7[1[!#$MB23&S4>\B-A1QM:G599BT>2TZ
M)(LJV%&D%;EBDJV&!1X?[G,:U NPP/(IAZE[RJ_-KFJN_XL.IM7<U)>#77VH
M*H#>:QK/J7W)E^W14,"]7?TR$)VO7M2>(/:IO%"$47NL. .HY_^ BWJ,A)#:
MS^4EK* V:94;3@(2J0H!G#-UH.V^(.+WA=I*/M[OJ3,[V'T<U$)+VQX;/'7\
ME8J8/(R(+M/GS1!:(58+Q*U;MW;NW#E[]NS8V-C&SZP1JT6X4R>OK%YU(&7:
MJJ[]\AYIE]CKU9F)R15S"S?/GOMN[LRJ[!EK,W/69&2M20TZ5A/EMVT3Q\24
MU=9^+V^$>ZC#4HL.R6*(]5),W^FF%MTRM3IE[NM8<<4D6XV'?)]752GYE,<L
M1M&-NMEBIJ)V^,#ZOUC2QQFM8]2#W70.JCY49;J8%^H]<].^Y./V:$7M,[Y?
MNM2YZNI%W3NN.(_92FT3:XM6G4'MJ_(25E";5/^3@$JJ@DN/%&WWA7K6]=C3
M&UU-/6!]/Y^H+>S7N!8JVO982X@+*'4R9EK$KA=-$4YU#Q*Q6E ^^^RS5:M6
M961D&.$:L5ID^G#?V<)YVT:,*7VI5_:SG2;W'S(G:?*RXOE;WUFXH[!XR^PY
M&_/>KIHQ<X-5L5J_P7,Z=L_\39N$8Y]=DC?%5=1AR9(BKJLU')+5[72FZ#_)
M#GY2I28IZIO^=*/6VI(BFD[/]Z>H![OI/$R]3>I7!U8?>VRJ+_FX/5I10U6_
M]K7:Y43CZ!E JWO'KVX0EM0VL;;X?AGL /4J75[""FJ3ZG\24$E5<.F1HNV^
M4(<DK3Y=1 >F(XOIL-L4]7C7?PJG;8^UBI</&&FJ=.L_4\Q)])Q4.(98S0*7
M+U_>LV=/:6GI^/'CC<?6B-4BP9;JSZ:EK>GW1GZ[;AD=>V0,'564DKJBJ*1Z
MQ?(/RLIW%,_?.G?>YCESWWW;TEBM_^ YO5Z;]<_/QB9/72EOD-NHPU*018S$
MNCVDUD#=6F>*_I-L=4;E[P6>&J9XM)_BJ#/1((N8ZXL)C5]S62>I!WM3.TCM
M#[Z_UT -6)OJ2[YOCR8LN;I3VU;/JQ??]V/D4'NLM46K%E8[JKR$%=0FU?PD
M8$JJ@OXCOBEM]X6Z82YM8?NHCS7Y=;^GSNP]I![MWW.@=@Q->JRUQ)12[$UU
M%WLO+3HDZSP=M16QFF5J:VO/G3NW:]>NW-Q<X^&UAG"-6"UL'/OLTMOYU6^\
M5=SJI:D=>V3V&SPG,67IS+<W+"S;L6[=AY4K]Y0MWE'ZSK;BDNIYQ5MLB=6&
MY+?MFM:Q>^;UZ[?EC7,;=5@*H(@ICO$F?\W/X.J6.U,TGP*J88&_]SD-ZG6X
MYA4//E83#27J*"KNBMN#ZL'>U!Q4;1D?\R-U:N[EX\-\WQX=7#7[P+@ OG-
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MG+K_0 1][R<      &&&6 TFB-5LBM5FS*Q*RUK=KFM:QQY9APY?D-L=
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M^\0V_^F%Y)BXQ1<N_$5N00      $.Z(U6""6*VI6$V4/7N.9N>NZ] ]H\?
M66O7'I+;#@      1 9B-9@@5E-CM1T[/MFSYVCERCVB%J*^63E5UZ_?EAL.
M      !$#&(UF"!6:QRK?;COF/COMFV'XY(6_ZIU_)NC2T^>J)&;#
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ML# VL3QA4L7X^++71Q3T')CW_,M3'VF7V+%GUJ"WBF?/J5ZYZL#1(Y?D#04
M      @18C68<")6>ZM@\,AYPT87CQI7.G1T4:]79[;KEO:KY^/^N=7X3KVR
MAX]]9\'"7;MVG3IUZLIM'DP#      #Z(5:#"3MBM5X#\_J\/JO_D/R!0_-?
M'3KWM6%SN_3-?KK3Y']Y=OR#3T>_U#LG:<K*Y2OVGSIUY>J7-_DJ3P
MH#EB-9BP-E;KUN]>IB9*SX&Y7?O-:--YVL/M$A]J-;YUE[2D*2O75WUR[OPU
M'DD#      #N0JP&$Y;$:B^^DMFE3W:7?CDO]YXN_K=EAZ1?/A_[>*?)@]XL
M$J]_[OPU>:T       #N0:P&$\'':IU>R1+E^<[WOG;@%\_%MNV6/BJFK&+)
M/K[!$P      A =B-9@()E9KUS6M;=>TEAV3?_Y,],-M)PZ/6K"P;/>%"W^1
MUP$      .!FQ&HP$5BL]F2GR<^]//7AMHEBL8X]LC*F;]B[YXS\T@
M &&!6 TF HC5'GLA^=>MXW[XV,C.O6<LK]S/1Z<!     (#P1JP&$[[':O_6
M)J%%NXF_;ATO?OMPVXGE%7N_NGI3?CD      ("P0ZP&$[[$:O_R[/A?MX[_
MU?-Q/WDBZF=/14],J;QQHU9^(0      @#!%K 83S<9J/Z^/U1YZ.OI'?QK5
M]_7\_0<_EU\"       @K!&KP83W6.W!I^\]K2;^_8OG8_/F5,M_#
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M^:<       "XCU@-        \!NQ&@       . W8C4       # ;\1J
M    @-^(U0        "_$:L!        ?B-6 P       /Q&K 8       #X
MC5@-        \!NQ&@       . W8C4       # ;\1J        @-^(U0
M      "_$:L!        ?B-6 P       /Q&K 8       #X[?\#24]-*U^W
..27$     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140067958709680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 08, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cumberland Pharmaceuticals Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">TN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">62-1765329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1600 West End Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 1300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Nashville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">37203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">255-0068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, no par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CPIX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,449,107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001087294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140067954927856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 16,386,166<span></span>
</td>
<td class="nump">$ 19,757,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">14,529,133<span></span>
</td>
<td class="nump">13,163,681<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">10,180,002<span></span>
</td>
<td class="nump">9,863,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">2,715,498<span></span>
</td>
<td class="nump">3,084,978<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">43,810,799<span></span>
</td>
<td class="nump">45,870,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">7,534,303<span></span>
</td>
<td class="nump">7,527,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">354,857<span></span>
</td>
<td class="nump">284,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">29,390,195<span></span>
</td>
<td class="nump">30,590,678<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">914,000<span></span>
</td>
<td class="nump">914,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">4,919,057<span></span>
</td>
<td class="nump">5,218,403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,545,424<span></span>
</td>
<td class="nump">2,520,661<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">89,468,635<span></span>
</td>
<td class="nump">92,925,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">11,222,333<span></span>
</td>
<td class="nump">10,819,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease current liabilities</a></td>
<td class="nump">158,369<span></span>
</td>
<td class="nump">172,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">14,326,712<span></span>
</td>
<td class="nump">17,587,911<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">25,707,414<span></span>
</td>
<td class="nump">28,579,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
<td class="nump">16,072,286<span></span>
</td>
<td class="nump">16,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease noncurrent liabilities</a></td>
<td class="nump">4,549,150<span></span>
</td>
<td class="nump">4,586,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">7,091,298<span></span>
</td>
<td class="nump">7,585,019<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">53,420,148<span></span>
</td>
<td class="nump">56,951,152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock&#8212;no par value; 100,000,000 shares authorized; 15,555,865 and 15,723,075 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively</a></td>
<td class="nump">47,377,168<span></span>
</td>
<td class="nump">47,474,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings (deficit)</a></td>
<td class="num">(11,016,657)<span></span>
</td>
<td class="num">(11,208,841)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">36,360,511<span></span>
</td>
<td class="nump">36,266,132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="num">(312,024)<span></span>
</td>
<td class="num">(292,126)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">36,048,487<span></span>
</td>
<td class="nump">35,974,006<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 89,468,635<span></span>
</td>
<td class="nump">$ 92,925,158<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1336-112600<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1314-112600<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140067955694176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">14,430,047<span></span>
</td>
<td class="nump">14,366,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">14,430,047<span></span>
</td>
<td class="nump">14,366,316<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140067955373168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">$ 9,224,638<span></span>
</td>
<td class="nump">$ 11,175,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">1,250,264<span></span>
</td>
<td class="nump">2,211,885<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and marketing</a></td>
<td class="nump">4,277,318<span></span>
</td>
<td class="nump">4,614,429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,499,670<span></span>
</td>
<td class="nump">1,745,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,498,993<span></span>
</td>
<td class="nump">2,302,349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="nump">1,230,071<span></span>
</td>
<td class="nump">1,593,245<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">10,756,316<span></span>
</td>
<td class="nump">12,467,044<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="num">(1,531,678)<span></span>
</td>
<td class="num">(1,291,999)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">50,190<span></span>
</td>
<td class="nump">16,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income</a></td>
<td class="nump">1,847,065<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(186,353)<span></span>
</td>
<td class="num">(119,575)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="nump">179,224<span></span>
</td>
<td class="num">(1,395,533)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (expense) benefit</a></td>
<td class="num">(6,938)<span></span>
</td>
<td class="num">(6,900)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">172,286<span></span>
</td>
<td class="num">(1,402,433)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss at subsidiary attributable to noncontrolling interests</a></td>
<td class="nump">19,898<span></span>
</td>
<td class="nump">17,180<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shareholders</a></td>
<td class="nump">$ 192,184<span></span>
</td>
<td class="num">$ (1,385,253)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings (loss) per share attributable to common shareholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Earnings (loss) per share attributable to common shareholders - Continuing operations - basic (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Earnings (loss) per share attributable to common shareholders - Continuing operations - diluted (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">- basic (in shares)</a></td>
<td class="nump">14,359,322<span></span>
</td>
<td class="nump">14,691,623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">- diluted (in shares)</a></td>
<td class="nump">14,587,843<span></span>
</td>
<td class="nump">14,691,623<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140067951556368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 172,286<span></span>
</td>
<td class="num">$ (1,402,433)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">1,255,675<span></span>
</td>
<td class="nump">1,653,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">90,156<span></span>
</td>
<td class="nump">159,901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Decrease in non-cash contingent consideration</a></td>
<td class="num">(267,637)<span></span>
</td>
<td class="nump">370,464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy', window );">Decrease (increase) in cash surrender value of life insurance policies over premiums paid</a></td>
<td class="num">(30,799)<span></span>
</td>
<td class="nump">222,209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Increase in noncash interest expense</a></td>
<td class="nump">4,296<span></span>
</td>
<td class="nump">2,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuredEventGainLoss', window );">Gain on receivable of FDA fees</a></td>
<td class="num">(1,847,065)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in assets and liabilities affecting operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">481,613<span></span>
</td>
<td class="num">(7,758,089)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(323,557)<span></span>
</td>
<td class="nump">2,271,484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other current assets and other assets</a></td>
<td class="nump">682,958<span></span>
</td>
<td class="nump">239,862<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and other current liabilities</a></td>
<td class="num">(1,105,263)<span></span>
</td>
<td class="nump">4,461,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="num">(530,872)<span></span>
</td>
<td class="num">(371,214)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(1,418,209)<span></span>
</td>
<td class="num">(150,498)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property and equipment</a></td>
<td class="num">(107,260)<span></span>
</td>
<td class="num">(26,986)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(13,500,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Additions to intangible assets</a></td>
<td class="num">(67,193)<span></span>
</td>
<td class="num">(14,912)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(174,453)<span></span>
</td>
<td class="num">(13,541,898)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit', window );">Borrowings on line of credit</a></td>
<td class="nump">8,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments on line of credit</a></td>
<td class="num">(8,127,714)<span></span>
</td>
<td class="num">(15,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Cash payment of contingent consideration</a></td>
<td class="num">(1,464,311)<span></span>
</td>
<td class="num">(501,505)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common shares</a></td>
<td class="num">(187,117)<span></span>
</td>
<td class="num">(580,130)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="num">(1,779,142)<span></span>
</td>
<td class="nump">3,918,365<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(3,371,804)<span></span>
</td>
<td class="num">(9,774,031)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">19,757,970<span></span>
</td>
<td class="nump">27,040,816<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 16,386,166<span></span>
</td>
<td class="nump">$ 17,266,785<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuredEventGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess (deficiency) of insurance recovery over the loss incurred from an insured event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6397426&amp;loc=d3e17499-108355<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuredEventGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140067955223904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Retained earnings (deficit)</div></th>
<th class="th"><div>Noncontrolling interests</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,742,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Dec. 31, 2021</a></td>
<td class="nump">$ 42,601,978<span></span>
</td>
<td class="nump">$ 48,452,906<span></span>
</td>
<td class="num">$ (5,638,600)<span></span>
</td>
<td class="num">$ (212,328)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">159,901<span></span>
</td>
<td class="nump">$ 159,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(174,149)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">(566,043)<span></span>
</td>
<td class="num">$ (566,043)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(1,402,433)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,385,253)<span></span>
</td>
<td class="num">(17,180)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,730,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Mar. 31, 2022</a></td>
<td class="nump">$ 40,793,403<span></span>
</td>
<td class="nump">$ 48,046,764<span></span>
</td>
<td class="num">(7,023,853)<span></span>
</td>
<td class="num">(229,508)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Dec. 31, 2022</a></td>
<td class="nump">14,366,316<span></span>
</td>
<td class="nump">14,366,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Dec. 31, 2022</a></td>
<td class="nump">$ 35,974,006<span></span>
</td>
<td class="nump">$ 47,474,973<span></span>
</td>
<td class="num">(11,208,841)<span></span>
</td>
<td class="num">(292,126)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">90,156<span></span>
</td>
<td class="nump">$ 90,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(86,829)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">(187,961)<span></span>
</td>
<td class="num">$ (187,961)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 172,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192,184<span></span>
</td>
<td class="num">(19,898)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Mar. 31, 2023</a></td>
<td class="nump">14,430,047<span></span>
</td>
<td class="nump">14,430,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Mar. 31, 2023</a></td>
<td class="nump">$ 36,048,487<span></span>
</td>
<td class="nump">$ 47,377,168<span></span>
</td>
<td class="num">$ (11,016,657)<span></span>
</td>
<td class="num">$ (312,024)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140067958613216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND BASIS OF PRESENTATION</a></td>
<td class="text">ORGANIZATION AND BASIS OF PRESENTATION<div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription pharmaceutical products.  The Company's primary target markets are hospital acute care, gastroenterology and oncology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be served effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.  The Company promotes its approved products through its hospital, oncology and field sales forces in the United States.  We are continuing to build a network of international partners to register and provide our medicines to patients in their countries.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#8217;s products are manufactured by third parties, which are overseen by Cumberland&#8217;s quality control and manufacturing professionals. The Company works closely with its hospital, field and oncology sales teams and its third-party distribution partners to make its products available in the United States.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the December 31, 2022, audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;), and certain information and disclosures have been condensed or omitted as permitted by the SEC for interim period presentation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2022 (the &#8220;2022 Annual Report on Form 10-K&#8221;). The results of operations for the three months ended March 31, 2023, are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies are required to use a new forward-looking &#8220;expected loss&#8221; model that generally result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies measure credit losses in a manner similar to what they do today, except that the losses are recognized as allowances rather than as reductions in the amortized cost of the securities. Companies have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies apply the ASU&#8217;s provisions as a cumulative-effect adjustment, if any, to retained earnings (deficit) as of the beginning of the first reporting period in which the guidance is adopted.</span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted both ASU 2016-13 and ASU 2019-05 on January 1, 2023.  Please refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trade and Notes Receivables Policy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Policies:</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of contingent consideration liabilities associated with business combinations.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Operating Segments</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Trade and Note Receivables Policy</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management performed a scoping exercise to ensure completeness over the application of Current Expected Credit Losses (CECL) across the various financial instruments including trade and note receivables. CECL is applicable to all financial assets measured at amortized cost. The authoritative guidance requires that all financial instruments should be evaluated, including cash equivalents such as 3-month T-Bills, even if the expected loss is determined to be zero, or materially zero.  All bank balances are maintained in cash or money market funds.  Therefore for the Company, this principally relates to trade receivables and two note receivables. CECL also requires the measurement of expected credit losses on a collective (pool) basis when similar risk characteristics exist. This may include, either individually or in combination, some of the following characteristics (326-20-55-5):</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Internal or external credit score/rating</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Risk ratings or classification</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Financial asset type</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Size</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Effective interest rate</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.17pt">Term</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Geographical location</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Historical or expected credit loss patterns</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">Reasonable and supportable forecast periods</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The standard requires entities to pool financial assets but allows them to choose which risk characteristics to use. Under the requirements of the guidance, the Company would need to reassess at the end of each reporting period whether the pool of assets continue to display similar risk characteristics. </span></div>With twenty years of experience, Cumberland has experienced virtually no write downs of receivables as most of our receivables are due from large successful pharmaceutical, healthcare or government customers, consistently making payments on account. Although the payment behaviors of all of our customers are consistently reliable, for the sake of transparency, we have separated our customer base into seven separate pools. The Company performs a monthly analysis of aged accounts receivable to determine how much, if any, of the accounts receivable balance should be reserved as potential bad debt. The Company reviews all balances over 90 days past due for a possible reserve and considers any specific factors or information for balances aged under 90 days if there are indicators that the balance should be reserved, such as other aged balances with the customer or bankruptcy as well as any economic issues with a customer industry or region.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140067960308544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS (LOSS) PER SHARE</a></td>
<td class="text">EARNINGS (LOSS) PER SHARE<div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the numerator and denominator used to calculate basic and diluted earnings (loss) per share for the three months ended March 31, 2023 and 2022:</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,286&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,402,433)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss at subsidiary attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,184&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,385,253)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,359,322&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,691,623&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,587,843&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,691,623&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:58.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.518%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023 and 2022, restricted stock awards and options to purchase 331,338 and 131,225 shares of common stock, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect would be antidilutive.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140067961599952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">REVENUES</a></td>
<td class="text">REVENUES<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenues</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net revenues consisted of the following for the three months ended March 31, 2023 and 2022:</span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.883%"><tr><td style="width:1.0%"/><td style="width:56.849%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.264%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.195%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,315,128&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,945,097&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sancuso</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,886,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,397,209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,848,187&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,501,434&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">935,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959,634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,856&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,090&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,518)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,737&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141,045)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,186&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,618&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,224,638&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,175,045&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Omeclamox-Pak net revenue for the first quarter of 2023 and 2022 was the result of Cumberland currently being out of commercial inventory of this product.  The packager for our Omeclamox-Pak product encountered financial difficulties due to the impact of COVID-19.  They are under new management and are in the process of a reorganization. Discussions with the packager are ongoing.  In the first quarter of 2023, the amounts noted were normal adjustments by channel partners.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With regard to Vaprisol, we are in the process of transitioning to a new manufacturer, who was issued an FDA Form 483 in the second quarter of 2022.  Once these 483 related issues are satisfactorily resolved by the manufacturing plant, we will then resubmit our application to the FDA for approval.  Net revenue was positively impacted by product return adjustments.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Revenues</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with international partners for commercialization of the Company's products with associated payments included in other revenues. Those agreements provide that each of the partners is responsible for seeking regulatory approvals for the product, and following approval, each partner will be responsible for the ongoing distribution and sales in the respective international territories. The Company provides a dossier for product registration and maintains responsibility for the relevant intellectual property. Cumberland is typically entitled to receive a non-refundable, up-front payment at the time each agreement is executed as consideration for the product dossier and for the rights to the distinct intellectual property rights in the respective international territory. These agreements also typically provide for additional payments upon a partner&#8217;s achievement of a defined regulatory approval and sales milestones. The Company may also be entitled to receive royalties on future sales of the products and a transfer price on supplies.  The contractual payments associated with the partner&#8217;s achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.</span></div>Other revenues also include funding from federal grant programs including those secured from the FDA and from those secured by Cumberland Emerging Technologies Inc. ("CET") through the Small Business Administration as well as lease income generated by CET&#8217;s Life Sciences Center. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from these federal grant  programs totaled approximately $0.1&#160;million and $0.04 million for the three months ended March 31, 2023 and 2022, respectively<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140067960225584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text">INVENTORIES<div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company works closely with third parties to manufacture and package finished goods for sale.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the arrangements with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival at the Company&#8217;s warehouses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company then holds such goods in inventory until distribution and sale. These finished goods inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving goods by comparing sales history and projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value.  At March 31, 2023, there were no cumulative obsolescence and discontinuance losses necessary. At December 31, 2022, the Company had recognized and maintained cumulative net realizable value charges for potential obsolescence and discontinuance losses of approximately $0.5 million.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is responsible for the purchase of the active pharmaceutical ingredient (&#8220;API&#8221;) for Kristalose and maintains the inventory at third-party packagers. As that API is consumed in production, the value of the API is transferred from raw materials to finished goods.  API for the Company's Vaprisol brand is also included in the raw materials inventory at March 31, 2023 and December 31, 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consigned inventory represents Authorized Generic inventory stored with our partner until shipment.   </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Vibativ acquisition, the Company acquired API and work in process inventories of $15.6 million that were all initially classified as non-current inventories at the date of acquisition.  At March 31, 2023 and December 31, 2022, total non-current inventory, including Vibativ and our clinical trial drug ifetroban, was $7.5 million for each period. The Company had Vibativ finished goods of $0.9 million included in non-current inventory at March 31, 2023, and no non-current inventory at December 31, 2022.  The Company also had $0.3 million in non-current inventory for API related to its ifetroban clinical initiatives at March 31, 2023 and December 31, 2022, and $0.2 million and $0.1 million of finished goods, respectively.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2023 and December 31, 2022, the Company's net inventories consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:57.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,548,636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,899,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,985,883&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,322,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,714,305&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,390,748&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,534,303)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,527,167)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,180,002&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,863,581&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140067958585360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 15, 2021, Cumberland entered into a lease, pursuant to which the Company leases approximately 16,903 rentable square feet of space at the new development Broadwest located in Nashville, Tennessee with 1600 West End Avenue Partners, LLC. The Leased Premise serves as the Company's new corporate headquarters. The initial term of the Lease is one hundred fifty-seven (157) months, with two consecutive options to renew for a period of five years each, with the commencement date of October 25, 2022.  This lease currently expires in November 2035.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is responsible for paying rent to the Landlord under the Lease beginning three months after the commencement date. The Company pays a base rent of $33.06 per square foot of rentable space with a gradual rental rate increase of 2.5% for each year period thereafter of the prior year's base rental. In addition to the monthly base rent, the Company is responsible for its percentage share of the operating expenses of the Building. The Lease also provides for a tenant improvement allowance for the space.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company's operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by CET, our majority-owned subsidiary, where it operates the CET Life Sciences Center.  The research lab space at CET, under an agreement amended in July 2012, is leased through April 2023, with an option to extend the lease through April 2028. The Company also subleases a portion of the space under these leases. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities were recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As the Company&#8217;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019 and October 25, 2022.  Incremental borrowing rates reflect the Company&#8217;s estimated interest rates for collateralized borrowings over similar lease terms.  The weighted-average remaining lease term for the Broadwest lease is 12.62 years at March 31, 2023.  The weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments is 9.28% for the Broadwest lease and 7.42% for the remaining CET lease.  </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease Position</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2023 and December 31, 2022, the Company's lease assets and liabilities were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-Use Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,919,057&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,218,403&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,369&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,910&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,549,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,586,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,707,519&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,759,211&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, cumulative future minimum sublease income under non-cancelable operating subleases totals approximately $0.03 million and will be paid through the leases ending in April 2023. Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.554%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of Lease Liabilities at March 31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587,511&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578,759&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608,015&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,324,178&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,264,685&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,557,166&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,707,519&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense is recognized over the expected term of the lease, including renewal option periods, if applicable, on a straight-line basis as a component of general and administrative expense. Rent expense and sublease income were as follows:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,863&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,631&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,804&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140067960710496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity and Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_EquityAndDebtAbstract', window );"><strong>Equity and Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDERS' EQUITY AND DEBT</a></td>
<td class="text">SHAREHOLDERS&#8217; EQUITY AND DEBT<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share repurchases</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland currently has a share repurchase program to repurchase up to $10 million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. In January 2019, the Company's Board of Directors established the current $10 million repurchase program to replace the prior authorizations.  During the three months ended March 31, 2023 and March 31, 2022, the Company repurchased 86,829 shares and 174,149 shares of common stock for approximately $0.2 million and $0.6 million, respectively.  At March 31, 2023, approximately $3.6 million of common shares was left to repurchase under this program.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share purchases and sales</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Company's May 2023 trading window, several members of Cumberland's Board of Directors will enter into share purchase agreements of the Company's stock pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934. These purchases are designed to increase ownership in the Company by the members of the Board.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Sales</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, Cumberland filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to $100 million in corporate securities. The Shelf Registration was declared effective in January 2018. It also included an At the Market ("ATM") feature that allowed the Company to sell common shares at market prices, along with an agreement with B. Riley FBR Inc. to support such a placement of shares. The Company filed an updated Form S-3 with the SEC in December 2020, which was declared effective in January 2021.  On December 27, 2021, the Company filed a related prospectus supplement in connection with the sale and issuance of shares having an aggregate gross sales price of up to $19 million.  The Company intends to continue an ATM feature through B. Riley FBR, Inc. that would allow the Company to issue shares of its common stock. The Company did not issue any shares under an ATM during the three months ended March 31, 2023 or March 31, 2022.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Share Grants and Incentive Stock Options</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023 and March 31, 2022, the Company issued 28,250 shares and 65,225 shares of restricted stock to employees, advisors and directors, respectively. Restricted stock issued to employees and advisors generally cliff-vests on the fourth anniversary of the date of grant and for directors on the one-year anniversary of the date of grant.  During the three months ended March 31, 2023 and 2022, the Company also issued 183,250 and 166,350 incentive stock options, respectively, to employees that cliff-vest on the fourth anniversary of the date of grant, that are set to expire in 2033 and 2032, respectively. Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations.  For the three months ended March 31, 2023, we recorded a credit of $0.04&#160;million to share-based compensation related to the forfeiture of unvested restricted stock awards.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Agreement</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2021, the Company entered into a Fifth Amendment to the Revolving Credit Note and Sixth Amendment (the "Sixth Amendment") to Revolving Credit Loan Agreement with Pinnacle Bank (the "Pinnacle Agreement"). The Sixth Amendment increased the principal amount by $5 million to $20 million. On October 28, 2021, the Company entered into a Fourth Amendment to the Revolving Credit Note and Fifth Amendment to Revolving Credit Loan Agreement with Pinnacle Bank. Among other terms, the Fourth Amendment extended the maturity date to October 1, 2024.  The Pinnacle Agreement includes specific financial covenants.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the Company and Pinnacle Bank agreed to modify the financial covenants to align with the current use of the line of credit.  On March 31, 2022, the Company and Pinnacle Bank entered into a Seventh Amendment to the Revolving Credit Loan Agreement to revise and update the Maximum Funded Debt Ratio financial covenant and to delete from the Pinnacle Agreement the Funded Debt to Tangible Capital Ratio financial covenant. These changes were made to more appropriately reflect the impact from the Sancuso acquisition. On June 30, 2022, the Company entered into the Eighth Amendment to the Revolving Credit Loan Agreement with Pinnacle Bank permitting the Maximum Funded Debt Ratio to be calculated on a rolling four-quarter basis to be no more than 3.00 to 1.00 for the second and third quarters of 2022 and 2.50 to 1.00 for each quarter thereafter.   On September 29, 2022, the Company entered into the Ninth Amendment to the Revolving Credit Loan Agreement with Pinnacle Bank (as amended, the "Pinnacle Agreement") to update the Funded Debt Ratio to mean the ratio of (i) Funded Debt less the amount of Unrestricted Cash in excess of $8,500,000, to (ii) EBITDA, as determined at the end of each fiscal quarter on a rolling four (4) quarter basis.  For the quarter ended March 31, 2023, we were in compliance with the Funded Debt Ratio financial covenant.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. The current pricing under the Pinnacle Agreement provides for an interest rate spread of 1.75% to 2.75% above LIBOR with a minimum LIBOR of 0.90%. The applicable interest rate under the Pinnacle Agreement was 7.375% at March 31, 2023.  In addition, a fee of 0.25% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  The LIBOR rate will no longer be used as of June 30, 2023, at which time the benchmark rate will be changed from LIBOR to Term SOFR.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023 and December 31, 2022, the Company had $16.1 million and $16.2 million, respectively, in borrowings outstanding under its revolving credit facility.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the line of credit are collateralized by substantially all of our assets.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joint Venture Agreement</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, Cumberland entered into an agreement with WinHealth Investment (Singapore) Ltd creating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">WHC Biopharmaceuticals, Pte. Ltd</span>. The joint venture, as a limited liability company, will focus on acquiring, developing, registering, and commercializing development stage and commercial stage biopharmaceuticals for China, Hong Kong and other Asian markets.  The agreement provides for initial investment from WinHealth in the form of a $0.2&#160;million equity contribution and an initial investment from Cumberland in the form of a $0.2&#160;million convertible note, which was funded during the first quarter of 2021. The joint venture will seek additional future capital from additional investors and has entered into exclusive option agreements to license product candidates from both Cumberland Pharmaceuticals Inc. and Cumberland Emerging Technologies Inc.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_EquityAndDebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity and Debt [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_EquityAndDebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140067960308544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXESAs of March 31, 2023, the Company has approximately $57.8 million in federal net operating loss carryforwards including approximately $44.1 million of net operating loss carryforwards resulting from the exercise of nonqualified stock options. These have historically been used to significantly offset income tax obligations. The Company expects it will continue to pay minimal income taxes during 2023 and beyond, through the continued utilization of these net operating loss carryforwards, on any taxable income generated from our operations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140067960321888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">Other Income</a></td>
<td class="text">OTHER INCOMEThe Company realized a $1.8&#160;million gain in the first quarter of 2023 for previously paid prescription drug fees.  In March 2023, the Company was granted a barrier-to-innovation waiver from the FDA for the fiscal year 2022 RediTrex prescription drug fees resulting in a refund of $1.8&#160;million.  This refund is expected to be paid in second quarter of 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -URI https://asc.fasb.org/topic&amp;trid=2122503<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 610<br> -URI https://asc.fasb.org/topic&amp;trid=49130413<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140067957245392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Agreements</a></td>
<td class="text">COLLABORATIVE AGREEMENTS<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment received related to RediTrex, do not meet the criteria for accounting under ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The agreements do not specifically designate each party&#8217;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party.  Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed consolidated statements of operations.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140067960154992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">ADDITIONS AND RETURN OF PRODUCT RIGHTS</a></td>
<td class="text">ADDITIONS AND RETURN OF PRODUCT RIGHTS<div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vibativ</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand.  Vibativ is a patented, Food and Drug Administration ("FDA") approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $20.0&#160;million at the closing of the transaction and a $5.0&#160;million milestone payment in early April 2019. In addition, Cumberland has agreed to pay a royalty of up to 20% of on-going net sales of the product after the $2.5&#160;million threshold is met. The future royalty payments were required to be recognized at their acquisition-date fair value as a contingent consideration liability, as part of the contingent consideration transferred in the business combination. Cumberland prepared the valuations of the contingent consideration liability utilizing significant unobservable inputs.  As a result, the valuation is classified as Level 3 fair value measurement. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to Theravance quarterly.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.345%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,154,823&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(245,391)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,085,554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liability of $4.1 million was accounted for as $1.2 million of other current liabilities and $2.9 million of other long-term liabilities on the condensed consolidated balance sheet as of March 31, 2023.  </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RediTrex</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, the Company announced an agreement with the Nordic Group B.V. ("Nordic") to acquire the exclusive U.S. rights to Nordic&#8217;s injectable methotrexate product line designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for the license, Cumberland paid a deposit of $100,000 at closing.  The Company provided $0.9&#160;million in consideration through a grant of 180,000 restricted shares of Cumberland common stock to be vested upon the FDA approval of the first Nordic product. Cumberland also agreed to provide Nordic a series of payments tied to the products&#8217; FDA approval, launch and achievement of certain sales milestones. Under the terms of the agreement, Cumberland is responsible for the product registration and commercialization in the U.S. Nordic is responsible for product manufacturing and supply.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2019, Cumberland received FDA approval for the first Nordic injectable product and authorization to market them under the RediTrex brand name.  The 180,000 shares of restricted Cumberland common stock previously provided to Nordic vested upon approval and were valued at $0.9&#160;million on the vesting date. The FDA approval also resulted in a $1.0&#160;million milestone payment due to Nordic.  During December 2020, Cumberland introduced RediTrex and the launch that took place in late 2021 resulted in a $1.0&#160;million milestone payment due to Nordic.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective July 12, 2022, the Company entered into an amendment to our agreement with Nordic whereby they may assume responsibility for RediTrex marketing authorization in the U.S. and the opportunity to commercialize the product in the U.S. after June 30, 2023. Cumberland will continue to distribute and support the product until then.  In accordance with the terms of the amendment, Nordic has returned the 180,000 restricted Cumberland shares we previously issued to Nordic which were cancelled, refunded to Cumberland the milestone payment of $1.0&#160;million we made associated with the brand's U.S. approval and issued a credit note in favor of the Company in the amount of $1.0&#160;million for the unpaid milestone payment due from us for launch of the product line. The companies will cooperate on any transition and Cumberland will receive a long-term royalty on any Nordic sales of the product.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sancuso</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 3, 2022, Cumberland acquired the U.S. rights to the FDA-approved oncology-supportive care medicine Sancuso from Kyowa Kirin, Inc. ("Kyowa Kirin"), the U.S. affiliate of Japan-based Kyowa Kirin Co., Ltd. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sancuso is the first and only FDA-approved prescription patch for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment. The active drug in Sancuso, granisetron, slowly dissolves in the thin layer of adhesive that sticks to the patient&#8217;s skin and is released into their bloodstream over several days, working continuously to prevent chemotherapy-induced nausea and vomiting (&#8220;CINV&#8221;). It is applied 24 to 48 hours before receiving chemotherapy and can prevent CINV for up to five consecutive days. Alternative oral treatments must be taken several times (day and night) to deliver the same therapeutic doses.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland acquired U.S. rights to Sancuso and assumed full commercial responsibility for the product in the U.S. &#8211; including its marketing, promotion, distribution, manufacturing and medical support activities.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $13.5&#160;million at the closing of the transaction. The Agreement calls for milestone payments of up to $3.5&#160;million based on the attainment of various approvals and sales performance. The Company believes that $1.5&#160;million of the milestone payments will be earned and paid.  In March 2023, Cumberland paid $1.0&#160;million of the $3.5&#160;million milestone payments to Kwoya Kirin for the approval by the FDA of the manufacturing site for the product.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Cumberland has agreed to pay a royalty of up to 10% of on-going net sales of the product.  The future royalty payments were required to be recognized at their acquisition-date fair value as a contingent consideration liability, as part of the contingent consideration transferred in the business combination. Cumberland has prepared a valuation of the contingent consideration liability utilizing significant unobservable inputs.  As a result, the valuation is classified as Level 3 fair value measurement.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition was funded by cash and the Company's revolving credit facility.  The Company worked with an outside consultant to finalize the Sancuso valuation of the transaction.  The fair value for the assets and liabilities assumed were as follows: prepaid expenses $1.8&#160;million, inventory $2.6&#160;million, goodwill $0.03&#160;million, intangible assets $14.1&#160;million, milestone payable $1.7&#160;million and contingent liability $3.4&#160;million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.345%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(244,920)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(443,759)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div>The contingent consideration liability earned and accrued in operating expenses is paid to Kyowa Kirin quarterly.  The contingent consideration liability of $2.5 million was accounted for as $1.3 million of current liabilities and $1.2 million of other long-term liabilities on the condensed consolidated balance sheet as of March 31, 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4946-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140067955730832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIESThe company is involved in litigation arising in the normal course of business.  The Company does not believe that the disposition or ultimate resolution of existing claims or lawsuits will have a material adverse effect on the business or financial condition of the Company.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140067955222336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Guidance</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies are required to use a new forward-looking &#8220;expected loss&#8221; model that generally result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies measure credit losses in a manner similar to what they do today, except that the losses are recognized as allowances rather than as reductions in the amortized cost of the securities. Companies have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies apply the ASU&#8217;s provisions as a cumulative-effect adjustment, if any, to retained earnings (deficit) as of the beginning of the first reporting period in which the guidance is adopted.</span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted both ASU 2016-13 and ASU 2019-05 on January 1, 2023.  Please refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trade and Notes Receivables Policy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of contingent consideration liabilities associated with business combinations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Operating Segments</a></td>
<td class="text">Operating SegmentsThe Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_TradeAndNoteReceivablesPolicyTextBlock', window );">Trade and Note Receivables Policy</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Trade and Note Receivables Policy</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management performed a scoping exercise to ensure completeness over the application of Current Expected Credit Losses (CECL) across the various financial instruments including trade and note receivables. CECL is applicable to all financial assets measured at amortized cost. The authoritative guidance requires that all financial instruments should be evaluated, including cash equivalents such as 3-month T-Bills, even if the expected loss is determined to be zero, or materially zero.  All bank balances are maintained in cash or money market funds.  Therefore for the Company, this principally relates to trade receivables and two note receivables. CECL also requires the measurement of expected credit losses on a collective (pool) basis when similar risk characteristics exist. This may include, either individually or in combination, some of the following characteristics (326-20-55-5):</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Internal or external credit score/rating</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Risk ratings or classification</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Financial asset type</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Size</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Effective interest rate</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.17pt">Term</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Geographical location</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Historical or expected credit loss patterns</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">Reasonable and supportable forecast periods</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The standard requires entities to pool financial assets but allows them to choose which risk characteristics to use. Under the requirements of the guidance, the Company would need to reassess at the end of each reporting period whether the pool of assets continue to display similar risk characteristics. </span></div>With twenty years of experience, Cumberland has experienced virtually no write downs of receivables as most of our receivables are due from large successful pharmaceutical, healthcare or government customers, consistently making payments on account. Although the payment behaviors of all of our customers are consistently reliable, for the sake of transparency, we have separated our customer base into seven separate pools. The Company performs a monthly analysis of aged accounts receivable to determine how much, if any, of the accounts receivable balance should be reserved as potential bad debt. The Company reviews all balances over 90 days past due for a possible reserve and considers any specific factors or information for balances aged under 90 days if there are indicators that the balance should be reserved, such as other aged balances with the customer or bankruptcy as well as any economic issues with a customer industry or region.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_TradeAndNoteReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trade and Note Receivables</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_TradeAndNoteReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140067955307344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Reconciliation of numerator and denominator</a></td>
<td class="text">The following table reconciles the numerator and denominator used to calculate basic and diluted earnings (loss) per share for the three months ended March 31, 2023 and 2022:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,286&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,402,433)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss at subsidiary attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,184&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,385,253)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,359,322&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,691,623&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,587,843&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,691,623&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140067960204976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Summary of net revenue</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net revenues consisted of the following for the three months ended March 31, 2023 and 2022:</span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.883%"><tr><td style="width:1.0%"/><td style="width:56.849%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.264%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.195%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,315,128&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,945,097&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sancuso</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,886,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,397,209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,848,187&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,501,434&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">935,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959,634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,856&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,090&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,518)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,737&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141,045)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,186&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,618&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,224,638&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,175,045&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140067960267248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2023 and December 31, 2022, the Company's net inventories consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:57.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,548,636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,899,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,985,883&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,322,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,714,305&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,390,748&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,534,303)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,527,167)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,180,002&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,863,581&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140067960604864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Lease Position</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2023 and December 31, 2022, the Company's lease assets and liabilities were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-Use Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,919,057&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,218,403&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,369&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,910&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,549,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,586,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,707,519&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,759,211&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity of Lease Liabilities</a></td>
<td class="text">Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.554%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of Lease Liabilities at March 31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587,511&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578,759&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608,015&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,324,178&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,264,685&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,557,166&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,707,519&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock', window );">Schedule of Rent Expense and Sublease Income</a></td>
<td class="text">Rent expense and sublease income were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,863&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,631&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,804&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets and Liabilities, Lessee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Rent Expense and Sublease Income [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140067960200496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Schedule of Business Acquisitions by Acquisition, Contingent Consideration</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to Theravance quarterly.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.345%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,154,823&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(245,391)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,085,554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.345%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(244,920)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(443,759)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140068040095168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation Organization (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140067952441776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 172,286<span></span>
</td>
<td class="num">$ (1,402,433)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss at subsidiary attributable to noncontrolling interests</a></td>
<td class="nump">19,898<span></span>
</td>
<td class="nump">17,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shareholders</a></td>
<td class="nump">$ 192,184<span></span>
</td>
<td class="num">$ (1,385,253)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding &#8211; basic (in shares)</a></td>
<td class="nump">14,359,322<span></span>
</td>
<td class="nump">14,691,623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive effect of other securities (in shares)</a></td>
<td class="nump">228,521<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding &#8211; diluted (in shares)</a></td>
<td class="nump">14,587,843<span></span>
</td>
<td class="nump">14,691,623<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Denominator.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Numerator.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140067960162528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Details Textual) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock available for purchase through restricted stock awards and options (in shares)</a></td>
<td class="nump">331,338<span></span>
</td>
<td class="nump">131,225<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140067954972144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Schedule of Revenue (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 9,224,638<span></span>
</td>
<td class="nump">$ 11,175,045<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_KristaloseMember', window );">Kristalose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">4,315,128<span></span>
</td>
<td class="nump">3,945,097<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_SancusoMember', window );">Sancuso</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,886,793<span></span>
</td>
<td class="nump">3,397,209<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_VIBATIVMember', window );">Vibativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,848,187<span></span>
</td>
<td class="nump">2,501,434<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_CaldolorMember', window );">Caldolor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">935,043<span></span>
</td>
<td class="nump">959,634<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_AcetadoteMember', window );">Acetadote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">169,856<span></span>
</td>
<td class="nump">111,090<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_VaprisolMember', window );">Vaprisol</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">16,008<span></span>
</td>
<td class="num">(117,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember', window );">Omeclamox-Pak</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="num">(2,518)<span></span>
</td>
<td class="nump">22,737<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_RediTrexMember', window );">RediTrex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="num">(141,045)<span></span>
</td>
<td class="nump">59,226<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_OtherProductsMember', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 197,186<span></span>
</td>
<td class="nump">$ 295,618<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ProductsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ProductsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_KristaloseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_KristaloseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_SancusoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_SancusoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_CaldolorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_CaldolorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_AcetadoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_AcetadoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_VaprisolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_VaprisolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_RediTrexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_RediTrexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_OtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_OtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140067952442096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 9,224,638<span></span>
</td>
<td class="nump">$ 11,175,045<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 40,000.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140067952291392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Obsolescence and discontinuance losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">7,534,303<span></span>
</td>
<td class="nump">7,527,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods, net of reserve</a></td>
<td class="nump">4,985,883<span></span>
</td>
<td class="nump">4,322,167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=cpix_IfetrobanClinicalMember', window );">Ifetroban Clinical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods, net of reserve</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">Vibativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods, net of reserve</a></td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=cpix_IfetrobanClinicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=cpix_IfetrobanClinicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140067954991264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Schedule of Inventories) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials and work in process</a></td>
<td class="nump">$ 12,548,636<span></span>
</td>
<td class="nump">$ 12,899,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment', window );">Consigned inventory</a></td>
<td class="nump">179,786<span></span>
</td>
<td class="nump">168,923<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">4,985,883<span></span>
</td>
<td class="nump">4,322,167<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total inventories</a></td>
<td class="nump">17,714,305<span></span>
</td>
<td class="nump">17,390,748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">less non-current inventories</a></td>
<td class="num">(7,534,303)<span></span>
</td>
<td class="num">(7,527,167)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories classified as current</a></td>
<td class="nump">$ 10,180,002<span></span>
</td>
<td class="nump">$ 9,863,581<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of inventory owned by the entity but in the hands of a customer, typically a reseller.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140067958498976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Nov. 15, 2021 </div>
<div>ft&#178; </div>
<div>renewalTerm </div>
<div>$ / ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_LesseeOperatingLeaseRentIncrease', window );">Rent increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Future minimum sublease income under noncancelable operating subleases | $</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_A1600WestEndAvenuePartnersLLCMember', window );">1600 West End Avenue Partners, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">12 years 7 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Present value of remaining lease payments, percent</a></td>
<td class="nump">9.28%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_CETMember', window );">CET</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Present value of remaining lease payments, percent</a></td>
<td class="nump">7.42%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=srt_OfficeBuildingMember', window );">Wet Laboratory and Office Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_LesseeOperatingLeaseLeasedArea', window );">Leased area</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">157 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_LesseeOperatingLeaseBaseRent', window );">Base rent per square foot | $ / ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Square feet of office space</a></td>
<td class="nump">14,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=cpix_BroadwestLeaseFiveYearRenewalOptionMember', window );">Broadwest Lease, Five Year Renewal Option | Wet Laboratory and Office Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_LesseeOperatingLeaseNumberOfRenewalTerms', window );">Number of renewal terms | renewalTerm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LesseeOperatingLeaseBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Base Rent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LesseeOperatingLeaseBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:monetaryPerAreaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LesseeOperatingLeaseLeasedArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Leased Area</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LesseeOperatingLeaseLeasedArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LesseeOperatingLeaseNumberOfRenewalTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Renewal Terms</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LesseeOperatingLeaseNumberOfRenewalTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LesseeOperatingLeaseRentIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Rent Increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LesseeOperatingLeaseRentIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_A1600WestEndAvenuePartnersLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_A1600WestEndAvenuePartnersLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_CETMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_CETMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=srt_OfficeBuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=srt_OfficeBuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=cpix_BroadwestLeaseFiveYearRenewalOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=cpix_BroadwestLeaseFiveYearRenewalOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140067952431184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Lease Position (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 4,919,057<span></span>
</td>
<td class="nump">$ 5,218,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease current liabilities</a></td>
<td class="nump">158,369<span></span>
</td>
<td class="nump">172,910<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease noncurrent liabilities</a></td>
<td class="nump">4,549,150<span></span>
</td>
<td class="nump">4,586,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_LeaseLiability', window );">Total</a></td>
<td class="nump">$ 4,707,519<span></span>
</td>
<td class="nump">$ 4,759,211<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140067951733104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Maturity of Lease Liabilities at March 31, 2023</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2023</a></td>
<td class="nump">$ 587,511<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">578,759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">543,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">608,015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">623,199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">After 2027</a></td>
<td class="nump">5,324,178<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">8,264,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="nump">3,557,166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 4,707,519<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140067958477872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Rent Expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense</a></td>
<td class="nump">$ 234,863<span></span>
</td>
<td class="nump">$ 285,963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="nump">$ 115,631<span></span>
</td>
<td class="nump">$ 161,804<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140067949827296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity and Debt - Shareholders' Equity (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 27, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Aug. 14, 2020</div></th>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 29, 2022 </div>
<div>USD ($) </div>
<div>qtr</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 13, 2010 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 187,961<span></span>
</td>
<td class="nump">$ 566,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities', window );">Shelf Registration, sale of corporate securities (up to)</a></td>
<td class="nump">$ 19,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,072,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_WinHealthInvestmentSingaporeLtdMember', window );">WinHealth</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Initial investment in joint ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_WinHealthInvestmentSingaporeLtdMember', window );">WinHealth | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember', window );">LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Sixth Amendment | Pinnacle Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity', window );">Additional borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Current borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Eight Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_DebtInstrumentCovenantFundedDebtRatioMaximum', window );">Maximum funded debt ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00<span></span>
</td>
<td class="nump">2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Ninth Amemdment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold', window );">Unrestricted cash threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_DebtInstrumentCovenantEvaluationFrequency', window );">Covenant evaluation frequency | qtr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Line of Credit | Pinnacle Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate spread</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Line of credit, unused capacity, commitment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Line of Credit | Pinnacle Bank | Minimum | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Line of Credit | Pinnacle Bank | Maximum | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted in period, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,250<span></span>
</td>
<td class="nump">65,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Restricted stock awards, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cpix_IncentiveStockOptionsMember', window );">Incentive Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted in period, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,250<span></span>
</td>
<td class="nump">166,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,829<span></span>
</td>
<td class="nump">174,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 187,961<span></span>
</td>
<td class="nump">$ 566,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Common shares left to repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DebtInstrumentCovenantEvaluationFrequency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Evaluation Frequency</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DebtInstrumentCovenantEvaluationFrequency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DebtInstrumentCovenantFundedDebtRatioMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Funded Debt Ratio, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DebtInstrumentCovenantFundedDebtRatioMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Unrestricted Cash Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DebtInstrumentCovenantUnrestrictedCashThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Additional Borrowing Capacity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LineOfCreditFacilityAdditionalBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1336-112600<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1314-112600<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_WinHealthInvestmentSingaporeLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_WinHealthInvestmentSingaporeLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cpix_SixthAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cpix_SixthAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cpix_EightAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cpix_EightAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cpix_NinthAmemdmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cpix_NinthAmemdmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cpix_IncentiveStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cpix_IncentiveStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140067951119376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details Textual)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 44,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 57,800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140067956975152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuredEventGainLoss', window );">Gain on receivable of FDA fees</a></td>
<td class="nump">$ 1,847,065<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Refund</a></td>
<td class="nump">$ 1,847,065<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuredEventGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess (deficiency) of insurance recovery over the loss incurred from an insured event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6397426&amp;loc=d3e17499-108355<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuredEventGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140067952214832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2022</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Nov. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 12, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment to acquire business upon closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">914,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 914,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_KyowaKirinMember', window );">Kyowa Kirin | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment', window );">Upfront payment</a></td>
<td class="nump">$ 13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum', window );">Sales milestone payments, maximum</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected', window );">Sales milestone payments, expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePayments', window );">Sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_KyowaKirinMember', window );">Kyowa Kirin | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent', window );">Tiered royalty, percent</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_NordicGroupBVMember', window );">Nordic Group B.V. | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable', window );">Milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue', window );">Milestone payment credit due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_NordicGroupBVMember', window );">Nordic Group B.V. | Restricted Stock | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable', window );">Restricted shares receivable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">Vibativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment to acquire business upon closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPaymentsToAcquireBusinesses', window );">Other Payments to Acquire Businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_TieredRoyaltyPaymentsPercentage', window );">Percentage of tiered royalty payments (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_TieredRoyaltyPaymentsThreshold', window );">Tiered royalty payment, threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Additional liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,085,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,154,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of the contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Noncurrent portion of the contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember', window );">Methotrexate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment to acquire business upon closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Additional liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Liability recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Vested common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember', window );">Methotrexate | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Unvested restricted shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_SancusoMember', window );">Sancuso</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPaymentsToAcquireBusinesses', window );">Other Payments to Acquire Businesses</a></td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Additional liability</a></td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of the contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Noncurrent portion of the contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses</a></td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory</a></td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">30,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">$ 14,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Milestone Payment Credit Due</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Milestone Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Restricted Shares Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Expected</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Tiered Royalty, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_TieredRoyaltyPaymentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tiered Royalty Payments, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_TieredRoyaltyPaymentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_TieredRoyaltyPaymentsThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tiered Royalty Payments, Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_TieredRoyaltyPaymentsThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPaymentsToAcquireBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPaymentsToAcquireBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_KyowaKirinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_KyowaKirinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_NordicGroupBVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_NordicGroupBVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_SancusoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_SancusoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140067957327328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights - Change in Consideration, Vibativ (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualRollForward', window );"><strong>Loss Contingency Accrual [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration included in operating expenses</a></td>
<td class="num">$ (267,637)<span></span>
</td>
<td class="nump">$ 370,464<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">Vibativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualRollForward', window );"><strong>Loss Contingency Accrual [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Beginning balance</a></td>
<td class="nump">4,154,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Cash payment of royalty during the period</a></td>
<td class="num">(245,391)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration included in operating expenses</a></td>
<td class="nump">176,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses', window );">Contingent consideration earned and accrued in operating expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Ending balance</a></td>
<td class="nump">$ 4,085,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140067955274640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights - Change in Consideration, Sancuso Acquisition (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualRollForward', window );"><strong>Loss Contingency Accrual [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration included in operating expenses</a></td>
<td class="num">$ (267,637)<span></span>
</td>
<td class="nump">$ 370,464<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_SancusoMember', window );">Sancuso</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualRollForward', window );"><strong>Loss Contingency Accrual [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Beginning balance</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Cash payment of royalty during the period</a></td>
<td class="num">(244,920)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration included in operating expenses</a></td>
<td class="num">(443,759)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses', window );">Contingent consideration earned and accrued in operating expenses</a></td>
<td class="nump">188,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Ending balance</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_SancusoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_SancusoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>cpix-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cpix="http://www.cumberlandpharma.com/20230331"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cpix-20230331.xsd" xlink:type="simple"/>
    <context id="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i27c4c4f9bc9f49feb1b517e2603bb2ba_I20230508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2023-05-08</instant>
        </period>
    </context>
    <context id="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i96d025b4c8184275861452edd929096a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3eac396c436f4fae8b8a3e449c851b53_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id21988457a994b099a86739b6cdbca82_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie1f4ea962c494b878bb4241ac43c41fa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie8ec9abedb8c43f19d55e4f7e45c8eb7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6e57b172666d4a2288b8e5fde755512d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie8e03fa7b331473ab77acfc2afa51189_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idc23b71a673d4599bd2a0ba1407fe4fb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icd26126c59e14812b272518a9b7d3f44_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic0a37457ed334e9b9592ba8aed5a1663_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i616be1943a9849518944ae4c97161c10_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i744c798ff3df40f18e613495868bac21_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ide3cf6fd3f4f4b59bea565cd4bff5a6e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i530b250ef27949bba5fb487444051c84_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icf9186d88cd34c189ca611958661dbf7_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i253227b0f5924873a6f1b2ff8dcc1d6f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i940da1c588fe4d13ad77dfd49e66aad3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ieaa823ff0ab54452af8bbfadfb40cf88_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie061a82abf3d48ddab2142be4e8bf214_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i44a1615e590c493a868e0826fbbf8abd_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic5ec9fd4fee24747aa5425a2da34ca15_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia1390383e91148dca5ab8bb6aec95eaa_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifaee959e87604f9b8afd1f3f35e7279f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:SancusoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0b5edc8419e647ee824fdb81e180ad31_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:SancusoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ica71cbb512a74596b40cd7a2f3f45ac6_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie245a45f71a44cf49e04fb9e7a1b64c0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6f492dd29e9e496ab0c32db9bde2fad5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4fa8cd8c9bc645fd917139e4733faee9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iff66fc78303f42288cd05a0391f52e8d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8b303705e50348069ce4d7d41176c589_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if7b3c21a06344e6daf54cef8c4bea836_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i34fd69d4d0114a3891b1fd1b5cd85e8f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if792fa0d44004e868ffe0fb9dcc009a6_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i877bdcd11bf84e83a844f6f7f0340018_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if834c35329184e12bfc00925eb9c78b3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:RediTrexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i89705d4ba770443aa81891ed098d2e82_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:RediTrexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iefe426f8f9cf4fadacc86244be87455b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i56a471ba8e2a4536a4fee60860c84a40_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if42572ad56a64b2a829bd4df6389654b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2233569d7a744fb9be2b55c9f18e5f65_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7c76ad6b0d9d43bea791e5d7ff63409c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if921eb31fa6f45b39876cdd2bde81d95_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0b68b7b01134465aa81635021c31c2ee_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:IfetrobanClinicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i939a45f5061a4a48958225d296e46077_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:IfetrobanClinicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4f1ce978139642ffa57f5d8efd6a152c_I20211115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-15</instant>
        </period>
    </context>
    <context id="i3a8364b46d1349f89526bbca803b9b2b_I20211115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cpix:BroadwestLeaseFiveYearRenewalOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-15</instant>
        </period>
    </context>
    <context id="iaf2b4c3ed09b49c69ab36803117edced_I20211115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2021-11-15</instant>
        </period>
    </context>
    <context id="i049b67a4ada841f8a2827489c1ede626_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i50b28adc088b4efea984106ab32c61d9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:A1600WestEndAvenuePartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia97aab9d7d684fd486afb0916cc296bb_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:CETMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4afbcb5fba4d4a1d8a087e5d9008e5d9_I20100513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2010-05-13</instant>
        </period>
    </context>
    <context id="i7d99bf36d0104e0388920db036eb3ed2_I20160131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-01-31</instant>
        </period>
    </context>
    <context id="i4b57a58712e74809ae2518a342bbfc8a_D20171101-20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="i1c55618f6c5a49939c91a52e719a9556_D20211227-20211227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2021-12-27</startDate>
            <endDate>2021-12-27</endDate>
        </period>
    </context>
    <context id="i418c071f773e493bbdd32949f539f542_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i013a01798b674990bda32746a63a9bcd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3dd89fce4bbe496ab54a639f67e6966d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4e8b5ebbe5f54d37acb467699b819d53_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cpix:IncentiveStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i63b30cb0dab0416e82e2367680b40f47_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cpix:IncentiveStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iffcd93d62bab4e44a26be01fd717844c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:SixthAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0ee792037ad24f32a193eaf0a425d5ac_D20220401-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:EightAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id8989818d082428f810a0f2d67d1ba2a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:EightAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7bf205d89d0f4bbc97a466819e38a259_I20220929">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:NinthAmemdmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-29</instant>
        </period>
    </context>
    <context id="ib87aa9b105bd42a19d2435ddfe7a7834_D20200814-20200814">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-14</startDate>
            <endDate>2020-08-14</endDate>
        </period>
    </context>
    <context id="i47da99f45e0440398ffd975817b2efce_D20200814-20200814">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-14</startDate>
            <endDate>2020-08-14</endDate>
        </period>
    </context>
    <context id="i8117fb7667394b2f8d51eb672ad660af_D20200814-20200814">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-14</startDate>
            <endDate>2020-08-14</endDate>
        </period>
    </context>
    <context id="ifa9c80f982f947eebf8cfe734dbb223d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i17124cadeabb43b783b97a30611b1131_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i314d6baf5bd141d09dc589a0d087077a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i014f95ecf28e47dc9a81e3356a78cbfa_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:WinHealthInvestmentSingaporeLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="idd2a67aac74043969c46355ae44bb9ff_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:WinHealthInvestmentSingaporeLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i90e00eccd5aa49ab87f56422938153e5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i910d1c8e30b447a685124ae92adb5f51_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="i499b37cd8cf54392a0f2ec322fe40eee_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="idee1724666bd4296b087588595669561_D20161101-20161130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-01</startDate>
            <endDate>2016-11-30</endDate>
        </period>
    </context>
    <context id="i8321269afd0c421ebdd0224b1a27d392_D20161101-20161130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-01</startDate>
            <endDate>2016-11-30</endDate>
        </period>
    </context>
    <context id="i47826f88ea0b4a6eb3f2a0fbce1e5c79_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4038ab9268e54e9ea5e0321e85b66082_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i55d3542573f24209aee0933490837ee7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i90fc46e8567a4446ba6f1f69166c1051_I20220712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:NordicGroupBVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-12</instant>
        </period>
    </context>
    <context id="id0e8f0a1b5ac44cfa0861149a172d293_I20220712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:NordicGroupBVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-12</instant>
        </period>
    </context>
    <context id="i20b2ea64a45e4649b835fa2bde154e6d_I20220103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:KyowaKirinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-03</instant>
        </period>
    </context>
    <context id="ibcdddac945434b87b9564d50977a987e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:KyowaKirinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i44f4dc27a7c64611b4e00cd930bd4746_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:KyowaKirinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="icb7fb24ed38f426d9b39670f3390245e_I20220103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:KyowaKirinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-03</instant>
        </period>
    </context>
    <context id="ie9300edb1e774e3ea979ca48d8d32a68_I20220103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:SancusoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-03</instant>
        </period>
    </context>
    <context id="id571878b227b429aabb39f702150f09b_D20220103-20220103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:SancusoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-01-03</endDate>
        </period>
    </context>
    <context id="i339eef896e214990b9293f54ead2c9f0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:SancusoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i34ec3c62de204f83a7f07694bba18e4f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:SancusoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i339bfc5c1c8e48d58f19079fc7a04235_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:SancusoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>cpix:Segment</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="renewalterm">
        <measure>cpix:renewalTerm</measure>
    </unit>
    <unit id="usdPerSqft">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>utr:sqft</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="q">
        <measure>utr:Q</measure>
    </unit>
    <dei:DocumentFiscalYearFocus
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80L2ZyYWc6YzJiODBlOGU4MTQ1NGE1M2FiZmY5Nzk5NzkxOWViNDEvdGFibGU6NDYxMGEyMzA2NWI5NGU4Yjk0ODMwM2M3YTYwN2M1NGUvdGFibGVyYW5nZTo0NjEwYTIzMDY1Yjk0ZThiOTQ4MzAzYzdhNjA3YzU0ZV81LTEtMS0xLTQ1OTA2_e91dbbd5-1772-4069-a4e0-721551a937e4">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80L2ZyYWc6YzJiODBlOGU4MTQ1NGE1M2FiZmY5Nzk5NzkxOWViNDEvdGFibGU6NDYxMGEyMzA2NWI5NGU4Yjk0ODMwM2M3YTYwN2M1NGUvdGFibGVyYW5nZTo0NjEwYTIzMDY1Yjk0ZThiOTQ4MzAzYzdhNjA3YzU0ZV82LTEtMS0xLTQ1OTA2_36bc45fc-12a0-4b9c-aab1-1f66cd59c20d">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80L2ZyYWc6YzJiODBlOGU4MTQ1NGE1M2FiZmY5Nzk5NzkxOWViNDEvdGFibGU6NDYxMGEyMzA2NWI5NGU4Yjk0ODMwM2M3YTYwN2M1NGUvdGFibGVyYW5nZTo0NjEwYTIzMDY1Yjk0ZThiOTQ4MzAzYzdhNjA3YzU0ZV83LTEtMS0xLTQ1OTA2_258061ea-699d-496c-ac95-b3c8fa0d8b76">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80L2ZyYWc6YzJiODBlOGU4MTQ1NGE1M2FiZmY5Nzk5NzkxOWViNDEvdGV4dHJlZ2lvbjpjMmI4MGU4ZTgxNDU0YTUzYWJmZjk3OTk3OTE5ZWI0MV83OA_34250378-6ef5-4082-b78a-f6f24b0a7182">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80L2ZyYWc6YzJiODBlOGU4MTQ1NGE1M2FiZmY5Nzk5NzkxOWViNDEvdGV4dHJlZ2lvbjpjMmI4MGU4ZTgxNDU0YTUzYWJmZjk3OTk3OTE5ZWI0MV83OQ_4aa1bcf5-8a18-4e5b-bcfd-0f3411d6ec03">0001087294</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGV4dHJlZ2lvbjpkODE2OTJiNTAxMDQ0NWEyYjIyZGU5M2Q2ZmVlZjA0ZV8xOTc4_eb280995-c009-44ad-84be-472cdf787274">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGFibGU6MGI3Njc5MDVhY2M3NDk5ZGIzY2NlMzJlNjVhMGViZDcvdGFibGVyYW5nZTowYjc2NzkwNWFjYzc0OTlkYjNjY2UzMmU2NWEwZWJkN18wLTAtMS0xLTQ1OTA2_f7f1cd2c-3205-43a6-894d-0c7373a2c6b5">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGV4dHJlZ2lvbjpkODE2OTJiNTAxMDQ0NWEyYjIyZGU5M2Q2ZmVlZjA0ZV8xMzA_a63e72d7-6d83-41ed-b7aa-3d24b5bd6f27">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGFibGU6N2FkZjNlMjRkZWFhNGY5MjhmYWQ2ODY2YjRmMjg4OTAvdGFibGVyYW5nZTo3YWRmM2UyNGRlYWE0ZjkyOGZhZDY4NjZiNGYyODg5MF8wLTAtMS0xLTQ1OTA2_735fe5b7-b0cc-4f3f-940b-88e36f739a3e">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGV4dHJlZ2lvbjpkODE2OTJiNTAxMDQ0NWEyYjIyZGU5M2Q2ZmVlZjA0ZV8xOTc5_f6576d62-11a4-4f54-b6e0-82dd3cbc6db6">001-33637</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGV4dHJlZ2lvbjpkODE2OTJiNTAxMDQ0NWEyYjIyZGU5M2Q2ZmVlZjA0ZV8xOTgw_4cd3f967-5aba-4551-975d-1ae1cd28f842">Cumberland Pharmaceuticals Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGFibGU6NmIwNTZhOTIyYzUyNGY0NTg2MjYzZjY5MGFiOTdhMjIvdGFibGVyYW5nZTo2YjA1NmE5MjJjNTI0ZjQ1ODYyNjNmNjkwYWI5N2EyMl8wLTAtMS0xLTQ1OTA2_0b940a30-fe8d-4f77-88d1-8497fc426aca">TN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGFibGU6NmIwNTZhOTIyYzUyNGY0NTg2MjYzZjY5MGFiOTdhMjIvdGFibGVyYW5nZTo2YjA1NmE5MjJjNTI0ZjQ1ODYyNjNmNjkwYWI5N2EyMl8wLTItMS0xLTQ1OTA2_4b710a0f-4c16-48db-8a9e-a874c7733132">62-1765329</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGFibGU6NmIwNTZhOTIyYzUyNGY0NTg2MjYzZjY5MGFiOTdhMjIvdGFibGVyYW5nZTo2YjA1NmE5MjJjNTI0ZjQ1ODYyNjNmNjkwYWI5N2EyMl8zLTAtMS0xLTQ1OTA2L3RleHRyZWdpb246ODVjYmU4OTQ3OTBlNGZkOWI4YzUzYWNlNWQ2NWJkOGVfNQ_33ec143c-0001-4c90-ad27-0edf7125ac50">1600 West End Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGFibGU6NmIwNTZhOTIyYzUyNGY0NTg2MjYzZjY5MGFiOTdhMjIvdGFibGVyYW5nZTo2YjA1NmE5MjJjNTI0ZjQ1ODYyNjNmNjkwYWI5N2EyMl8zLTAtMS0xLTQ1OTA2L3RleHRyZWdpb246ODVjYmU4OTQ3OTBlNGZkOWI4YzUzYWNlNWQ2NWJkOGVfOQ_db723715-6376-4734-bf26-e1211ac3cd17">Suite 1300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGFibGU6NmIwNTZhOTIyYzUyNGY0NTg2MjYzZjY5MGFiOTdhMjIvdGFibGVyYW5nZTo2YjA1NmE5MjJjNTI0ZjQ1ODYyNjNmNjkwYWI5N2EyMl8zLTAtMS0xLTQ1OTA2L3RleHRyZWdpb246ODVjYmU4OTQ3OTBlNGZkOWI4YzUzYWNlNWQ2NWJkOGVfMTM_73865011-75a0-4674-a453-66edbb0fe090">Nashville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGFibGU6NmIwNTZhOTIyYzUyNGY0NTg2MjYzZjY5MGFiOTdhMjIvdGFibGVyYW5nZTo2YjA1NmE5MjJjNTI0ZjQ1ODYyNjNmNjkwYWI5N2EyMl8zLTAtMS0xLTQ1OTA2L3RleHRyZWdpb246ODVjYmU4OTQ3OTBlNGZkOWI4YzUzYWNlNWQ2NWJkOGVfMTc_a8ae3e36-64a8-41d5-a754-38efec4ced61">TN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGFibGU6NmIwNTZhOTIyYzUyNGY0NTg2MjYzZjY5MGFiOTdhMjIvdGFibGVyYW5nZTo2YjA1NmE5MjJjNTI0ZjQ1ODYyNjNmNjkwYWI5N2EyMl8zLTItMS0xLTQ1OTA2_7bb1f5e5-c8df-4de9-bddd-d66ca9e0a55f">37203</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGV4dHJlZ2lvbjpkODE2OTJiNTAxMDQ0NWEyYjIyZGU5M2Q2ZmVlZjA0ZV8xOTc2_dd4ff52a-9bb0-4f1d-bd4e-8d951d4d9b58">615</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGV4dHJlZ2lvbjpkODE2OTJiNTAxMDQ0NWEyYjIyZGU5M2Q2ZmVlZjA0ZV8xOTc3_4bc63d07-dd48-482d-86c1-4f0ed0b7e261">255-0068</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGFibGU6NWJjNTYxZGM4NjNhNGMxYmI5OGJiN2E5ZmQ1M2YxYWMvdGFibGVyYW5nZTo1YmM1NjFkYzg2M2E0YzFiYjk4YmI3YTlmZDUzZjFhY18yLTAtMS0xLTQ1OTA2_669c1c3d-df60-4cad-b95b-501ad4dfeb4d">Common stock, no par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGFibGU6NWJjNTYxZGM4NjNhNGMxYmI5OGJiN2E5ZmQ1M2YxYWMvdGFibGVyYW5nZTo1YmM1NjFkYzg2M2E0YzFiYjk4YmI3YTlmZDUzZjFhY18yLTItMS0xLTQ1OTA2_dc4d9de5-6041-4b71-b6a5-090e46699ffd">CPIX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGFibGU6NWJjNTYxZGM4NjNhNGMxYmI5OGJiN2E5ZmQ1M2YxYWMvdGFibGVyYW5nZTo1YmM1NjFkYzg2M2E0YzFiYjk4YmI3YTlmZDUzZjFhY18yLTQtMS0xLTQ1OTA2_7a869293-0705-4f7f-b275-449a83a9a2e3">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGV4dHJlZ2lvbjpkODE2OTJiNTAxMDQ0NWEyYjIyZGU5M2Q2ZmVlZjA0ZV8xOTgx_b53a9907-2ce4-4445-84c1-586343aa3574">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGV4dHJlZ2lvbjpkODE2OTJiNTAxMDQ0NWEyYjIyZGU5M2Q2ZmVlZjA0ZV8xOTcx_3570e918-7d27-4a96-b85c-4153695c1a60">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGFibGU6OTc2NDk5ODc1NDQzNDEzMGJkYjQ5NzM1ZGM2YmNlMjAvdGFibGVyYW5nZTo5NzY0OTk4NzU0NDM0MTMwYmRiNDk3MzVkYzZiY2UyMF8xLTAtMS0xLTQ1OTA2_4527e1e6-0d82-4a15-9609-326daa172a0b">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGFibGU6OTc2NDk5ODc1NDQzNDEzMGJkYjQ5NzM1ZGM2YmNlMjAvdGFibGVyYW5nZTo5NzY0OTk4NzU0NDM0MTMwYmRiNDk3MzVkYzZiY2UyMF8xLTUtMS0xLTQ1OTA2_e38f9779-56ed-435f-9a95-71be5b060999">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGFibGU6OTc2NDk5ODc1NDQzNDEzMGJkYjQ5NzM1ZGM2YmNlMjAvdGFibGVyYW5nZTo5NzY0OTk4NzU0NDM0MTMwYmRiNDk3MzVkYzZiY2UyMF8yLTItMS0xLTQ1OTA2_9f6fe5f6-1705-4e37-b1a7-c883d1d1c208">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGV4dHJlZ2lvbjpkODE2OTJiNTAxMDQ0NWEyYjIyZGU5M2Q2ZmVlZjA0ZV8xMDk5NTExNjI5NzU4_c90b406b-1099-4403-b521-c9ef7ed66cb5">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i27c4c4f9bc9f49feb1b517e2603bb2ba_I20230508"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xL2ZyYWc6ZDgxNjkyYjUwMTA0NDVhMmIyMmRlOTNkNmZlZWYwNGUvdGV4dHJlZ2lvbjpkODE2OTJiNTAxMDQ0NWEyYjIyZGU5M2Q2ZmVlZjA0ZV8xOTM2_2d088b15-f3cb-43f4-9ad1-509cd36dc7d5"
      unitRef="shares">14449107</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMy0xLTEtMS00NTkwNg_a56c3c10-7ba8-4990-beac-f208dd46079a"
      unitRef="usd">16386166</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMy0zLTEtMS00NTkwNg_880a2df1-a79a-431f-a531-e86248d01360"
      unitRef="usd">19757970</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfNS0xLTEtMS00NTkwNg_3cf420bb-ebf2-46ef-8361-c8cfc35ff6af"
      unitRef="usd">14529133</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfNS0zLTEtMS00NTkwNg_14324f0d-e24c-4c73-8086-b69dadad8850"
      unitRef="usd">13163681</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfNi0xLTEtMS00NTkwNg_5a9a75d0-57f3-4bdc-868b-2b4e8bdcdcab"
      unitRef="usd">10180002</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfNi0zLTEtMS00NTkwNg_dd3af581-6c64-46fe-a41f-29093c94937f"
      unitRef="usd">9863581</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfNy0xLTEtMS00NTkwNg_89a417c2-df29-4767-ad9c-48a169861bdf"
      unitRef="usd">2715498</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfNy0zLTEtMS00NTkwNg_dc096af7-11f3-40f9-a4a4-6530440b08de"
      unitRef="usd">3084978</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfOC0xLTEtMS00NTkwNg_090d2977-d3f9-41a6-9d10-4bdd580087b0"
      unitRef="usd">43810799</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfOC0zLTEtMS00NTkwNg_f8d57035-5185-45c3-8a3a-5f995c532135"
      unitRef="usd">45870210</us-gaap:AssetsCurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfOS0xLTEtMS00NTkwNg_dd1d229e-99f8-40fa-8160-7a6bc17a4522"
      unitRef="usd">7534303</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfOS0zLTEtMS00NTkwNg_25de867d-342e-4a2f-81b1-a0460151e24d"
      unitRef="usd">7527167</us-gaap:InventoryNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMTAtMS0xLTEtNDU5MDY_05d7ab5c-ca33-401b-940c-74af713670b4"
      unitRef="usd">354857</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMTAtMy0xLTEtNDU5MDY_8005443d-c397-4a28-92f7-e7589b3f953c"
      unitRef="usd">284039</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMTEtMS0xLTEtNDU5MDY_54ec5223-02f5-47dd-9caf-e1384419821d"
      unitRef="usd">29390195</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMTEtMy0xLTEtNDU5MDY_86f2ee84-426b-4299-874e-e7338080b516"
      unitRef="usd">30590678</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMTItMS0xLTEtNDU5MDY_de45a86c-64d6-4f6d-9bba-547be00d3f15"
      unitRef="usd">914000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMTItMy0xLTEtNDU5MDY_0037ca50-1824-452c-9f85-347018fbced0"
      unitRef="usd">914000</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMTMtMS0xLTEtNDU5MDY_fe814e99-2316-4fc7-bc16-8b89207dd3c2"
      unitRef="usd">4919057</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMTMtMy0xLTEtNDU5MDY_1fb1f54e-49bc-4d03-acca-49f1251cccb3"
      unitRef="usd">5218403</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMTQtMS0xLTEtNDU5MDY_e8bf450a-3ca7-44c5-aeae-631e7be06fd1"
      unitRef="usd">2545424</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMTQtMy0xLTEtNDU5MDY_07d85e11-ee9a-4bee-8f7e-65e2eeaf639f"
      unitRef="usd">2520661</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMTUtMS0xLTEtNDU5MDY_ae96760f-fa46-4587-85f4-be1d8809a8a3"
      unitRef="usd">89468635</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMTUtMy0xLTEtNDU5MDY_4c6911a8-4aee-4331-b61a-f872ec63c21a"
      unitRef="usd">92925158</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMTgtMS0xLTEtNDU5MDY_8f2f2e65-e7c1-4d02-b7a1-a9baecc601b8"
      unitRef="usd">11222333</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMTgtMy0xLTEtNDU5MDY_5c507205-49a3-49ed-978a-41ca85a3f381"
      unitRef="usd">10819011</us-gaap:AccountsPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMTktMS0xLTEtNDU5MDY_625592fc-26c1-4aef-a368-e3f63d6aa880"
      unitRef="usd">158369</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMTktMy0xLTEtNDU5MDY_27bceb99-63df-4736-b85f-1937d17866ff"
      unitRef="usd">172910</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjAtMS0xLTEtNDU5MDY_bf40b15b-ce1c-466f-9a64-0abd251a952e"
      unitRef="usd">14326712</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjAtMy0xLTEtNDU5MDY_4f54f7b7-a621-423e-8b8b-5eea91210acf"
      unitRef="usd">17587911</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjEtMS0xLTEtNDU5MDY_f8711102-a83b-48b5-98e5-bb8254513f61"
      unitRef="usd">25707414</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjEtMy0xLTEtNDU5MDY_1414c7b4-f333-4dd7-b2c1-f00e76dbee07"
      unitRef="usd">28579832</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermLineOfCredit
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjItMS0xLTEtNDU5MDY_f320458a-4117-4286-8880-9f3e4e895174"
      unitRef="usd">16072286</us-gaap:LongTermLineOfCredit>
    <us-gaap:LongTermLineOfCredit
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjItMy0xLTEtNDU5MDY_ea2b9cd5-fbe7-41a5-a8f1-9084ac8cee58"
      unitRef="usd">16200000</us-gaap:LongTermLineOfCredit>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjMtMS0xLTEtNDU5MDY_26722223-5f54-4237-b6cd-cbdb09e88c91"
      unitRef="usd">4549150</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjMtMy0xLTEtNDU5MDY_72671995-3378-470a-ab53-704fa0cbdb4b"
      unitRef="usd">4586301</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjQtMS0xLTEtNDU5MDY_0b126fd1-3a4b-4427-8854-e22483ba8c03"
      unitRef="usd">7091298</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjQtMy0xLTEtNDU5MDY_e61de44f-883d-4665-982a-1b8d2b30356e"
      unitRef="usd">7585019</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjUtMS0xLTEtNDU5MDY_0c1025f9-51f9-41a3-8847-5247a00835b3"
      unitRef="usd">53420148</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjUtMy0xLTEtNDU5MDY_68773356-161b-4fde-8cc3-7951f6a5dfe0"
      unitRef="usd">56951152</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjYtMS0xLTEtNDU5MDY_9a5b7527-aa83-4a22-a8fb-3d5d16bcbc81"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjYtMy0xLTEtNDU5MDY_2f959384-b609-4900-9d49-90d50db57e59"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockNoParValue
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjktMC0xLTEtNDU5MDYvdGV4dHJlZ2lvbjoxNGQwNzUwY2MyNWI0YTgzYTYxOTY4MjU2MzZhNjgxOF8xNw_796cdd08-b154-44d2-a010-6a49d7e0e236"
      unitRef="usdPerShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjktMC0xLTEtNDU5MDYvdGV4dHJlZ2lvbjoxNGQwNzUwY2MyNWI0YTgzYTYxOTY4MjU2MzZhNjgxOF8xNw_9564c557-af45-4f13-9037-324faa01c50a"
      unitRef="usdPerShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjktMC0xLTEtNDU5MDYvdGV4dHJlZ2lvbjoxNGQwNzUwY2MyNWI0YTgzYTYxOTY4MjU2MzZhNjgxOF8zMQ_4d6f73ea-b037-4b0d-a91b-e57a0e85507a"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjktMC0xLTEtNDU5MDYvdGV4dHJlZ2lvbjoxNGQwNzUwY2MyNWI0YTgzYTYxOTY4MjU2MzZhNjgxOF8zMQ_a668b94f-79d6-4e65-9c94-8d6fb39902ff"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjktMC0xLTEtNDU5MDYvdGV4dHJlZ2lvbjoxNGQwNzUwY2MyNWI0YTgzYTYxOTY4MjU2MzZhNjgxOF81Mw_d566e791-201f-49c3-89a7-1c755233c38b"
      unitRef="shares">14430047</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjktMC0xLTEtNDU5MDYvdGV4dHJlZ2lvbjoxNGQwNzUwY2MyNWI0YTgzYTYxOTY4MjU2MzZhNjgxOF81Mw_dfc5f9d7-cc1b-43bb-aa36-3d08b1ab52c3"
      unitRef="shares">14430047</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjktMC0xLTEtNDU5MDYvdGV4dHJlZ2lvbjoxNGQwNzUwY2MyNWI0YTgzYTYxOTY4MjU2MzZhNjgxOF82MA_483eb954-9161-423e-a74a-bab28e7d4ec8"
      unitRef="shares">14366316</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjktMC0xLTEtNDU5MDYvdGV4dHJlZ2lvbjoxNGQwNzUwY2MyNWI0YTgzYTYxOTY4MjU2MzZhNjgxOF82MA_5d91b084-7042-44b6-aebd-342378e6f5c6"
      unitRef="shares">14366316</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjktMS0xLTEtNDU5MDY_e7ae363e-91e6-463c-b095-5d663e917342"
      unitRef="usd">47377168</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMjktMy0xLTEtNDU5MDY_edc123a8-d798-4e82-8c98-7a72c83604c4"
      unitRef="usd">47474973</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMzAtMS0xLTEtNDU5MDY_5c6c6891-8379-47ce-bb55-2cc3d2a848b4"
      unitRef="usd">-11016657</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMzAtMy0xLTEtNDU5MDY_befbf3de-900f-476e-816c-e2b6ada33229"
      unitRef="usd">-11208841</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMzEtMS0xLTEtNDU5MDY_dd2eaed8-17d9-4059-8991-f27b339bed77"
      unitRef="usd">36360511</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMzEtMy0xLTEtNDU5MDY_09b26740-a511-4f30-bdb2-0895c0e071b8"
      unitRef="usd">36266132</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMzItMS0xLTEtNDU5MDY_1f7d4575-2615-4621-aa0e-1b1c1034db57"
      unitRef="usd">-312024</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMzItMy0xLTEtNDU5MDY_b58bbf7d-a3db-4f6d-a463-bda3633ad109"
      unitRef="usd">-292126</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMzMtMS0xLTEtNDU5MDY_4bf829a3-ad2a-4808-9c60-e1bee6c648ad"
      unitRef="usd">36048487</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMzMtMy0xLTEtNDU5MDY_65e149c9-e976-41d6-a80b-f7a82e9a0217"
      unitRef="usd">35974006</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMzQtMS0xLTEtNDU5MDY_49a0250a-7c78-4957-9718-b5432977dfad"
      unitRef="usd">89468635</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xNi9mcmFnOmRjYTE0MzNmZDg4ODQwNGI5ZTY5ODE4MTlmYTQ4Yjg2L3RhYmxlOmRmZjZiYjFiN2Y0ZDQzYjVhNzJjNzZkNTRkOWE3NzE0L3RhYmxlcmFuZ2U6ZGZmNmJiMWI3ZjRkNDNiNWE3MmM3NmQ1NGQ5YTc3MTRfMzQtMy0xLTEtNDU5MDY_bec5dc1c-a6b1-4f93-a997-446adb4bebc4"
      unitRef="usd">92925158</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMi0xLTEtMS00NTkwNg_ebe1a0b1-7037-4e47-bfe1-ba00584cc0c5"
      unitRef="usd">9224638</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMi0zLTEtMS00NTkwNg_6bc33ea4-5f60-4aea-a8ff-74ce5216684b"
      unitRef="usd">11175045</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfNC0xLTEtMS00NTkwNg_dcfba141-4df3-49e1-8c28-8c41571c6b92"
      unitRef="usd">1250264</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfNC0zLTEtMS00NTkwNg_f038a7e5-cee2-4c7c-bceb-4be4289f1929"
      unitRef="usd">2211885</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingAndMarketingExpense
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfNS0xLTEtMS00NTkwNg_9ec22f6f-8ae8-472f-8c80-292dfaeeea2f"
      unitRef="usd">4277318</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfNS0zLTEtMS00NTkwNg_ae3b5cac-7aa9-4ae4-b66c-4f7e3724e8bb"
      unitRef="usd">4614429</us-gaap:SellingAndMarketingExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfNi0xLTEtMS00NTkwNg_4d0d22bb-ed3e-488b-be10-4aa83dbebd1a"
      unitRef="usd">1499670</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfNi0zLTEtMS00NTkwNg_acc35761-4b12-4c8a-b456-adc388add733"
      unitRef="usd">1745136</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfNy0xLTEtMS00NTkwNg_1bc226b2-510a-4559-9280-4bc41151a2e7"
      unitRef="usd">2498993</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfNy0zLTEtMS00NTkwNg_1647bfc4-b067-46f4-8bd8-743c5e57371d"
      unitRef="usd">2302349</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfOC0xLTEtMS00NTkwNg_03eff909-93b5-4e53-af8a-7f263df133af"
      unitRef="usd">1230071</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfOC0zLTEtMS00NTkwNg_a831904f-8ec2-47bc-8afe-3d2c3833ac3c"
      unitRef="usd">1593245</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:CostsAndExpenses
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfOS0xLTEtMS00NTkwNg_14028cf5-1a2c-4567-8657-e1f44d8eee8f"
      unitRef="usd">10756316</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfOS0zLTEtMS00NTkwNg_1b541a13-8db5-4324-91d2-fcaea3610afc"
      unitRef="usd">12467044</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMTAtMS0xLTEtNDU5MDY_bbb3fc65-14b1-4e2b-928c-82d317c1c384"
      unitRef="usd">-1531678</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMTAtMy0xLTEtNDU5MDY_f87e7195-fc3e-471d-a31f-cb556ed5432a"
      unitRef="usd">-1291999</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMTEtMS0xLTEtNDU5MDY_7c6d2cbf-3bb2-480f-8b3a-b8b293285972"
      unitRef="usd">50190</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMTEtMy0xLTEtNDU5MDY_9cd6d27c-d8af-423a-80bf-190d76b21d86"
      unitRef="usd">16041</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherIncome
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMTItMS0xLTEtNDU5MDY_aa383fd2-a70a-4fc3-a6a4-1a7249e9117f"
      unitRef="usd">1847065</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMTItMy0xLTEtNDU5MDY_2746ca63-edb2-4cc2-88b3-77f7030aede5"
      unitRef="usd">0</us-gaap:OtherIncome>
    <us-gaap:InterestExpense
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMTQtMS0xLTEtNDU5MDY_35d29e7f-a457-4ae6-bb32-7152f7424f90"
      unitRef="usd">186353</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMTQtMy0xLTEtNDU5MDY_04624263-e175-468d-87f8-0895016732c7"
      unitRef="usd">119575</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMTUtMS0xLTEtNDU5MDY_806a88c5-4721-4c1b-b846-c8f360aa0332"
      unitRef="usd">179224</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMTUtMy0xLTEtNDU5MDY_1c13fe6c-d86c-419e-ba92-f7558eb33499"
      unitRef="usd">-1395533</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMTYtMS0xLTEtNDU5MDY_f5ed8099-02d2-4db5-b95c-65edf8e74478"
      unitRef="usd">6938</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMTYtMy0xLTEtNDU5MDY_d99c7b4b-fdb6-4165-a7a3-2a3ab739b6fc"
      unitRef="usd">6900</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMTctMS0xLTEtNDU5MDY_dac7a762-07af-4eef-ad3c-2e4b2904da5d"
      unitRef="usd">172286</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMTctMy0xLTEtNDU5MDY_42df67d0-8226-42f5-8dd2-a81458216df1"
      unitRef="usd">-1402433</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMjAtMS0xLTEtNDU5MDY_6c485852-ab79-4700-aaf5-61a01f38492c"
      unitRef="usd">-19898</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMjAtMy0xLTEtNDU5MDY_7fbe3dd3-3ebd-4632-afb8-bf4977ff3bbd"
      unitRef="usd">-17180</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMjEtMS0xLTEtNDU5MDY_bbc16342-8d6a-4237-a6cc-6fdee92e670e"
      unitRef="usd">192184</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMjEtMy0xLTEtNDU5MDY_cb3570f5-137c-4426-bef8-0b65078e1d72"
      unitRef="usd">-1385253</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMjMtMS0xLTEtNDU5MDY_3cbce3fc-3d2c-4285-8c4c-0e3a3cc72279"
      unitRef="usdPerShare">0.01</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMjMtMy0xLTEtNDU5MDY_d9b20e2c-d02c-4f9e-8a14-f859f9c907d6"
      unitRef="usdPerShare">-0.09</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMjctMS0xLTEtNDU5MDY_ec675850-e82f-4772-a306-134820e9e4f4"
      unitRef="usdPerShare">0.01</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMjctMy0xLTEtNDU5MDY_93eeccc2-80ef-4fb2-804a-1111719e8401"
      unitRef="usdPerShare">-0.09</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMzEtMS0xLTEtNDU5MDY_9cb396bd-0c06-4f16-bc03-2b7324b4a7e1"
      unitRef="shares">14359322</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMzEtMy0xLTEtNDU5MDY_86597605-03c9-4828-ac13-efebb90a7ea0"
      unitRef="shares">14691623</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMzItMS0xLTEtNDU5MDY_920c7810-d3b9-4a1c-b38e-e0e4f535cb90"
      unitRef="shares">14587843</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8xOS9mcmFnOmYzZjgwMGRjNjdkMjRmN2Y5OGZhZjZlMWQzODQ4MjUzL3RhYmxlOmU0NDkxYzRlYWY5NDQyOWVhYWU3ODRmMjVlOGI4NTkyL3RhYmxlcmFuZ2U6ZTQ0OTFjNGVhZjk0NDI5ZWFhZTc4NGYyNWU4Yjg1OTJfMzItMy0xLTEtNDU5MDY_bcca58ed-032f-4718-a6fa-baf785d59798"
      unitRef="shares">14691623</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMy0xLTEtMS00NTkwNg_abb0169a-acaf-4736-8b2b-c89f2bc77ce3"
      unitRef="usd">172286</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMy0zLTEtMS00NTkwNg_af524ac1-49ad-4592-aa62-7110a0952c1d"
      unitRef="usd">-1402433</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfNy0xLTEtMS00NTkwNg_f78909b4-0111-4500-b245-c9524fc80205"
      unitRef="usd">1255675</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfNy0zLTEtMS00NTkwNg_8a6f4e78-2053-4e94-a42b-79bc4cc01dd3"
      unitRef="usd">1653746</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfOC0xLTEtMS00NTkwNg_595a3f02-b43a-4cd5-b1d6-afa95eeb60bc"
      unitRef="usd">90156</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfOC0zLTEtMS00NTkwNg_441a1ff3-454f-47e6-bd14-c19e08eba497"
      unitRef="usd">159901</us-gaap:ShareBasedCompensation>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfOS0xLTEtMS00NTkwNg_410cdd8d-39d7-450f-8f67-9a614cec978a"
      unitRef="usd">-267637</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfOS0zLTEtMS00NTkwNg_6a7cc043-224f-483b-83ea-2613f32ec6ba"
      unitRef="usd">370464</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMTAtMS0xLTEtNDU5MDY_7329a324-1dde-4919-9d62-f6eefe9381f0"
      unitRef="usd">30799</cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy>
    <cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMTAtMy0xLTEtNDU5MDY_0e24217e-5c60-4f03-8e31-7104b9f11e79"
      unitRef="usd">-222209</cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMTEtMS0xLTEtNDU5MDY_ca39e02a-2aa1-41fe-9231-cc87c6aee351"
      unitRef="usd">4296</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMTEtMy0xLTEtNDU5MDY_53da35d6-e1c7-4453-ad40-c66172584403"
      unitRef="usd">2183</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InsuredEventGainLoss
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMTMtMS0xLTEtNDU5MDY_abf4484c-a74f-4191-973f-bdf2b998a66b"
      unitRef="usd">1847065</us-gaap:InsuredEventGainLoss>
    <us-gaap:InsuredEventGainLoss
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMTMtMy0xLTEtNDU5MDY_c22318b1-1ba3-4ed3-89fb-0385681cffda"
      unitRef="usd">0</us-gaap:InsuredEventGainLoss>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMTUtMS0xLTEtNDU5MDY_10e3e7aa-6205-4685-8e25-990917d0575e"
      unitRef="usd">-481613</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMTUtMy0xLTEtNDU5MDY_34139708-0440-4f2e-adaf-0a732b3d4278"
      unitRef="usd">7758089</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMTYtMS0xLTEtNDU5MDY_e8fa922b-562a-478a-8078-2c74f1de708f"
      unitRef="usd">323557</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMTYtMy0xLTEtNDU5MDY_175bdcc5-b357-4f9d-a836-1faaac620987"
      unitRef="usd">-2271484</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMTctMS0xLTEtNDU5MDY_a101869a-96e2-42e3-918e-b9bb1863fe57"
      unitRef="usd">-682958</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMTctMy0xLTEtNDU5MDY_6cf89de2-f542-4dd2-88ea-9bdc4a1a78fd"
      unitRef="usd">-239862</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMTgtMS0xLTEtNDU5MDY_e1d01de6-0a00-49cc-8aea-7138926931a5"
      unitRef="usd">-1105263</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMTgtMy0xLTEtNDU5MDY_44d60043-c80c-44b5-aeeb-afd36a76bbc2"
      unitRef="usd">4461389</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMTktMS0xLTEtNDU5MDY_068b2954-53b2-43e5-be93-64f97ccd8f75"
      unitRef="usd">-530872</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMTktMy0xLTEtNDU5MDY_8270cd08-13f7-4257-aad9-3139308ffbc4"
      unitRef="usd">-371214</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMjAtMS0xLTEtNDU5MDY_7ce7ead2-6b61-42c2-93f1-ed3ad831ef39"
      unitRef="usd">-1418209</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMjAtMy0xLTEtNDU5MDY_d9169438-d092-4d17-998d-ab1b099c9ee0"
      unitRef="usd">-150498</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMjQtMS0xLTEtNDU5MDY_4def164f-57cc-43db-ab54-339a3063d6fa"
      unitRef="usd">107260</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMjQtMy0xLTEtNDU5MDY_392e0ee3-1599-4318-95ce-2a347c176c28"
      unitRef="usd">26986</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMjgtMS0xLTEtNDU5MDY_3a0367b7-714e-4f96-a857-9d3f7c82555d"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMjgtMy0xLTEtNDU5MDY_334ed57b-4b0d-45b8-a1c9-99e40fe32429"
      unitRef="usd">13500000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMjktMS0xLTEtNDU5MDY_39fcbf30-a7b4-4857-ba4e-479f2ad15ec7"
      unitRef="usd">67193</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMjktMy0xLTEtNDU5MDY_2ad82271-8234-4a75-86ab-3513f42ccd70"
      unitRef="usd">14912</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMzAtMS0xLTEtNDU5MDY_28d3c5d0-7a22-4baf-adce-162d3b91f595"
      unitRef="usd">-174453</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMzAtMy0xLTEtNDU5MDY_789147fb-228e-4c03-80f9-a96a92f62c9c"
      unitRef="usd">-13541898</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMzMtMS0xLTEtNDU5MDY_abdd7ff3-ff66-45ed-929b-3e13dfac2f05"
      unitRef="usd">8000000</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMzMtMy0xLTEtNDU5MDY_15079344-6451-4b45-a6cd-c36716b24033"
      unitRef="usd">20000000</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMzQtMS0xLTEtNDU5MDY_80aaf450-e572-4352-be8f-dbb380f37fc0"
      unitRef="usd">8127714</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMzQtMy0xLTEtNDU5MDY_d0613347-dd66-4898-8cbd-b620e177d214"
      unitRef="usd">15000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMzUtMS0xLTEtNDU5MDY_ee880d01-a149-4a93-af9d-021a4bd04a84"
      unitRef="usd">1464311</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMzUtMy0xLTEtNDU5MDY_b08247c5-f758-4789-ae9e-e6b1e22c9e49"
      unitRef="usd">501505</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMzYtMS0xLTEtNDU5MDY_90be9e48-ae6d-49cd-af33-93ad839113b7"
      unitRef="usd">187117</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMzYtMy0xLTEtNDU5MDY_a82dbfc3-00ae-4d14-990a-a001c59d2b3e"
      unitRef="usd">580130</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMzctMS0xLTEtNDU5MDY_f03086b0-76b5-46db-9778-af5b434d3f68"
      unitRef="usd">-1779142</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMzctMy0xLTEtNDU5MDY_185a5331-0add-427b-925a-c7fd5fc717c8"
      unitRef="usd">3918365</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMzgtMS0xLTEtNDU5MDY_b4806f08-d5aa-41ed-9cf6-00f62c02c3da"
      unitRef="usd">-3371804</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMzgtMy0xLTEtNDU5MDY_4bab6ff4-95ea-434e-8421-ffb67a766b47"
      unitRef="usd">-9774031</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMzktMS0xLTEtNDU5MDY_fb9d3654-ed2c-4c6a-b9f3-50e67d9b176b"
      unitRef="usd">19757970</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i96d025b4c8184275861452edd929096a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfMzktMy0xLTEtNDU5MDY_cbb5862d-79d8-4df4-9e4d-c3ce560c6d64"
      unitRef="usd">27040816</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfNDAtMS0xLTEtNDU5MDY_568d0fcc-b1cb-4c1c-9157-3b68a5fa413a"
      unitRef="usd">16386166</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3eac396c436f4fae8b8a3e449c851b53_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yMi9mcmFnOjUxZjE3YjQ0MTM5YjRjZjg4YWEwNDdiNjQyZGM3OWFkL3RhYmxlOmE1MGIwYjk4MzE2OTQ5MThiOTcyMGNmNjk1ZGJhOGZmL3RhYmxlcmFuZ2U6YTUwYjBiOTgzMTY5NDkxOGI5NzIwY2Y2OTVkYmE4ZmZfNDAtMy0xLTEtNDU5MDY_f188d91b-7d35-4c41-8bdf-5e2a7c653c95"
      unitRef="usd">17266785</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id21988457a994b099a86739b6cdbca82_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOjY4MjMzNDJjOGQ1YTQzYzQ4YzBhOWRjZGJlYjI3ODM5L3RhYmxlcmFuZ2U6NjgyMzM0MmM4ZDVhNDNjNDhjMGE5ZGNkYmViMjc4MzlfMi0xLTEtMS00NTkwNg_24917ba4-d758-41bb-b51a-3b9a62ec48e8"
      unitRef="shares">14742754</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id21988457a994b099a86739b6cdbca82_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOjY4MjMzNDJjOGQ1YTQzYzQ4YzBhOWRjZGJlYjI3ODM5L3RhYmxlcmFuZ2U6NjgyMzM0MmM4ZDVhNDNjNDhjMGE5ZGNkYmViMjc4MzlfMi0zLTEtMS00NTkwNg_4ed5e19c-b02f-4e81-bfd3-651468ac88b8"
      unitRef="usd">48452906</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie1f4ea962c494b878bb4241ac43c41fa_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOjY4MjMzNDJjOGQ1YTQzYzQ4YzBhOWRjZGJlYjI3ODM5L3RhYmxlcmFuZ2U6NjgyMzM0MmM4ZDVhNDNjNDhjMGE5ZGNkYmViMjc4MzlfMi01LTEtMS00NTkwNg_57decc3c-7c20-4e3e-90af-eb9ee14f3898"
      unitRef="usd">-5638600</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie8ec9abedb8c43f19d55e4f7e45c8eb7_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOjY4MjMzNDJjOGQ1YTQzYzQ4YzBhOWRjZGJlYjI3ODM5L3RhYmxlcmFuZ2U6NjgyMzM0MmM4ZDVhNDNjNDhjMGE5ZGNkYmViMjc4MzlfMi03LTEtMS00NTkwNg_d981d84f-0ade-4142-833a-c49b2e6cdd31"
      unitRef="usd">-212328</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i96d025b4c8184275861452edd929096a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOjY4MjMzNDJjOGQ1YTQzYzQ4YzBhOWRjZGJlYjI3ODM5L3RhYmxlcmFuZ2U6NjgyMzM0MmM4ZDVhNDNjNDhjMGE5ZGNkYmViMjc4MzlfMi05LTEtMS00NTkwNg_d39f1229-8639-473a-a756-df300ce0416d"
      unitRef="usd">42601978</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i6e57b172666d4a2288b8e5fde755512d_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOjY4MjMzNDJjOGQ1YTQzYzQ4YzBhOWRjZGJlYjI3ODM5L3RhYmxlcmFuZ2U6NjgyMzM0MmM4ZDVhNDNjNDhjMGE5ZGNkYmViMjc4MzlfMy0xLTEtMS00NTkwNg_463b9ef9-4bb6-4804-b6d7-ed0c43092f8b"
      unitRef="shares">162155</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6e57b172666d4a2288b8e5fde755512d_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOjY4MjMzNDJjOGQ1YTQzYzQ4YzBhOWRjZGJlYjI3ODM5L3RhYmxlcmFuZ2U6NjgyMzM0MmM4ZDVhNDNjNDhjMGE5ZGNkYmViMjc4MzlfMy0zLTEtMS00NTkwNg_2b33cb74-35c4-4096-8883-41c7131e0b35"
      unitRef="usd">159901</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOjY4MjMzNDJjOGQ1YTQzYzQ4YzBhOWRjZGJlYjI3ODM5L3RhYmxlcmFuZ2U6NjgyMzM0MmM4ZDVhNDNjNDhjMGE5ZGNkYmViMjc4MzlfMy05LTEtMS00NTkwNg_537b05c0-1273-4c91-89e9-32c39646c2d4"
      unitRef="usd">159901</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i6e57b172666d4a2288b8e5fde755512d_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOjY4MjMzNDJjOGQ1YTQzYzQ4YzBhOWRjZGJlYjI3ODM5L3RhYmxlcmFuZ2U6NjgyMzM0MmM4ZDVhNDNjNDhjMGE5ZGNkYmViMjc4MzlfNC0xLTEtMS00NTkwNg_4f707b8e-735e-4f3d-80c4-f3928d0e1ab4"
      unitRef="shares">174149</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i6e57b172666d4a2288b8e5fde755512d_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOjY4MjMzNDJjOGQ1YTQzYzQ4YzBhOWRjZGJlYjI3ODM5L3RhYmxlcmFuZ2U6NjgyMzM0MmM4ZDVhNDNjNDhjMGE5ZGNkYmViMjc4MzlfNC0zLTEtMS00NTkwNg_dff7d4fd-059c-4eaf-9146-45b66e1eccdd"
      unitRef="usd">566043</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOjY4MjMzNDJjOGQ1YTQzYzQ4YzBhOWRjZGJlYjI3ODM5L3RhYmxlcmFuZ2U6NjgyMzM0MmM4ZDVhNDNjNDhjMGE5ZGNkYmViMjc4MzlfNC05LTEtMS00NTkwNg_667c151b-1baf-4082-8ff7-fd0af7023492"
      unitRef="usd">566043</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ProfitLoss
      contextRef="ie8e03fa7b331473ab77acfc2afa51189_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOjY4MjMzNDJjOGQ1YTQzYzQ4YzBhOWRjZGJlYjI3ODM5L3RhYmxlcmFuZ2U6NjgyMzM0MmM4ZDVhNDNjNDhjMGE5ZGNkYmViMjc4MzlfNS01LTEtMS00NTkwNg_013d813b-e512-4e2d-bc64-a55de4039299"
      unitRef="usd">-1385253</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="idc23b71a673d4599bd2a0ba1407fe4fb_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOjY4MjMzNDJjOGQ1YTQzYzQ4YzBhOWRjZGJlYjI3ODM5L3RhYmxlcmFuZ2U6NjgyMzM0MmM4ZDVhNDNjNDhjMGE5ZGNkYmViMjc4MzlfNS03LTEtMS00NTkwNg_25cf2a3c-adf3-4d02-82fc-f5bfe8fe5985"
      unitRef="usd">-17180</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOjY4MjMzNDJjOGQ1YTQzYzQ4YzBhOWRjZGJlYjI3ODM5L3RhYmxlcmFuZ2U6NjgyMzM0MmM4ZDVhNDNjNDhjMGE5ZGNkYmViMjc4MzlfNS05LTEtMS00NTkwNg_d4f9bf67-1f95-4685-9d10-3693d4775210"
      unitRef="usd">-1402433</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="icd26126c59e14812b272518a9b7d3f44_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOjY4MjMzNDJjOGQ1YTQzYzQ4YzBhOWRjZGJlYjI3ODM5L3RhYmxlcmFuZ2U6NjgyMzM0MmM4ZDVhNDNjNDhjMGE5ZGNkYmViMjc4MzlfNi0xLTEtMS00NTkwNg_c576c66f-52bd-4b1c-8292-009031d2c272"
      unitRef="shares">14730760</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icd26126c59e14812b272518a9b7d3f44_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOjY4MjMzNDJjOGQ1YTQzYzQ4YzBhOWRjZGJlYjI3ODM5L3RhYmxlcmFuZ2U6NjgyMzM0MmM4ZDVhNDNjNDhjMGE5ZGNkYmViMjc4MzlfNi0zLTEtMS00NTkwNg_0054dbc0-a943-4360-9a8e-d8fcf44fe9a9"
      unitRef="usd">48046764</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic0a37457ed334e9b9592ba8aed5a1663_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOjY4MjMzNDJjOGQ1YTQzYzQ4YzBhOWRjZGJlYjI3ODM5L3RhYmxlcmFuZ2U6NjgyMzM0MmM4ZDVhNDNjNDhjMGE5ZGNkYmViMjc4MzlfNi01LTEtMS00NTkwNg_6344b46c-3bfd-4f5d-86f1-2fba9ad14002"
      unitRef="usd">-7023853</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i616be1943a9849518944ae4c97161c10_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOjY4MjMzNDJjOGQ1YTQzYzQ4YzBhOWRjZGJlYjI3ODM5L3RhYmxlcmFuZ2U6NjgyMzM0MmM4ZDVhNDNjNDhjMGE5ZGNkYmViMjc4MzlfNi03LTEtMS00NTkwNg_796a37e4-ba5a-4be1-a6d9-baf34020f321"
      unitRef="usd">-229508</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3eac396c436f4fae8b8a3e449c851b53_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOjY4MjMzNDJjOGQ1YTQzYzQ4YzBhOWRjZGJlYjI3ODM5L3RhYmxlcmFuZ2U6NjgyMzM0MmM4ZDVhNDNjNDhjMGE5ZGNkYmViMjc4MzlfNi05LTEtMS00NTkwNg_27506859-8138-444b-b166-f38408e680c5"
      unitRef="usd">40793403</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i744c798ff3df40f18e613495868bac21_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOmNlZWEzZjhlOWFhYjQ5NjNiYWMzOTFmYzIzN2FiMGVhL3RhYmxlcmFuZ2U6Y2VlYTNmOGU5YWFiNDk2M2JhYzM5MWZjMjM3YWIwZWFfMi0xLTEtMS00NTkwNg_8a399381-78f0-4802-93c0-75ed1656b48f"
      unitRef="shares">14366616</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i744c798ff3df40f18e613495868bac21_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOmNlZWEzZjhlOWFhYjQ5NjNiYWMzOTFmYzIzN2FiMGVhL3RhYmxlcmFuZ2U6Y2VlYTNmOGU5YWFiNDk2M2JhYzM5MWZjMjM3YWIwZWFfMi0zLTEtMS00NTkwNg_eb2166bb-0d8f-4bd4-91fb-feec26c0b50f"
      unitRef="usd">47474973</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ide3cf6fd3f4f4b59bea565cd4bff5a6e_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOmNlZWEzZjhlOWFhYjQ5NjNiYWMzOTFmYzIzN2FiMGVhL3RhYmxlcmFuZ2U6Y2VlYTNmOGU5YWFiNDk2M2JhYzM5MWZjMjM3YWIwZWFfMi01LTEtMS00NTkwNg_b0f01dae-7127-4c33-9c5b-31f32cf0d982"
      unitRef="usd">-11208841</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i530b250ef27949bba5fb487444051c84_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOmNlZWEzZjhlOWFhYjQ5NjNiYWMzOTFmYzIzN2FiMGVhL3RhYmxlcmFuZ2U6Y2VlYTNmOGU5YWFiNDk2M2JhYzM5MWZjMjM3YWIwZWFfMi03LTEtMS00NTkwNg_7961d971-98fb-470c-b9f3-0972f2123ca0"
      unitRef="usd">-292126</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOmNlZWEzZjhlOWFhYjQ5NjNiYWMzOTFmYzIzN2FiMGVhL3RhYmxlcmFuZ2U6Y2VlYTNmOGU5YWFiNDk2M2JhYzM5MWZjMjM3YWIwZWFfMi05LTEtMS00NTkwNg_f9abb5fb-4b78-4b4d-ab70-7a2301ce32bb"
      unitRef="usd">35974006</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="icf9186d88cd34c189ca611958661dbf7_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOmNlZWEzZjhlOWFhYjQ5NjNiYWMzOTFmYzIzN2FiMGVhL3RhYmxlcmFuZ2U6Y2VlYTNmOGU5YWFiNDk2M2JhYzM5MWZjMjM3YWIwZWFfMy0xLTEtMS00NTkwNg_73115917-b8b2-465f-97f4-491785b9f522"
      unitRef="shares">150260</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="icf9186d88cd34c189ca611958661dbf7_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOmNlZWEzZjhlOWFhYjQ5NjNiYWMzOTFmYzIzN2FiMGVhL3RhYmxlcmFuZ2U6Y2VlYTNmOGU5YWFiNDk2M2JhYzM5MWZjMjM3YWIwZWFfMy0zLTEtMS00NTkwNg_2579e97b-ffbd-43cd-8df7-0f318ca2cf62"
      unitRef="usd">90156</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOmNlZWEzZjhlOWFhYjQ5NjNiYWMzOTFmYzIzN2FiMGVhL3RhYmxlcmFuZ2U6Y2VlYTNmOGU5YWFiNDk2M2JhYzM5MWZjMjM3YWIwZWFfMy05LTEtMS00NTkwNg_9c44c9c3-4125-4615-ae7e-b666cd21cc83"
      unitRef="usd">90156</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="icf9186d88cd34c189ca611958661dbf7_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOmNlZWEzZjhlOWFhYjQ5NjNiYWMzOTFmYzIzN2FiMGVhL3RhYmxlcmFuZ2U6Y2VlYTNmOGU5YWFiNDk2M2JhYzM5MWZjMjM3YWIwZWFfNC0xLTEtMS00NTkwNg_c303cd8d-d3bc-42f0-9f4d-6d5f64a13897"
      unitRef="shares">86829</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="icf9186d88cd34c189ca611958661dbf7_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOmNlZWEzZjhlOWFhYjQ5NjNiYWMzOTFmYzIzN2FiMGVhL3RhYmxlcmFuZ2U6Y2VlYTNmOGU5YWFiNDk2M2JhYzM5MWZjMjM3YWIwZWFfNC0zLTEtMS00NTkwNg_124e231c-811e-48f0-bd08-06b27f62c1e7"
      unitRef="usd">187961</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOmNlZWEzZjhlOWFhYjQ5NjNiYWMzOTFmYzIzN2FiMGVhL3RhYmxlcmFuZ2U6Y2VlYTNmOGU5YWFiNDk2M2JhYzM5MWZjMjM3YWIwZWFfNC05LTEtMS00NTkwNg_2ec0ca12-46f3-4798-b567-89b385e2eb54"
      unitRef="usd">187961</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ProfitLoss
      contextRef="i253227b0f5924873a6f1b2ff8dcc1d6f_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOmNlZWEzZjhlOWFhYjQ5NjNiYWMzOTFmYzIzN2FiMGVhL3RhYmxlcmFuZ2U6Y2VlYTNmOGU5YWFiNDk2M2JhYzM5MWZjMjM3YWIwZWFfNS01LTEtMS00NTkwNg_42659e2a-fa5f-41b6-8007-9730ef480435"
      unitRef="usd">192184</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i940da1c588fe4d13ad77dfd49e66aad3_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOmNlZWEzZjhlOWFhYjQ5NjNiYWMzOTFmYzIzN2FiMGVhL3RhYmxlcmFuZ2U6Y2VlYTNmOGU5YWFiNDk2M2JhYzM5MWZjMjM3YWIwZWFfNS03LTEtMS00NTkwNg_d00eb749-94d0-4e59-b059-181068b4a403"
      unitRef="usd">-19898</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOmNlZWEzZjhlOWFhYjQ5NjNiYWMzOTFmYzIzN2FiMGVhL3RhYmxlcmFuZ2U6Y2VlYTNmOGU5YWFiNDk2M2JhYzM5MWZjMjM3YWIwZWFfNS05LTEtMS00NTkwNg_835ce9d5-1287-4c38-8459-2b743455702b"
      unitRef="usd">172286</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ieaa823ff0ab54452af8bbfadfb40cf88_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOmNlZWEzZjhlOWFhYjQ5NjNiYWMzOTFmYzIzN2FiMGVhL3RhYmxlcmFuZ2U6Y2VlYTNmOGU5YWFiNDk2M2JhYzM5MWZjMjM3YWIwZWFfNi0xLTEtMS00NTkwNg_a2713dab-0984-4de7-a9f1-86ad394a4203"
      unitRef="shares">14430047</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieaa823ff0ab54452af8bbfadfb40cf88_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOmNlZWEzZjhlOWFhYjQ5NjNiYWMzOTFmYzIzN2FiMGVhL3RhYmxlcmFuZ2U6Y2VlYTNmOGU5YWFiNDk2M2JhYzM5MWZjMjM3YWIwZWFfNi0zLTEtMS00NTkwNg_4b600f22-b6bc-4105-b535-cb9706f92c48"
      unitRef="usd">47377168</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie061a82abf3d48ddab2142be4e8bf214_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOmNlZWEzZjhlOWFhYjQ5NjNiYWMzOTFmYzIzN2FiMGVhL3RhYmxlcmFuZ2U6Y2VlYTNmOGU5YWFiNDk2M2JhYzM5MWZjMjM3YWIwZWFfNi01LTEtMS00NTkwNg_dfbebf09-f6fb-4d50-af75-b442b637a02c"
      unitRef="usd">-11016657</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i44a1615e590c493a868e0826fbbf8abd_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOmNlZWEzZjhlOWFhYjQ5NjNiYWMzOTFmYzIzN2FiMGVhL3RhYmxlcmFuZ2U6Y2VlYTNmOGU5YWFiNDk2M2JhYzM5MWZjMjM3YWIwZWFfNi03LTEtMS00NTkwNg_32945ab8-fc09-4bf5-9f76-6ed1854c83cf"
      unitRef="usd">-312024</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8yNS9mcmFnOjQ5M2I5MGIzNjI1NzRlYzViNDQxOGNlYjY1NmI5MDA5L3RhYmxlOmNlZWEzZjhlOWFhYjQ5NjNiYWMzOTFmYzIzN2FiMGVhL3RhYmxlcmFuZ2U6Y2VlYTNmOGU5YWFiNDk2M2JhYzM5MWZjMjM3YWIwZWFfNi05LTEtMS00NTkwNg_b056946f-e3f2-4e6f-b7b8-a0962e9aaf7b"
      unitRef="usd">36048487</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zMS9mcmFnOmVkZGY1NGVkYzVhYTRmZWE5ODlkZWViMmNkOTE5MGQ3L3RleHRyZWdpb246ZWRkZjU0ZWRjNWFhNGZlYTk4OWRlZWIyY2Q5MTkwZDdfOTUyOQ_b4c54bbf-b01b-436f-acb4-5316df3eb60f">ORGANIZATION AND BASIS OF PRESENTATION&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland Pharmaceuticals Inc. (&#x201c;Cumberland,&#x201d; the &#x201c;Company,&#x201d; or as used in the context of &#x201c;we,&#x201d; &#x201c;us,&#x201d; or &#x201c;our&#x201d;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription pharmaceutical products.  The Company's primary target markets are hospital acute care, gastroenterology and oncology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be served effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.  The Company promotes its approved products through its hospital, oncology and field sales forces in the United States.  We are continuing to build a network of international partners to register and provide our medicines to patients in their countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#x2019;s products are manufactured by third parties, which are overseen by Cumberland&#x2019;s quality control and manufacturing professionals. The Company works closely with its hospital, field and oncology sales teams and its third-party distribution partners to make its products available in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the December 31, 2022, audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;), and certain information and disclosures have been condensed or omitted as permitted by the SEC for interim period presentation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2022 (the &#x201c;2022 Annual Report on Form 10-K&#x201d;). The results of operations for the three months ended March 31, 2023, are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Guidance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, &#x201c;Financial Instruments-Credit Losses,&#x201d; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies are required to use a new forward-looking &#x201c;expected loss&#x201d; model that generally result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies measure credit losses in a manner similar to what they do today, except that the losses are recognized as allowances rather than as reductions in the amortized cost of the securities. Companies have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies apply the ASU&#x2019;s provisions as a cumulative-effect adjustment, if any, to retained earnings (deficit) as of the beginning of the first reporting period in which the guidance is adopted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopted both ASU 2016-13 and ASU 2019-05 on January 1, 2023.  Please refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Trade and Notes Receivables Policy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Policies:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of contingent consideration liabilities associated with business combinations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Operating Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#x2019;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Trade and Note Receivables Policy&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management performed a scoping exercise to ensure completeness over the application of Current Expected Credit Losses (CECL) across the various financial instruments including trade and note receivables. CECL is applicable to all financial assets measured at amortized cost. The authoritative guidance requires that all financial instruments should be evaluated, including cash equivalents such as 3-month T-Bills, even if the expected loss is determined to be zero, or materially zero.  All bank balances are maintained in cash or money market funds.  Therefore for the Company, this principally relates to trade receivables and two note receivables. CECL also requires the measurement of expected credit losses on a collective (pool) basis when similar risk characteristics exist. This may include, either individually or in combination, some of the following characteristics (326-20-55-5):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt"&gt;Internal or external credit score/rating&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;b.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Risk ratings or classification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;c.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt"&gt;Financial asset type&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;d.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Size&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;e.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt"&gt;Effective interest rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;f.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.17pt"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;g.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Geographical location&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;h.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Historical or expected credit loss patterns&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;i.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt"&gt;Reasonable and supportable forecast periods&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The standard requires entities to pool financial assets but allows them to choose which risk characteristics to use. Under the requirements of the guidance, the Company would need to reassess at the end of each reporting period whether the pool of assets continue to display similar risk characteristics. &lt;/span&gt;&lt;/div&gt;With twenty years of experience, Cumberland has experienced virtually no write downs of receivables as most of our receivables are due from large successful pharmaceutical, healthcare or government customers, consistently making payments on account. Although the payment behaviors of all of our customers are consistently reliable, for the sake of transparency, we have separated our customer base into seven separate pools. The Company performs a monthly analysis of aged accounts receivable to determine how much, if any, of the accounts receivable balance should be reserved as potential bad debt. The Company reviews all balances over 90 days past due for a possible reserve and considers any specific factors or information for balances aged under 90 days if there are indicators that the balance should be reserved, such as other aged balances with the customer or bankruptcy as well as any economic issues with a customer industry or region.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zMS9mcmFnOmVkZGY1NGVkYzVhYTRmZWE5ODlkZWViMmNkOTE5MGQ3L3RleHRyZWdpb246ZWRkZjU0ZWRjNWFhNGZlYTk4OWRlZWIyY2Q5MTkwZDdfOTUzMQ_762ee2f5-ff64-4245-b64d-7987cefd6c30">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Guidance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, &#x201c;Financial Instruments-Credit Losses,&#x201d; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies are required to use a new forward-looking &#x201c;expected loss&#x201d; model that generally result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies measure credit losses in a manner similar to what they do today, except that the losses are recognized as allowances rather than as reductions in the amortized cost of the securities. Companies have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies apply the ASU&#x2019;s provisions as a cumulative-effect adjustment, if any, to retained earnings (deficit) as of the beginning of the first reporting period in which the guidance is adopted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopted both ASU 2016-13 and ASU 2019-05 on January 1, 2023.  Please refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Trade and Notes Receivables Policy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zMS9mcmFnOmVkZGY1NGVkYzVhYTRmZWE5ODlkZWViMmNkOTE5MGQ3L3RleHRyZWdpb246ZWRkZjU0ZWRjNWFhNGZlYTk4OWRlZWIyY2Q5MTkwZDdfOTUyNg_2842a09c-46ee-4e41-a1d6-8b75b770e908">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of contingent consideration liabilities associated with business combinations.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zMS9mcmFnOmVkZGY1NGVkYzVhYTRmZWE5ODlkZWViMmNkOTE5MGQ3L3RleHRyZWdpb246ZWRkZjU0ZWRjNWFhNGZlYTk4OWRlZWIyY2Q5MTkwZDdfOTUyOA_49237524-ac7e-4dd0-a2b4-ea0c58ddc7bc">Operating SegmentsThe Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#x2019;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zMS9mcmFnOmVkZGY1NGVkYzVhYTRmZWE5ODlkZWViMmNkOTE5MGQ3L3RleHRyZWdpb246ZWRkZjU0ZWRjNWFhNGZlYTk4OWRlZWIyY2Q5MTkwZDdfODcxOQ_20b74a07-f26e-4d09-bbd5-602d2983259d"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <cpix:TradeAndNoteReceivablesPolicyTextBlock
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zMS9mcmFnOmVkZGY1NGVkYzVhYTRmZWE5ODlkZWViMmNkOTE5MGQ3L3RleHRyZWdpb246ZWRkZjU0ZWRjNWFhNGZlYTk4OWRlZWIyY2Q5MTkwZDdfMTA5OTUxMTY1MDgzOQ_b4af2038-4fb2-4af3-8d3d-6ed025b4d588">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Trade and Note Receivables Policy&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management performed a scoping exercise to ensure completeness over the application of Current Expected Credit Losses (CECL) across the various financial instruments including trade and note receivables. CECL is applicable to all financial assets measured at amortized cost. The authoritative guidance requires that all financial instruments should be evaluated, including cash equivalents such as 3-month T-Bills, even if the expected loss is determined to be zero, or materially zero.  All bank balances are maintained in cash or money market funds.  Therefore for the Company, this principally relates to trade receivables and two note receivables. CECL also requires the measurement of expected credit losses on a collective (pool) basis when similar risk characteristics exist. This may include, either individually or in combination, some of the following characteristics (326-20-55-5):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt"&gt;Internal or external credit score/rating&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;b.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Risk ratings or classification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;c.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt"&gt;Financial asset type&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;d.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Size&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;e.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt"&gt;Effective interest rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;f.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.17pt"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;g.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Geographical location&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;h.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Historical or expected credit loss patterns&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;i.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt"&gt;Reasonable and supportable forecast periods&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The standard requires entities to pool financial assets but allows them to choose which risk characteristics to use. Under the requirements of the guidance, the Company would need to reassess at the end of each reporting period whether the pool of assets continue to display similar risk characteristics. &lt;/span&gt;&lt;/div&gt;With twenty years of experience, Cumberland has experienced virtually no write downs of receivables as most of our receivables are due from large successful pharmaceutical, healthcare or government customers, consistently making payments on account. Although the payment behaviors of all of our customers are consistently reliable, for the sake of transparency, we have separated our customer base into seven separate pools. The Company performs a monthly analysis of aged accounts receivable to determine how much, if any, of the accounts receivable balance should be reserved as potential bad debt. The Company reviews all balances over 90 days past due for a possible reserve and considers any specific factors or information for balances aged under 90 days if there are indicators that the balance should be reserved, such as other aged balances with the customer or bankruptcy as well as any economic issues with a customer industry or region.</cpix:TradeAndNoteReceivablesPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNC9mcmFnOjZmYTc5OTIzZDg1YTRjNDJhMjJjMWVhZTViZDk3ZmYzL3RleHRyZWdpb246NmZhNzk5MjNkODVhNGM0MmEyMmMxZWFlNWJkOTdmZjNfNDI2_0f74ff20-e483-4260-af92-e496d7d9a180">EARNINGS (LOSS) PER SHARE&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the numerator and denominator used to calculate basic and diluted earnings (loss) per share for the three months ended March 31, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,402,433)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss at subsidiary attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,385,253)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,359,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,691,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,587,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,691,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2023 and 2022, restricted stock awards and options to purchase 331,338 and 131,225 shares of common stock, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect would be antidilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNC9mcmFnOjZmYTc5OTIzZDg1YTRjNDJhMjJjMWVhZTViZDk3ZmYzL3RleHRyZWdpb246NmZhNzk5MjNkODVhNGM0MmEyMmMxZWFlNWJkOTdmZjNfNDI5_75bd5f1f-887d-4e40-8ec0-6840458bed71">The following table reconciles the numerator and denominator used to calculate basic and diluted earnings (loss) per share for the three months ended March 31, 2023 and 2022:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,402,433)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss at subsidiary attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,385,253)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,359,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,691,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,587,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,691,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ProfitLoss
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNC9mcmFnOjZmYTc5OTIzZDg1YTRjNDJhMjJjMWVhZTViZDk3ZmYzL3RhYmxlOjM5NmUzNjM2NTQwZjQ5ZDFiNjRjNTZkYTM0ZTc5ZmZkL3RhYmxlcmFuZ2U6Mzk2ZTM2MzY1NDBmNDlkMWI2NGM1NmRhMzRlNzlmZmRfNC0xLTEtMS00NTkwNg_dac7a762-07af-4eef-ad3c-2e4b2904da5d"
      unitRef="usd">172286</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNC9mcmFnOjZmYTc5OTIzZDg1YTRjNDJhMjJjMWVhZTViZDk3ZmYzL3RhYmxlOjM5NmUzNjM2NTQwZjQ5ZDFiNjRjNTZkYTM0ZTc5ZmZkL3RhYmxlcmFuZ2U6Mzk2ZTM2MzY1NDBmNDlkMWI2NGM1NmRhMzRlNzlmZmRfNC0zLTEtMS00NTkwNg_42df67d0-8226-42f5-8dd2-a81458216df1"
      unitRef="usd">-1402433</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNC9mcmFnOjZmYTc5OTIzZDg1YTRjNDJhMjJjMWVhZTViZDk3ZmYzL3RhYmxlOjM5NmUzNjM2NTQwZjQ5ZDFiNjRjNTZkYTM0ZTc5ZmZkL3RhYmxlcmFuZ2U6Mzk2ZTM2MzY1NDBmNDlkMWI2NGM1NmRhMzRlNzlmZmRfNy0xLTEtMS00NTkwNg_6c485852-ab79-4700-aaf5-61a01f38492c"
      unitRef="usd">-19898</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNC9mcmFnOjZmYTc5OTIzZDg1YTRjNDJhMjJjMWVhZTViZDk3ZmYzL3RhYmxlOjM5NmUzNjM2NTQwZjQ5ZDFiNjRjNTZkYTM0ZTc5ZmZkL3RhYmxlcmFuZ2U6Mzk2ZTM2MzY1NDBmNDlkMWI2NGM1NmRhMzRlNzlmZmRfNy0zLTEtMS00NTkwNg_7fbe3dd3-3ebd-4632-afb8-bf4977ff3bbd"
      unitRef="usd">-17180</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNC9mcmFnOjZmYTc5OTIzZDg1YTRjNDJhMjJjMWVhZTViZDk3ZmYzL3RhYmxlOjM5NmUzNjM2NTQwZjQ5ZDFiNjRjNTZkYTM0ZTc5ZmZkL3RhYmxlcmFuZ2U6Mzk2ZTM2MzY1NDBmNDlkMWI2NGM1NmRhMzRlNzlmZmRfOC0xLTEtMS00NTkwNg_bbc16342-8d6a-4237-a6cc-6fdee92e670e"
      unitRef="usd">192184</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNC9mcmFnOjZmYTc5OTIzZDg1YTRjNDJhMjJjMWVhZTViZDk3ZmYzL3RhYmxlOjM5NmUzNjM2NTQwZjQ5ZDFiNjRjNTZkYTM0ZTc5ZmZkL3RhYmxlcmFuZ2U6Mzk2ZTM2MzY1NDBmNDlkMWI2NGM1NmRhMzRlNzlmZmRfOC0zLTEtMS00NTkwNg_cb3570f5-137c-4426-bef8-0b65078e1d72"
      unitRef="usd">-1385253</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNC9mcmFnOjZmYTc5OTIzZDg1YTRjNDJhMjJjMWVhZTViZDk3ZmYzL3RhYmxlOjM5NmUzNjM2NTQwZjQ5ZDFiNjRjNTZkYTM0ZTc5ZmZkL3RhYmxlcmFuZ2U6Mzk2ZTM2MzY1NDBmNDlkMWI2NGM1NmRhMzRlNzlmZmRfMTAtMS0xLTEtNDU5MDY_b1d693f6-7c89-4180-b374-831fd2c8dec9"
      unitRef="shares">14359322</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNC9mcmFnOjZmYTc5OTIzZDg1YTRjNDJhMjJjMWVhZTViZDk3ZmYzL3RhYmxlOjM5NmUzNjM2NTQwZjQ5ZDFiNjRjNTZkYTM0ZTc5ZmZkL3RhYmxlcmFuZ2U6Mzk2ZTM2MzY1NDBmNDlkMWI2NGM1NmRhMzRlNzlmZmRfMTAtMy0xLTEtNDU5MDY_86597605-03c9-4828-ac13-efebb90a7ea0"
      unitRef="shares">14691623</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNC9mcmFnOjZmYTc5OTIzZDg1YTRjNDJhMjJjMWVhZTViZDk3ZmYzL3RhYmxlOjM5NmUzNjM2NTQwZjQ5ZDFiNjRjNTZkYTM0ZTc5ZmZkL3RhYmxlcmFuZ2U6Mzk2ZTM2MzY1NDBmNDlkMWI2NGM1NmRhMzRlNzlmZmRfMTEtMS0xLTEtNDU5MDY_82d32efb-2022-43ca-92f8-91dcdb8497e1"
      unitRef="shares">228521</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNC9mcmFnOjZmYTc5OTIzZDg1YTRjNDJhMjJjMWVhZTViZDk3ZmYzL3RhYmxlOjM5NmUzNjM2NTQwZjQ5ZDFiNjRjNTZkYTM0ZTc5ZmZkL3RhYmxlcmFuZ2U6Mzk2ZTM2MzY1NDBmNDlkMWI2NGM1NmRhMzRlNzlmZmRfMTEtMy0xLTEtNDU5MDY_95ab9514-8366-459c-91b7-2073428e7c2e"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNC9mcmFnOjZmYTc5OTIzZDg1YTRjNDJhMjJjMWVhZTViZDk3ZmYzL3RhYmxlOjM5NmUzNjM2NTQwZjQ5ZDFiNjRjNTZkYTM0ZTc5ZmZkL3RhYmxlcmFuZ2U6Mzk2ZTM2MzY1NDBmNDlkMWI2NGM1NmRhMzRlNzlmZmRfMTItMS0xLTEtNDU5MDY_920c7810-d3b9-4a1c-b38e-e0e4f535cb90"
      unitRef="shares">14587843</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNC9mcmFnOjZmYTc5OTIzZDg1YTRjNDJhMjJjMWVhZTViZDk3ZmYzL3RhYmxlOjM5NmUzNjM2NTQwZjQ5ZDFiNjRjNTZkYTM0ZTc5ZmZkL3RhYmxlcmFuZ2U6Mzk2ZTM2MzY1NDBmNDlkMWI2NGM1NmRhMzRlNzlmZmRfMTItMy0xLTEtNDU5MDY_bcca58ed-032f-4718-a6fa-baf785d59798"
      unitRef="shares">14691623</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNC9mcmFnOjZmYTc5OTIzZDg1YTRjNDJhMjJjMWVhZTViZDk3ZmYzL3RleHRyZWdpb246NmZhNzk5MjNkODVhNGM0MmEyMmMxZWFlNWJkOTdmZjNfMjQ5_2f38b626-ee48-4503-843f-8bd285d6eccf"
      unitRef="shares">331338</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNC9mcmFnOjZmYTc5OTIzZDg1YTRjNDJhMjJjMWVhZTViZDk3ZmYzL3RleHRyZWdpb246NmZhNzk5MjNkODVhNGM0MmEyMmMxZWFlNWJkOTdmZjNfMjU2_85238779-b7e2-4a9c-853b-930cd68d4b7e"
      unitRef="shares">131225</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RleHRyZWdpb246NTM4MGQzMjg5YjkwNDk3YTk1YmIwNDU5MWU2M2MxNTdfMzI2MQ_af8f61f2-cf59-4cbe-9627-04c39e298ab8">REVENUES&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s net revenues consisted of the following for the three months ended March 31, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.883%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Products:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kristalose&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,315,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,945,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sancuso&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,886,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,397,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vibativ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,848,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,501,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Caldolor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;935,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;959,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acetadote&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vaprisol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(117,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Omeclamox-Pak&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,518)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RediTrex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(141,045)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,224,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,175,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Omeclamox-Pak net revenue for the first quarter of 2023 and 2022 was the result of Cumberland currently being out of commercial inventory of this product.  The packager for our Omeclamox-Pak product encountered financial difficulties due to the impact of COVID-19.  They are under new management and are in the process of a reorganization. Discussions with the packager are ongoing.  In the first quarter of 2023, the amounts noted were normal adjustments by channel partners.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With regard to Vaprisol, we are in the process of transitioning to a new manufacturer, who was issued an FDA Form 483 in the second quarter of 2022.  Once these 483 related issues are satisfactorily resolved by the manufacturing plant, we will then resubmit our application to the FDA for approval.  Net revenue was positively impacted by product return adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has agreements with international partners for commercialization of the Company's products with associated payments included in other revenues. Those agreements provide that each of the partners is responsible for seeking regulatory approvals for the product, and following approval, each partner will be responsible for the ongoing distribution and sales in the respective international territories. The Company provides a dossier for product registration and maintains responsibility for the relevant intellectual property. Cumberland is typically entitled to receive a non-refundable, up-front payment at the time each agreement is executed as consideration for the product dossier and for the rights to the distinct intellectual property rights in the respective international territory. These agreements also typically provide for additional payments upon a partner&#x2019;s achievement of a defined regulatory approval and sales milestones. The Company may also be entitled to receive royalties on future sales of the products and a transfer price on supplies.  The contractual payments associated with the partner&#x2019;s achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.&lt;/span&gt;&lt;/div&gt;Other revenues also include funding from federal grant programs including those secured from the FDA and from those secured by Cumberland Emerging Technologies Inc. ("CET") through the Small Business Administration as well as lease income generated by CET&#x2019;s Life Sciences Center. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from these federal grant  programs totaled approximately $0.1&#160;million and $0.04 million for the three months ended March 31, 2023 and 2022, respectively</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RleHRyZWdpb246NTM4MGQzMjg5YjkwNDk3YTk1YmIwNDU5MWU2M2MxNTdfMzI2MA_f4e6b726-c837-48e7-a54e-feaf0cd564f9">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s net revenues consisted of the following for the three months ended March 31, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.883%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Products:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kristalose&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,315,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,945,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sancuso&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,886,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,397,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vibativ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,848,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,501,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Caldolor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;935,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;959,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acetadote&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vaprisol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(117,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Omeclamox-Pak&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,518)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RediTrex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(141,045)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,224,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,175,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic5ec9fd4fee24747aa5425a2da34ca15_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RhYmxlOmEzYjE2ZThjYjcwMzQxNDI4NjkxMDM1ODQxMzQ2ZDkyL3RhYmxlcmFuZ2U6YTNiMTZlOGNiNzAzNDE0Mjg2OTEwMzU4NDEzNDZkOTJfMy0xLTEtMS00NTkwNg_a4b8f7ab-af32-440c-96bd-2389738a0fc0"
      unitRef="usd">4315128</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia1390383e91148dca5ab8bb6aec95eaa_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RhYmxlOmEzYjE2ZThjYjcwMzQxNDI4NjkxMDM1ODQxMzQ2ZDkyL3RhYmxlcmFuZ2U6YTNiMTZlOGNiNzAzNDE0Mjg2OTEwMzU4NDEzNDZkOTJfMy0zLTEtMS00NTkwNg_09b53694-a33e-4b5a-ac98-4b8443137084"
      unitRef="usd">3945097</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifaee959e87604f9b8afd1f3f35e7279f_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RhYmxlOmEzYjE2ZThjYjcwMzQxNDI4NjkxMDM1ODQxMzQ2ZDkyL3RhYmxlcmFuZ2U6YTNiMTZlOGNiNzAzNDE0Mjg2OTEwMzU4NDEzNDZkOTJfNC0xLTEtMS00NTkwNg_ea3b6f32-a390-4970-b577-a3749644a280"
      unitRef="usd">1886793</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b5edc8419e647ee824fdb81e180ad31_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RhYmxlOmEzYjE2ZThjYjcwMzQxNDI4NjkxMDM1ODQxMzQ2ZDkyL3RhYmxlcmFuZ2U6YTNiMTZlOGNiNzAzNDE0Mjg2OTEwMzU4NDEzNDZkOTJfNC0zLTEtMS00NTkwNg_e248cb8a-1752-4026-9f49-4a0d2f4e669e"
      unitRef="usd">3397209</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ica71cbb512a74596b40cd7a2f3f45ac6_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RhYmxlOmEzYjE2ZThjYjcwMzQxNDI4NjkxMDM1ODQxMzQ2ZDkyL3RhYmxlcmFuZ2U6YTNiMTZlOGNiNzAzNDE0Mjg2OTEwMzU4NDEzNDZkOTJfNS0xLTEtMS00NTkwNg_989ee7e1-67de-4a13-9ca8-9ffc8e8acd26"
      unitRef="usd">1848187</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie245a45f71a44cf49e04fb9e7a1b64c0_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RhYmxlOmEzYjE2ZThjYjcwMzQxNDI4NjkxMDM1ODQxMzQ2ZDkyL3RhYmxlcmFuZ2U6YTNiMTZlOGNiNzAzNDE0Mjg2OTEwMzU4NDEzNDZkOTJfNS0zLTEtMS00NTkwNg_111983b1-9a45-4075-a3aa-094a9bc55b29"
      unitRef="usd">2501434</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f492dd29e9e496ab0c32db9bde2fad5_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RhYmxlOmEzYjE2ZThjYjcwMzQxNDI4NjkxMDM1ODQxMzQ2ZDkyL3RhYmxlcmFuZ2U6YTNiMTZlOGNiNzAzNDE0Mjg2OTEwMzU4NDEzNDZkOTJfNi0xLTEtMS00NTkwNg_ce9da458-d5dc-4ddc-ba62-f990a78452e8"
      unitRef="usd">935043</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4fa8cd8c9bc645fd917139e4733faee9_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RhYmxlOmEzYjE2ZThjYjcwMzQxNDI4NjkxMDM1ODQxMzQ2ZDkyL3RhYmxlcmFuZ2U6YTNiMTZlOGNiNzAzNDE0Mjg2OTEwMzU4NDEzNDZkOTJfNi0zLTEtMS00NTkwNg_c3a6d18a-22fc-4436-b89f-933732ad4757"
      unitRef="usd">959634</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff66fc78303f42288cd05a0391f52e8d_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RhYmxlOmEzYjE2ZThjYjcwMzQxNDI4NjkxMDM1ODQxMzQ2ZDkyL3RhYmxlcmFuZ2U6YTNiMTZlOGNiNzAzNDE0Mjg2OTEwMzU4NDEzNDZkOTJfNy0xLTEtMS00OTIzMA_3ad15e86-50fa-4ab8-b228-7e9956ee22bf"
      unitRef="usd">169856</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8b303705e50348069ce4d7d41176c589_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RhYmxlOmEzYjE2ZThjYjcwMzQxNDI4NjkxMDM1ODQxMzQ2ZDkyL3RhYmxlcmFuZ2U6YTNiMTZlOGNiNzAzNDE0Mjg2OTEwMzU4NDEzNDZkOTJfNy0zLTEtMS00OTIzNA_cb2a7742-70e9-4fc9-a0f7-529367fd21de"
      unitRef="usd">111090</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if7b3c21a06344e6daf54cef8c4bea836_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RhYmxlOmEzYjE2ZThjYjcwMzQxNDI4NjkxMDM1ODQxMzQ2ZDkyL3RhYmxlcmFuZ2U6YTNiMTZlOGNiNzAzNDE0Mjg2OTEwMzU4NDEzNDZkOTJfNy0xLTEtMS00NTkwNg_f8cdd0fa-d5a2-45e6-9672-433e07534db6"
      unitRef="usd">16008</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i34fd69d4d0114a3891b1fd1b5cd85e8f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RhYmxlOmEzYjE2ZThjYjcwMzQxNDI4NjkxMDM1ODQxMzQ2ZDkyL3RhYmxlcmFuZ2U6YTNiMTZlOGNiNzAzNDE0Mjg2OTEwMzU4NDEzNDZkOTJfNy0zLTEtMS00NTkwNg_a0d263a8-449d-4a4c-99c7-96002783a646"
      unitRef="usd">-117000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if792fa0d44004e868ffe0fb9dcc009a6_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RhYmxlOmEzYjE2ZThjYjcwMzQxNDI4NjkxMDM1ODQxMzQ2ZDkyL3RhYmxlcmFuZ2U6YTNiMTZlOGNiNzAzNDE0Mjg2OTEwMzU4NDEzNDZkOTJfOS0xLTEtMS00NTkwNg_8b47b794-4725-4ed6-ba6f-476ff384ec82"
      unitRef="usd">-2518</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i877bdcd11bf84e83a844f6f7f0340018_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RhYmxlOmEzYjE2ZThjYjcwMzQxNDI4NjkxMDM1ODQxMzQ2ZDkyL3RhYmxlcmFuZ2U6YTNiMTZlOGNiNzAzNDE0Mjg2OTEwMzU4NDEzNDZkOTJfOS0zLTEtMS00NTkwNg_29015bfa-743d-489d-810d-7a410baff4e7"
      unitRef="usd">22737</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if834c35329184e12bfc00925eb9c78b3_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RhYmxlOmEzYjE2ZThjYjcwMzQxNDI4NjkxMDM1ODQxMzQ2ZDkyL3RhYmxlcmFuZ2U6YTNiMTZlOGNiNzAzNDE0Mjg2OTEwMzU4NDEzNDZkOTJfMTAtMS0xLTEtNDU5MDY_1d37848c-fd4b-4a2c-92fc-5a43dc168ffb"
      unitRef="usd">-141045</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i89705d4ba770443aa81891ed098d2e82_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RhYmxlOmEzYjE2ZThjYjcwMzQxNDI4NjkxMDM1ODQxMzQ2ZDkyL3RhYmxlcmFuZ2U6YTNiMTZlOGNiNzAzNDE0Mjg2OTEwMzU4NDEzNDZkOTJfMTAtMy0xLTEtNDU5MDY_5467682e-e2d2-4e90-ab12-6e8adcf8c8af"
      unitRef="usd">59226</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iefe426f8f9cf4fadacc86244be87455b_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RhYmxlOmEzYjE2ZThjYjcwMzQxNDI4NjkxMDM1ODQxMzQ2ZDkyL3RhYmxlcmFuZ2U6YTNiMTZlOGNiNzAzNDE0Mjg2OTEwMzU4NDEzNDZkOTJfMTEtMS0xLTEtNDU5MDY_f11e78f0-19fc-40a7-980f-f4bf5c006f27"
      unitRef="usd">197186</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i56a471ba8e2a4536a4fee60860c84a40_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RhYmxlOmEzYjE2ZThjYjcwMzQxNDI4NjkxMDM1ODQxMzQ2ZDkyL3RhYmxlcmFuZ2U6YTNiMTZlOGNiNzAzNDE0Mjg2OTEwMzU4NDEzNDZkOTJfMTEtMy0xLTEtNDU5MDY_5c1f36f2-db73-457a-b8c3-0f07c1e02c82"
      unitRef="usd">295618</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RhYmxlOmEzYjE2ZThjYjcwMzQxNDI4NjkxMDM1ODQxMzQ2ZDkyL3RhYmxlcmFuZ2U6YTNiMTZlOGNiNzAzNDE0Mjg2OTEwMzU4NDEzNDZkOTJfMTItMS0xLTEtNDU5MDY_764ba6c2-496a-405f-8e90-86b79f65fb98"
      unitRef="usd">9224638</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RhYmxlOmEzYjE2ZThjYjcwMzQxNDI4NjkxMDM1ODQxMzQ2ZDkyL3RhYmxlcmFuZ2U6YTNiMTZlOGNiNzAzNDE0Mjg2OTEwMzU4NDEzNDZkOTJfMTItMy0xLTEtNDU5MDY_c8b6f868-27f2-43d0-82a6-856657219fff"
      unitRef="usd">11175045</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if42572ad56a64b2a829bd4df6389654b_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RleHRyZWdpb246NTM4MGQzMjg5YjkwNDk3YTk1YmIwNDU5MWU2M2MxNTdfMzE3Mw_a9190535-be4b-4279-9a53-7c708756c3dd"
      unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2233569d7a744fb9be2b55c9f18e5f65_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV8zNy9mcmFnOjUzODBkMzI4OWI5MDQ5N2E5NWJiMDQ1OTFlNjNjMTU3L3RleHRyZWdpb246NTM4MGQzMjg5YjkwNDk3YTk1YmIwNDU5MWU2M2MxNTdfMzE4MA_bbe0916b-6eb8-474f-91a7-e83d55c613bd"
      unitRef="usd">40000.00</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RleHRyZWdpb246Zjk2ZDdkYmQ2ZGQxNDRmODk1M2UzOWYzYTZmNDkzZWFfMjMxMQ_8486ce76-4110-438e-9b5e-2b9a245d92c9">INVENTORIES&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company works closely with third parties to manufacture and package finished goods for sale.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the arrangements with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival at the Company&#x2019;s warehouses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company then holds such goods in inventory until distribution and sale. These finished goods inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving goods by comparing sales history and projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value.  At March 31, 2023, there were no cumulative obsolescence and discontinuance losses necessary. At December 31, 2022, the Company had recognized and maintained cumulative net realizable value charges for potential obsolescence and discontinuance losses of approximately $0.5 million.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is responsible for the purchase of the active pharmaceutical ingredient (&#x201c;API&#x201d;) for Kristalose and maintains the inventory at third-party packagers. As that API is consumed in production, the value of the API is transferred from raw materials to finished goods.  API for the Company's Vaprisol brand is also included in the raw materials inventory at March 31, 2023 and December 31, 2022.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consigned inventory represents Authorized Generic inventory stored with our partner until shipment.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the Vibativ acquisition, the Company acquired API and work in process inventories of $15.6 million that were all initially classified as non-current inventories at the date of acquisition.  At March 31, 2023 and December 31, 2022, total non-current inventory, including Vibativ and our clinical trial drug ifetroban, was $7.5 million for each period. The Company had Vibativ finished goods of $0.9 million included in non-current inventory at March 31, 2023, and no non-current inventory at December 31, 2022.  The Company also had $0.3 million in non-current inventory for API related to its ifetroban clinical initiatives at March 31, 2023 and December 31, 2022, and $0.2 million and $0.1 million of finished goods, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March 31, 2023 and December 31, 2022, the Company's net inventories consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.681%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,548,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,899,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consigned inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,985,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,322,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,714,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,390,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;less non-current inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,534,303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,527,167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories classified as current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,180,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,863,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:InventoryValuationReserves
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RleHRyZWdpb246Zjk2ZDdkYmQ2ZGQxNDRmODk1M2UzOWYzYTZmNDkzZWFfMTA5OTUxMTYzMTE4Ng_9716c19b-ac7e-46e1-abdf-b3f2658da2b5"
      unitRef="usd">0</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RleHRyZWdpb246Zjk2ZDdkYmQ2ZGQxNDRmODk1M2UzOWYzYTZmNDkzZWFfMTA0Ng_b8ba1925-79d6-4a59-a3e7-3817ee2e5327"
      unitRef="usd">500000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNoncurrent
      contextRef="i7c76ad6b0d9d43bea791e5d7ff63409c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RleHRyZWdpb246Zjk2ZDdkYmQ2ZGQxNDRmODk1M2UzOWYzYTZmNDkzZWFfMTYzOQ_5bbde86d-a4d3-4191-880a-fbd45c0aa713"
      unitRef="usd">15600000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RleHRyZWdpb246Zjk2ZDdkYmQ2ZGQxNDRmODk1M2UzOWYzYTZmNDkzZWFfMTk0Mg_1adc7a15-5645-48e6-8671-161044dd6713"
      unitRef="usd">7500000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RleHRyZWdpb246Zjk2ZDdkYmQ2ZGQxNDRmODk1M2UzOWYzYTZmNDkzZWFfMTk0Mg_414a73c9-9eb8-49a4-93d2-fc627c350be8"
      unitRef="usd">7500000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="if921eb31fa6f45b39876cdd2bde81d95_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RleHRyZWdpb246Zjk2ZDdkYmQ2ZGQxNDRmODk1M2UzOWYzYTZmNDkzZWFfNTQ5NzU1ODE2NDc3_0dfeff50-30ce-4caa-9151-f488b35a3864"
      unitRef="usd">900000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i7c76ad6b0d9d43bea791e5d7ff63409c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RleHRyZWdpb246Zjk2ZDdkYmQ2ZGQxNDRmODk1M2UzOWYzYTZmNDkzZWFfMTY0OTI2NzQ0NTQxMg_280aa7cc-c282-4e3f-a3cb-cefe120c764d"
      unitRef="usd">0</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNoncurrent
      contextRef="i0b68b7b01134465aa81635021c31c2ee_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RleHRyZWdpb246Zjk2ZDdkYmQ2ZGQxNDRmODk1M2UzOWYzYTZmNDkzZWFfMjEwNA_4117e1cc-abe1-426b-be6e-20999edd1a50"
      unitRef="usd">300000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i0b68b7b01134465aa81635021c31c2ee_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RleHRyZWdpb246Zjk2ZDdkYmQ2ZGQxNDRmODk1M2UzOWYzYTZmNDkzZWFfNTQ5NzU1ODE2NTY4_f330e456-cd33-41b9-a3d6-7e8d2f235ac9"
      unitRef="usd">200000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i939a45f5061a4a48958225d296e46077_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RleHRyZWdpb246Zjk2ZDdkYmQ2ZGQxNDRmODk1M2UzOWYzYTZmNDkzZWFfNTQ5NzU1ODE2NTgw_f7f8124d-cbaf-4c94-b470-eb89bf2acf45"
      unitRef="usd">100000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RleHRyZWdpb246Zjk2ZDdkYmQ2ZGQxNDRmODk1M2UzOWYzYTZmNDkzZWFfMjMxMg_4b5e32d0-7ce1-4dda-b4e9-6e256da9bbb0">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March 31, 2023 and December 31, 2022, the Company's net inventories consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.681%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,548,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,899,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consigned inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,985,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,322,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,714,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,390,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;less non-current inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,534,303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,527,167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories classified as current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,180,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,863,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RhYmxlOjlmZmI5Y2M3ODY3MDQ5YWZiMDNlZDE2MjYxMTE4ZDUxL3RhYmxlcmFuZ2U6OWZmYjljYzc4NjcwNDlhZmIwM2VkMTYyNjExMThkNTFfMi0yLTEtMS00NTkwNg_d244e1cd-538d-4c39-9290-23bac93ae6e8"
      unitRef="usd">12548636</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RhYmxlOjlmZmI5Y2M3ODY3MDQ5YWZiMDNlZDE2MjYxMTE4ZDUxL3RhYmxlcmFuZ2U6OWZmYjljYzc4NjcwNDlhZmIwM2VkMTYyNjExMThkNTFfMi00LTEtMS00NTkwNg_001aece3-3fec-4820-a944-c9c3ec43593b"
      unitRef="usd">12899659</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RhYmxlOjlmZmI5Y2M3ODY3MDQ5YWZiMDNlZDE2MjYxMTE4ZDUxL3RhYmxlcmFuZ2U6OWZmYjljYzc4NjcwNDlhZmIwM2VkMTYyNjExMThkNTFfMy0yLTEtMS00NTkwNg_1495a8e7-4c47-4cad-8067-a7f5058b3071"
      unitRef="usd">179786</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
    <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RhYmxlOjlmZmI5Y2M3ODY3MDQ5YWZiMDNlZDE2MjYxMTE4ZDUxL3RhYmxlcmFuZ2U6OWZmYjljYzc4NjcwNDlhZmIwM2VkMTYyNjExMThkNTFfMy00LTEtMS00NTkwNg_b538d69c-d39f-44f8-b8d3-7dfd4dac3f4c"
      unitRef="usd">168923</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RhYmxlOjlmZmI5Y2M3ODY3MDQ5YWZiMDNlZDE2MjYxMTE4ZDUxL3RhYmxlcmFuZ2U6OWZmYjljYzc4NjcwNDlhZmIwM2VkMTYyNjExMThkNTFfNC0yLTEtMS00NTkwNg_f3ca0144-49ce-47d2-81e8-59342d2235e8"
      unitRef="usd">4985883</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RhYmxlOjlmZmI5Y2M3ODY3MDQ5YWZiMDNlZDE2MjYxMTE4ZDUxL3RhYmxlcmFuZ2U6OWZmYjljYzc4NjcwNDlhZmIwM2VkMTYyNjExMThkNTFfNC00LTEtMS00NTkwNg_7d16ae11-a3ed-448f-83c9-66befeda1722"
      unitRef="usd">4322167</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryGross
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RhYmxlOjlmZmI5Y2M3ODY3MDQ5YWZiMDNlZDE2MjYxMTE4ZDUxL3RhYmxlcmFuZ2U6OWZmYjljYzc4NjcwNDlhZmIwM2VkMTYyNjExMThkNTFfNS0yLTEtMS00NTkwNg_93be856f-2978-4277-af6e-bc996914c1e5"
      unitRef="usd">17714305</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RhYmxlOjlmZmI5Y2M3ODY3MDQ5YWZiMDNlZDE2MjYxMTE4ZDUxL3RhYmxlcmFuZ2U6OWZmYjljYzc4NjcwNDlhZmIwM2VkMTYyNjExMThkNTFfNS00LTEtMS00NTkwNg_5d5500e3-a0de-4421-b618-60136a7c5982"
      unitRef="usd">17390748</us-gaap:InventoryGross>
    <us-gaap:InventoryNoncurrent
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RhYmxlOjlmZmI5Y2M3ODY3MDQ5YWZiMDNlZDE2MjYxMTE4ZDUxL3RhYmxlcmFuZ2U6OWZmYjljYzc4NjcwNDlhZmIwM2VkMTYyNjExMThkNTFfNi0yLTEtMS00NTkwNg_64f7c503-45e8-4e4b-bc1f-8a3481d74350"
      unitRef="usd">7534303</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RhYmxlOjlmZmI5Y2M3ODY3MDQ5YWZiMDNlZDE2MjYxMTE4ZDUxL3RhYmxlcmFuZ2U6OWZmYjljYzc4NjcwNDlhZmIwM2VkMTYyNjExMThkNTFfNi00LTEtMS00NTkwNg_d285bd5c-85e4-401c-9766-114cdcee0e3f"
      unitRef="usd">7527167</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNet
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RhYmxlOjlmZmI5Y2M3ODY3MDQ5YWZiMDNlZDE2MjYxMTE4ZDUxL3RhYmxlcmFuZ2U6OWZmYjljYzc4NjcwNDlhZmIwM2VkMTYyNjExMThkNTFfNy0yLTEtMS00NTkwNg_da4b3a9f-9392-4bb1-bb82-d11438780d1c"
      unitRef="usd">10180002</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80MC9mcmFnOmY5NmQ3ZGJkNmRkMTQ0Zjg5NTNlMzlmM2E2ZjQ5M2VhL3RhYmxlOjlmZmI5Y2M3ODY3MDQ5YWZiMDNlZDE2MjYxMTE4ZDUxL3RhYmxlcmFuZ2U6OWZmYjljYzc4NjcwNDlhZmIwM2VkMTYyNjExMThkNTFfNy00LTEtMS00NTkwNg_389a371d-9817-4257-b6fc-5645ad10c779"
      unitRef="usd">9863581</us-gaap:InventoryNet>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RleHRyZWdpb246NDY2ZTlhMGExYWIwNGE4YzhkMWIzNDRjMjhiMjcyNjFfMjk4Mw_8271889e-d5aa-4b54-aff5-e4e9c9f4cce2">LEASES&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 15, 2021, Cumberland entered into a lease, pursuant to which the Company leases approximately 16,903 rentable square feet of space at the new development Broadwest located in Nashville, Tennessee with 1600 West End Avenue Partners, LLC. The Leased Premise serves as the Company's new corporate headquarters. The initial term of the Lease is one hundred fifty-seven (157) months, with two consecutive options to renew for a period of five years each, with the commencement date of October 25, 2022.  This lease currently expires in November 2035.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is responsible for paying rent to the Landlord under the Lease beginning three months after the commencement date. The Company pays a base rent of $33.06 per square foot of rentable space with a gradual rental rate increase of 2.5% for each year period thereafter of the prior year's base rental. In addition to the monthly base rent, the Company is responsible for its percentage share of the operating expenses of the Building. The Lease also provides for a tenant improvement allowance for the space.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company's operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by CET, our majority-owned subsidiary, where it operates the CET Life Sciences Center.  The research lab space at CET, under an agreement amended in July 2012, is leased through April 2023, with an option to extend the lease through April 2028. The Company also subleases a portion of the space under these leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities were recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As the Company&#x2019;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019 and October 25, 2022.  Incremental borrowing rates reflect the Company&#x2019;s estimated interest rates for collateralized borrowings over similar lease terms.  The weighted-average remaining lease term for the Broadwest lease is 12.62 years at March 31, 2023.  The weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments is 9.28% for the Broadwest lease and 7.42% for the remaining CET lease.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lease Position&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March 31, 2023 and December 31, 2022, the Company's lease assets and liabilities were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Right-of-Use Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,919,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,218,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,549,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,586,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,707,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,759,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2023, cumulative future minimum sublease income under non-cancelable operating subleases totals approximately $0.03 million and will be paid through the leases ending in April 2023. Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Maturity of Lease Liabilities at March 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;587,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;578,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;608,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;623,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,324,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,264,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,557,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,707,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:4pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rent expense is recognized over the expected term of the lease, including renewal option periods, if applicable, on a straight-line basis as a component of general and administrative expense. Rent expense and sublease income were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rent expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <cpix:LesseeOperatingLeaseLeasedArea
      contextRef="i4f1ce978139642ffa57f5d8efd6a152c_I20211115"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RleHRyZWdpb246NDY2ZTlhMGExYWIwNGE4YzhkMWIzNDRjMjhiMjcyNjFfNTQ5NzU1ODE3MTgz_d021e62c-18c6-4dc1-9e07-9a1f2ab651ba"
      unitRef="sqft">16903</cpix:LesseeOperatingLeaseLeasedArea>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i4f1ce978139642ffa57f5d8efd6a152c_I20211115"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RleHRyZWdpb246NDY2ZTlhMGExYWIwNGE4YzhkMWIzNDRjMjhiMjcyNjFfNTQ5NzU1ODE3NDUy_ad3e66d6-17a5-4b96-a8ae-82452e8a76be">P157M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <cpix:LesseeOperatingLeaseNumberOfRenewalTerms
      contextRef="i3a8364b46d1349f89526bbca803b9b2b_I20211115"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RleHRyZWdpb246NDY2ZTlhMGExYWIwNGE4YzhkMWIzNDRjMjhiMjcyNjFfNTQ5NzU1ODE3NDcw_c2b2dd94-e6ef-41bb-8bf5-3e1654f5ce2e"
      unitRef="renewalterm">2</cpix:LesseeOperatingLeaseNumberOfRenewalTerms>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i3a8364b46d1349f89526bbca803b9b2b_I20211115"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RleHRyZWdpb246NDY2ZTlhMGExYWIwNGE4YzhkMWIzNDRjMjhiMjcyNjFfNTQ5NzU1ODE3NTE5_3c370c86-6662-48ed-9fed-bfa7463e184f">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <cpix:LesseeOperatingLeaseBaseRent
      contextRef="i4f1ce978139642ffa57f5d8efd6a152c_I20211115"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RleHRyZWdpb246NDY2ZTlhMGExYWIwNGE4YzhkMWIzNDRjMjhiMjcyNjFfNTQ5NzU1ODE3Nzg0_44424a3f-d8ac-412c-be4c-e2ca3075c7c5"
      unitRef="usdPerSqft">33.06</cpix:LesseeOperatingLeaseBaseRent>
    <cpix:LesseeOperatingLeaseRentIncrease
      contextRef="iaf2b4c3ed09b49c69ab36803117edced_I20211115"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RleHRyZWdpb246NDY2ZTlhMGExYWIwNGE4YzhkMWIzNDRjMjhiMjcyNjFfNTQ5NzU1ODE3ODYx_d6794c16-1f4d-4c08-8929-d27c87f27686"
      unitRef="number">0.025</cpix:LesseeOperatingLeaseRentIncrease>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i049b67a4ada841f8a2827489c1ede626_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RleHRyZWdpb246NDY2ZTlhMGExYWIwNGE4YzhkMWIzNDRjMjhiMjcyNjFfMjg5_0c37f554-d94c-4922-9313-3bec9cc733ef"
      unitRef="sqft">14200</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i50b28adc088b4efea984106ab32c61d9_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RleHRyZWdpb246NDY2ZTlhMGExYWIwNGE4YzhkMWIzNDRjMjhiMjcyNjFfNTQ5NzU1ODMwMTAz_2096a5d3-8d5d-4c20-b2a6-cdfab5dd282c">P12Y7M13D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i50b28adc088b4efea984106ab32c61d9_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RleHRyZWdpb246NDY2ZTlhMGExYWIwNGE4YzhkMWIzNDRjMjhiMjcyNjFfNTQ5NzU1ODMwMTIw_87f96d81-fb9a-4a5f-be6c-26a28d61ebb7"
      unitRef="number">0.0928</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ia97aab9d7d684fd486afb0916cc296bb_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RleHRyZWdpb246NDY2ZTlhMGExYWIwNGE4YzhkMWIzNDRjMjhiMjcyNjFfMTIzNw_ff11c69b-3ef8-420a-b464-da9a7b9783d9"
      unitRef="number">0.0742</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <cpix:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RleHRyZWdpb246NDY2ZTlhMGExYWIwNGE4YzhkMWIzNDRjMjhiMjcyNjFfMjk4NA_652c4b3e-b983-4d0a-8ac0-6a40ae3afd86">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March 31, 2023 and December 31, 2022, the Company's lease assets and liabilities were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Right-of-Use Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,919,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,218,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,549,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,586,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,707,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,759,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cpix:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RhYmxlOjYyZDg0ODlhMmE3ZjQzNjVhZGQwMTZlOGIxNWM1ZGFiL3RhYmxlcmFuZ2U6NjJkODQ4OWEyYTdmNDM2NWFkZDAxNmU4YjE1YzVkYWJfMS0yLTEtMS00NTkwNg_fe814e99-2316-4fc7-bc16-8b89207dd3c2"
      unitRef="usd">4919057</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RhYmxlOjYyZDg0ODlhMmE3ZjQzNjVhZGQwMTZlOGIxNWM1ZGFiL3RhYmxlcmFuZ2U6NjJkODQ4OWEyYTdmNDM2NWFkZDAxNmU4YjE1YzVkYWJfMS00LTEtMS00NTkwNg_1fb1f54e-49bc-4d03-acca-49f1251cccb3"
      unitRef="usd">5218403</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RhYmxlOjI0ZGU5YWE2MmExZjQzZmE4Mjg1YWY0NmZkYTcxMTRiL3RhYmxlcmFuZ2U6MjRkZTlhYTYyYTFmNDNmYTgyODVhZjQ2ZmRhNzExNGJfMS0yLTEtMS00NTkwNg_625592fc-26c1-4aef-a368-e3f63d6aa880"
      unitRef="usd">158369</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RhYmxlOjI0ZGU5YWE2MmExZjQzZmE4Mjg1YWY0NmZkYTcxMTRiL3RhYmxlcmFuZ2U6MjRkZTlhYTYyYTFmNDNmYTgyODVhZjQ2ZmRhNzExNGJfMS00LTEtMS00NTkwNg_27bceb99-63df-4736-b85f-1937d17866ff"
      unitRef="usd">172910</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RhYmxlOjI0ZGU5YWE2MmExZjQzZmE4Mjg1YWY0NmZkYTcxMTRiL3RhYmxlcmFuZ2U6MjRkZTlhYTYyYTFmNDNmYTgyODVhZjQ2ZmRhNzExNGJfMy0yLTEtMS00NTkwNg_26722223-5f54-4237-b6cd-cbdb09e88c91"
      unitRef="usd">4549150</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RhYmxlOjI0ZGU5YWE2MmExZjQzZmE4Mjg1YWY0NmZkYTcxMTRiL3RhYmxlcmFuZ2U6MjRkZTlhYTYyYTFmNDNmYTgyODVhZjQ2ZmRhNzExNGJfMy00LTEtMS00NTkwNg_72671995-3378-470a-ab53-704fa0cbdb4b"
      unitRef="usd">4586301</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <cpix:LeaseLiability
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RhYmxlOjI0ZGU5YWE2MmExZjQzZmE4Mjg1YWY0NmZkYTcxMTRiL3RhYmxlcmFuZ2U6MjRkZTlhYTYyYTFmNDNmYTgyODVhZjQ2ZmRhNzExNGJfNC0yLTEtMS00NTkwNg_342d7b11-a3c7-47a5-9b15-04119a326b35"
      unitRef="usd">4707519</cpix:LeaseLiability>
    <cpix:LeaseLiability
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RhYmxlOjI0ZGU5YWE2MmExZjQzZmE4Mjg1YWY0NmZkYTcxMTRiL3RhYmxlcmFuZ2U6MjRkZTlhYTYyYTFmNDNmYTgyODVhZjQ2ZmRhNzExNGJfNC00LTEtMS00NTkwNg_7b3e01f2-5e2a-4719-b425-5b660f2c72a9"
      unitRef="usd">4759211</cpix:LeaseLiability>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RleHRyZWdpb246NDY2ZTlhMGExYWIwNGE4YzhkMWIzNDRjMjhiMjcyNjFfMjQ3Mw_1ad1c4ac-77b6-4bfd-972a-61fe72840d5e"
      unitRef="usd">30000.00</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RleHRyZWdpb246NDY2ZTlhMGExYWIwNGE4YzhkMWIzNDRjMjhiMjcyNjFfMjk4NQ_13dfa298-e87d-4f83-bcd7-7bfeb4dc94ba">Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Maturity of Lease Liabilities at March 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;587,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;578,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;608,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;623,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,324,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,264,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,557,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,707,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RhYmxlOjhkMjE0YzIzMGY0NDQ5NGRhYmVhMGMxODIyOWZmZDk4L3RhYmxlcmFuZ2U6OGQyMTRjMjMwZjQ0NDk0ZGFiZWEwYzE4MjI5ZmZkOThfMS0yLTEtMS00ODAzNg_5c4f2d8a-6895-4866-90f9-084f8fa65aa0"
      unitRef="usd">587511</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RhYmxlOjhkMjE0YzIzMGY0NDQ5NGRhYmVhMGMxODIyOWZmZDk4L3RhYmxlcmFuZ2U6OGQyMTRjMjMwZjQ0NDk0ZGFiZWEwYzE4MjI5ZmZkOThfMi0yLTEtMS00ODAzNg_b461ba31-4e29-4d6a-86cf-f63a6580ad17"
      unitRef="usd">578759</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RhYmxlOjhkMjE0YzIzMGY0NDQ5NGRhYmVhMGMxODIyOWZmZDk4L3RhYmxlcmFuZ2U6OGQyMTRjMjMwZjQ0NDk0ZGFiZWEwYzE4MjI5ZmZkOThfMy0yLTEtMS00ODAzNg_011276fb-b9f6-4b3b-8402-67c2a2fbdd5d"
      unitRef="usd">543023</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RhYmxlOjhkMjE0YzIzMGY0NDQ5NGRhYmVhMGMxODIyOWZmZDk4L3RhYmxlcmFuZ2U6OGQyMTRjMjMwZjQ0NDk0ZGFiZWEwYzE4MjI5ZmZkOThfMS0yLTEtMS00NTkwNg_de52644f-7835-4603-9971-6d6139e89a84"
      unitRef="usd">608015</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RhYmxlOjhkMjE0YzIzMGY0NDQ5NGRhYmVhMGMxODIyOWZmZDk4L3RhYmxlcmFuZ2U6OGQyMTRjMjMwZjQ0NDk0ZGFiZWEwYzE4MjI5ZmZkOThfMi0yLTEtMS00NTkwNg_9e20af19-7af2-4509-a860-b648b952f9eb"
      unitRef="usd">623199</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RhYmxlOjhkMjE0YzIzMGY0NDQ5NGRhYmVhMGMxODIyOWZmZDk4L3RhYmxlcmFuZ2U6OGQyMTRjMjMwZjQ0NDk0ZGFiZWEwYzE4MjI5ZmZkOThfNi0yLTEtMS00ODAzNg_0d1f0946-2e3d-4c47-bf15-3f278b817b94"
      unitRef="usd">5324178</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RhYmxlOjhkMjE0YzIzMGY0NDQ5NGRhYmVhMGMxODIyOWZmZDk4L3RhYmxlcmFuZ2U6OGQyMTRjMjMwZjQ0NDk0ZGFiZWEwYzE4MjI5ZmZkOThfMy0yLTEtMS00NTkwNg_adefbaaa-aece-47c4-9a1f-fd0a19a41440"
      unitRef="usd">8264685</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RhYmxlOjhkMjE0YzIzMGY0NDQ5NGRhYmVhMGMxODIyOWZmZDk4L3RhYmxlcmFuZ2U6OGQyMTRjMjMwZjQ0NDk0ZGFiZWEwYzE4MjI5ZmZkOThfNC0yLTEtMS00NTkwNg_fcc103e2-7e9a-46db-a0d0-9937c14ab741"
      unitRef="usd">3557166</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RhYmxlOjhkMjE0YzIzMGY0NDQ5NGRhYmVhMGMxODIyOWZmZDk4L3RhYmxlcmFuZ2U6OGQyMTRjMjMwZjQ0NDk0ZGFiZWEwYzE4MjI5ZmZkOThfNS0yLTEtMS00NTkwNg_44ed131a-90b9-4ddb-96d3-f87e67df16bb"
      unitRef="usd">4707519</us-gaap:OperatingLeaseLiability>
    <cpix:ScheduleofRentExpenseandSubleaseIncomeTableTextBlock
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RleHRyZWdpb246NDY2ZTlhMGExYWIwNGE4YzhkMWIzNDRjMjhiMjcyNjFfMjk4Mg_3d7a1101-f9b5-479b-b9fe-b2866787f829">Rent expense and sublease income were as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rent expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</cpix:ScheduleofRentExpenseandSubleaseIncomeTableTextBlock>
    <us-gaap:OperatingLeaseExpense
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RhYmxlOmZmYzE1ZjU3NzlmMzRkNjJiN2IzOGRlMDRkNzJkMjY5L3RhYmxlcmFuZ2U6ZmZjMTVmNTc3OWYzNGQ2MmI3YjM4ZGUwNGQ3MmQyNjlfMi0yLTEtMS00NTkwNg_7e307118-b835-4da6-8041-d84297356e1e"
      unitRef="usd">234863</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RhYmxlOmZmYzE1ZjU3NzlmMzRkNjJiN2IzOGRlMDRkNzJkMjY5L3RhYmxlcmFuZ2U6ZmZjMTVmNTc3OWYzNGQ2MmI3YjM4ZGUwNGQ3MmQyNjlfMi00LTEtMS00NTkwNg_8ecc0cbe-81f5-4e2e-948e-02cf7494cb39"
      unitRef="usd">285963</us-gaap:OperatingLeaseExpense>
    <us-gaap:SubleaseIncome
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RhYmxlOmZmYzE1ZjU3NzlmMzRkNjJiN2IzOGRlMDRkNzJkMjY5L3RhYmxlcmFuZ2U6ZmZjMTVmNTc3OWYzNGQ2MmI3YjM4ZGUwNGQ3MmQyNjlfNC0yLTEtMS00NTkwNg_1904dc81-5cd7-4d5c-8c3f-a16df0a00fcb"
      unitRef="usd">115631</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="ibba680830ba242bcb44427bccbf7460f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80My9mcmFnOjQ2NmU5YTBhMWFiMDRhOGM4ZDFiMzQ0YzI4YjI3MjYxL3RhYmxlOmZmYzE1ZjU3NzlmMzRkNjJiN2IzOGRlMDRkNzJkMjY5L3RhYmxlcmFuZ2U6ZmZjMTVmNTc3OWYzNGQ2MmI3YjM4ZGUwNGQ3MmQyNjlfNC00LTEtMS00NTkwNg_ec8f0de9-5e52-4778-bfac-ca766b9aaa21"
      unitRef="usd">161804</us-gaap:SubleaseIncome>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfNjU1Mg_960ed3e8-142c-4c24-b568-fdbacc3612ed">SHAREHOLDERS&#x2019; EQUITY AND DEBT&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland currently has a share repurchase program to repurchase up to $10 million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. In January 2019, the Company's Board of Directors established the current $10 million repurchase program to replace the prior authorizations.  During the three months ended March 31, 2023 and March 31, 2022, the Company repurchased 86,829 shares and 174,149 shares of common stock for approximately $0.2 million and $0.6 million, respectively.  At March 31, 2023, approximately $3.6 million of common shares was left to repurchase under this program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share purchases and sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the Company's May 2023 trading window, several members of Cumberland's Board of Directors will enter into share purchase agreements of the Company's stock pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934. These purchases are designed to increase ownership in the Company by the members of the Board.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2017, Cumberland filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to $100 million in corporate securities. The Shelf Registration was declared effective in January 2018. It also included an At the Market ("ATM") feature that allowed the Company to sell common shares at market prices, along with an agreement with B. Riley FBR Inc. to support such a placement of shares. The Company filed an updated Form S-3 with the SEC in December 2020, which was declared effective in January 2021.  On December 27, 2021, the Company filed a related prospectus supplement in connection with the sale and issuance of shares having an aggregate gross sales price of up to $19 million.  The Company intends to continue an ATM feature through B. Riley FBR, Inc. that would allow the Company to issue shares of its common stock. The Company did not issue any shares under an ATM during the three months ended March 31, 2023 or March 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Share Grants and Incentive Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2023 and March 31, 2022, the Company issued 28,250 shares and 65,225 shares of restricted stock to employees, advisors and directors, respectively. Restricted stock issued to employees and advisors generally cliff-vests on the fourth anniversary of the date of grant and for directors on the one-year anniversary of the date of grant.  During the three months ended March 31, 2023 and 2022, the Company also issued 183,250 and 166,350 incentive stock options, respectively, to employees that cliff-vest on the fourth anniversary of the date of grant, that are set to expire in 2033 and 2032, respectively. Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations.  For the three months ended March 31, 2023, we recorded a credit of $0.04&#160;million to share-based compensation related to the forfeiture of unvested restricted stock awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 31, 2021, the Company entered into a Fifth Amendment to the Revolving Credit Note and Sixth Amendment (the "Sixth Amendment") to Revolving Credit Loan Agreement with Pinnacle Bank (the "Pinnacle Agreement"). The Sixth Amendment increased the principal amount by $5 million to $20 million. On October 28, 2021, the Company entered into a Fourth Amendment to the Revolving Credit Note and Fifth Amendment to Revolving Credit Loan Agreement with Pinnacle Bank. Among other terms, the Fourth Amendment extended the maturity date to October 1, 2024.  The Pinnacle Agreement includes specific financial covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2022, the Company and Pinnacle Bank agreed to modify the financial covenants to align with the current use of the line of credit.  On March 31, 2022, the Company and Pinnacle Bank entered into a Seventh Amendment to the Revolving Credit Loan Agreement to revise and update the Maximum Funded Debt Ratio financial covenant and to delete from the Pinnacle Agreement the Funded Debt to Tangible Capital Ratio financial covenant. These changes were made to more appropriately reflect the impact from the Sancuso acquisition. On June 30, 2022, the Company entered into the Eighth Amendment to the Revolving Credit Loan Agreement with Pinnacle Bank permitting the Maximum Funded Debt Ratio to be calculated on a rolling four-quarter basis to be no more than 3.00 to 1.00 for the second and third quarters of 2022 and 2.50 to 1.00 for each quarter thereafter.   On September 29, 2022, the Company entered into the Ninth Amendment to the Revolving Credit Loan Agreement with Pinnacle Bank (as amended, the "Pinnacle Agreement") to update the Funded Debt Ratio to mean the ratio of (i) Funded Debt less the amount of Unrestricted Cash in excess of $8,500,000, to (ii) EBITDA, as determined at the end of each fiscal quarter on a rolling four (4) quarter basis.  For the quarter ended March 31, 2023, we were in compliance with the Funded Debt Ratio financial covenant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. The current pricing under the Pinnacle Agreement provides for an interest rate spread of 1.75% to 2.75% above LIBOR with a minimum LIBOR of 0.90%. The applicable interest rate under the Pinnacle Agreement was 7.375% at March 31, 2023.  In addition, a fee of 0.25% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  The LIBOR rate will no longer be used as of June 30, 2023, at which time the benchmark rate will be changed from LIBOR to Term SOFR.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2023 and December 31, 2022, the Company had $16.1 million and $16.2 million, respectively, in borrowings outstanding under its revolving credit facility.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the line of credit are collateralized by substantially all of our assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Joint Venture Agreement&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, Cumberland entered into an agreement with WinHealth Investment (Singapore) Ltd creating &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;WHC Biopharmaceuticals, Pte. Ltd&lt;/span&gt;. The joint venture, as a limited liability company, will focus on acquiring, developing, registering, and commercializing development stage and commercial stage biopharmaceuticals for China, Hong Kong and other Asian markets.  The agreement provides for initial investment from WinHealth in the form of a $0.2&#160;million equity contribution and an initial investment from Cumberland in the form of a $0.2&#160;million convertible note, which was funded during the first quarter of 2021. The joint venture will seek additional future capital from additional investors and has entered into exclusive option agreements to license product candidates from both Cumberland Pharmaceuticals Inc. and Cumberland Emerging Technologies Inc.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i4afbcb5fba4d4a1d8a087e5d9008e5d9_I20100513"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfMTMw_6360c4bd-9252-466b-844f-0ea053cccce8"
      unitRef="usd">10000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i7d99bf36d0104e0388920db036eb3ed2_I20160131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfMjkx_20d2a2e8-7240-4bb3-bc9f-d99c6c0c756b"
      unitRef="usd">10000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="icf9186d88cd34c189ca611958661dbf7_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfMzk3_8f22d20f-b4e9-464a-aa47-931ad1a83efc"
      unitRef="shares">86829</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i6e57b172666d4a2288b8e5fde755512d_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfNDEx_781aa853-665f-4488-aa27-ec67f74223e2"
      unitRef="shares">174149</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="icf9186d88cd34c189ca611958661dbf7_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfNDU1_8126f23c-dab0-44c9-80a6-4714e1fb10c1"
      unitRef="usd">200000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i6e57b172666d4a2288b8e5fde755512d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfNDYy_7bccb21c-fa32-401d-9435-1f3ce8b0a262"
      unitRef="usd">600000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="ieaa823ff0ab54452af8bbfadfb40cf88_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfNTAy_572d7316-a17c-4881-9371-45e3104cb0f4"
      unitRef="usd">3600000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities
      contextRef="i4b57a58712e74809ae2518a342bbfc8a_D20171101-20171130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfMTE1NQ_9855b1b6-fa39-493b-9060-6580bb20177b"
      unitRef="usd">100000000</cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities>
    <cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities
      contextRef="i1c55618f6c5a49939c91a52e719a9556_D20211227-20211227"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfMTczMw_b914d49b-36e4-442a-bb20-73be3c5339a6"
      unitRef="usd">19000000</cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i418c071f773e493bbdd32949f539f542_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfMjA0Mg_7a78c78e-dac3-433e-b217-dffe109a28c9"
      unitRef="shares">28250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i013a01798b674990bda32746a63a9bcd_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfMjA1Ng_268d6065-692d-4389-b93b-11ea281f97c2"
      unitRef="shares">65225</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i3dd89fce4bbe496ab54a639f67e6966d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfNjU1MQ_6263aa08-e990-491c-8fc2-0b1f38613735">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i4e8b5ebbe5f54d37acb467699b819d53_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfMjM3MQ_bae6d6b4-72d4-4b41-a96b-7eee617efc15"
      unitRef="shares">183250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i63b30cb0dab0416e82e2367680b40f47_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfMjM3OA_0cae8b9a-4885-4124-9f83-0683c56ad9b3"
      unitRef="shares">166350</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i418c071f773e493bbdd32949f539f542_D20230101-20230331"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfMjczOA_aedd9cb4-370b-417b-91e1-231a377da2d2"
      unitRef="usd">-40000.00</us-gaap:AllocatedShareBasedCompensationExpense>
    <cpix:LineOfCreditFacilityAdditionalBorrowingCapacity
      contextRef="iffcd93d62bab4e44a26be01fd717844c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfNTQ5NzU1ODIyNDQ5_d0807d08-3279-49f2-95e9-a09a170bf5f6"
      unitRef="usd">5000000</cpix:LineOfCreditFacilityAdditionalBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="iffcd93d62bab4e44a26be01fd717844c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfNTQ5NzU1ODIyMzk3_072026e6-ce51-41b8-a54e-d4317711c925"
      unitRef="usd">20000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <cpix:DebtInstrumentCovenantFundedDebtRatioMaximum
      contextRef="i0ee792037ad24f32a193eaf0a425d5ac_D20220401-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfMTA5OTUxMTY0MDY4Nw_f5d45ca5-a473-4e09-b2c4-1fb8524db413"
      unitRef="number">3.00</cpix:DebtInstrumentCovenantFundedDebtRatioMaximum>
    <cpix:DebtInstrumentCovenantFundedDebtRatioMaximum
      contextRef="id8989818d082428f810a0f2d67d1ba2a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfMTA5OTUxMTY0MDY5OQ_a6acafb5-616b-4402-ba25-642fb11dbcb8"
      unitRef="number">2.50</cpix:DebtInstrumentCovenantFundedDebtRatioMaximum>
    <cpix:DebtInstrumentCovenantUnrestrictedCashThreshold
      contextRef="i7bf205d89d0f4bbc97a466819e38a259_I20220929"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfMzEzMQ_4e0e615b-2c2a-4edd-85ec-536a2daedc25"
      unitRef="usd">8500000</cpix:DebtInstrumentCovenantUnrestrictedCashThreshold>
    <cpix:DebtInstrumentCovenantEvaluationFrequency
      contextRef="i7bf205d89d0f4bbc97a466819e38a259_I20220929"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfMzIxOA_092e4f5c-0842-49b7-b119-72466f0e6ebe"
      unitRef="q">4</cpix:DebtInstrumentCovenantEvaluationFrequency>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ib87aa9b105bd42a19d2435ddfe7a7834_D20200814-20200814"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfNTA0Mg_73314cd3-2abe-4722-95d3-71b1729f4691"
      unitRef="number">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i47da99f45e0440398ffd975817b2efce_D20200814-20200814"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfNTA0OA_c6aeb981-c29e-4325-b784-660b787f40e0"
      unitRef="number">0.0275</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i8117fb7667394b2f8d51eb672ad660af_D20200814-20200814"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfNTA4Nw_0334973d-957d-44ae-82f9-89c8cd535803"
      unitRef="number">0.0090</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ifa9c80f982f947eebf8cfe734dbb223d_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfNTE1Mw_f3dc0a45-6b1b-4153-ae1e-30d7e505fe2c"
      unitRef="number">0.07375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i17124cadeabb43b783b97a30611b1131_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfNTE4Ng_c7a8eee2-3b42-48de-a6ef-67d719b9724a"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:LongTermLineOfCredit
      contextRef="i314d6baf5bd141d09dc589a0d087077a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfNTUwNQ_8ff6ca57-e06d-4f0e-85be-c733125db3fb"
      unitRef="usd">16100000</us-gaap:LongTermLineOfCredit>
    <us-gaap:LongTermLineOfCredit
      contextRef="i32a3a0c770dd4a9aacc98814f4d15ea5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfNTUxMg_ea2b9cd5-fbe7-41a5-a8f1-9084ac8cee58"
      unitRef="usd">16200000</us-gaap:LongTermLineOfCredit>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i014f95ecf28e47dc9a81e3356a78cbfa_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfNjE1Mg_ba99d4c2-a890-49c7-857d-b226048e1b53"
      unitRef="usd">200000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="idd2a67aac74043969c46355ae44bb9ff_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80Ni9mcmFnOjJhZWIzMjhmMTAzMjQ2ZjI4Nzk2YmI3YWZhODVhMDk5L3RleHRyZWdpb246MmFlYjMyOGYxMDMyNDZmMjg3OTZiYjdhZmE4NWEwOTlfNjIzNA_3ea8b28e-3f8a-49a6-bfa5-0dd7db3eeb6a"
      unitRef="usd">200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80OS9mcmFnOjY3MTRlN2Q5OWQxNTQ0MGRiZTYzMDY0ZjQyMTMxNGNkL3RleHRyZWdpb246NjcxNGU3ZDk5ZDE1NDQwZGJlNjMwNjRmNDIxMzE0Y2RfNjM3_0e9cd085-5fe0-4ad7-909b-9b5e2b5eae56">INCOME TAXESAs of March 31, 2023, the Company has approximately $57.8 million in federal net operating loss carryforwards including approximately $44.1 million of net operating loss carryforwards resulting from the exercise of nonqualified stock options. These have historically been used to significantly offset income tax obligations. The Company expects it will continue to pay minimal income taxes during 2023 and beyond, through the continued utilization of these net operating loss carryforwards, on any taxable income generated from our operations.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i90e00eccd5aa49ab87f56422938153e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80OS9mcmFnOjY3MTRlN2Q5OWQxNTQ0MGRiZTYzMDY0ZjQyMTMxNGNkL3RleHRyZWdpb246NjcxNGU3ZDk5ZDE1NDQwZGJlNjMwNjRmNDIxMzE0Y2RfNjI_e1b077bc-e246-4cf0-91b5-a1afa9ebcc6a"
      unitRef="usd">57800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i1cfe8482250b40a4a99b93d7167bf9ef_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV80OS9mcmFnOjY3MTRlN2Q5OWQxNTQ0MGRiZTYzMDY0ZjQyMTMxNGNkL3RleHRyZWdpb246NjcxNGU3ZDk5ZDE1NDQwZGJlNjMwNjRmNDIxMzE0Y2RfMTMz_813d8a8b-1752-40ad-95f6-e8500897cef7"
      unitRef="usd">44100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81Mi9mcmFnOjQyODNmYjFiMzJlYjQxOWZiOTg5MTU2NDdjNTBkNzAzL3RleHRyZWdpb246NDI4M2ZiMWIzMmViNDE5ZmI5ODkxNTY0N2M1MGQ3MDNfMTA5OTUxMTYyOTAyNA_259319d0-f854-4089-af46-bc932ff0288e">OTHER INCOMEThe Company realized a $1.8&#160;million gain in the first quarter of 2023 for previously paid prescription drug fees.  In March 2023, the Company was granted a barrier-to-innovation waiver from the FDA for the fiscal year 2022 RediTrex prescription drug fees resulting in a refund of $1.8&#160;million.  This refund is expected to be paid in second quarter of 2023.</us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
    <us-gaap:InsuredEventGainLoss
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81Mi9mcmFnOjQyODNmYjFiMzJlYjQxOWZiOTg5MTU2NDdjNTBkNzAzL3RleHRyZWdpb246NDI4M2ZiMWIzMmViNDE5ZmI5ODkxNTY0N2M1MGQ3MDNfMTA5OTUxMTYyOTAxMQ_2b6b8a87-1690-4211-8201-8fdba17a1a6f"
      unitRef="usd">1800000</us-gaap:InsuredEventGainLoss>
    <us-gaap:OtherIncome
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81Mi9mcmFnOjQyODNmYjFiMzJlYjQxOWZiOTg5MTU2NDdjNTBkNzAzL3RleHRyZWdpb246NDI4M2ZiMWIzMmViNDE5ZmI5ODkxNTY0N2M1MGQ3MDNfMTA5OTUxMTYyOTAzOQ_9b1b1083-3649-413a-942e-beae61cc46c5"
      unitRef="usd">1800000</us-gaap:OtherIncome>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81NS9mcmFnOjhkZmY1ZjA1N2EyZTQ4M2FhOTE2ZWU1ZWM3NjQ2ODcyL3RleHRyZWdpb246OGRmZjVmMDU3YTJlNDgzYWE5MTZlZTVlYzc2NDY4NzJfMTAyNg_04821286-0202-477d-8704-0fc66bc47aed">COLLABORATIVE AGREEMENTS&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment received related to RediTrex, do not meet the criteria for accounting under ASC Topic 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The agreements do not specifically designate each party&#x2019;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party.  Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed consolidated statements of operations.&lt;/span&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81MjYvZnJhZzo4M2I5MjA3MmRkYzI0MTU1OTY0OTdhMzc0YzFlNmFkZS90ZXh0cmVnaW9uOjgzYjkyMDcyZGRjMjQxNTU5NjQ5N2EzNzRjMWU2YWRlXzEwOTk1MTE2MjgwOTI_d5510047-2655-4d80-91a3-d2c4a041d456">COMMITMENTS AND CONTINGENCIESThe company is involved in litigation arising in the normal course of business.  The Company does not believe that the disposition or ultimate resolution of existing claims or lawsuits will have a material adverse effect on the business or financial condition of the Company.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfOTQ1MA_f2b38df6-c7cb-4ce1-a60b-09bffd0a1142">ADDITIONS AND RETURN OF PRODUCT RIGHTS&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Vibativ&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand.  Vibativ is a patented, Food and Drug Administration ("FDA") approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $20.0&#160;million at the closing of the transaction and a $5.0&#160;million milestone payment in early April 2019. In addition, Cumberland has agreed to pay a royalty of up to 20% of on-going net sales of the product after the $2.5&#160;million threshold is met. The future royalty payments were required to be recognized at their acquisition-date fair value as a contingent consideration liability, as part of the contingent consideration transferred in the business combination. Cumberland prepared the valuations of the contingent consideration liability utilizing significant unobservable inputs.  As a result, the valuation is classified as Level 3 fair value measurement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to Theravance quarterly.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,154,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(245,391)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration earned and accrued in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,085,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contingent consideration liability of $4.1 million was accounted for as $1.2 million of other current liabilities and $2.9 million of other long-term liabilities on the condensed consolidated balance sheet as of March 31, 2023.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;RediTrex&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2016, the Company announced an agreement with the Nordic Group B.V. ("Nordic") to acquire the exclusive U.S. rights to Nordic&#x2019;s injectable methotrexate product line designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As consideration for the license, Cumberland paid a deposit of $100,000 at closing.  The Company provided $0.9&#160;million in consideration through a grant of 180,000 restricted shares of Cumberland common stock to be vested upon the FDA approval of the first Nordic product. Cumberland also agreed to provide Nordic a series of payments tied to the products&#x2019; FDA approval, launch and achievement of certain sales milestones. Under the terms of the agreement, Cumberland is responsible for the product registration and commercialization in the U.S. Nordic is responsible for product manufacturing and supply.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 27, 2019, Cumberland received FDA approval for the first Nordic injectable product and authorization to market them under the RediTrex brand name.  The 180,000 shares of restricted Cumberland common stock previously provided to Nordic vested upon approval and were valued at $0.9&#160;million on the vesting date. The FDA approval also resulted in a $1.0&#160;million milestone payment due to Nordic.  During December 2020, Cumberland introduced RediTrex and the launch that took place in late 2021 resulted in a $1.0&#160;million milestone payment due to Nordic.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective July 12, 2022, the Company entered into an amendment to our agreement with Nordic whereby they may assume responsibility for RediTrex marketing authorization in the U.S. and the opportunity to commercialize the product in the U.S. after June 30, 2023. Cumberland will continue to distribute and support the product until then.  In accordance with the terms of the amendment, Nordic has returned the 180,000 restricted Cumberland shares we previously issued to Nordic which were cancelled, refunded to Cumberland the milestone payment of $1.0&#160;million we made associated with the brand's U.S. approval and issued a credit note in favor of the Company in the amount of $1.0&#160;million for the unpaid milestone payment due from us for launch of the product line. The companies will cooperate on any transition and Cumberland will receive a long-term royalty on any Nordic sales of the product.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sancuso&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 3, 2022, Cumberland acquired the U.S. rights to the FDA-approved oncology-supportive care medicine Sancuso from Kyowa Kirin, Inc. ("Kyowa Kirin"), the U.S. affiliate of Japan-based Kyowa Kirin Co., Ltd. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sancuso is the first and only FDA-approved prescription patch for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment. The active drug in Sancuso, granisetron, slowly dissolves in the thin layer of adhesive that sticks to the patient&#x2019;s skin and is released into their bloodstream over several days, working continuously to prevent chemotherapy-induced nausea and vomiting (&#x201c;CINV&#x201d;). It is applied 24 to 48 hours before receiving chemotherapy and can prevent CINV for up to five consecutive days. Alternative oral treatments must be taken several times (day and night) to deliver the same therapeutic doses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland acquired U.S. rights to Sancuso and assumed full commercial responsibility for the product in the U.S. &#x2013; including its marketing, promotion, distribution, manufacturing and medical support activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $13.5&#160;million at the closing of the transaction. The Agreement calls for milestone payments of up to $3.5&#160;million based on the attainment of various approvals and sales performance. The Company believes that $1.5&#160;million of the milestone payments will be earned and paid.  In March 2023, Cumberland paid $1.0&#160;million of the $3.5&#160;million milestone payments to Kwoya Kirin for the approval by the FDA of the manufacturing site for the product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, Cumberland has agreed to pay a royalty of up to 10% of on-going net sales of the product.  The future royalty payments were required to be recognized at their acquisition-date fair value as a contingent consideration liability, as part of the contingent consideration transferred in the business combination. Cumberland has prepared a valuation of the contingent consideration liability utilizing significant unobservable inputs.  As a result, the valuation is classified as Level 3 fair value measurement.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition was funded by cash and the Company's revolving credit facility.  The Company worked with an outside consultant to finalize the Sancuso valuation of the transaction.  The fair value for the assets and liabilities assumed were as follows: prepaid expenses $1.8&#160;million, inventory $2.6&#160;million, goodwill $0.03&#160;million, intangible assets $14.1&#160;million, milestone payable $1.7&#160;million and contingent liability $3.4&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(244,920)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(443,759)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration earned and accrued in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The contingent consideration liability earned and accrued in operating expenses is paid to Kyowa Kirin quarterly.  The contingent consideration liability of $2.5 million was accounted for as $1.3 million of current liabilities and $1.2 million of other long-term liabilities on the condensed consolidated balance sheet as of March 31, 2023.</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i910d1c8e30b447a685124ae92adb5f51_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfOTY5_1b29ccf8-545d-4927-8e30-ea874b179332"
      unitRef="usd">20000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:OtherPaymentsToAcquireBusinesses
      contextRef="i910d1c8e30b447a685124ae92adb5f51_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfMTAxMg_55b86aed-d7b0-44f0-b62b-1b069c028511"
      unitRef="usd">5000000</us-gaap:OtherPaymentsToAcquireBusinesses>
    <cpix:TieredRoyaltyPaymentsPercentage
      contextRef="i910d1c8e30b447a685124ae92adb5f51_D20181101-20181130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfMTExNQ_6f871b39-2025-4ee8-8840-9289a1520246"
      unitRef="number">0.20</cpix:TieredRoyaltyPaymentsPercentage>
    <cpix:TieredRoyaltyPaymentsThreshold
      contextRef="i910d1c8e30b447a685124ae92adb5f51_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfMTE2NQ_2ab9d591-826a-4199-9112-d0f59b9ed204"
      unitRef="usd">2500000</cpix:TieredRoyaltyPaymentsThreshold>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock
      contextRef="id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfOTQ0NQ_9857956f-2e03-41d8-a65d-02a1877aad64">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to Theravance quarterly.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,154,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(245,391)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration earned and accrued in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,085,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(244,920)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(443,759)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration earned and accrued in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7c76ad6b0d9d43bea791e5d7ff63409c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RhYmxlOjdjNTJhZDVjYjgxMDQ5Yzk4ZDcxYzNkMjdlMDkyMzIzL3RhYmxlcmFuZ2U6N2M1MmFkNWNiODEwNDljOThkNzFjM2QyN2UwOTIzMjNfOS0xLTEtMS00NTkwNg_24184fc6-90c7-43fb-857f-98e8689f2979"
      unitRef="usd">4154823</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:PaymentsForRoyalties
      contextRef="i499b37cd8cf54392a0f2ec322fe40eee_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RhYmxlOjdjNTJhZDVjYjgxMDQ5Yzk4ZDcxYzNkMjdlMDkyMzIzL3RhYmxlcmFuZ2U6N2M1MmFkNWNiODEwNDljOThkNzFjM2QyN2UwOTIzMjNfMTAtMS0xLTEtNDU5MDY_265a02c3-c277-413c-815f-7048223bb938"
      unitRef="usd">245391</us-gaap:PaymentsForRoyalties>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i499b37cd8cf54392a0f2ec322fe40eee_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RhYmxlOjdjNTJhZDVjYjgxMDQ5Yzk4ZDcxYzNkMjdlMDkyMzIzL3RhYmxlcmFuZ2U6N2M1MmFkNWNiODEwNDljOThkNzFjM2QyN2UwOTIzMjNfMTEtMS0xLTEtNDU5MDY_62b9ad52-cb21-4295-add7-adfb9ddf582f"
      unitRef="usd">176122</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses
      contextRef="i499b37cd8cf54392a0f2ec322fe40eee_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RhYmxlOjdjNTJhZDVjYjgxMDQ5Yzk4ZDcxYzNkMjdlMDkyMzIzL3RhYmxlcmFuZ2U6N2M1MmFkNWNiODEwNDljOThkNzFjM2QyN2UwOTIzMjNfMTItMS0xLTEtNDU5MDY_2c1c599d-a774-4e64-be47-72af42a439c1"
      unitRef="usd">0</cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="if921eb31fa6f45b39876cdd2bde81d95_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RhYmxlOjdjNTJhZDVjYjgxMDQ5Yzk4ZDcxYzNkMjdlMDkyMzIzL3RhYmxlcmFuZ2U6N2M1MmFkNWNiODEwNDljOThkNzFjM2QyN2UwOTIzMjNfMTMtMS0xLTEtNDU5MDY_5d87c106-bb2e-49f3-adc2-bd12e5b287ed"
      unitRef="usd">4085554</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="if921eb31fa6f45b39876cdd2bde81d95_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfMTg5MQ_9cb055aa-0a76-455b-a7a7-ba49e405144b"
      unitRef="usd">4100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="if921eb31fa6f45b39876cdd2bde81d95_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfMTkxNQ_fc975862-6c51-4913-81d4-d1c225b87d1b"
      unitRef="usd">1200000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="if921eb31fa6f45b39876cdd2bde81d95_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfMTk1MQ_daf37173-b453-4556-84f9-2ec9d42aaf7e"
      unitRef="usd">2900000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="idee1724666bd4296b087588595669561_D20161101-20161130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfMjQ0MA_9bdc7028-1ac9-492e-885e-6d315f596e85"
      unitRef="usd">100000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="idee1724666bd4296b087588595669561_D20161101-20161130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfMjQ3Nw_e5d419d1-356a-4dfd-8ae0-42deb02f0f87"
      unitRef="usd">900000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="i8321269afd0c421ebdd0224b1a27d392_D20161101-20161130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfMjUxNg_3e5a05c9-f228-4cc3-b7ac-93258c8c7bce"
      unitRef="shares">180000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="i8321269afd0c421ebdd0224b1a27d392_D20161101-20161130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfMzEyNw_702e1a3e-3480-43e2-9120-d8a6885d71af"
      unitRef="shares">180000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i47826f88ea0b4a6eb3f2a0fbce1e5c79_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfMzI0NQ_1425efcc-852b-469d-b507-62a58c094f3d"
      unitRef="usd">900000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i4038ab9268e54e9ea5e0321e85b66082_I20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfMzMwNQ_df46be43-66e4-4f20-8457-30e7c426f9e1"
      unitRef="usd">1000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i55d3542573f24209aee0933490837ee7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfMzQ1Mw_f5c1ec60-593b-4279-8bdc-ec9837be9c0d"
      unitRef="usd">1000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <cpix:CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable
      contextRef="i90fc46e8567a4446ba6f1f69166c1051_I20220712"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfMzkxMA_aa321a13-a666-4991-a872-6b67c90838c8"
      unitRef="shares">180000</cpix:CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable>
    <cpix:CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable
      contextRef="id0e8f0a1b5ac44cfa0861149a172d293_I20220712"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfNDA0NA_02a13b8b-0841-436c-ab12-ec9944e7824c"
      unitRef="usd">1000000</cpix:CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable>
    <cpix:CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue
      contextRef="id0e8f0a1b5ac44cfa0861149a172d293_I20220712"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfNDE2Mg_4f65be64-18d9-43d8-b6ba-117f2d444267"
      unitRef="usd">1000000</cpix:CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue>
    <cpix:CollaborativeArrangementRightsAndObligationsUpfrontPayment
      contextRef="i20b2ea64a45e4649b835fa2bde154e6d_I20220103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfNTY5Nw_157d2d64-cc9f-433b-855e-eb9cc603ff27"
      unitRef="usd">13500000</cpix:CollaborativeArrangementRightsAndObligationsUpfrontPayment>
    <cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum
      contextRef="i20b2ea64a45e4649b835fa2bde154e6d_I20220103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfNTc4Nw_24eeee42-5097-460e-8fda-9a716660eb5e"
      unitRef="usd">3500000</cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum>
    <cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected
      contextRef="ibcdddac945434b87b9564d50977a987e_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfNTg4NA_2ff37bf9-e681-4695-95ad-81f72e0b8602"
      unitRef="usd">1500000</cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected>
    <cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePayments
      contextRef="i44f4dc27a7c64611b4e00cd930bd4746_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfMTA5OTUxMTY0MTUwNg_9335a07b-c666-4bb5-9bb2-89c29a7f35e9"
      unitRef="usd">1000000</cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePayments>
    <cpix:CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent
      contextRef="icb7fb24ed38f426d9b39670f3390245e_I20220103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfNTk5OQ_8b65df24-f29c-4d3c-b16e-d237978fa673"
      unitRef="number">0.10</cpix:CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="ie9300edb1e774e3ea979ca48d8d32a68_I20220103"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfNjgyMA_3013a448-d682-4ac0-b36e-e294e0ed2cdb"
      unitRef="usd">1800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="ie9300edb1e774e3ea979ca48d8d32a68_I20220103"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfNjgzNA_e9616d76-1efd-4a2e-ab47-6e7556700dce"
      unitRef="usd">2600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:Goodwill
      contextRef="ie9300edb1e774e3ea979ca48d8d32a68_I20220103"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfNjg0Nw_0c26028c-0837-4bae-a848-65a076ae8bf0"
      unitRef="usd">30000.00</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="ie9300edb1e774e3ea979ca48d8d32a68_I20220103"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfNjg2OQ_ebf49070-4296-4a7f-b2d6-9960f353e269"
      unitRef="usd">14100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:OtherPaymentsToAcquireBusinesses
      contextRef="id571878b227b429aabb39f702150f09b_D20220103-20220103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfNjg5MQ_2c449dc7-7d7d-4ab3-9230-1ead20c3051b"
      unitRef="usd">1700000</us-gaap:OtherPaymentsToAcquireBusinesses>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ie9300edb1e774e3ea979ca48d8d32a68_I20220103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfNjkxOQ_6afaddc2-500f-4b56-be60-7f2e0dc975c9"
      unitRef="usd">3400000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i339eef896e214990b9293f54ead2c9f0_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RhYmxlOjMxYzgwNDNjMGNkYjQ4YmE5ODJkZGZkYWUxMjFiMjE0L3RhYmxlcmFuZ2U6MzFjODA0M2MwY2RiNDhiYTk4MmRkZmRhZTEyMWIyMTRfOS0xLTEtMS00NTkwNg_6a585d64-268e-4844-a720-5b691d52196f"
      unitRef="usd">3000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:PaymentsForRoyalties
      contextRef="i34ec3c62de204f83a7f07694bba18e4f_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RhYmxlOjMxYzgwNDNjMGNkYjQ4YmE5ODJkZGZkYWUxMjFiMjE0L3RhYmxlcmFuZ2U6MzFjODA0M2MwY2RiNDhiYTk4MmRkZmRhZTEyMWIyMTRfMTAtMS0xLTEtNDU5MDY_770bc2c4-67fe-492f-a534-0ccbd6b1e311"
      unitRef="usd">244920</us-gaap:PaymentsForRoyalties>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i34ec3c62de204f83a7f07694bba18e4f_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RhYmxlOjMxYzgwNDNjMGNkYjQ4YmE5ODJkZGZkYWUxMjFiMjE0L3RhYmxlcmFuZ2U6MzFjODA0M2MwY2RiNDhiYTk4MmRkZmRhZTEyMWIyMTRfMTEtMS0xLTEtNDU5MDY_4d83979e-3158-46fc-932a-c6c818c109e0"
      unitRef="usd">-443759</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses
      contextRef="i34ec3c62de204f83a7f07694bba18e4f_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RhYmxlOjMxYzgwNDNjMGNkYjQ4YmE5ODJkZGZkYWUxMjFiMjE0L3RhYmxlcmFuZ2U6MzFjODA0M2MwY2RiNDhiYTk4MmRkZmRhZTEyMWIyMTRfMTItMS0xLTEtNDU5MDY_bb2924e5-37ef-43a0-9e0b-4fca8b7b6fb9"
      unitRef="usd">188679</cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i339bfc5c1c8e48d58f19079fc7a04235_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RhYmxlOjMxYzgwNDNjMGNkYjQ4YmE5ODJkZGZkYWUxMjFiMjE0L3RhYmxlcmFuZ2U6MzFjODA0M2MwY2RiNDhiYTk4MmRkZmRhZTEyMWIyMTRfMTMtMS0xLTEtNDU5MDY_9787da57-2e6e-4f0a-aa52-a7ebdb87feef"
      unitRef="usd">2500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i339bfc5c1c8e48d58f19079fc7a04235_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfNzIyMw_d0b6f7ea-f38e-4b0d-8b35-10cf36f8efa3"
      unitRef="usd">2500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i339bfc5c1c8e48d58f19079fc7a04235_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfNzI0Nw_c2e13cc0-5f5a-49d3-89d0-12562ac9d466"
      unitRef="usd">1300000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i339bfc5c1c8e48d58f19079fc7a04235_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0YzM0MWNkZmFmMTRkYTU5MTExYWU3ZDgxNDJmYTNhL3NlYzowNGMzNDFjZGZhZjE0ZGE1OTExMWFlN2Q4MTQyZmEzYV81OC9mcmFnOmYwMzUwMWExOGIwYjQyZDE5NGFjZjY4NmQzNDFkN2MzL3RleHRyZWdpb246ZjAzNTAxYTE4YjBiNDJkMTk0YWNmNjg2ZDM0MWQ3YzNfNzI3Nw_d57b3f88-5f69-4c10-b0c6-23b1097c1a03"
      unitRef="usd">1200000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>57
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MN8>'YOYH%ZL\33B'T?%*H^/9?<I;QL,^;B5EC=PG;#Q3.(?I\4K3X]F]R@0
M@QPRHL8F62-0V0GM<6W!2J_C-?,Z@"8@=P])P%[1[\PXSM1(N:Z+W:LAN>X9
M.<_A=;R3,S"[,SF:N=-^:#MIJ)'K=C'I>N:6^EW-CG-R-JHGO.S(6")?;[OF
MQZ3%T^)8>I(=QCKEY_F9]B/5\Z5$$5M"J'LYA %/Y,?$^8WBF^RD=<&5XG%V
MN68T8$)_ .^7G*OCC?X'Q6']^']02P,$%     @ 0XBL5K863_A3!@  ?!D
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MSY6XDN7?1:Y7E[-D%N1BR3>EOI6/OXE=0LS$RV2IVK_!X\X6S8)LH[2L=LZ
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M((?J.GLW,;)QS7$I#;9:-ZSP,@1E _#]2DKS.+']=KA>\[]02P,$%     @
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MO13I80VN0UFG-H]K,\%QP$G@D9#V%F8H1PC&<3RR+E&+,W+B?("].RNWU<H
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MIQD!N+^24C^?F ?LO\ M_P=02P,$%     @ 0XBL5LMB-%IH!0  *Q\  !@
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M\/Q>"/E\TYQF]N?CJW\!4$L#!!0    ( $.(K%9AY/Q^- X  +TC   8
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M CQ?>B1WNJ #^E_LG/P?4$L#!!0    ( $.(K%8=%POFO ,  #H(   8
M>&PO=V]R:W-H965T<R]S:&5E=#@N>&ULG591;]LV$/XK!W4H6D"++,IV9,<V
MX#396F#- GM;'X8]T-+9(D*1*DG%[;_?D;(5=W-2;"\Q*=Y]]]UWQV-F>VT>
M;(7HX$LME9U'E7/--$EL46'-[85N4-')5IN:.]J:76(;@[P,3K5,V& P3FHN
M5+28A6_W9C'3K9-"X;T!V]8U-U^O4>K]/$JCXX>5V%7.?T@6LX;O<(WN]^;>
MT"[I44I1H[)"*S"XG4?+='H]]/;!X ^!>WNR!I_)1NL'O_E0SJ.!)X02"^<1
M./T\XCN4T@,1C<\'S*@/Z1U/UT?TGT+NE,N&6WRGY2=1NFH>Y1&4N.6M="N]
M?X^'?$8>K]#2AK^P[VRS001%:YVN#\[$H!:J^^5?#CJ<..3/.;"# PN\NT"!
MY0UW?#$S>@_&6Q.:7X14@S>1$\H79>T,G0KR<XM;;I10.PMO?M'6OH5[-+"N
MN,%9X@C>&R7% >JZ@V+/0&7P42M76;A5)9;?^B=$J^?&CMRNV8N '[FY@"R-
M@0U8]@)>UN>:!;SL>[GV2<*?RXUUAEKCKW/Y=G##\W#^NDQMPPN<1W0?+)I'
MC!:O7Z7CP=4+9(<]V>%+Z(O;Y>KNP]W/:RK,K^LU%>9V!>OWR]7M.:+_$PI^
MJQ"V6M+-)%W \8U$NFF%5H60:,'1L6IK--QI UR5U.]*4Q>&?6NQ!*>AX+)H
M)7?HKX<H.CLA6T?'V+>7#.W5D/(V*$_S)."[RB!"W74.^LX!JGM1]84/>+1@
M4Z+[/5MO!W='RE.XH[$F5*%K/#+X =)+%K-\3*LW:3P<L'B896^#I;< [FA"
M;:PH!0TIVCDC-FTG#26K2!N*;T@T+YE0#JGV#M))G$]RPH[3?' F[#]QZ(SR
MZ+2HM"S16$]MPLA_V%'+\E',1D3MYDGT*7P*<P;+'_DC);G##L("#5SK2"K/
MZO6KG*7IU:$>Z3#.1I,X(V5H.9ZD\9B4NO$5HH$(N-W2A 2]!4WUH/)@T1KA
M!&$REL<CEG9X[.H_Q3YV (4<Y9=Q/LQ.HR^M#_A,H6/PDAI1>'^:@,4#\#TW
MI0T6NO'CW'H1FY;\:21#1AA9EH?SE-:,C7INVUYKCQ2P&PQO@?P:PY[*]PU_
MJE'W4>E00]GZ-A,J-"LA-53#\)X0\+^Z_*F]-UAPNB#!ZZ#P7K>RI -BZ41Y
MD/_BW*A(3N8YM?(NO%J6HK?*=:.]_]H_C,ON/7@R[UY5DG@G2"V)6W(=7%R.
M(C#=2]5MG&["Z[#1CMZ:L*SH<4?C#>A\J[4[;GR _M^%Q=]02P,$%     @
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M;"]W;W)K<VAE971S+W-H965T,3 N>&ULE5=M;]LV$/XKA!MT+:#8DAR_Y<5
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M/1TX.*3E0=(87]3&\3/&0_9)*Y=9]D&E(NW:#P!DBR9NT5S$+SK\Q$V?#:.
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M==N57M6>U$4*<8N\ZH@&(GB=EXH]X.9CR][6E,NN9?J5:<@5UJ9,X^ 0V^Y
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M)N/'%8);62+ [XE!+UN]T '-M\'3_P)02P,$%     @ 0XBL5H[O4(H+ P
ML08  !D   !X;"]W;W)K<VAE971S+W-H965T,3,N>&ULC55=3]LP%/TK5]FT
M)]2T21F(M9%:8!H/; C8AS3MP75N$@O'#K9#V_WZ73MMZ*92]I+XZQR?<W/O
MS62IS8.M$!VL:JGL-*J<:\[BV/(*:V8'ND%%.X4V-7,T-65L&X,L#Z!:QLEP
M^#ZNF5!1-@EK-R:;Z-9)H?#&@&WKFIGU'*5>3J-1M%VX%67E_$*<31I6XAVZ
MK\V-H5G<L^2B1F6%5F"PF$:ST=E\[,^' ]\$+NW.&+R3A=8/?G*53Z.A%X02
MN?,,C%Y/>(Y2>B*2\;CAC/HK/7!WO&7_&+R3EP6S>*[E=Y&[:AJ=1I!CP5KI
M;O7R$V[\''L^KJ4-3UAV9],T MY:I^L-F!340G5OMMK$80=P.GP!D&P 2=#=
M71147C#'LHG12S#^-+'Y0; :T"1.*/]1[IRA74$XEUTIKFN$>[9".XD=,?KU
MF&_0\PZ=O(!.X5HK5UFX5#GF?^-C4M++2;9RYLE!PFMF!I".CB 9)ND!OK2W
MEP:^]%5[<"$LE]JV!N'G;&&=H83XM<]RQSC>S^B+Y,PVC.,THBJP:)XPRMZ]
M&;T??CB@=]SK'1]BSZX^GW^YOH3[V8_+NWW:_A\]LZ +H'CRJ@_H$;@*X5S7
M#5-KJ)@%UC1&KP1E-\HUO#T^&9Q2EDGI"T8H*#!'PR0HZ@[4!PQS0I5 4;3
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M$,Z$>1.X;>AP':4 ]6!98%$F^11;TQI;L+RN8M:!+$:J"*(4X7"IK?---L1
M]5J%S)WI]N%@2+-#,G<,RK1MTNNPMM-_74R2G@Y#D4OD:!:Q(-,(T!UJRLV\
MI1((U0>43LP<5%?;L]H<[X6*43RR^WS'@IN,!$O?L>G&B\J"PZ*YM72-=G#F
M1Z/W"&T$WAT$7%U5!.)ON^5Z,F3RTU,5W45I(O&],#4:]^+4*;26WY +:Q2=
M;11' ,*\0OL+M.;&;2V"\.0A2EE$6MBDVBZ_.DEW7ZJA^ZYI>,@[2=Y"0R\%
M6YM(!E,I;C;,FWIE$=.5]I(7=[RUYQE.S$ K0@N1A-L/T<\4G:U5;=2,FVU+
M!;Z.^\E3>O:N2G<^:RAZS%RF"MX8^"''\$MJY 1YD#7Y4\I]OVPFMY]JN'8R
M#>V^#_(T(P;:1XB-0R I+2+]-[6]#?PQ*!OT)[4@GJ-H!MC26%H7:M\<W-K=
MCKZWLJQ;'HUO3%49Z^N2N93IU93JE5]O,Q/TGVJX9#9NFETG&!MX+C;XX*EV
M E=MG>'4GOR:)E-Z4H8QX];8=1=#&O\-&U?1$&+Y.BN2Y3UPW%$R5LY&=<M"
MP[N]HMB@<66A A+2)L]ITK=J237*"SLB^=[A3K9PS^GDTT;%8>Z^"X;O7'1S
MMPBC9IA'D$7H9*7QD0FN$?OHE";98K!D05SIC@(-3M4E=\?]^8TI$T#D>'$L
MH%MC&E&$AE?3L=1:8N0#0U3A\F<;QA[= O?M3(EH"MMV1*R='H.$&(U]X^)(
MW" P-0 &L/T3,%W:K9@U)=CMCLU-2)O'.W846^YA>SMCRL3D9K4]C+E*^B4T
MW1?P?D+DJ#F5'?7SUFRD^%D#I89(WX0H6N?9X/&P6SU+%"V[9PF%X;E#NF5.
MNT(0R=%0_.+3G77:=9H+V6-*)&Q/:9JN$JLK]C1(%V*VZZ**+W\"[2UE[52X
MY%F;0C-6:-ZBF16$B-#3IK?[;14\3]\1,&N6U7;'!T,>1$9(ES$D+FH^9(*D
MG0)"PSL. R$4!R2 3*]WXQ\H(@'R5G$VRS133&,9M=%<DD]MH**:+9=M[Z:X
MV>>*G<DX&T;\16Y,ZDC70L!/-K!+U%4JM^";]"4"FQH *P !TR=V6<_B0UV&
M)K//@X](H^GX^>7K-Q_YY>3Y8[X5HWM", NB6M,YB9Z?B@R8[\#\$"#5]7?7
MO=S T2L:34@P1S1<J"PY*=$%,.L&Q\,>\&/T,4L7"7ABR,PV2B!G-9('=-/+
M3ZIL_>!U@3@\2F4XLJ2RX,DB5;E>1RKB@+@B:*9JHNRI<<3Q]E78K>IJ4IC7
M</_"2%$S4C3M9E]#NZ_]<. GSSN7AII,VUWX8A.<R)=47[O[Y7+&\4U+VET
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M.CD>!!;5O/&FXA]V+(SWIN"7F4)/M[0 GR\-IL+XA@YH?^ES]A]02P,$%
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MR8I$MD,O"?.<AP*85NY!G<?G4@NN8U"O,WF(Y)Y5=UYZP?BD 4NTVS!FR%=
MN[87C];C))NT#?SLWHY!_N&W4A,HS!G:[7RXB,"VHZ4].%.%=MX8Q\,A; N>
MQFB] ]_GQKC#P0<XSO?Q;U!+ P04    " !#B*Q6X[*2(YL*  !P&@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6R=6=MRVS@2_164IFK6KM+%EF-G
M-K%=97N3F4Q-)J[8V7W8V@<(A"2L28 !0,O*U^_I!DA1CJ)D]L462:#1U].G
MR?.5\P]AJ7443U5IP\5@&6/]:C():JDK&<:NUA9/YLY7,N+2+R:A]EH6O*DJ
M)].CH[-))8T=7)[SO5M_>>Z:6!JK;[T(355)O[[6I5M=#(X'[8V/9K&,=&-R
M>5[+A;[3\5-]ZW$UZ:04IM(V&&>%U_.+P=7QJ^N7M)X7_-/H5>C]%F3)S+D'
MNGA77 R.2"%=:A5)@L2_1WVCRY($08W/6>:@.Y(V]G^WTM^R[;!E)H.^<>6_
M3!&7%X-?!J+0<]F4\:-;_::S/:<D3[DR\%^QRFN/!D(U(;HJ;X8&E;'IOWS*
M?OB1#=.\8<IZIX-8RW_(*"_/O5L)3ZLAC7ZPJ;P;RAE+0;F+'D\-]L7+#WXA
MK?DBDXML(:YE,$&XN;CU.F@;TY.#6U<:970X/)]$'$N;)RH?<9V.F'[CB!/Q
MWMFX#.*-+72QO7\"=3N=IZW.U].] M]+/Q8GQT,Q/9J>[)%WTOG@A.6=_( /
MAN+&V0!CBXU+MCP!S[PU5EIE9"GN<%,C16,0_[Z:A>B19/_9Y:&DP(O="E#A
MO0JU5/IB4--9_E$/+G_^Z?CLZ/4>\UYTYKW8)_WRHU;04%PIY1H;C5V(7QN8
M9Y7>I>G_*TM\_>C6.XO?*GOHG16_-U8C:L=G0Q&7NN?(WB[XU!;2%T%<._P3
M!X.W5W?7@T-A0FAT(:[N/HD_W9C%C(Y/AN+GGWZ93H]>;X2]LXA$PX>.;KPN
M3!1_N!!T&/+2X]=BM31J*=12VH4.K(JI:FD\[1&5*W0I@'?X%:*8=W(E9, .
M2@FE?03B"8>]7IC-@6,!L!!(A$+SPK3 PS?F4<Y*Z""6NBQ&T8T *8TW<0T0
MF441M*(K0RM*)VWH;>_)'PKEH*K%.B&]AN3/C8&-(CK1!)PI+) 0RJ_@NU$)
M-"2?9A?IIQI@B,4EW-'Z(ID;ES**A;;:R[)<0VP K.%@=HZ6OC3)#+>PIJT#
MK'0KBGU@;Y7LX^0 ^2A-2?:.\&049*F?6PF<BTO16'22TGS).NDM^RHM0P,;
M58IA6D Z22"@A:HBF K'>#)^109 6;C3X;J0ZZ'03TK7,=E&=F0)R6]L"ATL
M0]\2+]GEV&/I"8YNN'^$UAFR<C[R1D7I 3_0W8UA8R!(:\%2/FI2KC!!X7!L
M+@IV'[+)V-12&72,56534*AZMY,Y%%6((&QY:%WQN8'3D#FSM5@C.*2$\V:!
M3.5]SW,78GL9V%=0UC6B30:@K"@CCE^^#J+V[M$$-IJ<@SY4-:6D]CG2\SE2
M"';\%[V),A*Z(Q,LO TEO::J@&N@E,6Q01R@0Z)QQ$.2E'TUT]"4'K<WYL9#
M6:]K\BQNU]H;5Y##4Z'2FD6+,^A.LG UTG@,S(%:*?F?P0*[O$&X$=^9>]3D
M8O%>KNGYWS/Z %;ZH$)/1D>G0S'X 2@1!_>N-DJ<3,\.7XE[Z1>:%+GWJ-Q4
M(-#-Z/D@F\ N+0AL-BL\K^!HY?-9<P0UK297X.1>N5!.EE%[R\$@LXWW^M$I
M!'8MF.HDAP++Q*,L&RW@J38E<-S"( .^AK1<:?!5?)[?34U=L,AB<L (8[:K
M,F341G)E:$RG&<[3C%*I#U3('.0 #HV,<8PP+4MK'U)B&NC +;@'@*/9>K2Y
M(D)FD-#W?1%($.OB!H*2[8;+>@<NX>'W$#D=D*IFW6:?F &<MP)'QO02B73_
M7=H&7%=DLC(6MR5<3? SUPQ;]UVG^--%^/'CIDX%<ZZU&._A *<=!SC=V[<_
MX4S$[DV(!D;JL*OS_S4)[!*PE5IZV4\-Y<#R;.#T:8D4+C8I%S:<"5F"181W
MY'3.\$_CNW&O#TE%"$Z)N2$(M0=:FIH\E/,J4#_ ",$ID?5HHP4?5_(!Z=$I
M3LY&WC=5G7"=VX-,N$8[$P[1F14=R;#5:_VED9S5)HO*V$Z-"@MA#RE)BFPM
M3*+)%SU'?<<];7'L4@A5KVV35:"^;JD*"R0L/$2;$H:.P:PBFD5NZ &G-B7I
M/*?\FWM783$UIHU[&L3/YQ5D1M]53'T08,:O[;+X6T@M)QBT54"^Q-:-T-3?
M]"MQ< PB%\-S[@ J!@2=H<7E^"CEH79ZZ/&@#1R0D1HR=9K&6]"%@^EA:LO;
M MT,SM6!*2DN&XN1\P'=B?# 6/@N.I0E23PX.62H[+*X%T**$5 [9_A60$-P
MB!=%A?-VU@043" '5[/<A\.^RCWK*O=L;]U]J/EX(L9ZP7FQJW;_JHP^GBVI
M,UOJ%.VJD%;EU@4\#>"-2$X4:8U 59A4FH@0EVTXD KO-Q5( A5EE:7J<VFZ
MTEM528,T@SO=C.N:JZ(5)A Z9.Z'Y_HDYH9X(#YSDY@;L44HWY:II8:I/2""
MR-;,-:T1(0&5YG)%\O2;8)]RP5B=LH$0/E$CM:0VO7%/ 6?P2PD"%C^D_&IO
MH84PX5YXU]3,.?*-=@%AU@)],G&RX!JO4NZJS;Q)8!-")D*L&M)ZJ]B&V:J&
MBOX;0+)EE84"\$MEF'8MD8*(3#Y6=XJ$WO']LX<II"X5<9$0$SN^GQ<<'_(V
M-&C).IBW=16X4RK)=&C[4!D/MDEL0E'?%7?-C"ZB2>V@+)_A>\=96X3V1/,5
M^R(3]D^86'#%LWH&51<9$EL(]=3)@%3>T!DQ>C-K$E3 2]21TBR>7L=HO[>N
M7W9U_7)O36XW_AU]?U>9[Q6Y^S7"=\_I5VZ..966" H$EQCHD_;*I"$$788'
M,OB^1%09\$"N?4)@HFRJ@]&;QG/_>-,.G<_X\\V;FS\P%2B/:][_"/^[)FRE
M<,>^>Q/29KBVCI.W/]E *$\(29<<0DJ;O\!Y4ZG)!IT1_"]1[6[\Z"A'H@U;
MDOOZAB5W6E#9#D_Z8YZ282E(%!ZF]0WJ&55V,JKH;9FX'UV;LD2#HRRE&8MI
M<G^ )SO;JDXS$ [[HKUC1**^ZU/5T#T0 :@ZD_8!?\K4)RGOZ;UMGMF(C9%6
M/#Q:3)ZI/L4<C"#U>K!6YQ.?CGTPBDL36EJ67Q^47&QI;BVV@I0J<.6^%3UT
M?=?WLFXCU;*[S@G;$PB!)\)7\AB B!W4SI6':4( 7.H- *$Y/##CD(I\!)*B
M@/I/)D7>$)M<MXQEV$X.!JP',UG#]CF?N&O7ZH?H655'[>:.R B'^=DI!Y@7
M1].CT>GIZ!1SHQQCPN1YKB29^BG_SI:A!+V>Y*XSP[A+BJ?+0.M5B5QFLL5%
MI\:]-VJ<Y:FUHI?>40-&#WG#-)?<8^A<36,W=8 Y+$<BB<58_*K=PLMZR3C>
M]:7E6/P&&U 0JM7UZRB(&N )"Y":-)O+X"R7( -\4Q.+;0<RC52+F:2F6:*=
M(#>Q[V9?I!$%\^L:!DPGXL>)4M%"$ _BLZD_[HQT>E,V1E\H,G)MC:<YAFW!
M#[=XRXJ+VNI4;U[G7IGIO:8W=DA024<_?YN!%,QOEG2R9C-6),;9M*^*ZA+Y
MMR]9QV)7 YKTO@*@2RWX6P<S?AO3!X'N;O<YY2I]1=@L3]]BWH.- \Q$J>?8
M>C1^B=G0I^\;Z2*ZFK\I8 9&2^2?2XU"][0 S^<.Q9TOZ(#N(]/E_P!02P,$
M%     @ 0XBL5G=M)8I& P  1@<  !D   !X;"]W;W)K<VAE971S+W-H965T
M,3DN>&ULE55M;]LV$/XK!W4H$D"+)$IV9,<VD#0=-F M@B1;/PS[0$LGBRA%
M>B05=_]^1\I6O,%QL2\V*=X]]]P+'RYVVGRU+:*#;YU4=AFUSFWG26*K%CMN
MK_06%9TTVG3<T=9L$KLUR.O@U,F$I>DTZ;A0T6H1OCV8U4+W3@J%#P9LWW7<
M_'V'4N^6418=/CR*3>O\AV2UV/(-/J'[;?M@:)>,*+7H4%FA%1ALEM%M-K\K
MO'TP^%W@SAZMP6>RUOJKW_Q2+Z/4$T*)E?,(G/Y>\ -*Z8&(QE][S&@,Z1V/
MUP?TGT+NE,N:6_R@Y1=1NW89E1'4V/!>ND>]^QGW^4P\7J6E#;^P&VR+(H*J
MMTYW>V=BT DU_/-O^SH<.93I&PYL[\ "[R%08'G/'5\MC-Z!\=:$YA<AU>!-
MY(3R37ERADX%^;G51VZ44!L+%[]J:R_A 0T\M=P@7#SSM41[N4@<Q?'62;7'
MO!LPV1N8.7S2RK46/JH:ZW_[)\1O),D.)._86<!/W%Q!GL7 4I:?P<O'I/.
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M:A= ^PNE[-9Q"?H_CMD?4$L#!!0    ( $.(K%9]_'&FY@,  ,()   9
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M=\#E;NZ%WM/&9[:NC=WPB]F&KN$1S)?-@\*5/[!4K &AF11$P6KNO0MO[\/
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M0 C*&N#[E93F:6$/&$;,XC]02P,$%     @ 0XBL5@^@5CM^ @  ZP4  !D
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M#D7I?K3T&ZL:WYTK9;'7_;+&:0S:!>#]6BF[W;@'QOF>_P902P,$%     @
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MM9D=E.#G!;AW /P3$SWPW5/P',^'+W<7\.;D+2S5K[^XP]'O+7AS,]XUW_;
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MRN#J/4I3=5.J)T96[EVOI,$NX88%]G%0-@#WUU*:X\0>T/XSI+\!4$L#!!0
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M\W!-VZ]9<NU6+)^>HJ9UO?('O$[;&]/!. =LA7:^]9R^YFD'Y1Z^1;)WCG?
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MN:CFH9J/:@&EM7M DR$<OG:&<(AF"%%-1S4#U4Q4LU#-1C4'U5Q4\U#-1[6
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M*%6^7*DG6*K\V^KIC/X'4$L#!!0    ( $.(K%:>"9G6=@,  &X,   9
M>&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;,57VV[C-A#]%4(MBEU@$]UE)[4%
MQ$Z+%N@"08+=/A1]H*6Q12Q%NB1EQW_?H20KLJ.H39"B+S9)S1S..9RA1K.]
M5-]T 6#(8\F%GCN%,=MKU]59 275EW(+ I^LI2JIP:G:N'JK@.:U4\G=P/,2
MMZ1,..FL7KM3Z4Q6AC,!=XKHJBRI.BR R_W<\9WCPCW;%,8NN.EL2S?P .;+
M]D[AS.U0<E:"T$P*HF ]=V[\ZZ5?.]067QGL=6],+)65E-_LY-=\[G@V(N"0
M&0M!\6\'2^#<(F$<?[6@3K>G=>R/C^@_U^21S(IJ6$K^.\M-,7>F#LEA32MN
M[N7^%V@)Q18ODUS7OV3?VGH.R2IM9-DZ8P0E$\T_?6R%Z#D@SK!#T#H$YP[1
M"PYAZQ#61)O(:EJWU-!TIN2>*&N-:'90:U-[(QLF[#$^&(5/&?J9]";/F=53
M$RIR<@^F4CB6:W*G9%YEAM0'J\D%6194;( P099HSG)0U#I^(E_9"D<[\N$6
M#&5<?T3C+P^WY,/W'V>NP1CM3F[6QK-HX@E>B"<DGZ4PA28_B1SR4W\7N74$
M@R/!13 *^)FJ2Q+ZGTC@!>% /,M_[QZ,A!-V>H<U7O@"WF]2:RN@82BFR [D
M)LM413GYXUYR3C U]U3E?PX)UP!'P\"VW*_UEF8P=[">-:@=..D/W_F)]^,0
MZW<".]$@ZC2(QM#3ITQ:4Z;(CO(*;,IE1UF,'3ZE&%IFO,)TL"YX@=E5L2'P
MB'>9!CVD51- 4@=@;[)=>A$DDR2<S-Q=7X;G=N'$BY*H,SLA&'<$XU&";44,
M!3;J^-I#?">P$XY)QS'YKQ(Y>4\-W@GL1(-)I\%D])P7L&%"V%Q<44Y%!D-L
M&XBXEV*1'T=3>QF=I.+H5F\D,NV(3,<KDNJ";.FAM+6'E:CD@7)S('FE+#M3
M ,&R8S(?(CA]1O BB.+PRC\C.!K"&PE>=02O_N\KY^J9#/XD\>U+XT2%T3C?
MJ(+O/;WMO7$=7N(+5 ED:YL :@OY-<S;/?O4O3/6XV&]E7:OR?%':6,S\0]5
MV@+TWP21-XWC.#IG,KK3:YFXO<ZM!+6I&UJ-9U,)T_0XW6K7--_4K>+9^L(V
MTW5'^ 33=.+8P> MI0F'-4)ZEQ,\)]4TM\W$R&W='ZZDP6ZS'A;X00#*&N#S
MM93F.+$;=)\8Z=]02P,$%     @ 0XBL5G*K^OAX P  @ P  !D   !X;"]W
M;W)K<VAE971S+W-H965T-# N>&ULQ5=A;^HV%/TK5C9-[TFO34A"@ XB%;II
MD_:DJM7;/DS[X"878CW'YMD.E'^_:R>D@:;96G4:'\!V?([O.?9U+O.]5%]U
M 6#(8\F%7GB%,=LKW]=9 275EW(+ I^LI2JIP:[:^'JK@.8.5'(_#(+$+RD3
M7CIW8[<JG<O*<";@5A%=E255AR5PN5]X(^\X<,<VA;$#?CK?T@W<@_FRO578
M\UN6G)4@-)."*%@OO.O1U6KD &[&[PSVNM,F5LJ#E%]MY]=\X04V(N"0&4M!
M\6<'*^#<,F$<WQI2KUW3 KOM(_O/3CR*>: :5I+_P7)3++RI1W)8TXJ;.[G_
M!1I!8\N72:[=-]DW<P./9)4VLFS &$')1/U+'QLC.@#DZ0>$#2 \!\0O *(&
M$#FA=61.U@TU-)TKN2?*SD8VVW#>.#2J8<)NX[U1^)0ASJ37><ZLGYI0D9,[
M,)7"MER36R7S*C/$;:PF%V154+$!P@19X726@Z(6^(G<4X&!2G*=?:N8=FSD
MPPT8RKC^B, O]S?DP_<?Y[[!>.VJ?M;$MJQC"U^(+2*?I3"%)C^)'/)3O(\Z
M6['A4>PR'"3\3-4EB4:?2!B$44\\JW\/#P?"B5KO(\<7O<#WF]3:FFD8&BNR
M SJ8J8IR\N>=Y)S@,=U3E?_59UQ-'/<3V]2_TEN:P<+#W-:@=N"E/WPW2H(?
M^U2_$]F)!W'K03S$GCZ=JC5EBNPHK\ >O^QHB['-I^.&,S->X7&P$+S,[*C8
M$'C$>TV#[O.J#B!Q =A;;9=>A,DDB29S?]>UX?F\:!+$2=Q..Q$X;@6.!P4V
MV=$7V"#PM9OX3F0G&I-68_)?'>3D/3UX)[(3#R:M!Y/!?5["A@EAS^(#Y;CG
MT*>VIAAWCUC@/F='<7"I-PJ9MD*FPQE)=4&V]%#:W,-,5/) N3F0O%)6G2F
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M R=DV_[*4K[.DV[4#2Q$,VK;_@+3Z\?=.=#FXC)E%4MG35<OYW4SL V;M;F
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MCMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " !#B*Q6$"DVN; #  #7&@  #P
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MG2U[%%-)L_:]3/M.Z>874$L#!!0    ( $.(K%8\8?4:C0$  $\8   :
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MB4)6B4)6B4)6B4+6\7^2]5WKU5]_.6_7I%9E<_1GW>^)^2=02P$"% ,4
M" !#B*Q6!T%-8H$   "Q    $               @ $     9&]C4')O<',O
M87!P+GAM;%!+ 0(4 Q0    ( $.(K%;_8YHW[@   "L"   1
M  "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( $.(K%:97)PC
M$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL
M4$L! A0#%     @ 0XBL5@XRA8KA!0  N!\  !@              ("!#0@
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( $.(K%:V%D_X
M4P8  'P9   8              " @20.  !X;"]W;W)K<VAE971S+W-H965T
M,BYX;6Q02P$"% ,4    " !#B*Q6#FP3GZ$"  !J!P  &
M@(&M%   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ 0XBL
M5BY0E06&!0  7!8  !@              ("!A!<  'AL+W=O<FMS:&5E=',O
M<VAE970T+GAM;%!+ 0(4 Q0    ( $.(K%;9&*H'T08  (T;   8
M      " @4 =  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M" !#B*Q6RV(T6F@%   K'P  &               @(%')   >&PO=V]R:W-H
M965T<R]S:&5E=#8N>&UL4$L! A0#%     @ 0XBL5F'D_'XT#@  O2,  !@
M             ("!Y2D  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4
M Q0    ( $.(K%8=%POFO ,  #H(   8              " @4\X  !X;"]W
M;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " !#B*Q63X+@ .H&  "@
M#P  &               @(%!/   >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL
M4$L! A0#%     @ 0XBL5B-OWG-S!@  G@\  !D              ("!84,
M 'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " !#B*Q6H*!"
MHS$(  "A$P  &0              @($+2@  >&PO=V]R:W-H965T<R]S:&5E
M=#$Q+GAM;%!+ 0(4 Q0    ( $.(K%8'SMEQEPH  "<<   9
M  " @7-2  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @
M0XBL5H[O4(H+ P  L08  !D              ("!05T  'AL+W=O<FMS:&5E
M=',O<VAE970Q,RYX;6Q02P$"% ,4    " !#B*Q62@+4.\ "   $!@  &0
M            @(&#8   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4
M Q0    ( $.(K%:I-G"H"00  ,T(   9              " @7IC  !X;"]W
M;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ 0XBL5MW\><R3#
M]2,  !D              ("!NF<  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX
M;6Q02P$"% ,4    " !#B*Q6BQ3K/; "  #K!0  &0              @(&$
M=   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( $.(K%;C
MLI(CFPH  ' :   9              " @6MW  !X;"]W;W)K<VAE971S+W-H
M965T,3@N>&UL4$L! A0#%     @ 0XBL5G=M)8I& P  1@<  !D
M     ("!/8(  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
M" !#B*Q6C'[)8!\#  !P!@  &0              @(&ZA0  >&PO=V]R:W-H
M965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( $.(K%8=L0LTX0(  $0&   9
M              " @1")  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L!
M A0#%     @ 0XBL5GW\<:;F P  P@D  !D              ("!*(P  'AL
M+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " !#B*Q6O!D%4U0#
M  #,"   &0              @(%%D   >&PO=V]R:W-H965T<R]S:&5E=#(S
M+GAM;%!+ 0(4 Q0    ( $.(K%8W[^(V00(  .X$   9              "
M@="3  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ 0XBL
M5K%5'3%A P  ;@H  !D              ("!2)8  'AL+W=O<FMS:&5E=',O
M<VAE970R-2YX;6Q02P$"% ,4    " !#B*Q6#Z!6.WX"  #K!0  &0
M        @('@F0  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0
M   ( $.(K%;E(K +D@0  '$;   9              " @96<  !X;"]W;W)K
M<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ 0XBL5D$.4S*7 @  + @
M !D              ("!7J$  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q0
M2P$"% ,4    " !#B*Q6\&QI-",#   9#0  &0              @($LI
M>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( $.(K%9,B-NP
MVP(  %D(   9              " @8:G  !X;"]W;W)K<VAE971S+W-H965T
M,S N>&UL4$L! A0#%     @ 0XBL5L*-=0RM!   :A8  !D
M ("!F*H  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " !#
MB*Q6V;>;^(<"   !!P  &0              @(%\KP  >&PO=V]R:W-H965T
M<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( $.(K%:[Q8-0RP(   D(   9
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M970S-RYX;6Q02P$"% ,4    " !#B*Q6<0CEH84+   :E@  &0
M    @('5RP  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    (
M $.(K%:>"9G6=@,  &X,   9              " @9'7  !X;"]W;W)K<VAE
M971S+W-H965T,SDN>&UL4$L! A0#%     @ 0XBL5G*K^OAX P  @ P  !D
M             ("!/ML  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"
M% ,4    " !#B*Q6FN6NGBL#  #0$@  #0              @ 'MW@  >&PO
M<W1Y;&5S+GAM;%!+ 0(4 Q0    ( $.(K%:7BKL<P    !,"   +
M      "  4/B  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( $.(K%80*3:YL ,
M -<:   /              "  2SC  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M    " !#B*Q6/&'U&HT!  !/&   &@              @ $)YP  >&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !#B*Q6F,0A):(!  "F
M&   $P              @ '.Z   6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
1    ,  P  <-  "AZ@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>95</ContextCount>
  <ElementCount>199</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>39</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="cpix-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cpix-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cpix-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cpix-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cpix-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cpix-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statement of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity</Role>
      <ShortName>Condensed Consolidated Statement of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cpix-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cpix-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Earnings (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShare</Role>
      <ShortName>Earnings (Loss) Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cpix-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cpix-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cpix-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cpix-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Shareholders' Equity and Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt</Role>
      <ShortName>Shareholders' Equity and Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cpix-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cpix-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Other Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OtherIncome</Role>
      <ShortName>Other Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cpix-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Collaborative Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CollaborativeAgreements</Role>
      <ShortName>Collaborative Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cpix-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Additions and Returns of Product Rights</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights</Role>
      <ShortName>Additions and Returns of Product Rights</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cpix-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cpix-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Organization and Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies</Role>
      <ShortName>Organization and Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cpix-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Earnings (Loss) Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareTables</Role>
      <ShortName>Earnings (Loss) Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EarningsLossPerShare</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="cpix-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Revenues</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="cpix-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Inventories</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cpix-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Leases</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cpix-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Additions and Returns of Product Rights (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables</Role>
      <ShortName>Additions and Returns of Product Rights (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cpix-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Organization and Basis of Presentation Organization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails</Role>
      <ShortName>Organization and Basis of Presentation Organization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="cpix-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Earnings (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails</Role>
      <ShortName>Earnings (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EarningsLossPerShareTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cpix-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Earnings (Loss) Per Share (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual</Role>
      <ShortName>Earnings (Loss) Per Share (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EarningsLossPerShareTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cpix-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Revenues - Schedule of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails</Role>
      <ShortName>Revenues - Schedule of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="cpix-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Revenues - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RevenuesAdditionalInformationDetails</Role>
      <ShortName>Revenues - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="cpix-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Inventories (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails</Role>
      <ShortName>Inventories (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/InventoriesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cpix-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Inventories (Schedule of Inventories) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails</Role>
      <ShortName>Inventories (Schedule of Inventories) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/InventoriesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cpix-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="cpix-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Leases - Lease Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails</Role>
      <ShortName>Leases - Lease Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="cpix-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails</Role>
      <ShortName>Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/LeasesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cpix-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Leases - Rent Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails</Role>
      <ShortName>Leases - Rent Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="cpix-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Shareholders' Equity and Debt - Shareholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity and Debt - Shareholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="cpix-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/IncomeTaxes</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cpix-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Other Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OtherIncomeDetails</Role>
      <ShortName>Other Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/OtherIncome</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="cpix-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Additions and Returns of Product Rights - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails</Role>
      <ShortName>Additions and Returns of Product Rights - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="cpix-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Additions and Returns of Product Rights - Change in Consideration, Vibativ (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationVibativDetails</Role>
      <ShortName>Additions and Returns of Product Rights - Change in Consideration, Vibativ (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="cpix-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Additions and Returns of Product Rights - Change in Consideration, Sancuso Acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationSancusoAcquisitionDetails</Role>
      <ShortName>Additions and Returns of Product Rights - Change in Consideration, Sancuso Acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept LondonInterbankOfferedRateLIBORMember in us-gaap/2022 used in 3 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. cpix-20230331.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="cpix-20230331.htm">cpix-20230331.htm</File>
    <File>a2023q1-exhibit311.htm</File>
    <File>a2023q1-exhibit312.htm</File>
    <File>a2023q1-exhibit321.htm</File>
    <File>ajkazimiemploymentagreemen.htm</File>
    <File>chrisbittermanemploymentag.htm</File>
    <File>cpix-20230331.xsd</File>
    <File>cpix-20230331_cal.xml</File>
    <File>cpix-20230331_def.xml</File>
    <File>cpix-20230331_lab.xml</File>
    <File>cpix-20230331_pre.xml</File>
    <File>jameshermanemploymentagree.htm</File>
    <File>johnhammemploymentagreemen.htm</File>
    <File>toddanthony-employmentagre.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="348">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>63
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cpix-20230331.htm": {
   "axisCustom": 0,
   "axisStandard": 17,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 348,
    "http://xbrl.sec.gov/dei/2022": 30
   },
   "contextCount": 95,
   "dts": {
    "calculationLink": {
     "local": [
      "cpix-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cpix-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "cpix-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cpix-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cpix-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cpix-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 322,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 5
   },
   "keyCustom": 25,
   "keyStandard": 174,
   "memberCustom": 22,
   "memberStandard": 15,
   "nsprefix": "cpix",
   "nsuri": "http://www.cumberlandpharma.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.cumberlandpharma.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Inventories",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.cumberlandpharma.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.cumberlandpharma.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Shareholders' Equity and Debt",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt",
     "shortName": "Shareholders' Equity and Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Other Income",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.cumberlandpharma.com/role/OtherIncome",
     "shortName": "Other Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Collaborative Agreements",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.cumberlandpharma.com/role/CollaborativeAgreements",
     "shortName": "Collaborative Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Additions and Returns of Product Rights",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights",
     "shortName": "Additions and Returns of Product Rights",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.cumberlandpharma.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Organization and Basis of Presentation (Policies)",
     "menuCat": "Policies",
     "order": "18",
     "role": "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies",
     "shortName": "Organization and Basis of Presentation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Earnings (Loss) Per Share (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareTables",
     "shortName": "Earnings (Loss) Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "i1cfe8482250b40a4a99b93d7167bf9ef_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "i1cfe8482250b40a4a99b93d7167bf9ef_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Revenues (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://www.cumberlandpharma.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Inventories (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://www.cumberlandpharma.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.cumberlandpharma.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Additions and Returns of Product Rights (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables",
     "shortName": "Additions and Returns of Product Rights (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Organization and Basis of Presentation Organization (Details)",
     "menuCat": "Details",
     "order": "24",
     "role": "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails",
     "shortName": "Organization and Basis of Presentation Organization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Earnings (Loss) Per Share (Details)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails",
     "shortName": "Earnings (Loss) Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Earnings (Loss) Per Share (Details Textual)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual",
     "shortName": "Earnings (Loss) Per Share (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Revenues - Schedule of Revenue (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails",
     "shortName": "Revenues - Schedule of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "ic5ec9fd4fee24747aa5425a2da34ca15_D20230101-20230331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Revenues - Additional Information (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.cumberlandpharma.com/role/RevenuesAdditionalInformationDetails",
     "shortName": "Revenues - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "if42572ad56a64b2a829bd4df6389654b_D20230101-20230331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "i1cfe8482250b40a4a99b93d7167bf9ef_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryValuationReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Inventories (Narrative) (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
     "shortName": "Inventories (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "i1cfe8482250b40a4a99b93d7167bf9ef_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryValuationReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "i1cfe8482250b40a4a99b93d7167bf9ef_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockNoParValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "i1cfe8482250b40a4a99b93d7167bf9ef_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockNoParValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "i1cfe8482250b40a4a99b93d7167bf9ef_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Inventories (Schedule of Inventories) (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails",
     "shortName": "Inventories (Schedule of Inventories) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "i1cfe8482250b40a4a99b93d7167bf9ef_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "iaf2b4c3ed09b49c69ab36803117edced_I20211115",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "cpix:LesseeOperatingLeaseRentIncrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Leases - Narrative (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "iaf2b4c3ed09b49c69ab36803117edced_I20211115",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "cpix:LesseeOperatingLeaseRentIncrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "i1cfe8482250b40a4a99b93d7167bf9ef_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Leases - Lease Position (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails",
     "shortName": "Leases - Lease Position (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "i1cfe8482250b40a4a99b93d7167bf9ef_I20230331",
      "decimals": "0",
      "lang": "en-US",
      "name": "cpix:LeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "i1cfe8482250b40a4a99b93d7167bf9ef_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails",
     "shortName": "Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "i1cfe8482250b40a4a99b93d7167bf9ef_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Leases - Rent Expense (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails",
     "shortName": "Leases - Rent Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchasedDuringPeriodValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Shareholders' Equity and Debt - Shareholders' Equity (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails",
     "shortName": "Shareholders' Equity and Debt - Shareholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "i1c55618f6c5a49939c91a52e719a9556_D20211227-20211227",
      "decimals": "-6",
      "lang": "en-US",
      "name": "cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "i1cfe8482250b40a4a99b93d7167bf9ef_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Income Taxes (Details Textual)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual",
     "shortName": "Income Taxes (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "i1cfe8482250b40a4a99b93d7167bf9ef_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InsuredEventGainLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Other Income (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.cumberlandpharma.com/role/OtherIncomeDetails",
     "shortName": "Other Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Additions and Returns of Product Rights - Narrative (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
     "shortName": "Additions and Returns of Product Rights - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "i20b2ea64a45e4649b835fa2bde154e6d_I20220103",
      "decimals": "-5",
      "lang": "en-US",
      "name": "cpix:CollaborativeArrangementRightsAndObligationsUpfrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Additions and Returns of Product Rights - Change in Consideration, Vibativ (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationVibativDetails",
     "shortName": "Additions and Returns of Product Rights - Change in Consideration, Vibativ (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "i499b37cd8cf54392a0f2ec322fe40eee_D20230101-20230331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRoyalties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Additions and Returns of Product Rights - Change in Consideration, Sancuso Acquisition (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationSancusoAcquisitionDetails",
     "shortName": "Additions and Returns of Product Rights - Change in Consideration, Sancuso Acquisition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "i34ec3c62de204f83a7f07694bba18e4f_D20230101-20230331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRoyalties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id21988457a994b099a86739b6cdbca82_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Consolidated Statement of Equity",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
     "shortName": "Condensed Consolidated Statement of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id21988457a994b099a86739b6cdbca82_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000007 - Disclosure - Organization and Basis of Presentation",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation",
     "shortName": "Organization and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Earnings (Loss) Per Share",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShare",
     "shortName": "Earnings (Loss) Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Revenues",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.cumberlandpharma.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230331.htm",
      "contextRef": "id6f3c1830d634b2086b95c19a4052d30_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 39,
   "tag": {
    "cpix_A1600WestEndAvenuePartnersLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1600 West End Avenue Partners, LLC",
        "label": "1600 West End Avenue Partners, LLC [Member]",
        "terseLabel": "1600 West End Avenue Partners, LLC"
       }
      }
     },
     "localname": "A1600WestEndAvenuePartnersLLCMember",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_AcetadoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acetadote",
        "label": "Acetadote [Member]",
        "terseLabel": "Acetadote"
       }
      }
     },
     "localname": "AcetadoteMember",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets and Liabilities, Lessee",
        "label": "Assets and Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Lease Position"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cpix_BroadwestLeaseFiveYearRenewalOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Broadwest Lease, Five Year Renewal Option",
        "label": "Broadwest Lease, Five Year Renewal Option [Member]",
        "terseLabel": "Broadwest Lease, Five Year Renewal Option"
       }
      }
     },
     "localname": "BroadwestLeaseFiveYearRenewalOptionMember",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses",
        "label": "Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses",
        "terseLabel": "Contingent consideration earned and accrued in operating expenses"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationSancusoAcquisitionDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationVibativDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_CETMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CET",
        "label": "CET [Member]",
        "terseLabel": "CET"
       }
      }
     },
     "localname": "CETMember",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_CaldolorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Caldolor",
        "label": "Caldolor [Member]",
        "terseLabel": "Caldolor"
       }
      }
     },
     "localname": "CaldolorMember",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Milestone Payment Credit Due",
        "label": "Collaborative Arrangement, Rights and Obligations, Milestone Payment Credit Due",
        "terseLabel": "Milestone payment credit due"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Milestone Payment Receivable",
        "label": "Collaborative Arrangement, Rights and Obligations, Milestone Payment Receivable",
        "terseLabel": "Milestone payment receivable"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Restricted Shares Receivable",
        "label": "Collaborative Arrangement, Rights and Obligations, Restricted Shares Receivable",
        "terseLabel": "Restricted shares receivable (in shares)"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments",
        "label": "Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments",
        "terseLabel": "Sales milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsSalesMilestonePayments",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Expected",
        "label": "Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Expected",
        "terseLabel": "Sales milestone payments, expected"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Maximum",
        "label": "Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Maximum",
        "terseLabel": "Sales milestone payments, maximum"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Tiered Royalty, Percent",
        "label": "Collaborative Arrangement, Rights and Obligations, Tiered Royalty, Percent",
        "terseLabel": "Tiered royalty, percent"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Upfront Payment",
        "label": "Collaborative Arrangement, Rights and Obligations, Upfront Payment",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsUpfrontPayment",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_DebtInstrumentCovenantEvaluationFrequency": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Evaluation Frequency",
        "label": "Debt Instrument, Covenant, Evaluation Frequency",
        "terseLabel": "Covenant evaluation frequency"
       }
      }
     },
     "localname": "DebtInstrumentCovenantEvaluationFrequency",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cpix_DebtInstrumentCovenantFundedDebtRatioMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Funded Debt Ratio, Maximum",
        "label": "Debt Instrument, Covenant, Funded Debt Ratio, Maximum",
        "terseLabel": "Maximum funded debt ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantFundedDebtRatioMaximum",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "cpix_DebtInstrumentCovenantUnrestrictedCashThreshold": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Unrestricted Cash Threshold",
        "label": "Debt Instrument, Covenant, Unrestricted Cash Threshold",
        "terseLabel": "Unrestricted cash threshold"
       }
      }
     },
     "localname": "DebtInstrumentCovenantUnrestrictedCashThreshold",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_DenominatorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Denominator.",
        "label": "Denominator [Abstract]",
        "verboseLabel": "Denominator:"
       }
      }
     },
     "localname": "DenominatorAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_EightAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eight Amendment",
        "label": "Eight Amendment [Member]",
        "terseLabel": "Eight Amendment"
       }
      }
     },
     "localname": "EightAmendmentMember",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_EquityAndDebtAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity and Debt [Abstract]",
        "label": "Equity and Debt [Abstract]"
       }
      }
     },
     "localname": "EquityAndDebtAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "xbrltype": "stringItemType"
    },
    "cpix_IfetrobanClinicalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ifetroban Clinical",
        "label": "Ifetroban Clinical [Member]",
        "terseLabel": "Ifetroban Clinical"
       }
      }
     },
     "localname": "IfetrobanClinicalMember",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_IncentiveStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive Stock Options",
        "label": "Incentive Stock Options [Member]",
        "terseLabel": "Incentive Stock Options"
       }
      }
     },
     "localname": "IncentiveStockOptionsMember",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy",
        "label": "Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy",
        "negatedTerseLabel": "Decrease (increase) in cash surrender value of life insurance policies over premiums paid"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_KristaloseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kristalose",
        "label": "Kristalose [Member]",
        "terseLabel": "Kristalose"
       }
      }
     },
     "localname": "KristaloseMember",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_KyowaKirinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kyowa Kirin",
        "label": "Kyowa Kirin [Member]",
        "terseLabel": "Kyowa Kirin"
       }
      }
     },
     "localname": "KyowaKirinMember",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_LeaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Liability",
        "label": "Lease, Liability",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "LeaseLiability",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_LesseeOperatingLeaseBaseRent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Base Rent",
        "label": "Lessee, Operating Lease, Base Rent",
        "terseLabel": "Base rent per square foot"
       }
      }
     },
     "localname": "LesseeOperatingLeaseBaseRent",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryPerAreaItemType"
    },
    "cpix_LesseeOperatingLeaseLeasedArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Leased Area",
        "label": "Lessee, Operating Lease, Leased Area",
        "terseLabel": "Leased area"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeasedArea",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "cpix_LesseeOperatingLeaseNumberOfRenewalTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number Of Renewal Terms",
        "label": "Lessee, Operating Lease, Number Of Renewal Terms",
        "terseLabel": "Number of renewal terms"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfRenewalTerms",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cpix_LesseeOperatingLeaseRentIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Rent Increase",
        "label": "Lessee, Operating Lease, Rent Increase",
        "terseLabel": "Rent increase"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRentIncrease",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cpix_LineOfCreditFacilityAdditionalBorrowingCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility, Additional Borrowing Capacity",
        "label": "Line Of Credit Facility, Additional Borrowing Capacity",
        "terseLabel": "Additional borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityAdditionalBorrowingCapacity",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_MethotrexateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Methotrexate [Member]",
        "label": "Methotrexate [Member]",
        "terseLabel": "Methotrexate"
       }
      }
     },
     "localname": "MethotrexateMember",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_NinthAmemdmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ninth Amemdment",
        "label": "Ninth Amemdment [Member]",
        "terseLabel": "Ninth Amemdment"
       }
      }
     },
     "localname": "NinthAmemdmentMember",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_NordicGroupBVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nordic Group B.V.",
        "label": "Nordic Group B.V. [Member]",
        "terseLabel": "Nordic Group B.V."
       }
      }
     },
     "localname": "NordicGroupBVMember",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_NumeratorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Numerator.",
        "label": "Numerator [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "localname": "NumeratorAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_OmeclamoxPakMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Omeclamox-Pak",
        "label": "Omeclamox-Pak [Member]",
        "terseLabel": "Omeclamox-Pak"
       }
      }
     },
     "localname": "OmeclamoxPakMember",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_OtherProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products",
        "label": "Other Products [Member]",
        "terseLabel": "Other revenue"
       }
      }
     },
     "localname": "OtherProductsMember",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_PinnacleBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pinnacle Bank",
        "label": "Pinnacle Bank [Member]",
        "terseLabel": "Pinnacle Bank"
       }
      }
     },
     "localname": "PinnacleBankMember",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ProductsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Products.",
        "label": "Products [Abstract]",
        "verboseLabel": "Products:"
       }
      }
     },
     "localname": "ProductsAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_RediTrexMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RediTrex",
        "label": "RediTrex [Member]",
        "terseLabel": "RediTrex"
       }
      }
     },
     "localname": "RediTrexMember",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_SancusoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sancuso",
        "label": "Sancuso [Member]",
        "terseLabel": "Sancuso"
       }
      }
     },
     "localname": "SancusoMember",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationSancusoAcquisitionDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Rent Expense and Sublease Income [Table Text Block]",
        "label": "Schedule of Rent Expense and Sublease Income [Table Text Block]",
        "terseLabel": "Schedule of Rent Expense and Sublease Income"
       }
      }
     },
     "localname": "ScheduleofRentExpenseandSubleaseIncomeTableTextBlock",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cpix_SixthAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sixth Amendment",
        "label": "Sixth Amendment [Member]",
        "terseLabel": "Sixth Amendment"
       }
      }
     },
     "localname": "SixthAmendmentMember",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shelf Registration, Proceeds From Sale of Corporate Securities",
        "terseLabel": "Shelf Registration, sale of corporate securities (up to)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_TieredRoyaltyPaymentsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tiered Royalty Payments, Percentage",
        "label": "Tiered Royalty Payments, Percentage",
        "terseLabel": "Percentage of tiered royalty payments (up to)"
       }
      }
     },
     "localname": "TieredRoyaltyPaymentsPercentage",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cpix_TieredRoyaltyPaymentsThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tiered Royalty Payments, Threshold",
        "label": "Tiered Royalty Payments, Threshold",
        "terseLabel": "Tiered royalty payment, threshold"
       }
      }
     },
     "localname": "TieredRoyaltyPaymentsThreshold",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_TradeAndNoteReceivablesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trade and Note Receivables",
        "label": "Trade and Note Receivables [Policy Text Block]",
        "terseLabel": "Trade and Note Receivables Policy"
       }
      }
     },
     "localname": "TradeAndNoteReceivablesPolicyTextBlock",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cpix_VIBATIVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "VIBATIV",
        "label": "VIBATIV [Member]",
        "terseLabel": "Vibativ"
       }
      }
     },
     "localname": "VIBATIVMember",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationVibativDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_VaprisolMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vaprisol",
        "label": "Vaprisol [Member]",
        "terseLabel": "Vaprisol"
       }
      }
     },
     "localname": "VaprisolMember",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_WinHealthInvestmentSingaporeLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "WinHealth Investment (Singapore) Ltd",
        "label": "WinHealth Investment (Singapore) Ltd [Member]",
        "terseLabel": "WinHealth"
       }
      }
     },
     "localname": "WinHealthInvestmentSingaporeLtdMember",
     "nsuri": "http://www.cumberlandpharma.com/20230331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r148",
      "r149",
      "r236",
      "r250",
      "r374",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r220",
      "r221",
      "r222",
      "r223",
      "r266",
      "r352",
      "r361",
      "r368",
      "r369",
      "r385",
      "r389",
      "r396",
      "r428",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r220",
      "r221",
      "r222",
      "r223",
      "r266",
      "r352",
      "r361",
      "r368",
      "r369",
      "r385",
      "r389",
      "r396",
      "r428",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OfficeBuildingMember": {
     "auth_ref": [
      "r449",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Building [Member]",
        "terseLabel": "Wet Laboratory and Office Space"
       }
      }
     },
     "localname": "OfficeBuildingMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r207",
      "r353",
      "r386",
      "r395",
      "r422",
      "r423",
      "r429",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesAdditionalInformationDetails",
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r207",
      "r353",
      "r386",
      "r395",
      "r422",
      "r423",
      "r429",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesAdditionalInformationDetails",
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r220",
      "r221",
      "r222",
      "r223",
      "r265",
      "r266",
      "r291",
      "r292",
      "r293",
      "r351",
      "r352",
      "r361",
      "r368",
      "r369",
      "r385",
      "r389",
      "r396",
      "r421",
      "r428",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r220",
      "r221",
      "r222",
      "r223",
      "r265",
      "r266",
      "r291",
      "r292",
      "r293",
      "r351",
      "r352",
      "r361",
      "r368",
      "r369",
      "r385",
      "r389",
      "r396",
      "r421",
      "r428",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r148",
      "r149",
      "r236",
      "r250",
      "r375",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r417",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r14",
      "r394"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r212",
      "r213"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net income (loss) to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r295"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "negatedTerseLabel": "Share-based compensation credit"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r28",
      "r248",
      "r339",
      "r409"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "verboseLabel": "Increase in noncash interest expense"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r42",
      "r54",
      "r56"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "verboseLabel": "Amortization"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Common stock available for purchase through restricted stock awards and options (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Square feet of office space"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r99",
      "r111",
      "r131",
      "r145",
      "r188",
      "r198",
      "r203",
      "r214",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r322",
      "r326",
      "r331",
      "r394",
      "r426",
      "r427",
      "r439"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r126",
      "r134",
      "r145",
      "r214",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r322",
      "r326",
      "r331",
      "r394",
      "r426",
      "r427",
      "r439"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r312",
      "r387",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationSancusoAcquisitionDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationVibativDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r77",
      "r78",
      "r312",
      "r387",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationSancusoAcquisitionDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationVibativDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]",
        "verboseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationSancusoAcquisitionDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationVibativDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "auth_ref": [
      "r81",
      "r83",
      "r84",
      "r315"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "terseLabel": "Liability recorded"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r317",
      "r408"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Change in fair value of contingent consideration included in operating expenses",
        "verboseLabel": "Decrease in non-cash contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationSancusoAcquisitionDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationVibativDetails",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r82",
      "r85",
      "r316"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Additional liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationSancusoAcquisitionDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationVibativDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r82",
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Current portion of the contingent consideration liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r82",
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Noncurrent portion of the contingent consideration liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r87",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "ADDITIONS AND RETURN OF PRODUCT RIGHTS"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "auth_ref": [
      "r79",
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of inventory recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r44",
      "r128",
      "r370"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r38",
      "r44",
      "r45"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r38",
      "r94"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r318",
      "r319",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborative Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CollaborativeAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement.",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r22",
      "r104",
      "r116"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r59",
      "r218",
      "r219",
      "r367",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r412",
      "r413",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "verboseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNoParValue": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount per share of no-par value common stock.",
        "label": "Common Stock, No Par Value",
        "verboseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockNoParValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r6",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance, End of Period (in shares)",
        "periodStartLabel": "Balance, Beginning of Period (in shares)",
        "verboseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r6",
      "r394"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock\u2014no par value; 100,000,000 shares authorized; 15,555,865 and 15,723,075 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r63",
      "r233",
      "r234",
      "r239",
      "r240",
      "r241",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r30",
      "r353"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "verboseLabel": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "verboseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r100",
      "r101",
      "r110",
      "r150",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r340",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r95",
      "r97",
      "r233",
      "r340",
      "r381",
      "r382"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Convertible note"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r19",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate spread"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r20",
      "r150",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r340",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r42",
      "r186"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "verboseLabel": "Earnings (loss) per share attributable to common shareholders"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r170",
      "r171",
      "r172",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "EARNINGS (LOSS) PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue from External Customer [Line Items]",
        "terseLabel": "Revenue from External Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesAdditionalInformationDetails",
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r64",
      "r123",
      "r137",
      "r138",
      "r139",
      "r151",
      "r152",
      "r153",
      "r155",
      "r160",
      "r162",
      "r174",
      "r215",
      "r262",
      "r296",
      "r297",
      "r298",
      "r303",
      "r304",
      "r329",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r350",
      "r362",
      "r363",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r55",
      "r354"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r129",
      "r217",
      "r355",
      "r379",
      "r394",
      "r419",
      "r420"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]",
        "terseLabel": "Grant"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r26",
      "r98",
      "r106",
      "r120",
      "r188",
      "r197",
      "r202",
      "r205",
      "r357",
      "r378"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (loss) before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r25",
      "r105",
      "r107",
      "r117",
      "r141",
      "r154",
      "r156",
      "r157",
      "r158",
      "r159",
      "r165",
      "r167",
      "r168",
      "r330",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Earnings (loss) per share attributable to common shareholders - Continuing operations - basic (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r25",
      "r117",
      "r119",
      "r141",
      "r154",
      "r156",
      "r157",
      "r158",
      "r159",
      "r165",
      "r167",
      "r168",
      "r169",
      "r330",
      "r356",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Earnings (loss) per share attributable to common shareholders - Continuing operations - diluted (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r72",
      "r73",
      "r74",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r146",
      "r300",
      "r301",
      "r302",
      "r305",
      "r307",
      "r309",
      "r310",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r147",
      "r161",
      "r162",
      "r187",
      "r299",
      "r306",
      "r308",
      "r360"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax (expense) benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Net changes in assets and liabilities affecting operating activities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other current assets and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InsuredEventGainLoss": {
     "auth_ref": [
      "r424"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess (deficiency) of insurance recovery over the loss incurred from an insured event.",
        "label": "Insured Event, Gain (Loss)",
        "negatedTerseLabel": "Gain on receivable of FDA fees",
        "terseLabel": "Gain on receivable of FDA fees"
       }
      }
     },
     "localname": "InsuredEventGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/OtherIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r96",
      "r109",
      "r140",
      "r185",
      "r338"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r53",
      "r372"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods, net of reserve",
        "verboseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r406"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Total inventories"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r132",
      "r371",
      "r394"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Total inventories classified as current",
        "verboseLabel": "Inventories, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net, Items Net of Reserve Alternative [Abstract]",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNetItemsNetOfReserveAlternativeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r403"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "negatedLabel": "less non-current inventories",
        "terseLabel": "Non-current inventories"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r53",
      "r373"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "verboseLabel": "Raw materials and work in process"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r52",
      "r406"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "terseLabel": "Obsolescence and discontinuance losses"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r32",
      "r184"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "verboseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "auth_ref": [
      "r404"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "terseLabel": "Initial investment in joint ventures"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturity of Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "After 2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r437"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "verboseLabel": "Less: Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "auth_ref": [
      "r349"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor for operating lease.",
        "label": "Lessor, Operating Lease, Payments to be Received",
        "terseLabel": "Future minimum sublease income under noncancelable operating subleases"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r16",
      "r145",
      "r214",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r323",
      "r326",
      "r327",
      "r331",
      "r377",
      "r426",
      "r439",
      "r440"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r10",
      "r103",
      "r114",
      "r394",
      "r411",
      "r418",
      "r433"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r18",
      "r127",
      "r145",
      "r214",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r323",
      "r326",
      "r327",
      "r331",
      "r394",
      "r426",
      "r439",
      "r440"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r15",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": {
     "auth_ref": [
      "r15"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Current Borrowing Capacity",
        "terseLabel": "Current borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityCurrentBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r15",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.",
        "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "terseLabel": "Line of credit, unused capacity, commitment fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermLineOfCredit": {
     "auth_ref": [
      "r20",
      "r60",
      "r61"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-Term Line of Credit, Noncurrent",
        "verboseLabel": "Revolving line of credit"
       }
      }
     },
     "localname": "LongTermLineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r20",
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyAccrualRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Loss Contingency Accrual [Roll Forward]",
        "terseLabel": "Loss Contingency Accrual [Roll Forward]"
       }
      }
     },
     "localname": "LossContingencyAccrualRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationSancusoAcquisitionDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationVibativDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r24",
      "r102",
      "r113",
      "r145",
      "r214",
      "r224",
      "r226",
      "r227",
      "r228",
      "r231",
      "r232",
      "r331"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r143"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r143"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r38",
      "r40",
      "r43"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r27",
      "r43",
      "r108",
      "r118",
      "r125",
      "r135",
      "r136",
      "r139",
      "r145",
      "r154",
      "r156",
      "r157",
      "r158",
      "r159",
      "r161",
      "r162",
      "r166",
      "r188",
      "r197",
      "r202",
      "r205",
      "r214",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r330",
      "r331",
      "r378",
      "r426"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income (loss) attributable to common shareholders",
        "totalLabel": "Net income (loss) attributable to common shareholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r90",
      "r92",
      "r135",
      "r136",
      "r161",
      "r162",
      "r407"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Net loss at subsidiary attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Guidance"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r88",
      "r262",
      "r412",
      "r413",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "verboseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r188",
      "r197",
      "r202",
      "r205",
      "r378"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income (loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r434"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Maturity of Lease Liabilities at March 31, 2023"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r342"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r342"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease current liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r342"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease noncurrent liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r341"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r346",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Present value of remaining lease payments, percent"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r345",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "ORGANIZATION AND BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r133",
      "r394"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "verboseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r130"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncome": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue and income classified as other.",
        "label": "Other Income",
        "terseLabel": "Other income",
        "verboseLabel": "Refund"
       }
      }
     },
     "localname": "OtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/OtherIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": {
     "auth_ref": [
      "r67",
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.",
        "label": "Other Income and Other Expense Disclosure [Text Block]",
        "terseLabel": "Other Income"
       }
      }
     },
     "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of inventory owned by the entity but in the hands of a customer, typically a reseller.",
        "label": "Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross",
        "terseLabel": "Consigned inventory"
       }
      }
     },
     "localname": "OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r17",
      "r394"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "verboseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPaymentsToAcquireBusinesses": {
     "auth_ref": [
      "r33"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.",
        "label": "Other Payments to Acquire Businesses",
        "terseLabel": "Other Payments to Acquire Businesses"
       }
      }
     },
     "localname": "OtherPaymentsToAcquireBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedLabel": "Cash payment of contingent consideration"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of common shares"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRoyalties": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for royalties during the current period.",
        "label": "Payments for Royalties",
        "negatedLabel": "Cash payment of royalty during the period",
        "negatedTerseLabel": "Cash payment of royalty during the period"
       }
      }
     },
     "localname": "PaymentsForRoyalties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationSancusoAcquisitionDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationVibativDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r33",
      "r314"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "negatedTerseLabel": "Cash paid for acquisitions",
        "terseLabel": "Payment to acquire business upon closing"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Additions to intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Additions to property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).",
        "label": "Proceeds from (Repayments of) Lines of Credit",
        "terseLabel": "Borrowings on line of credit"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r125",
      "r135",
      "r136",
      "r142",
      "r145",
      "r154",
      "r161",
      "r162",
      "r188",
      "r197",
      "r202",
      "r205",
      "r214",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r321",
      "r324",
      "r325",
      "r330",
      "r331",
      "r357",
      "r378",
      "r391",
      "r392",
      "r407",
      "r426"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r58",
      "r115",
      "r358",
      "r394"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PublicUtilitiesInventoryAxis": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of inventory held.",
        "label": "Inventory [Axis]",
        "terseLabel": "Inventory [Axis]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PublicUtilitiesInventoryTypeDomain": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.",
        "label": "Inventory [Domain]",
        "terseLabel": "Inventory [Domain]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedTerseLabel": "Repayments on line of credit"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r70",
      "r122",
      "r447"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r7",
      "r65",
      "r112",
      "r365",
      "r366",
      "r394"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings (deficit)"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r123",
      "r151",
      "r152",
      "r153",
      "r155",
      "r160",
      "r162",
      "r215",
      "r296",
      "r297",
      "r298",
      "r303",
      "r304",
      "r329",
      "r362",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "verboseLabel": "Retained earnings (deficit)"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r182",
      "r183",
      "r196",
      "r200",
      "r201",
      "r207",
      "r208",
      "r210",
      "r263",
      "r264",
      "r353"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues",
        "verboseLabel": "Net revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/RevenuesAdditionalInformationDetails",
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Net Revenues"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r77",
      "r78",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationSancusoAcquisitionDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationVibativDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Reconciliation of numerator and denominator"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table]",
        "terseLabel": "Revenue from External Customers by Products and Services [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesAdditionalInformationDetails",
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Summary of net revenue"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r1",
      "r11",
      "r12",
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r188",
      "r189",
      "r199",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r209",
      "r210",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "REVENUES"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "verboseLabel": "Operating Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling and Marketing Expense",
        "verboseLabel": "Selling and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Restricted stock awards, vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock granted in period, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r23",
      "r64",
      "r123",
      "r137",
      "r138",
      "r139",
      "r151",
      "r152",
      "r153",
      "r155",
      "r160",
      "r162",
      "r174",
      "r215",
      "r262",
      "r296",
      "r297",
      "r298",
      "r303",
      "r304",
      "r329",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r350",
      "r362",
      "r363",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r174",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r5",
      "r6",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Unvested restricted shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r5",
      "r6",
      "r64",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r23",
      "r64",
      "r65"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Vested common stock, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r5",
      "r6",
      "r65",
      "r68"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock Repurchase Program, Authorized Amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Common shares left to repurchase"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r5",
      "r6",
      "r64",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedTerseLabel": "Repurchase of shares (in shares)",
        "terseLabel": "Repurchase of shares (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r5",
      "r6",
      "r64",
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedTerseLabel": "Repurchase of common shares",
        "verboseLabel": "Repurchase of shares"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r6",
      "r8",
      "r9",
      "r51",
      "r394",
      "r411",
      "r418",
      "r433"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Shareholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r88",
      "r89",
      "r91",
      "r123",
      "r124",
      "r138",
      "r151",
      "r152",
      "r153",
      "r155",
      "r160",
      "r215",
      "r262",
      "r296",
      "r297",
      "r298",
      "r303",
      "r304",
      "r329",
      "r332",
      "r333",
      "r337",
      "r350",
      "r363",
      "r364",
      "r411",
      "r418",
      "r433"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance, End of Period",
        "periodStartLabel": "Balance, Beginning of Period",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r66",
      "r144",
      "r249",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "SHAREHOLDERS' EQUITY AND DEBT"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r344",
      "r393"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "terseLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Text Block [Abstract]"
       }
      }
     },
     "localname": "TextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r47",
      "r48",
      "r49",
      "r175",
      "r176",
      "r177",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r415"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "terseLabel": "Dilutive effect of other securities (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r164",
      "r169"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted-average shares outstanding \u2013 diluted (in shares)",
        "verboseLabel": "- diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "Weighted-average shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r163",
      "r169"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares outstanding \u2013 basic (in shares)",
        "verboseLabel": "- basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.4)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868656-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r397": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r398": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r399": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r401": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r402": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=d3e1314-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=d3e1336-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "610",
   "URI": "https://asc.fasb.org/topic&trid=49130413",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "720",
   "URI": "https://asc.fasb.org/topic&trid=2122503",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>64
<FILENAME>0001628280-23-017951-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-017951-xbrl.zip
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M.%&]NA> ;V.&AI <H3X+MB3#)X';\>/!;;W:WH3MSCRU@=[=&6YG$ /PISQ
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M%[@:(LUZ7=2ZY;J'JT_Y#_+==F;N^'AL#]WQ= +38[!/QLXQ.&\<^]P=_^W
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M5\L7-RVSCS@3;<'10NS?^WH1.Z(_5@,76! *,D]>48=QLX<5D8"2">'K&C&
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M*2;'==6DZ 1$2.&86U0K8TMPNJ+1MP9!=\]2PG!)<V6QU9W"'CHC:?[<N7"
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M%>:'S,HOU6F::UXCU"2_V2'/Y2>=USGK]JHY )&:"&E[/E,)Y0$!H^4YV>9
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M+_XM?]>YODO#CVQCE[8;%']&I/V2S.ZF15J=GT.3SN"_295GS_\?4$L#!!0
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M(R+-/J!-[U)V"_QW@<ISD^M"!ZY%181#T+^>:P=Z8;"62+&OP, AH$01:[0
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M:38*O=-,@(A.C%J5;JL='63:I!0)*7R&LP/-'BP'U[T+/- ,?+B!C%F7'II
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M!$?WQ(U$*&7@G'G7) ON@?W2(5M&7>6*]/T027\I?'I09$Y2 2!Z]%\DB3R
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MGF(YI?[,O*]" W46"RTLIVDVGGH(TXHC:!P5= Y* 94Z]@)S!M:(8##UCLA
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M.C\ ]^^<?O!UR-87#>VG#H1%GXXVZUG VO#/AWQ[-Y'/$QF4$ HP'GN1$A:
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MB"O)D7$1DW!%(%:A2LZ0-U-&)F:33I0&/%4#'B,5%BJN@P ()8< !A5)A::
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M4,O$*=7!F#,I P[8<P:\L"A-!6)@A$9 *Z.]M1PB(Y?>(53!&%?(TS>GF+V
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M6F9O)=L<E"K>\7T=?W29U]UV;'HO^\/YD-N\_^<K6]+VQW,0BEY\S7\M@=O
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MI:TSGSR#7Z8_+6#LJ7_HNT]A/J\B/V+2S*?H]0%,EO X.7C<&B,[6A-)@L-
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M*FW]66S]%G>*8M1,^N@ED6)2!D7NQ(,&1@<AF8O$2LE)<J?7.SL_.F5HB:0
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MH^GT!"](FRV)YS1^EOORLW3ZO1,T"H/N3Q.6S;6[UI2P9 $=]GLUHVS ZT[
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MD1I,'?,FP6AJA*'P"M)HUN;@W0J]1D_6]+JS4W<-Q&PPQ,RW [3&%C%RI$4
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MZ<U1Z9M89HV8&C$U8EJ_CAO-!OEP&^2\[5T4TA%!+"(6]D:.%44*]DP4/39
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M:=?[T(Q#8CSU0[BI;>)F;9,XM4V&4YZ9[CH+V:<&T-*F]0'P#M-=[7DF(3S
M;[I= A!8KEFZZ9N[P86TC"85LBDL]LMQ?.?I6>*Y) B\3%(FGZ8\?]:>/"V]
M&XRRWX,UU4N%0#J@O6X\R*OQRA=Z,)3A,.^4_58T90+P\XIIYZ&6O:J02)K-
M(0 [_ 8O<1H&H>R!+0K/3\6BR@AHWQM56CHA &FFQY,1PP;8&U;E+X8S,P:[
M71=><E0Q%#=+^2L]^3$)+1$)W#X-:.!3A?)+40"\CSNF&E8MU]=IILIJ<X>1
M[WV![;UWDN7=+;,6MWZ9(5VO]YY/F%&%62X,1@8>-SMUZ>]^:I_,#O#RM6 '
M[7?+47HI0+WS,*A_R= $P]I[GO?@/,=E-UU0]OU$6)=3-OS121N>]L< -39-
MBIG(X^.X5U6^F<[8[59JK]KIJ_6:;YKVSIT></Y.ZU4XA^64M.5/F*D6P>A_
M\BNFQUP$,VB%3  7U.7*_.<_7'_#B6RJY023->Y4*MR'":P%/WDF4(\ ^P*@
MS.FP?O;52O;MO!_ .TWU!B ,7BHSK$2EZB4T>4PB&Z$5O@!?S+-4/R?MCXE1
ME:D.3_6FB:HGTCQ.VU$MV^T%<^D.36\ X)U*85.EH4&_!S^Z2I!_@YC=1?7O
M$S:MOQZ\_" +&@*- L58<,0I%\@6W".IE70A^L(E/_Y54WE-]LU\Q]\2J2C=
M#;P]KT(R6UJ7:Z+U8EQF\%Q'4G#MRRVG"8LO=W7%K^,K?H_W_'O<"P!2I*AX
MSJ57=>8M7Z?.#F;@AZT_^O"?UB];?^Z\_F,KF?3#,0#4SNLWK</^=KX-(@!W
M-<9>WFR_!]QRG"<)/8=]M1RU4EN;<.DSJ'ASM6<.*PX!?* <9,;>[?O0R3C8
M[0]',]N&@7O46\9D_P3:'])V-WW@=D+UQ"02\TF$.%\ Q":4GQ*'!3IS"F09
MI(-@VTU[.'#A8$= 7"8[>KO5Z<,TSWQ]YO[MVG<Q,>L'X3_C<E 9SF %98OQ
M<QK\9Y@[U.GWS]*<UE,T!?G4$W0R%]7K9K/Z)  +![YV46\.$\(-X \6?WZ-
M/A"IB?,#KNQ_3MI6[4Z=/,?5!$PY.X)/4#(&YM^RVJS'/=C'.]DE47U]]OVZ
MP20FTG*5#*L+,DE*C!F&"KP.UBGL3/#RGVLO!4QG'W[WYJ(-FYH+YZ-+!T9]
MAVK>\JM\K8C,S)O ?INF'+[32Y_ H\<U(ZPGPW13B;NOF5T,1Y/=]/+%MFO2
M74XH% RNIE4A^2/*VH"?H5[MFGQ4/H]+1I9?)TD5;I&<[6>3J9B8<T"[JIT9
MJ,*@/"DK[\#"VH7;SJS V0&:\_-.1=U K69-T$_E,+]TFIR6&W?'E;,(54Z>
M&7X.8X^)%K0K1T32BN0+,H,>/';8^L4'X-WEZ-=TIWJN;("1]FK^G_X0RP$,
M=I")4;9%*]H($UXI:KKFI$;V[-GS_7-8QJLS_:[M-G9?V/@J.>,J+9[#M[QV
MQL-$CXT%*S^M%6!\%^ES7<,HX.,L.J9/$!;MUM8-,+'URS%8HJ[%:/'K;ZWC
MB;?N.-E"E::_2NZ^N%7+HG8O#2MKJ;IBD*_(RZY^?AZYO9CQY24^>:GW2;DZ
MM3NK4I%R, B?^@Y6Z 587&F-Y94!H-SZE'IX Q>>KFUXW$F9' (+V%Q#!LS5
M:%Y1Q^?)QO'U;>J5E\#R*KP,Z^T'M*3&^.II95:X&FXKVZ$+:REQY^1,S/9C
M@LHT]/2 R8=)P\K:W.[-(#FR%^CRM\H0K_C_]!:PTA.-O_1_Y'<O,SXM 5CX
M\'M;RW9KHC(/00!F?4JU"E>.L]E%DR9R9A&G>?NW <,)K/_:P-ENM?[N@)P3
MB,>0P?^.W^J6S.UXNOM78>57E]C;JBR4AY3"?(K*?/1K+N+U#5S]1CK#(_Y.
MDY.3!BJNS\E9W_2:I<'<[P9GYX*Y1D1->$RI$H1[1A0.G,D0*=R&<R6^94RO
MC>4\:U4F1(*]X;?[].2\&8:CN =4K)M\^$_/3W-Q>/*!*DX-U@[Q(@3$ R?(
M$%\@9:6P4N*@L;JYGV9-_!850'FPKBK'Y6_ J<,@7;7U#(2>>-=4[!OGP4@$
MIG+6FUD2>1L'=N6Q3B9>HF>9"[_9?KT]8WH;EXS61&$O=?1\  9B>9X(1,U
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M,/+,@DUEB$.6J8 "#CP*)AP85MFF$DJV%;^E3;4*G7HP5TD#" _K8FD X5X
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MH]*=:F0%Z$_=ZNTX3TRZZQ 8Z7"BZ9==I.=F&'X>E$F)JPFX%$[][B A($6
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M)"VJ_9[;;OVR]7SO>.O7U">U/SZI5O!K8+N=UA_C(4P%L+X=WRU[,W +^QL
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MO[FQW8_:]X\4EWD!N*>'!?TWU&ROPS4/GLY?GA#F/+2T:ZWS[J'SEI-\4NY
ML4780-H"UD'F<*4IN'0RYCDU&8^Q-"QK)S%"G>7XS*_KT,P_8?<^-EA9[][O
MLGL7$8MA>:),HDF>6$YX1#4169H2"DZ* <$%,./\[F79REC,D^S>?WSNRU+T
M98%4IMX9WR,F<T^LN;JCYT_:Q_TQI^9Y6X2GA'-V;0D>SQ(L9P<9R54LA2,B
M%HQPI<!W53DC!DQ!G&=Y9"CF#$1MFD?M*%JNMOXFW_6;-LT3A[/6*G.M,I]E
MP&^M,A]792Z"YS@7,LZH(2*G&<'F9D2E3GLZ-FDHKJ1X]5JT\S1N)_E-7;->
MDL:<[U*^V'SCEOZ']^S,%-_2F6E*P/ D[622[]Y.YD]L1F9WSWVCU,'QG]AY
ML'HV? ^3UF,?6+?_,3D\>',"GX-MMG>R^[X#VPM^O_X 8]CAAZ<[,6Z[I=9C
M6X?L\T'OI/,>Q[0#]]_FA]<G9YU/.S".O=/.Z4G1.=6P[9#OX8QW+HYREM$\
M%Y:81$I )0DGTKF$6&Z%%HZ#5\D6&\I@JTJ;"&Y4"K/O<F5!=QK!4^&<%E8M
M\D/\N;VY_U6]9.Z^T?S (A"/+$]S&'7&TP1V@,Q4'"F1P>M"VY?1>V9WT.J6
M7T)A.$U\83AMS[;B](7LOF[#]T[W'33;2(!=C;&C)+QX<5+HDSF27?^A:H'W
M_4;36?W'C19L)W=46Y'E-!8I:!,GD\PE)K?.I)(F+/#)@;ZAR4K;J<_A7JLV
MH/_'; ZM?"&F] ?OTQFJGKAS<'Q]9&":;<HTH;E."3>:$F&CC A)'9,J3:B2
MF'O<%BN"P2T,:P0^D_^,L;.*L]8S-==]3@-I[@ $N>YMZKODO!F6TES8:M0"
M1>DYQ J045F=?"EZV(3CP X&?FD#GS48W:CU"3^^#=*Z&1J@_E4W'&^W_OSS
M;=VZU2]]ZZ^A[1>^[^S0$X]52Y0M%R"*P_,2.\.V3JPT./21YUH_\)SLGAD8
M^T_W&Q:7/T-76>QZ#%\!&^_9U LWNH)="0-J_7*;K7F(K-]M8@Y@7+NN:90Y
M)^78[^TW,Q[Z=HT_L6!WMSY>'4D3VS0U*:&93, 4B93(7%J2,YXPF\LL518Y
MH[-%2_)KW>ZR'<3O1JT&LF\O9 _E9-$QD'F<<L530V,N7"X2EBJE91[%2BBF
M5BNWF68M-ZJWKE?;F/CH[XVR4"V+ "B["\"5E1VL]9P7!WUQI)EB!HP]L:EU
M2$NG2*X F<26I@EW"0 3$(?1Q:K6+>4 FUB'WBWGDU9$?OU#S_F:M!?5Q6V*
MX"%R<;<BF)&!E5I@(@(_[\(?;"='L8ZS2.<I2=.4(>LV^'\._E%. JJ#Y<^Y
M>_7:X>)>63FL%M6!9V5N3]O)Z;+?QXXXWI0U?/"[>E0BP&+)#'EJT;0CK^/_
MV$+K\KP8^@9:4U#&HCAYV4W"5O10.9>^VY;/R:C;=OT)8!/&9D"#&CN<L:O*
MPA,.0B>UF6[#OIOJZBF?9\>&>V&#=H77\C>\BQ/[+SO<?RQ(RN[4V6_"7AVM
M=3%NR>OCZ(ASSKB,'3&YU*"+ 7TJRS6Q3$MPK1*=Z>35ZSC>B%;T<X"YG:#-
MLO2+/46A'G;ZK2I;QT-IQ@#D_+OP [=J,=!#6[?UN5%"!M[(+DB'=$QQ'5L3
M"<6%3H54<0J*&YEVC;9FM73$=TH'2L9./:J)A!#V$XO([M;AY9%),\$U!?3F
M.'+11#G)!1/$L$SGF6-9FJ>O7K,5%/O_-:721WW>F&;?=B^HE!K4G\/K0_\9
M\ HFRD/V-EH[@Q8&W[Q4U,K+ZR10X)//S3>=6:$!D109[HT\<=BZM3I!B:UO
M738B@ ;!#NHN:OC.FW'1P[#?C$L3J+?!T<;VAE4-.$9V@,YYT<?7@V*4R#3I
M&[,US9O\=GB)#;IF%F"1<7,Z=4T,8J8+5>CGV6SPKX].1%RH-)-<&IESZG+)
M<I;Q7&AJ#3C+Z3T/0S$,@5A=]K9]R]&_ACCZT=4Z-+$ZA'B<'$6 UER2< )0
M'4R#8(R(F,8D5E8+K;,XMH#6*&^S*%JV#0M1B OXT9,*/?VFG6CI7*$;0W%3
MV$%=M=YN'[1][YV^/"V'!3CZY062FU1C516FD-BPY\)W\BQ&M4S:.M*P?=#Z
MLW"VM:\+!"U5ZZV/L-5\^MC.RS-6PL"F81)_NX"+8+?)8X!!84_#OW5GAS_&
M(,0LHJS=:H E:K5A.3X^:6V",NO5G1V"^1O4KDIHQ KJPLQLCJ6OY1O+9/\5
MGE*$+=8Z+X>CFI5YHEBF.*ZJKUMM+*B:U8<+#U0^JUK=SURF5AP<Z7#/R]"3
MZ3=/3@^0OF;!K8_V9KY5'\=$TZ](['8Y'MW\E27RSR=2CF)ACF?^/9G0>YZ#
MS2$*],\9\4;O-]F[ )C\ZE_S2P#S7U\[X7#SFQY]GG@XA4_.+!XVU[MEJ6X)
MR#]R@#V\5(!4#F"N?L39TPT1]WD3U>H54A6]PC=W]PW(L%'KT(3<L(!$?(^_
M:?_&H<4^D=,K@(<3FIICS^(KT&KGLC 3,U_O:8Q7^@ZMX\%HKC>U![W]@()!
M&0X]'W7 P[*J2EWX&*Q7&QXV^>MMM!8?PY\WDM*1<>6_:$?5M#_AHEV>>VAI
M<(5L&'%X&\:$769]A!:[2=9!5P/>L1[Y/MM-Z\OEINFU5C*EGPX4*XD-POOG
MO4*#-IY_Q*I]QQS4:P(V5X]#1PO5])0O!L%.^YX$7V31\TX&J.L_),@Q6!3/
MLTN%?X05(8"=6VXZM*Z'C[KJ 2V(<[\.C./93#6JOX3SYRG"X55LX8N#;:X+
MT.@+ND8%2+0<S@A%55N>(+/6$(GMKH_MDI1Y"6J$:B9(WP2_;PMM)9%BN32
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ML+4">T0%ANCJX*)<ZZU'TUM72WHKHI1EJ5-$"8=QREB1G$>,I)EFDCEE3&)
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M#/]Q=D>0<M7Y&M[F#<:G<&!V4'F=N#D<H@N"-N+-U?0C-3_GY@7X#"'A9&<
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M"Q (8*H:9,O5\>$"  '>JIB*IX?)4\$MFK(7@,N@&^6#0$4$^$$D5CN66U
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ME\F6*2L[T__MI>RG52IL07TU6\Y_QKOOV%C/F[_&VU[ES]_D?7M!I;_/M$+
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MRY0P<WX@O:OE,EADF<)<Y)EZW)$%6?5,4U6H?EMX'$"6L'JP8[[ 3&%@H ;
MTUH_>,Y)(_*9"6M/5-C<BT-[//:6Y:J-PQACI:OO/] .*>WMNE37;ZY!4SEG
M7VB%PZJ)"5->U,U K:^G#'JBWLL#>UR."J_RFRF<DTK8TW90-1.D2Q)*"ORY
M$*B.IOP\5%@L+4&]XJAYP@W C[<C+,- 98=K@]:Y7<M(%62M,6#5"& #CK/N
M*A_>1J7B%4]532JVJY%TKIJF_/OR<L )H?POC*ZI>\'/S\E"RR>Q^:MA*5()
MVZ.R08TNR P 9*_'_2U/BO/9&O-IC4Z0^5FQ"N43WF@T6]F76U;GN!54*!&O
M]]G$P/OP>3$E/X#MZZLAD+0"RS\F]:!@R$;#0HU#Y5!=7N$MPL"S6WA%,UO)
MCU<SH!3@0:^6AO\LD>A]]^/]6'J^YCOKBE9?T9J^T(K69U7$^7YO]]/!OUO[
M!WN;!]OO#U^<K9EBG$D-?(T**E_5=GS5T+H@W\EET2^NFY8_U5AKM%"UUIF@
MC[HJZ<+S9:RN!ILK:0I,%&C4ZBJZF0+)FB(#V2G ['@R&AS\%"M-:Z&N)C!U
M=5%;C<!]2=O\J "2]$KO8MY8W(9C'S:^UHV5:(%+8J82;7-"D=*[\NX=DB($
M ^'Q&/+F%>$Z,(B&DF(&"")7RI1FI;X73-]Y8VXG=7\32SM"1QOL3$#G4\:#
M:D)Y,0&##KP5I"S!'NA?$/T=>\^]P%$%9SQ8[3!Y3:VB9]FQRT_0D+K,##B8
MSIE%G7/[,0N%@+D_MG,P8X4#BW,+ Z_+/5<4:@9+/9T##Y0FX"GX6^?%N8]W
M^6.HX+HLWJ>'-^AYNIH[*V=?W%:O-P"N?L]#O7HC5W8&GTP94*P<@J\Q;!9H
M.#Z>]VI&K1G_:!N0SC%>[\#JDP&6G.*U)D7@VP=3%]GO('E:#@&^D/(".7 !
M E:%*< Z;K3@LU/@XP<CM30^6H#"['D!"TRL'8WK#5 VD#B@H5D/];QVB;U[
M EBW\.!W]>(W+NS,4VG/X>'03<?\J/#T2_Z<?7FBX-EW7'#VO%[R@F&M)VR9
M<CA6,$@);A2BVL97O+JSRG3E(42\NG/R2SB$>-(LC2#,C?,1C$1C@.O 4#GQ
M4>:LYQ/S!\W2?4W"67/6;:;QMZ_@GI8VHP8O8;^A$*+"+N;HRB9:'K:MK/=H
M;3W#A6K:,D\\5UE/'0<?D/USS)F=Q+N0]0TG#)2Z!)NII_>&.9V4[/JK-#5S
MDQKW^74 9\SV:L;!$$RI(1 R+'M>*PR??*JQ!V8X!$13ZY5P,6N6KS6Y+]HC
MG*Q6,?+T&$B $%X&K_#8#L/E/0?2W+S7P :0VLFRO9X"FBF)0!F4XS+.N+>.
M6^_Z1]CU'I4%M!7>#T<DWFICP"7(U]/N\85#C?*&H-%LZ.-B!H(WUF8&.$[$
M$$3[_MAP@5IPI8NQ>O8^V4#YTO(,UMCUH*;8,&U41F3B6R#XJ>Z/7&OBC[NY
M5U;MV1KCKHC?S3VTO\$D$EW4PC+O2K6#IO/*%TTX^C<]E*QQB#:?VR%RQS0<
M>/#**(A=XVPU5)U>]8S]5$\BSG,NWWS .8#Q.2I&6(/ZV-Q?L4X^K'6IU\SU
M"0V ]L;Q7*N<'ZAR)H='M4F8GCPV7E,X$]!C%4[?&C+*6D[GK0LZ!]L'WXE
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M<']H+QE'(;SR.7%JQIH%D.#2S=8\(;;@JUM"W4B3:K#P0O$<TU"98F;&([J
M3,'Y&K):48BP-!$33&1^#&=/U:&B_) SW!*Q_1KOATV16PD'D2Z7=D+S,<E*
M6'5$T_!VP969ZJMJQBX7FI#C1$2=[A6PB_"KVD8,]WKDZOWH=6_LTT0&MBKZ
MW_4P51H!I1'T]B.-H'!,6EYXCTW6L1?%B>A?"ZPBPXBS?8?M!.[M"Z'PRB0W
MXOV4>TXN69JY:6@ Q:81@Y)#I2J@+A"L@&"\R033C^Q[#F/9SL0E=S2[AL Z
M_*:$CYBFXF IIE<L85T<Y04'_7SHAZ$3XURGA BC,NT<(#U3N9B$"A[.8ZX
M%UN663&FQ<W1<9^W@ZK<^?3L]]2./Z7B _*ZP7N-%@[=ZAD38*,Q<-0Q%NAI
M^ZUO+_E="=*-9X(#TXG.9SC*F 0MB#1W-.>-A_74C($O B\8\8\($4"<$C![
M(&5DXXG]S4TS#A.BUP/'YD\&2'WO])PORG-&3P+/C/R+&)LK:31&UQGN&*M-
MQ6*R>;,9G>)<Z#GF(A :Z>I\!>2+I!&C'(\\,K+'' BD%LQ"I6$UG!H@\T=5
M=)[.3K6/%FAR+LYY4<?6U"+2 :25N9F[_W<7B_!S&KCKD;O/WI1P-"1U\TO*
MJR89C)97K>71IPI+37YMLU[L[*S#Z9*U!;]2W '5L$Q:M.QOK>EY&6PF,J=E
M75^J/+%1'LZ3/*00,5$\02VNNWQ&[$#/2Z>F9'.&W*-L[,-[(#E,"IZ*,!D\
MH$?)$C=PY(M:I7-R%QKX9DQG^RLH:EB^B$X3CO!378_1K!_BS05KSV.]S'''
M]MPG7ZE8BL..A;'M^:BQ27/,CF0M,' ($!8I>:3.3K19;:J<] W7%[Y0,8!Z
M/I-^3@6,L4"F N%!Y<PAG-B-1 @#JQ/_1 %!V'FLB!H@57 VM)D=>X>).,RT
M''<DLIC>TP.">-[\(]FE7Y)*XXD1J#[RQD=W&#&)M*5O[3JSE2KH2[06#3TM
MR0=OW3R (T"I[+ S(99H93;!XZS@'R)Z@P2D#1E/J#*?XKBN4\9T(57-=R2+
M(:\8#Z? 2UE9OD45)12MVQPYEO%,?5G3@(W&AN%W&T:'1X$+!Z'GD.XR2X">
MI("XOHB4=+"!;]R$H/P1BZ#A*/B/BN0"-"!I2H2SB9-$Y8*\5 $+:\MLH2-N
M/OS3E84DZMDQHME142=RZ;$KB-;'_ @?L]-Y),YBNZ<*-)!P,MGQUF:\XSS0
M@R(3[8-N4XQ5*/@L<GV$45H?M 9C6$?L2*E#MP_P]C\I#LRNC-:-\7Y-X^ -
M0OV^>;<*X_?ACN<EV)!\<.:G &)&: )$+MD.D'D/MK3Y;COL[37 V[CS:]&U
M612S&D6&-6'H>&&4"0S%WX"G$U0WL,2(G0D^(D/C<'X9;3J]8+&"V"[1P2VE
M1E(] =9P1Z'ODZ8IL/_4&:*Z<+\DC0QDSA1*%CF\Z*>AK59@P7JZD<O@4>1@
M47J(1RAP8@;R&:J0D$8N?UNB0-EWMJ?R$J6])RY?^8Y"ZH@"(%-&(-;H";3O
MJQ4$XY,[0QE*+4:O[@,'^%6*F__I\DK3$A?;Y%P@4H=O?,+^. EB5L,MD6]>
M?$J=:P,-'!,443E%&M#SPV1)R\Q><SQ%V5%!MV&E8VP%+"9#;)8QY8.@O4$[
M-#AW .B:TNH\ :/$AVZ0,T D]Q^Q0^90*) I*"CR-MN__X\KLR HZ(U7QE0)
MSC#J[)"B[5(FL5=@A X5D7@RQ)*3#$R*G:1^ZTR:KWYV&CO,P#^)?, )Y_=J
MV7_T8^".O01#7O<+!!=&LPELBY"CL12DPMD#1+(' * YB%UK3E>B;9*=E!@?
M,  ,HA,/\ ^XR&G9T"?1"8;91\HYB"6LA)7-=# A!@HS&279^RESDUA'1]'N
M4BA4./=DCO@*87!-:%((O^<*]'CQ92EDR+(4OC%$Z5(VH#T:17/!1]SO$QN.
M#7-CYX3YQTX5?7O8  U"*M[SN(N"PN)*2[70IF5[@9>#9,3N3>ECI"U#A/V8
MW2V!\ VZV%DGBO7DGH482!+B"01VC*SN?@H&^11T]A#!N ;&;#Y4NH9(6].G
MKU)7QG/?%ULD[ZN,^V*MQ@3.EM8/AKKP[L OF&7BJ/Q;]2*%^@G/2R<",3HY
MM6&EW#U"^9-DH,KC& Q-F]R\.F\'/H.G(*ZHXTYAD$08^8IPAGXX^F8[^)&)
M-R3O+O80D+AF^BF@ZU,V-P)M80I&#D- (@V5) 1=K&&J@#CY%OI50/Q9_+*R
M@:AQQ66)7[$\R"V=-#YVI[:(^F33D)C_.\*HJ\O,5N;Z 4%A9[J(L C1K4:%
M*"OLVH4T)]FZ+=;LGUC_#'M*.8=K!'OM95*5+ X^3;S93+!5K@7G) (,5(?<
MBT3_+#ML;TE<8/,:)[5X.7K N4-+KT7TAN;(5*!!-863Q)4HRQFB>B;6PKA+
M>4Z<;[]<,B9+;T".R3P!):J$O2YQ/J71\!'=@JU>D\_(CFAC?*[#%U$5DC08
M=4=<4%"6L:]-MJI2KWV1'YSJYZQBJ"9[SKRI+-,5>*<A)YO*%5/.-K9AYPY/
ME-HL="990)NQ9X5R(O<G@\R,O)S\#O(J%ED7SF<BYU/0*.QI^/WPPOY6<DYR
M39P!])T;42.671RHH)CD2XD .CP1 EK,J7N"QFI<Z8Q*U?&C\]]/CP^MOJG5
M=.FP1RXA3 ,U(KTM1'+O$+%2V -<%+R&/^2S!@;O3!G /,BR@(PG!K\[G:7.
M3M*XU5P5H:.+@\&Q/16(MM.T&1$2!VT^[2.0R9GDW49=N,#$LB*+66+Z\[6^
M=(F;%'@9^31_PMTIV,*@[(H[5YI1#E<,4V.)S&+!AH] U$G7 </AR8P3#2!U
MQDEOLCU,<.M%8< Y$*9!WGHV#6]P .HR)QA[S?@$<_0Y51IO(F7VLE_)?;^Y
MOZA4,&WV#O'-%A#:K%J]*]",!51$H]90=0V4L+;8)$W''OQY3T]H6)P3J@N$
M>WO,>.7QC&,H>"IX&QMFMUTW2'FAHP(NK9H+._841%S:X^+I0X2%.;%1<4Y,
MWJE/-B6H!J&2V9&+NB2%AY,T'6FA$=5B[AEYNY#7 M.\"4,]_I+ <=I1&3VK
M@UC 1C" TM +5Z0UCH563N90BB[FJH*L+YYS2  (W*DD]$EOBEU?:"5DGL&7
M\3-JP^BB@"3DZ QO+AMW%-R@YZ121Q#HG"<(YQ?>!%R^23$M-F148I#0  /9
M-9::+K'!D$QTD"DYO"8IT4D:*6#T!3DL/,&H:=$RERH@,PV=I'TEK9>TLRP+
M7=/ CN() 1?X[BW6_-_,/8<JB,4NB.Q1"C6H#2HRF>7K;J@3?W1=XP\;L[(+
M//V5\8<OU+^+,UBEEL^H+ ):6VC\B%N!50,<P1W:482MR)+P4&+T4X8U[D*F
M0(G-#C:ON=R2/+UHNG[WIL">0.:\M6H]I1*(%.N,UYEK,:-L-075-,CT@;'K
M+I<[ZI6F92VTWRGH7:8ZM(2QU6M!SY)N*;BYAG)%,3RB[2GD;A%$$6$YZAG#
M>0=V,B>S&9D@3,\VC:%>O:\-ODB7.1T^TSA)VDLKIT^%*4"2*/ 5BTY;0U=B
M2LYC]CS:SBU)%+:V99R=;V7:\UX^R[Q<3P3=B]BJ.'RUQ1CC5G4@%&6B$"M#
M94I('(&V0V$P1S@IF BT-$YEU,)O9Z C,QQ/SQ2N6"8BSIAW@]$]L4Z1C((:
MMAN@1R6'"%*X'<X&EU1)S%--G^UH]5W+%$A ^@218:8N&TSQB_$DR2HG U@K
MP%_+4I>*TM=P;OP?F/40:SC.1TF(LVO)V>%IT(CDG+(1[R7.@*-<Z!,YQHE\
MA8,GX3H8)27,^[U>%*;: 852[DK(#3/E-$PTBBC.">46M_ZC\A02WCEG_2-M
M4<JU'7];B%QK\C81NR]%LQ>+C#7!DN"86VU1K%;@C5ZA@[D.>?G/SB\&IV=(
M+05>PDH]3-6)-;-5\PJ84"IB"N"2_QTKQ+9*Q7G$SB_CHZ9Y%##+FQ0(E6,[
M I28*D2]Z1 -P2FG(TE&5BPXY;,P.#R?>:$'ZL*%*%K%%+V17BQWQG).NSD[
MP772P;?2RYSV*4Z!3=S YE32F,*!DL4=8<J4[[&$'*"D@DLE@B(##IUP#5;I
M& 0*DW1+2%OQ,&M&4:->%HG(F9C"FZ50).( J"$D:ECLC!BY2GL4?2AF6&0N
M0M#<TQ2UPS2-E[* $YF?)2/8&%R"$Q%%B:R[P"0$M"^.P]X7R@,1<.;:PK@H
MFYKGT,F:8F$+4\6$HQ$G?NJI6K9_ YHM@XVB%H)N!9C]?"83&T,G%:QB'V2Q
M5%[%HU3Z,RPWR<Z8$>"IX&\5;] ;QYIYBI]V+'(1HV7DYF=/?:JRA*C@IEYE
M"3T;#R,\.H<+Q-G46L>BD -E@L"IE%VZ@90N0.[8,'9S6,9X'@6<N@C&\AUJ
MS+)ZFRVH-B,G9_[64U@1 2@PWLQ6>94<GF\)-L',C*:O6,!_V]/9S^*?L)8K
M-[HE'_#!T9>K=SQG<I9*Y'/.=YQJC2<7EIFMWF9W;^"(GI1CY"RD+TI+C:>6
M+PO*9\PK5&(O3B&41.(LE?I_Q, %;@"9C@,';EZ:I7X =ACC(LQ%&J^C4M_3
M;N,J83GVOJ,#.YGP$Z'OH%-3IH5-4^,+](DI-BU%H1F2NT"(39O\*:$OX3GN
M^7!6#"%?Q5PBKF-4@^!4_P3]G_.C B&T,(,X]=:D2;E+I164C)5)R&5?AMQ-
M#977QPQC1%+1ZFYM+\@D:.0\SAE9O'&R4QLZC!CBGQ7/0NM;JW(R2"@5>-X/
M%AMS"B!!GH@:-U%A('U,#((KHO):I]TL[P26A+>-Z%;6;6$^FP1G5[=&#PRM
M;;"=!9'&%'=$TN6\$3DWN-I:F\-,YW!MIMS^0F^PO8SR:1M33*D:VR.7"QVX
ME;5DXY0'PCY5W>&*B$QP(EI_;ZW7.'EILMT#=004V<_TG-JUH39) '6.1P4#
ME$Z5@;V<L$$S]%4OTSO7I@0H+#6@ MS1Q/9]%X&%Q764+874*4LHO5N5+N;>
MAC[%A^4),!J*.@*!L"]13AS5ZI5AO4,))I=MVHI%27:$V6+S)$--"P N/"^'
MH:/P#^A[K#38E]%@K=4:+*[!<_[^QJNW1LV6-7+&]MAJ.7:[;UF6[7:=GM5J
MC.VF_;^=[IM2J;VY1Y+;A/"EA<G1Y>GUZ='@LS$X.CK_>G9]>O:+<7'^^?3H
M].3*&)P=&U>GOYR=?H1'SJZ-7[\>_T)MZ.B7DZOKTR^#ZY,B-Z7+)\(+0GT#
M-04]T=AY<ZZD#B4OR-0!;)XV9X5W!BQ^)#'?]88!?\Z=FZD2,EBZ-"6>[&'\
M!10G2_(\8;#_3XRN( >Q?IVL4RCUH1.TE!AT)))!6+$FS#K.Z)8-I84ACE(F
M038MG%2I'UZ9\L?I2O'M 19D"FR%]-M'4G&G9RY%?18\<JX28X772]9:4]!F
M$&#'4)D@"F]37KM5/_QMRRZ<+WT!!ND9GZC#(W-+'FSIR/MZ(B6H*H0=*9(;
MZ227)GC'*<EY5!"/@2'"-<.H,)DQB"4149A0]?_0+T@$"HLW8]0SX0'4; GR
MW7USTPMB+MP<@N"=L<7(AC'[K5A@(U6YTH(4!7FQQ WSO6Q+=[S1?A@+[#+.
M%+K!260>3&31OBIZR=T-><_RYJ :WHJNTMP75Z_ (4AY4FNX=R+VSU541K";
M,4=-P&#"J+@(P'&..=:5A%',:?$NZE-V' ;< A=T!O8;CKQH-)_&E*8%BMT%
M#BBK*B>N/V/<&<XN$)<=9Z%M_E#J1:0\X=2QU-9=L\G<Y@C#/P0/2; A(%>1
MH*C)+\V>D7_1=3E*YBG4@4@,8-58UGUB>QJU+^QX3=GE-,3L-8WEZDQ6Y$H?
M6.\HWD1-)VDKN(1E@CEV0QOA0!FHFBIU8^'?&:K+GB8I(J [$.=!XQWKTMD!
M0U2^W'A$>GB$R0BDN-*9I-4*..)!\YTA2I;5%91TF WA9ZAR(1U#MIA'2VGH
M!0)HJM(QU^N8C:?0,;OU_=$Q\[_0V9G0O3RY^OH9U,CSC\;YQ<GEX/KT_.Q!
M-;)HB[@F9#3AC..R>Y$XP1[:)N?Q1JH#A,!26_U&XT%GU.[V8+6JH76B(#Z8
M:1H[#[#3'L?D1-UA*EM1%J6E8=PGAM)Z*:DX^\LF^\=%E+B1"FZ.IZ08':*-
M'5+'E%GLOI?_\3-6%OCV_7LO8,Q.?&GA[N0D"Q"_XY_3*UZK\S5/(OA?1WY9
M_%RCGWY*G.7?6KU:M]U<^7.]9JW\;=VP5KMF-7J/&G;];^WFZH^^FLDV-YX0
MD!H2Y-_?--_(YR31!2'FF_"3/Q'91*M>$;46[^N&15=^:72KO?1L8_8=GUZ6
MSDNY+T3)+\],ZP\Q4\44GV*'TD<%-R!9.TL,LHH,N=)R[1[ROLPN_<"*7]W.
M-3;8N=>Y.4<3;&BXP?8\@I6A478388'3H5C.:.2ZX_&Z+<(2LR4A',Y>7O>A
MW3ES$^4!6-RCAQ:Y,9'4C0WWX84()7\KWC[?^O5U4U>I0BV\;S8:+;/3[/WW
M?UF=^L_/M@WXZY;;L8Y%/73W%ME<1<ZO@YPMR[2Z;;/>:E?T7-%S^>GYP#+[
M[;K9JG??E824?\ H++S"=!3&2396\OYI5>\R/?HJ56:D@$R#<[A6SDH::&RW
M\EQ>7#R>9)D-8$F-3NMQ(K9 4G3/#ZIA-D ?ZO4>J0M5!_5B4K[?L<Q.P]I:
MQE=B_#';?>7ZOFI7+)L<;\#$2TA9+;/1[9I-:[UY_WQDM,6%+N7N=JR6V6KT
MJ]U]#J[8;'9-RUK)%0O%_,JOVEX*B'Q1"Z72]5^==MOJ]\U.MUXI344_J&ZK
M;5K-3G50Q3ZH@P:<4ZO3J;3;%]GN7SC+692,I:6:MZOCH*56$QK L'MFO]^L
ME+!GV=UF'?ZW5:FXSR+#^AVSTUKO2"L4%RR_FCN8AI'LJ/7J5-M&LV[6NU:E
M,17]H-K]IMEX;!"[.JB7<U%TFJ;5;56J[8ML]S5U_1LM16$WX>,_E!!1/,JS
MZF:WW3&;U@/F[VZ2 +9A!_MV,&"/=+IF_0&MKCJ8':32=/'6-'HKN75I,F;*
MKX:+8GP"QQE1HVP_C..ED]E&?]A#@FTW+;/374VP!<O]>E;U< ^/M]&WS'Z_
M7QWO/AYOHXEAI-(<[C[;#:?4#C).A*S93S]XNVY:_?51RT+HE27<6JL#^OQZ
MKUFUM8_;VF;+M'867'B=FC>!VVS,"??)76>9O1:8YIW*KUKP@R+$M\;/U3$5
M^Y@*>Y\>P=CS7GG-3VXM!\?T_\HC!Y51(*((CY*%.8LNR=T]L'H=L]EN;FZ?
MYA_PL[+7A4\^BKV6^8BLOMGNMJLC*NX1=3IF=QL'[;.?T*NT:4[U&((Q=,<A
M]3&B/R;V]\TBQ%L[Y,I(L%:7$#^>&!VAK#KW7AWM@64V^VVSW=Q"IE<'6X*#
MM4 ):)G==K<\M_:56A12X!@'PJA 812X8^]Q551EUHO,?K-(:E&EN"X?4+U>
M'5!Q#ZA0U^=56A6(C[@V.^D9M9 ]AN J$_Z6U6V8C=XC2TQ+H557-+SO- QV
M8:O>,%O[:A=6%+SO%"P,8&M]GDBAJ'B-PB0?D0U6B)@?F?NS@?ZLK;X)2W3"
M.3:4R"S_1X:OIO@4F(D_4<>.?Y2Z;0JW[(%!8B/0D,6QW:SL3B7[H'!;L5AV
M6G&=]ZIQ3-7OI&0M1$HUV0W[G51=3*HN)E47DY?=N:J+R19=3/;>]W8A )8W
M =C^L5*:1VF%FX8J7^\DGRC:QU9YO\BD^EODQ8GMA\LIA#\<EBBQ_R%OB<7V
M,K3,IM4V09_=TLM0O-!817=EHKNFV6^US7I_V_2.BNXJNOLANNO6S7IS6S"P
M)Z2Z)U)B2Z B7-G!:!Z'KZ_<KM<QNP\@<U9U7#L_J*;9['?-1OV1\97JH%XP
ME-NVZF;+V@V8\NNQZ7[WA@B9_,JR-K&>LV=:O?)KHGM^4 VS7;?,5G/;.H[J
MH%X\S;:-0*Y;=&^L].O'M.6S?0<_]<H4['X36]U6ZG71CZG=-SM;\^KJF%Z:
M5S=:9KN_FR9\KT>S'HS<Q';"Y+7A+5B=OMEK;YM)7BEL+WU,EF76'X#1JXYI
MY\?4[IG=S@XOT^M1K7^W9Y$7A_XK4ZT1\K&^;22X4ME>W!]J=>&<MJACK8[H
MI2]2L[G;F_1Z5.OSJ3OR[6GX_?#"_O;*U.N#AMFVBE0Q76EL"R[KAMEM5H&%
M@I_20:-M-MJ[09Q[/3KUI>MXUY'[_97IU =6"XSKUA;456EK+VU7(SI<U5&[
MX*=TT*C7S4:W<E4_LSY-2/FBCO65Z=-6OVM:6P.?5/K:2VO5_;;9L<I?L;#G
MQW30[YFM9J/,:G5QV31WA=4A!QX)$"*  Q;P'7#R%83,$^Q.L:\HP2*;G>8C
M/95/M$GE@%)ZQ"JKN[+M!A7[NEB6:74Q^^R1O5^>;J.J*U,HPJBNS)KBC7Z[
M;K;J6V0#%^:VK$>ITL;Z<QXGWOC^^?:81GSO@<[GC=;ONM40(*Y2+ZS)?7_A
MXZ>)&/I,%!)6L@9PQT \&=.X<R/7>-NO-0R8E>^% ?"MZ<R.X-$D--Y:EO;+
MIL,V:H8QB(T@3. 7+^!W"'G+'H:WKJFKTXB!&[EV#$\Z\XCPON#IO^9VE+@1
M?_$N-,*Q$<XC8VI'WUP<="8!/(P4'\&P \=0"8 P!74/5L">(3WWL@SOV>EK
M+>Z9MA:Y.[#PMZU:<^D(QEX4)VJ;X"D^S<A5H&>P'6IO:9AZK:6&N9NXV8,F
MW+3(@]'O73L2$&JPAPC%ID:YLQ%4S4,<-O^>7H&/S?T$AT^/,9YXLRE,(<8_
M\[AT6+72G8<B)IU8_;DC,.ABVW=C29KIL\,("1'_%_\>3V"+\:'TC7$43OF=
M>3()$=/.,7YQ YCCJ&8<IY=@Q1FCWY#/8OF$+77"XMK19-(+\S^Q6LIF) "7
MTL4??^1XQ9ZV$#-O%L9> O-['[D^UL"Y*50>XJ-I;PEQ5$]?L8<@>>;)ZE?@
MG$>'0#R1/4K>,V#@_3+ZTHZ(20/OH@W2__^)@NV<V3?NX1"V^MNA/8;)OK?]
M._L^?O-3]L+ ;9$ GRWX^JH-68OO:#44P.,__O\P@B_DS*\$M_1:W8<@-&1"
MH2+S!QCFNBNT>#EB>RK!)0W?AM'PGM2 17IQ.HBGLTAQ>8(PFMJ^83NX47QW
MX*_N]YD7I5<3>:D;W8(>81A_@#"[L[W$^'@\,.P9/'$+[\.4;& C=R &@_D8
M:'P>N?#]TK%564^5LB(X.]CY_J92+O;@06!1XESRGFJ43]J(JN#LKEBUWM;J
M%VIU$P_^[;@C_(R#F]M-AT'QD]+S"J$/[PJ"#C+J6I;ITR2SBH ?@DIIS .@
M7B4J'CR,? Y5J.,1*!N+Q[,QT?*1B+?:ZBW>KF1B!VMH61T)3DOL-1PKG21<
MA!MX-.4BP!8"T WB.!QY-CYVYR43&MP+8.I)&-T;]NBO.3$?.Z%?Z-\L9A=/
M&!49GB1I+_MPE)E41F-B.R@YA&[V@+B(C:/Y=.A&/FX+\/K1/(I@3X'7AW,B
M?Q :4S>"G?>U[:8M)<G JA(=YPSL<?M&&#FH#F:G)???#49@LV,W63AP+P J
MQ+$=;SSV1D &GHO"!Z=7!S+1K,!MV$7DCGT7S"FQ"? (?!EI01-9)3GXS0UX
MED5A3,<F#4IT;C@[,N1I0JD\U[^^,H;W8C([W.6FY)S1^IM*7 M9I_!O6)H)
MC3^];:1N#23_> ;D#]:(?U\S<DF"KKZ-(A*-"+BVTJ23/A?A2;&:M<[?=$_&
M!K=/US.M?JVWU?M2.'A3U!)=O*K(#T9YB\A53HG]W]J@4 T]WTON>6%W@N?3
M.)K<0&'@QK'VI[O(2]S#<#S>4PYQY0*5P&'@TMG_!/_:+8?(G9+L-/[ Q9!Z
M'2F%S6UM'39V4MU0IR<[22)O.&=''PS#!!2%][8/5"5FMZ=$<@FV&]U*/!('
M6((?DN:[6SI9-2NZU0_H.LL<M)WEH%9J4BQR4&-@S,)(*I.HVD3K9P)T= M$
M1)0S).(,61T.2-DB_0E^]H'+QLG<N0<+,$&6F_X\ ].)#&O\ +Y)C&N&BC'_
M@DS1M6$&8D:H2F,\ CGD361/P>S^ ]\*X"XQ8QS/A0LO#&Y"O&#J%?@_B4?>
MJV4]&U^8>3.7-'6IPXU@5IX##\4YUM4FA\$JOW =\L5"U\#85=I?$T9^T!50
MRKM%KE%TGZ!7U9G"YL=)1+N_V]MEK)Z8XL6IVQ2#*0WM#CU@:&2",(T- P"-
M)7\6,GFEZ-36>?,7N;=\C.C+<<=NA+/!:<'";+K;&[-T061KG(V5MWC16]S:
M#V_Q2HZS.V<Q$7$8Z"&,. '>K((:(8@-HG#0=+QX-(_Q_E+D4AK*? -5AR+0
MO>V1Y,["C:=:"Y2FY5"[5VNW^F5IM].K-5NM,DVV^Y2]@8J5JY/?6.2C<E:=
MTOW J_40\N46S5CZ/[PI^2DF+\3V?Z!#$C/<I^V3]#I[WU0ME9ZLI=*+%@+0
M#=A%EIWN7W\6ZZ-3:V\PD1S%&(GJL%G+41+0H,8!,$?P70X3>=E4U=>>B5KZ
M1-/'PCAONPWER+RNR+GDY-PP.^W'@%V_%#D_K4&P8_&9&UHKHR!M;"Y(MRA*
M+6'M::/5,;NMQMK+\WQ<?;_WMM_HFK"MS[ZW>U_#>REBD)23S<Z]-%ZZ5,];
M080\N*%MJV]V*@#+HA]3IV>93>N1BGI1E9==;*1,S<7P,$7)0&/X 1]FUAV4
M7W?W.E !GF('BGT'+;,.M[#W$#CA$VS$RZA6%>V^*MIM-<Q^N[BTN[YP6(LX
MMUXDQZ5=:VP0A5YE=#9JO0V]MT\ZZ=Y&@7/.!5LHW.5:2-MX:[7KB)1MS.Q[
M2NM*0CU//G)%M0%H&:Y(2G>C*07;N:+)]T:HB[N&?1.Y%(G?**ED'TZUL<M3
MQ70(J=RD*;WB9%7M-F>HI7X;=MMH2<HB491J4E5E"1S\S/8X47MXK],#)A[9
M42*S+W**3[B&5GRA4;=Z)4D;W7'NB:A1>O_$FU6EL%0I+%4*BTAA>:C;=I7"
M4J6P5"DLY=BY'::P[#A[Y3F<WE7(_'6$S"VSU^N8W?XC6\-6&2 5.1=IX4VS
MV>^:C7J_H.1<98 4,0-DBU3*_<Y2:/3Z9JN[/A9<98 \DC7U>F:CLSXUK<H
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M5*QHQ+R>WRMBU9GNP.3R G7\3]'J.+4%8ZYA@8TE+5/X9^#<?'N%5V+W6_$
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M8O7,#DSEB-R_YEY$-0_QAEELIG@1NS]'.!1V+7?FV*3;GL?4LM>+L<DNUA_
M9X:N$</YP ]A8'CPF:$[L?TQEC?@0)0$(Q[ MO+N/,#.Y3B>[-WK.LM-ME]C
M#]IZO_\8V,->K=%[>H#"1JO6[ZW^^;%=71LUJ_?TC6V;M4[G&7K%-A_=V';]
M9.O=1EDVMEUK69T*^+&HCSZ]15#<1_OE4_8?* C,*/X[OC];I&T_W:./]S\6
M#X/_V$[<]\_88GL7:\)^F5:#RT#+!/]>>,;PX7X;4MFGE?\4_\2%TU@UG<<
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MKS]*X0?N*F?!OTSW@^MR<JUV$#I3XU5S>Y,J^K-;G"M&D?LDXZO?1#>2B_\
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M/CX6C,G'9^]^=/KVSU^]_Y/LW\V]]X_[?SU_ZWQ\W1OIL?SQ/_]X]3[MXT&
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M6ZJA%D^A+ 4*D#"+NB =P$?O0;@H QHEDMIA#76-2"3,]ZN_H[^J5H_"I/>
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M4"Z#',F"Z)Q*(')D!(:&'W(I4)3C7'J,WK:>;#= &5+(MA/VM%#)0W2^(SX
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M3Y&CUXGPBOLBW%6L=SSNZ-^'>1LI=<5ZS>GK]4LD&+_^\/]02P,$%     @
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MV,T/=F]:Z2/';;4(O\F[SH73YU\OA#>.[]/DTS"DZ7+K3T>C+ 5.5*;%3%=
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M(46U<[IZ7;;.T&H97GQY,?U^.(7QQ6@!T,2-V1#EA",X!T=B2WTO50ZZB\3
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M#4PBC6/$.J<(BRE)$[S*6O>?G7V!IWO'^G*"[*+EY4D(DSF,WJ&E^^NRS^W
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M /N6+O08N?' K5[OTL7B0YI]IYF885^%42!]B!,F](Y84$AB/X0"!0C[W!Q
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MS)_UC)5'G#.:"!4D(8*">TKK,H8@CBB'$K$X4"KV.>'=@YFWA*:FTPX"=Z^
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M^?+QANH'3?]I1H(DD7&(82"-VYF' 21A@J O(Y]27P81LFI6UH7XU#34EE7
M:EX!KYAU\(NXSH&%-VE 9 ?67(9S4_RMY!W4S%^!';0W_(.;X=%V\% -B/I(
MWJN>T7=S<76$K]7]Y3KF>*ZQCM+NN<VZCN'VHLBSU>S.!)97/EO%0[TM9@R*
M(-$6:H I9"3TH/ "WY0)X#B1-N^ @W&GIMX+UARWNH=0M:OJ"P 86 N;_B3S
M?#4WM>%_E=1$79?9_KWM5T_(WF80ZEMVC$'];6L('HXVRC(^(4*]0D_]N6L
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MURQ]F0LIWKW^EDOQ<?FQJ!:K-RO7?#5_*7PV,QG$V(M) $.LB-Y!)#[$89A
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M_+=5%7YK#A*6^BEX-?VZJO)[*)(,"Q5!/R 8(A^'$/LA@8H'OC:[D)1<N*C
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M(^IL\KA U)/-8T5R5*/'!81#J\?I7O<CGJH4P:L?L(?YRN@9'G"]O0H@58)
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MJAG8*N:A&==^L=MZS[/5[(M2<R[?K><+4TRK[MP119&4G,-$FF@R'%%(DC"
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M@T&9F*UCHC DE(50(AR&F/J^SZSB9UIH3$US5=&\%9]7P'"J<02&5]=(YV-
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M9E='6:'2'!0LD]71O:!V!95IS&1*E2(RJ']UK92I&7X'TH7CG< L]PW>K9:
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M!JF&<,U!_(H()S)>JBK"M9HME1%J+AXX*^DR4/M12SW_MHMCH#DR60$$,]:
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M_1(+[2CC-?JJO!_JB2[AHPQ%]_5^'/%1P[UK6@0<EA,BEY+*3 $[?R5 .-6
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ML-927(PBGV@ET'IM(=2;(U5\@5BS,JUW%E/B+LHT4 A]-U5=QBX#8[*5DKH
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M1LO*9ZE*\_RC:P2,<[HZ-'(>)=:QC^1?X'QQ7,]3KDB"<9D](KG=#@OY]J&
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M8@A&.BT\>PS^!B\\>[3"1XQ75LOUY(R'-\LS#HZ^3E<3$T*(D7S>*+('E:T
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M('1P13 ;N-WI[.,ODL'T*)WNE,'T& %W<,SP]V68K\_O]"SYK;$H,*)>V;/
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MNU#;Z&#L]%67C1ER2M[6S@B,"U"D9' \2O EAJ(#"S&U/@RZ3L&AAN-UK5/
MS3-?X"HMIY^K&DZO2VTH3KD8"<N\EEQS"@ X$Z"E%;(8ET/SK>@><L8]9#A
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MKY$.X+2_X"[9GN<Z7>%*BV(29D&2 ]B020:8)01EZ-L8LXZHG;_9F/EP-VL
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M9M.S^<S$1RM-],:#B;F:^"+ T092&Q!R9TRAY[1N%[^5D,Y'N@R.CT5K976
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M.^$*_7L"?.E6+>S^,D]^+?-X<D;>"2 0\&IHZM;A9HVL!,^2 8_0Q*,@6?)
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MPRA/YO<#K"CET+BQIAV1JX1-P3BKO#/HD^C]S>U/B"1R<?MYI1C'A?':)@H
M'FK@^H9O0/>%NO)'(>F*DEVHDO)OH<Y B1^VWV\GIR->RYE[G*Z>E[Y$<)J
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M:U<C!!1H]&BTM03*N+(=P[.E/U$%8@'6JI;7BP0^$&0'1+@!4Y:?H? %V/;
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M&X,#9JKK:PHCXRFT##.MPFE@ ZZR7#5,.HJITQ-^0 !5+-G0CQ;I^YA6-<2
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MN\O"B$VZ!5,]A\0- \),_%&4.69RBW#L10.!^2HO)E@[#:?KDPK;O@W=F<]
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MQ,>.4YEIG&@,L*6?H"*@^:OPT3UY?Q,CK:?37"Z)0("54CA9HB882Z>17E;
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M!1C4=5ZVL<"*H3,<:$@N'-+_UF+/XQL&/6^ H:?7 7E^B=DCC*I.^I$7G_T
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M^@AR*V)XOFK2I#* VAGZUCY?YG.!E CK:G2)7$1[?@$!T#+&O3$#%PXDX,E
MQ>%H;EY%O8=]US>LI^?8L?^<:EA50:=/,:Q.U_E">VP4YD_N^3J8J<$&3%0I
MW34+(S;I%DSU'!(W# A3^:,H2\SD%N'8BP8"<RLO)E@[#Z?KDPK;O@W=F<]
MK-=^[U##7 P.:<U-PT8B->VD7#N?QQ#@)+9)3C,G=7$Y+2GS1N?X5\@8]':Y
M[%/T5S,FBC >I61A,Y]&94/8TY8B+J!'Y\BCSO 9RN[&:$-\UX*8B_?*P5W(
MRJ=H$7 [Z<1O6 /[5WN?Q.&Z]TG<=%4A1C?M!/VI&H-]1^\'V;HI_9E4&048
MN1,&QH5QXJ'M;JAV&-8V#\J4XZD(?V^_G9MKQR[T$=U_A+U*03CPM_']8-&]
M4GC\IQ2OZ.T-I[:=9E[!N@J@-1?'^2TVA,3HIAW]?4M-1+9][@<8D;N9).:
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M"DI40>'[!_]]\/0@>[R_O[N__S##:1"::'BH!8_0.OQ5_1L?7\.JI]4"/G
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M_LR 1;18M;M(+:Z]E-=H4<$@X!<8%4&WV<^8581'JN =A"6PB\$.XI)SC2O
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M,C R,W$Q+65X:&EB:70S,C$N:'1M4$L! A0#%     @ 0XBL5E?:Y0N!&@
M*)$  !X              ( !SQ8  &%J:V%Z:6UI96UP;&]Y;65N=&%G<F5E
M;65N+FAT;5!+ 0(4 Q0    ( $.(K%;/=0J-41D  .^%   >
M  "  8PQ  !C:')I<V)I='1E<FUA;F5M<&QO>6UE;G1A9RYH=&U02P$"% ,4
M    " !#B*Q6L/4 8@0Z 0#Y0PP $0              @ $92P  8W!I>"TR
M,#(S,#,S,2YH=&U02P$"% ,4    " !#B*Q6D3D3S#4,  "P?@  $0
M        @ %,A0$ 8W!I>"TR,#(S,#,S,2YX<V102P$"% ,4    " !#B*Q6
M" )?BX@5   ]QP  %0              @ &PD0$ 8W!I>"TR,#(S,#,S,5]C
M86PN>&UL4$L! A0#%     @ 0XBL5NSHE&[++@  Q^@! !4
M ( !:Z<! &-P:7@M,C R,S S,S%?9&5F+GAM;%!+ 0(4 Q0    ( $.(K%8#
MSL=Q98\  +3E!0 5              "  6G6 0!C<&EX+3(P,C,P,S,Q7VQA
M8BYX;6Q02P$"% ,4    " !#B*Q63W:25=]8  "*UP, %0
M@ $!9@( 8W!I>"TR,#(S,#,S,5]P<F4N>&UL4$L! A0#%     @ 0XBL5MM&
M$IQ8&0  288  !X              ( !$[\" &IA;65S:&5R;6%N96UP;&]Y
M;65N=&%G<F5E+FAT;5!+ 0(4 Q0    ( $.(K%8[/1V_.QD  *J%   >
M          "  :?8 @!J;VAN:&%M;65M<&QO>6UE;G1A9W)E96UE;BYH=&U0
M2P$"% ,4    " !#B*Q6R @6BCH9  #BA0  '@              @ $>\@(
M=&]D9&%N=&AO;GDM96UP;&]Y;65N=&%G<F4N:'1M4$L%!@     .  X T@,
' )0+ P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
